



Final Risk Evaluation for Cyclic Aliphatic Bromides Cluster (HBCD)


Systematic Review Supplemental File:

Data Quality Evaluation of Human Health Hazard Studies – Animal, *In Vitro* and Epidemiological Studies

CASRN: 25637-99-4

CASRN: 3194-55-6

CASRN: 3194-57-8



September 2020

Animal and *In Vitro* Studies

Table Listing

Acute (<24 hr)

| | | |
|---|--|---|
| 1 | Animal toxicity evaluation results of Ameribrom Inc 1990 study for primary skin irritation study on irritation outcomes | 4 |
| 2 | Animal toxicity evaluation results of Ameribrom Inc 1990 on mortality, body weight outcomes | 6 |
| 3 | Animal toxicity evaluation results of IRDC 1978 for acute toxicity studies (oral, dermal and ocular) study on gastrointestinal, irritation, and skin and connective tissues outcomes | 9 |

Short-term (1-30 days)

| | | |
|----|--|----|
| 4 | Animal toxicity evaluation results of Maranghi et al 2013 for 28-day dietary study on hepatic, body weight, thyroid, hematological and immune, and reproductive outcomes | 12 |
| 5 | Animal toxicity evaluation results of Watanabe et al 2010 for 28 day feeding study in mice - mechanistic study, animals also infected with rsv study on nutrition and metabolic/adult exposure body weight, and hematological and immune outcomes | 14 |
| 6 | Animal toxicity evaluation results of Genskow et al 2015 for 30 day oral toxicity study (daily gavage) with in vitro data on mechanistic and neurological/behavior outcomes | 16 |
| 7 | Animal toxicity evaluation results of Song et al 2016 for acute and 14-day inhalation-systemic toxicity study on body weight, hematological and immune, clinical chemistry/biochemical, hepatic, renal, respiratory, and reproductive outcomes | 19 |
| 8 | Animal toxicity evaluation results of Miller et al 2016 for mechanism of liver and thyroid toxicity study on hepatic, thyroid outcomes | 21 |
| 9 | Animal toxicity evaluation results of Wang et al 2016 for 28 day oral gavage metabolomic study in mice study on nutrition and metabolic/adult exposure body weight, and gene expression/omics outcomes | 23 |
| 10 | Animal toxicity evaluation results of Bernhard et al 2016 for 28-day dietary study on hematological and immune, hepatic, and adult body weight outcomes | 25 |
| 11 | Animal toxicity evaluation results of Bernhard et al 2016 for 28-day oral exposure in mice via diet study on hepatic, and body weight outcomes | 27 |
| 12 | Animal toxicity evaluation results of American Chemistry Council 2003 for short term sensitization study in mice on ear swelling response | 30 |
| 13 | Animal toxicity evaluation results of American Chemistry Council 2003 for LLN assay for skin sensitization | 32 |
| 14 | Animal toxicity evaluation results of W. I. L. Research 1997 for 28-day repeated oral study on mortality, nutrition and metabolic/adult exposure body weight, neurological/behavior, hematological and immune, clinical chemistry/biochemical, hepatic, renal, cardiovascular, reproductive, endocrine, gastrointestinal, and respiratory outcomes | 34 |

Other

| | | |
|----|---|----|
| 15 | Animal toxicity evaluation results of Miller et al 2016 for 7 day gavage study on proteomic endpoints | 38 |
|----|---|----|

Subchronic (30-90 days)

| | | |
|----|--|----|
| 16 | Animal toxicity evaluation results of W. I. L. Research 2001 for 90-day gavage study on reproductive, hematological and immune, neurological/behavior, renal, hepatic, ocular and sensory, cardiovascular, clinical chemistry/biochemical, endocrine, gastrointestinal, body weight, and respiratory outcomes | 41 |
| 17 | Animal toxicity evaluation results of W. I. L. Research 2001 for 90-day gavage study on thyroid outcomes | 43 |
| 18 | Animal toxicity evaluation results of BASF et al 1990 for 28-day and 90-day dietary studies study on reproductive, hematological and immune, neurological, renal, hepatic, endocrine, gastrointestinal, respiratory, and thyroid outcomes . . . | 46 |
| 19 | Animal toxicity evaluation results of Acc et al 2002 for 90-day gavage-systemic with sperm evaluations and neurobehavior, same as (2990994) study on reproductive, hematological, neurological/behavior, renal, hepatic, clinical chemistry/biochemical, body weight, ocular and sensory, and thyroid outcomes | 48 |

Chronic (>90 days)

| | | |
|----|---|----|
| 20 | Animal toxicity evaluation results of Yanagisawa et al 2014 for 14-week study (animals dosed by gavage 1x per week) study on hepatic, body weight, and nutrition and metabolic/adult exposure body weight outcomes | 51 |
| 21 | Animal toxicity evaluation results of van der Ven et al 2006 for 280day oral toxicity study (gavage) study on hepatic, clinical chemistry/biochemical, endocrine, musculoskeletal/motor function, ADME/PBPK, thyroid, nutrition and metabolic/adult exposure body weight, hematological and immune, reproductive outcomes | 54 |

Genetic toxicity studies

| | | |
|----|--|----|
| 22 | In vitro evaluation results of Zeiger et al 1987 for Salmonella mutagenicity assay | 58 |
| 23 | In vitro evaluation results of Ethyl Corporation 1990 for Salmonella/microsomal assay for HBCD | 61 |
| 24 | In vitro evaluation results of Helleday et al 1999 for hprt recombination spd8 and sp5 cells | 64 |
| 25 | In vitro evaluation results of Huntingdon Research Center 1990 for bacterial reverse mutation | 66 |
| 26 | In vitro evaluation results of IBT Labs 1990 for in vitro Ames assay in S. typhimurium | 68 |
| 27 | In vitro evaluation results of Litton Bionetics 1990 for mutagenicity evaluation . . | 71 |
| 28 | In vitro evaluation results of Microbiological Associates 1996 for CAs in human PBLs | 74 |
| 29 | In vitro evaluation results of Pharmakologisches Institut 1990 for Ames test . . . | 76 |
| 30 | In vitro evaluation results of SRI International 1990 for mutagenicity studies . . . | 79 |
| 31 | In vitro evaluation results of An et al 2013 for Comet assay on L02 cell line | 82 |
| 32 | In vitro evaluation results of Ethyl Corporation 1990 for DNA repair in rat hepatocytes | 84 |
| 33 | In vitro evaluation results of Ameribrom Inc 1990 for bacterial reverse mutation | 88 |
| 34 | In vitro evaluation results of GSRI 1978 for Ames assay in S. typhimurium | 90 |
| 35 | In vitro evaluation results of An et al 2016 for Comet assay | 93 |
| 36 | In vitro evaluation results of Huang et al 2016 for DNA damage | 96 |

Developmental and Reproductive

| | | |
|----|---|-----|
| 37 | Animal toxicity evaluation results of van der Ven et al 2009 for 1-generation reproduction study, oral dietary study on endocrine, reproductive, hematological and immune, thyroid, growth (early life) and development, musculoskeletal/motor function, clinical chemistry/biochemical, nutrition and metabolic/adult exposure body weight, and hepatic outcomes | 99 |
| 38 | Animal toxicity evaluation results of Hachisuka et al 2010 for oral developmental immunotoxicity study on hematological and immune outcomes | 102 |
| 39 | Animal toxicity evaluation results of Miller-Rhodes et al 2014 for developmental study and gestation day 1-parturition study on growth (early life) and development, and neurological/behavior outcomes | 104 |
| 40 | Animal toxicity evaluation results of Szabo et al 2016 for single dose gavage (PND 10) study in mice on metabolomics outcomes | 107 |
| 41 | Animal toxicity evaluation results of Ema et al 2008 study on reproductive, growth (early life) and development, hepatic, neurological/behavior, and thyroid outcomes | 111 |
| 42 | Animal toxicity evaluation results of Eriksson et al 2006 for oral neurodevelopmental study (single dose PND 10) study on neurological/behavior, and growth (early life) and development outcomes | 114 |
| 43 | Animal toxicity evaluation results of Lilienthal et al 2009 for 1-generation reproductive study, dietary exposure study on neurological/behavior outcomes | 117 |
| 44 | Animal toxicity evaluation results of Saegusa et al 2009 for 1-generation developmental toxicity (dietary exposure) study on reproductive, growth (early life) and development, neurological, hepatic, endocrine, thyroid, nutrition and metabolic/adult exposure body weight outcomes | 120 |

Mechanistic

| | | |
|----|---|-----|
| 45 | In vitro evaluation results of Anisuzzaman and Whalen 2016 for secretion of IL-1beta | 123 |
| 46 | In vitro evaluation results of Wang et al 2016 for metabolic pathways for mechanism of toxicity | 126 |
| 47 | In vitro evaluation results of Kim et al 2016 for cancer progression (cell growth, apoptosis, migration, gene expression) | 129 |
| 48 | In vitro evaluation results of Koike et al 2016 for immune response in respiratory cells | 132 |
| 49 | In vitro evaluation results of Wu et al 2016 for cardiac toxicity | 135 |
| 50 | In vitro evaluation results of Almughamsi and Whalen 2016 for altered inflammatory cytokine in human cells | 138 |
| 51 | In vitro evaluation results of Canbaz et al 2016 for immune effects | 140 |

1 Acute (<24 hr)

Table 1: Animal toxicity evaluation results of Ameribrom Inc 1990 study for primary skin irritation study on irritation outcomes

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|---|--|---------------------|------|-------|--|
| Study Citation: (1990). Letter from Ameribrom Inc to US EPA regarding 8D submission for hexabromocyclododecane with attachments | | | | | |
| Data Type: Primary skin irritation | | | | | |
| HERO ID: 1928284 | | | | | |
| Domain 1: Test Substance | | | | | |
| Metric 1: | Test Substance Identity | High | × 2 | 2 | The test substance was identified definitely and CASRN provided. |
| Metric 2: | Test Substance Source | Medium | × 1 | 2 | The source of the test substance was reported, but the batch/lot number were not reported. |
| Metric 3: | Test Substance Purity | Low | × 1 | 3 | Purity and/or grade of test substance were not reported and there was no report of any analysis conducted for measurement of impurities. |
| Domain 2: Test Design | | | | | |
| Metric 4: | Negative and Vehicle Controls | Low | × 2 | 6 | Use of a control group was not reported. |
| Metric 5: | Positive Controls | Not Rated | NA | NA | No positive controls are required for this kind of study. |
| Metric 6: | Randomized Allocation | Not Rated | NA | NA | The study authors did not report how animals were allocated to study groups but there was only one group. |
| Domain 3: Exposure Characterization | | | | | |
| Metric 7: | Preparation and Storage of Test Substance | Low | × 1 | 3 | The authors report that the test substance was used as supplied by the supplier (in carboxymethyl cellulose); however, storage was not reported. |
| Metric 8: | Consistency of Exposure Administration | Medium | × 1 | 2 | The study reported consistent exposure administration; however, some details were lacking, such whether the exposures occurred at the same approximate time for all animals. |
| Metric 9: | Reporting of Doses/Concentrations | High | × 2 | 2 | Administered dose level was reported. |
| Metric 10: | Exposure Frequency and Duration | High | × 1 | 1 | Exposure frequency and duration were reported. |
| Metric 11: | Number of Exposure Groups and Dose Spacing | High | × 1 | 1 | Only one dose level was tested, but this is acceptable for studies of this type. |
| Metric 12: | Exposure Route and Method | High | × 1 | 1 | The route of exposure was reported and was suited to the test substance. |
| Domain 4: Test Organism | | | | | |
| Metric 13: | Test Animal Characteristics | High | × 2 | 2 | Test animal source, life stage, initial body weight, species, strain, and sex were reported; test animal was from a laboratory-maintained colony |
| Continued on next page ... | | | | | |

... continued from previous page

Study Citation: (1990). Letter from Ameribrom Inc to US EPA regarding 8D submission for hexabromocyclododecane with attachments
 Data Type: Primary skin irritation
 HERO ID: 1928284

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|--|--|---------------------|------|-------|---|
| | Metric 14: Adequacy and Consistency of Animal Husbandry Conditions | High | × 1 | 1 | Husbandry conditions were reported, including lighting, temperature, and humidity. |
| | Metric 15: Number per Group | High | × 1 | 1 | The number of animals per study group was reported, appropriate for the study type and outcome analysis. |
| Domain 5: Outcome Assessment | | | | | |
| | Metric 16: Outcome Assessment Methodology | High | × 2 | 2 | The outcome assessment methodology addressed or reported the intended outcome(s) of interest and was sensitive for the outcomes(s) of interest. |
| | Metric 17: Consistency of Outcome Assessment | High | × 1 | 1 | The study authors reported details of the outcome assessment protocol, including time points for post-exposure observations. |
| | Metric 18: Sampling Adequacy | Medium | × 1 | 2 | Details regarding sampling for the outcomes of interest were partially reported (e.g., sampling for general condition was not indicated, such as how many animals were examined.. |
| | Metric 19: Blinding of Assessors | Not Rated | NA | NA | This metric is not applicable for this kind of study. |
| | Metric 20: Negative Control Response | Low | × 1 | 3 | The study authors did not report the use of a negative control solvent. |
| Domain 6: Confounding / Variable Control | | | | | |
| | Metric 21: Confounding Variables in Test Design and Procedures | Not Rated | NA | NA | This metric is not applicable. |
| | Metric 22: Health Outcomes Unrelated to Exposure | Low | × 1 | 3 | There were not reported. |
| Domain 7: Data Presentation and Analysis | | | | | |
| | Metric 23: Statistical Methods | Not Rated | NA | NA | Since most of the endpoints are negative this metric is not applicable. |
| | Metric 24: Reporting of Data | Low | × 2 | 6 | There were some deficiencies in reporting of data (e.g., initial body weights were based on a range, rather than actual values.) |
| Overall Quality Determination [‡] | | Medium | | 1.8 | |
| Extracted | | Yes | | | |

* MWF = Metric Weighting Factor

† High = 1; Medium = 2; Low = 3; Unacceptable = 4; N/A has no value.

‡ The overall rating is calculated as necessary. EPA may not always provide a comment for a metric that has been categorized as High.

$$\text{Overall rating} = \begin{cases} 4 & \text{if any metric is Unacceptable} \\ \left\lfloor \frac{\sum_i (\text{Metric Score}_i \times \text{MWF}_i)}{\sum_j \text{MWF}_j} \right\rfloor_{0.1} & \text{(round to the nearest tenth) otherwise} \end{cases}$$

where High = ≥ 1 to < 1.7 ; Medium = ≥ 1.7 to < 2.3 ; Low = ≥ 2.3 to ≤ 3.0 . If the reviewer determines that the overall rating needs adjustment, the original rating is crossed out and an arrow points to the new rating.

†† This metric met the criteria for high confidence as expected for this type of study₅

Table 2: **Animal toxicity evaluation results of Ameribrom Inc 1990 on mortality, body weight outcomes**

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|---|--|---------------------|------|-------|--|
| Study Citation: (1990). Letter from Ameribrom Inc to US EPA regarding 8D submission for hexabromocyclododecane with attachments | | | | | |
| Data Type: Acute oral | | | | | |
| HERO ID: 1928284 | | | | | |
| <hr/> | | | | | |
| Domain 1: Test Substance | | | | | |
| Metric 1: | Test Substance Identity | Medium | × 2 | 4 | The test substance was identified. |
| Metric 2: | Test Substance Source | Low | × 1 | 3 | The source of the test substance, including manufacturer, was not specifically reported. Lot number was not reported. |
| Metric 3: | Test Substance Purity | Low | × 1 | 3 | Purity and grade were not reported and there was no analysis conducted for measurement of impurities, if present. |
| <hr/> | | | | | |
| Domain 2: Test Design | | | | | |
| Metric 4: | Negative and Vehicle Controls | Low | × 2 | 6 | Use of a control group was not reported, but is not required for studies of this type and outcome |
| Metric 5: | Positive Controls | Not Rated | NA | NA | Not applicable since this is a range finding study. |
| Metric 6: | Randomized Allocation | Not Rated | NA | NA | This is not applicable since there is only one group. |
| <hr/> | | | | | |
| Domain 3: Exposure Characterization | | | | | |
| Metric 7: | Preparation and Storage of Test Substance | Low | × 1 | 3 | The study authors reported some details on test item preparation, but they were incomplete (e.g., time of stirring, temperature, etc.) and the storage conditions were not reported, |
| Metric 8: | Consistency of Exposure Administration | Low | × 1 | 3 | A few details were reported that indicted that dosing methods were equivalent (e.g., similar dosing volumes at 10 mL/kg), but insufficient details were reported to allow determination of whether exposure administration was consistent. |
| Metric 9: | Reporting of Doses/Concentrations | High | × 2 | 2 | Administered dose level was reported. |
| Metric 10: | Exposure Frequency and Duration | Low | × 1 | 3 | The exposure frequency and duration were incompletely reported to allow a determination of whether they were suitable. Stated to be an acute study though, so suggests one exposure. |
| Metric 11: | Number of Exposure Groups and Dose Spacing | High | × 1 | 1 | Only one dose was tested, but this is acceptable for studies of this type. |
| Metric 12: | Exposure Route and Method | High | × 1 | 1 | The route of exposure was reported and was suited to the test substance. |
| <hr/> | | | | | |
| Domain 4: Test Organism | | | | | |
| Metric 13: | Test Animal Characteristics | Medium | × 2 | 4 | The test animal source, life stage, and starting body weight were not reported; species, strain, and sex were reported. |

Continued on next page ...

...continued from previous page

| Study Citation: | (1990). Letter from Ameribrom Inc to US EPA regarding 8D submission for hexabromocyclododecane with attachments | | | | | |
|--|---|---------------------|------|-------|--|--|
| Data Type: | Acute oral | | | | | |
| HERO ID: | 1928284 | | | | | |
| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} | |
| | Metric 14: Adequacy and Consistency of Animal Husbandry Conditions | Low | × 1 | 3 | Husbandry conditions were not sufficiently reported to evaluate if husbandry was adequate and/or if differences existed between the exposed and control groups. These deficiencies may have a substantial impact on the results. | |
| | Metric 15: Number per Group | High | × 1 | 1 | The number of animals was appropriate for the study type and outcome analysis. | |
| Domain 5: Outcome Assessment | | | | | | |
| | Metric 16: Outcome Assessment Methodology | Low | × 2 | 6 | Details on the outcome assessment methodology were incompletely reported (e.g., the frequency of observations during the post-exposure observation period). Due to incomplete reporting, it's not clear whether methods were sensitive for the outcomes of interest other than non-lethal outcomes | |
| | Metric 17: Consistency of Outcome Assessment | Unacceptable | × 1 | 4 | Consistency of the outcome assessments was not adequately reported for meaningful interpretation of results. These are serious flaws that make the study unusable. | |
| | Metric 18: Sampling Adequacy | Low | × 1 | 3 | Details regarding sampling adequacy was not reported and this deficiency is likely to have a substantial impact on results. | |
| | Metric 19: Blinding of Assessors | Not Rated | NA | NA | Blinding is not applicable for this study. | |
| | Metric 20: Negative Control Response | Not Rated | NA | NA | This is not applicable since there is only one group. | |
| Domain 6: Confounding / Variable Control | | | | | | |
| | Metric 21: Confounding Variables in Test Design and Procedures | Low | × 2 | 6 | Lack of reporting of initial body weights and whether there were any differences among the study groups in this or other parameters is considered to have a substantial impact on the results. | |
| | Metric 22: Health Outcomes Unrelated to Exposure | High | × 1 | 1 | Data on attrition and/or health outcomes unrelated to exposure for each study group were not reported. | |
| Domain 7: Data Presentation and Analysis | | | | | | |
| | Metric 23: Statistical Methods | Not Rated | NA | NA | Not applicable. | |
| | Metric 24: Reporting of Data | Low | × 2 | 6 | Data reporting was minimal and data on outcomes of exposure were reported in the text only. | |
| Overall Quality Determination [‡] | | Unacceptable** | | 2.4 | | |
| Extracted | | No | | | | |
| Continued on next page ... | | | | | | |

...continued from previous page

Study Citation: (1990). Letter from Ameribrom Inc to US EPA regarding 8D submission for hexabromocyclododecane with attachments
 Data Type: Acute oral
 HERO ID: 1928284

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|--------|--------|---------------------|------|-------|------------------------|
|--------|--------|---------------------|------|-------|------------------------|

** Consistent with our *Application of Systematic Review in TSCARisk Evaluations* document, if a metric for a data source receives a score of Unacceptable (score = 4), EPA will determine the study to be unacceptable. In this case, one or more of the metrics were rated as unacceptable. As such, the study is considered unacceptable and the score is presented solely to increase transparency.

* MWF = Metric Weighting Factor

† High = 1; Medium = 2; Low = 3; Unacceptable = 4; N/A has no value.

‡ The overall rating is calculated as necessary. EPA may not always provide a comment for a metric that has been categorized as High.

$$\text{Overall rating} = \begin{cases} 4 & \text{if any metric is Unacceptable} \\ \left[\sum_i (\text{Metric Score}_i \times \text{MWF}_i) / \sum_j \text{MWF}_j \right]_{0.1} & \text{(round to the nearest tenth) otherwise} \end{cases} ,$$

where High $\Rightarrow \geq 1$ to < 1.7 ; Medium $\Rightarrow \geq 1.7$ to < 2.3 ; Low $\Rightarrow \geq 2.3$ to ≤ 3.0 . If the reviewer determines that the overall rating needs adjustment, the original rating is crossed out and an arrow points to the new rating.

†† This metric met the criteria for high confidence as expected for this type of study

Table 3: **Animal toxicity evaluation results of IRDC 1978 for acute toxicity studies (oral, dermal and ocular) study on gastrointestinal, irritation, and skin and connective tissues outcomes**

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|---|---|---------------------|------|-------|---|
| Study Citation: IRDC (1978). Acute toxicity studies in rabbits and rats with residue of hexabromocyclododecane with attachments and cover letter dated 030178 | | | | | |
| Data Type: Acute toxicity studies (oral, dermal and ocular) | | | | | |
| HERO ID: 787686 | | | | | |
| Domain 1: Test Substance | | | | | |
| Metric 1: | Test Substance Identity | Unacceptable | × 2 | 8 | The test substance was identified as residue of HBCD (FM 100 residue). EPA requested additional information for the TSCA 8e submitter (Velsicol Chemical Corp.) as follows: "0088-Please provide information concerning the composition and physical/chemical properties of the "FM 100 Residue" which was tested. Of particular interest in this regard is the amount of hexabromocyclododecane present in the residue. Available toxicity data on hexabromocyclododecane would be useful for correlation purposes." This information is not contained in the pdf; however, it may have been submitted as CBI. The test substance identity and form cannot be determined from the information provided |
| Metric 2: | Test Substance Source | Medium | × 1 | 2 | The manufacturer was reported without batch or lot no. |
| Metric 3: | Test Substance Purity | Low | × 1 | 3 | Purity was not reported, but is expected to be low because the 2 samples of the residue had different physical descriptions. |
| Domain 2: Test Design | | | | | |
| Metric 4: | Negative and Vehicle Controls | Not Rated | NA | NA | No vehicle was used for irritation studies. Negative controls are not used for acute toxicity/lethality studies. |
| Metric 5: | Positive Controls | Not Rated | NA | NA | Positive controls are not required for irritation or acute toxicity/lethality studies. |
| Metric 6: | Randomized Allocation | Low | × 1 | 3 | The study did not report how animals were allocated to study groups. |
| Domain 3: Exposure Characterization | | | | | |
| Metric 7: | Preparation and Storage of Test Substance | Unacceptable | × 1 | 4 | Information on preparation and storage was not reported. |
| Metric 8: | Consistency of Exposure Administration | High | × 1 | 1 | Details of exposure administration were reported. |

Continued on next page ...

... continued from previous page

| Study Citation: | IRDC (1978). Acute toxicity studies in rabbits and rats with residue of hexabromocyclododecane with attachments and cover letter dated 030178 | | | | | |
|--|---|---------------------|------|-------|---|--|
| Data Type: | Acute toxicity studies (oral, dermal and ocular) | | | | | |
| HERO ID: | 787686 | | | | | |
| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} | |
| | Metric 9: Reporting of Doses/Concentrations | Low | × 2 | 6 | Doses were reported mg/kg in oral acute toxicity studies in rabbits. But the concentration of the test chemical dose (mg) exposed to rabbits for eye or skin irritation study was not specified. Only volume (mL) was provided. | |
| | Metric 10: Exposure Frequency and Duration | High | × 1 | 1 | Adequate follow up time for examinations for all experiments. | |
| | Metric 11: Number of Exposure Groups and Dose Spacing | High | × 1 | 1 | 5 dose groups dermal acute; 6 dose groups oral acute. | |
| | Metric 12: Exposure Route and Method | High | × 1 | 1 | The route and method of exposure were reported and were suited to the test substance. | |
| Domain 4: Test Organism | | | | | | |
| | Metric 13: Test Animal Characteristics | High | × 2 | 2 | Species, strain and starting body weight were provided (commercial source, rats and rabbits). | |
| | Metric 14: Adequacy and Consistency of Animal Husbandry Conditions | Medium | × 1 | 2 | Temperature and humidity controls. Compliance with animal care guidance was indicated. | |
| | Metric 15: Number per Group | Medium | × 1 | 2 | 4-5/sex for oral acute; 2/sex/group for dermal acute; adequate numbers for irritation. | |
| Domain 5: Outcome Assessment | | | | | | |
| | Metric 16: Outcome Assessment Methodology | Medium | × 2 | 4 | EPA requested further information from the TSCA 8e submitter (Velisicol Chemical Corp.) as follows: "Please describe any gross pathological findings or clinical observation made on the test animals." | |
| | Metric 17: Consistency of Outcome Assessment | High | × 1 | 1 | Details of the outcome assessment protocol were reported. | |
| | Metric 18: Sampling Adequacy | High | × 1 | 1 | Details regarding sampling for the outcome(s) of interest were reported and the study used adequate sampling for the outcome(s) of interest. | |
| | Metric 19: Blinding of Assessors | Low | × 1 | 3 | Information in the study report did not report whether assessors were blinded to treatment group for objective outcomes | |
| | Metric 20: Negative Control Response | Not Rated | NA | NA | No negative controls | |
| Domain 6: Confounding / Variable Control | | | | | | |
| | Metric 21: Confounding Variables in Test Design and Procedures | High | × 2 | 2 | There were no reported differences among the study groups in initial body weight that could influence the outcome assessment. , Information on food or water intake, or respiratory rate was not reported. | |

Continued on next page ...

...continued from previous page

| Study Citation: | IRDC (1978). Acute toxicity studies in rabbits and rats with residue of hexabromocyclododecane with attachments and cover letter dated 030178 | | | | | |
|--|---|---------------------|------|-------|--|--|
| Data Type: | Acute toxicity studies (oral, dermal and ocular) | | | | | |
| HERO ID: | 787686 | | | | | |
| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} | |
| | Metric 22: Health Outcomes Unrelated to Exposure | Low | × 1 | 3 | Data on attrition and/or health outcomes unrelated to exposure were not reported for each study group. | |
| Domain 7: Data Presentation and Analysis | | | | | | |
| | Metric 23: Statistical Methods | High | × 1 | 1 | Provided references for statistical methods. | |
| | Metric 24: Reporting of Data | High | × 2 | 2 | Data for exposure-related findings were presented for all outcomes by exposure group and sex. | |
| Overall Quality Determination [‡] | | Unacceptable** | | 2.0 | | |
| Extracted | | No | | | | |

** Consistent with our *Application of Systematic Review in TSCARisk Evaluations* document, if a metric for a data source receives a score of Unacceptable (score = 4), EPA will determine the study to be unacceptable. In this case, one or more of the metrics were rated as unacceptable. As such, the study is considered unacceptable and the score is presented solely to increase transparency.

* MWF = Metric Weighting Factor

† High = 1; Medium = 2; Low = 3; Unacceptable = 4; N/A has no value.

‡ The overall rating is calculated as necessary. EPA may not always provide a comment for a metric that has been categorized as High.

$$\text{Overall rating} = \begin{cases} 4 & \text{if any metric is Unacceptable} \\ \left\lfloor \frac{\sum_i (\text{Metric Score}_i \times \text{MWF}_i)}{\sum_j \text{MWF}_j} \right\rfloor_{0,1} & \text{(round to the nearest tenth) otherwise} \end{cases}$$

where High $\Rightarrow \geq 1$ to < 1.7 ; Medium $\Rightarrow \geq 1.7$ to < 2.3 ; Low $\Rightarrow \geq 2.3$ to ≤ 3.0 . If the reviewer determines that the overall rating needs adjustment, the original rating is crossed out and an arrow points to the new rating.

†† This metric met the criteria for high confidence as expected for this type of study

2 Short-term (1-30 days)

Table 4: Animal toxicity evaluation results of Maranghi et al 2013 for 28-day dietary study on hepatic, body weight, thyroid, hematological and immune, and reproductive outcomes

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|--|--|---------------------|------|-------|--|
| Study Citation: Maranghi, F., Tassinari, R., Moracci, G., Altieri, I., Rasinger, J.D., Carroll, T.S., Hogstrand, C., Lundebye, A.,K., Mantovani, A. (2013). Dietary exposure of juvenile female mice to polyhalogenated seafood contaminants (HBCD, BDE-47, PCB-153, TCDD): Comparative assessment of effects in potential target tissues Food and Chemical Toxicology, 56 443-449 | | | | | |
| Data Type: 28-day dietary study | | | | | |
| HERO ID: 1927558 | | | | | |
| Domain 1: Test Substance | | | | | |
| Metric 1: | Test Substance Identity | Medium | × 2 | 4 | Chemical name provided, no CAS #, and no structure provided. |
| Metric 2: | Test Substance Source | Low | × 1 | 3 | The source was no reported, no verification or analytical assessment |
| Metric 3: | Test Substance Purity | Low | × 1 | 3 | Substance purity was not provided |
| Domain 2: Test Design | | | | | |
| Metric 4: | Negative and Vehicle Controls | High | × 2 | 2 | An appropriate negative control was used |
| Metric 5: | Positive Controls | Not Rated | NA | NA | Positive control was not required |
| Metric 6: | Randomized Allocation | High | × 1 | 1 | Mice were allocated at random; method used was not detailed |
| Domain 3: Exposure Characterization | | | | | |
| Metric 7: | Preparation and Storage of Test Substance | Medium | × 1 | 2 | Preparation of exposure diets were described, however the frequency of preparation and details of storage were not indicated. |
| Metric 8: | Consistency of Exposure Administration | High | × 1 | 1 | Exposure was consistent across groups. - Animals were restricted to 15% w/w food intake. |
| Metric 9: | Reporting of Doses/Concentrations | Medium | × 2 | 4 | Do to methodological limitations, the intended HBCD concentration in feed could not be verified. It was therefore presumed that the concentration was equivalent to the intended dose. Analysis of other chemicals evaluated in the same study, indicated they were essentially the same as the intended inclusion levels. |
| Metric 10: | Exposure Frequency and Duration | High | × 1 | 1 | Frequency and duration were clearly reported |
| Metric 11: | Number of Exposure Groups and Dose Spacing | High | × 1 | 1 | Single dose and a control. - Justification of dose was provided. |
| Metric 12: | Exposure Route and Method | High | × 1 | 1 | Exposure route and method was acceptable |
| Domain 4: Test Organism | | | | | |
| Metric 13: | Test Animal Characteristics | High | × 2 | 2 | Appropriate test organism |

Continued on next page ...

... continued from previous page

| Study Citation: | Maranghi, F., Tassinari, R., Moracci, G., Altieri, I., Rasinger, J.D., Carroll, T.S., Hogstrand, C., Lundebye, A.,K., Mantovani, A. (2013). Dietary exposure of juvenile female mice to polyhalogenated seafood contaminants (HBCD, BDE-47, PCB-153, TCDD): Comparative assessment of effects in potential target tissues Food and Chemical Toxicology, 56 443-449 | | | | | |
|--|--|---------------------|------|-------|---|--|
| Data Type: | 28-day dietary study | | | | | |
| HERO ID: | 1927558 | | | | | |
| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} | |
| | Metric 14: Adequacy and Consistency of Animal Husbandry Conditions | High | × 1 | 1 | Animal husbandry acceptable | |
| | Metric 15: Number per Group | High | × 1 | 1 | 15/control group 10/treatment group | |
| Domain 5: Outcome Assessment | | | | | | |
| | Metric 16: Outcome Assessment Methodology | High | × 2 | 2 | Methods of outcome assessment were appropriate. | |
| | Metric 17: Consistency of Outcome Assessment | High | × 1 | 1 | Outcomes were assessed consistently across groups | |
| | Metric 18: Sampling Adequacy | High | × 1 | 1 | Sampling sizes were adequate | |
| | Metric 19: Blinding of Assessors | Medium | × 1 | 2 | Blinding of assessors was not reported, but is not required for initial histology evaluation. | |
| | Metric 20: Negative Control Response | High | × 1 | 1 | No abnormal control responses were reported | |
| Domain 6: Confounding / Variable Control | | | | | | |
| | Metric 21: Confounding Variables in Test Design and Procedures | High | × 2 | 2 | No confounding variables were identified. | |
| | Metric 22: Health Outcomes Unrelated to Exposure | High | × 1 | 1 | There were no unrelated exposure health outcomes | |
| Domain 7: Data Presentation and Analysis | | | | | | |
| | Metric 23: Statistical Methods | High | × 1 | 1 | Appropriate statistical methods were utilized | |
| | Metric 24: Reporting of Data | High | × 2 | 2 | Data reporting was acceptable | |
| Overall Quality Determination [‡] | | High | | 1.3 | | |
| Extracted | | Yes | | | | |

* MWF = Metric Weighting Factor

[†] High = 1; Medium = 2; Low = 3; Unacceptable = 4; N/A has no value.

[‡] The overall rating is calculated as necessary. EPA may not always provide a comment for a metric that has been categorized as High.

$$\text{Overall rating} = \begin{cases} 4 & \text{if any metric is Unacceptable} \\ \left\lfloor \frac{\sum_i (\text{Metric Score}_i \times \text{MWF}_i)}{\sum_j \text{MWF}_j} \right\rfloor_{0.1} & \text{(round to the nearest tenth) otherwise} \end{cases}$$

where High ≥ 1 to < 1.7 ; Medium ≥ 1.7 to < 2.3 ; Low ≥ 2.3 to ≤ 3.0 . If the reviewer determines that the overall rating needs adjustment, the original rating is crossed out and an arrow points to the new rating.

^{††} This metric met the criteria for high confidence as expected for this type of study

Table 5: **Animal toxicity evaluation results of Watanabe et al 2010 for 28 day feeding study in mice - mechanistic study, animals also infected with rsv study on nutrition and metabolic/adult exposure body weight, and hematological and immune outcomes**

| Study Citation: | Watanabe, W., Shimizu, T., Sawamura, R., Hino, A., Konno, K., Hirose, A., Kurokawa, M. (2010). Effects of tetrabromobisphenol A, a brominated flame retardant, on the immune response to respiratory syncytial virus infection in mice <i>International Immunopharmacology</i> , 10(4), 393-397 | | | | | |
|-------------------------------------|---|---------------------|------|-------|---|--|
| Data Type: | 28 day feeding study in mice - mechanistic study, animals also infected with RSV | | | | | |
| HERO ID: | 1927692 | | | | | |
| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} | |
| Domain 1: Test Substance | | | | | | |
| Metric 1: | Test Substance Identity | High | × 2 | 2 | Substance reported as HBCD, no CAS # was provided | |
| Metric 2: | Test Substance Source | High | × 1 | 1 | Purchased from a commercial source | |
| Metric 3: | Test Substance Purity | Low | × 1 | 3 | Purity was not reported; no validation was done to assess purity | |
| Domain 2: Test Design | | | | | | |
| Metric 4: | Negative and Vehicle Controls | Medium | × 2 | 4 | The study indicates there was a control, it is presumed that this was the powdered diet alone. It does not appear as though a vehicle was used? | |
| Metric 5: | Positive Controls | Not Rated | NA | NA | Positive control not necessary | |
| Metric 6: | Randomized Allocation | Low | × 1 | 3 | Randomization was not reported | |
| Domain 3: Exposure Characterization | | | | | | |
| Metric 7: | Preparation and Storage of Test Substance | Low | × 1 | 3 | Preparation nor storage was reported. Study authors only indicate that HBCD was mixed into a powder diet. | |
| Metric 8: | Consistency of Exposure Administration | High | × 1 | 1 | Control and treated Animals were fed ad libitum | |
| Metric 9: | Reporting of Doses/Concentrations | High | × 2 | 2 | Reported as 1% in diet., body weights and food consumption were provided, | |
| Metric 10: | Exposure Frequency and Duration | High | × 1 | 1 | Daily for 28 days | |
| Metric 11: | Number of Exposure Groups and Dose Spacing | Medium | × 1 | 2 | Single exposure and control; There was no explanation or justification of chosen dose; not useful for dose-response analysis, but single dose may be appropriate for the endpoints evaluated. There were no responses, so it is unclear whether the dose used was appropriate or not. | |
| Metric 12: | Exposure Route and Method | High | × 1 | 1 | Standard exposure route and method | |
| Domain 4: Test Organism | | | | | | |
| Metric 13: | Test Animal Characteristics | High | × 2 | 2 | Test animals were acceptable | |
| Metric 14: | Adequacy and Consistency of Animal Husbandry Conditions | Low | × 1 | 3 | Animal husbandry was not reported | |
| Continued on next page ... | | | | | | |

... continued from previous page

| Study Citation: | Watanabe, W., Shimizu, T., Sawamura, R., Hino, A., Konno, K., Hirose, A., Kurokawa, M. (2010). Effects of tetrabromobisphenol A, a brominated flame retardant, on the immune response to respiratory syncytial virus infection in mice International Immunopharmacology, 10(4), 393-397 | | | | | |
|--|---|---------------------------------------|------|-------|--|--|
| Data Type: | 28 day feeding study in mice - mechanistic study, animals also infected with RSV | | | | | |
| HERO ID: | 1927692 | | | | | |
| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} | |
| | Metric 15: Number per Group | Medium | × 1 | 2 | Study reports use of 6-7 mice/ group; OECD guidelines for 28-day repeated dose study recommends 10 animals/group (5/sex) | |
| Domain 5: Outcome Assessment | | | | | | |
| | Metric 16: Outcome Assessment Methodology | High | × 2 | 2 | CK: The outcome assessment methodology addressed the intended outcomes | |
| | Metric 17: Consistency of Outcome Assessment | High | × 1 | 1 | Methods were acceptable for what they were looking at. | |
| | Metric 18: Sampling Adequacy | High | × 1 | 1 | Sampling was done on all of the mice/group | |
| | Metric 19: Blinding of Assessors | Not Rated | NA | NA | Histology was not done on HBCD treated animals; there were no other subjective outcomes | |
| | Metric 20: Negative Control Response | High | × 1 | 1 | Control responses were as expected | |
| Domain 6: Confounding / Variable Control | | | | | | |
| | Metric 21: Confounding Variables in Test Design and Procedures | High | × 2 | 2 | There were no apparently confounding factors that would influence the outcomes | |
| | Metric 22: Health Outcomes Unrelated to Exposure | High | × 1 | 1 | There were no unrelated health outcomes | |
| Domain 7: Data Presentation and Analysis | | | | | | |
| | Metric 23: Statistical Methods | High | × 1 | 1 | Statistical method was appropriate for outcome | |
| | Metric 24: Reporting of Data | High | × 2 | 2 | Reporting of data was acceptable | |
| Overall Quality Determination [‡] | | High → Medium [§] | | 1.4 | | |
| Extracted | | Yes | | | | |

* MWF = Metric Weighting Factor

[†] High = 1; Medium = 2; Low = 3; Unacceptable = 4; N/A has no value.

[‡] The overall rating is calculated as necessary. EPA may not always provide a comment for a metric that has been categorized as High.

$$\text{Overall rating} = \begin{cases} 4 & \text{if any metric is Unacceptable} \\ \left\lfloor \frac{\sum_i (\text{Metric Score}_i \times \text{MWF}_i)}{\sum_j \text{MWF}_j} \right\rfloor_{0.1} & \text{(round to the nearest tenth) otherwise} \end{cases}$$

where High = ≥ 1 to < 1.7 ; Medium = ≥ 1.7 to < 2.3 ; Low = ≥ 2.3 to ≤ 3.0 . If the reviewer determines that the overall rating needs adjustment, the original rating is crossed out and an arrow points to the new rating.

^{††} This metric met the criteria for high confidence as expected for this type of study

[§] Evaluator's explanation for rating change: "Some study details regarding preparation of diets, and validation of dosing were omitted. Since there was no justification of dose, it is unknown whether the dose used was appropriate to elicit an effect. This limited endpoints evaluated do not greatly inform mechanism of the potential effects of HBCD on immunity."

Table 6: **Animal toxicity evaluation results of Genskow et al 2015 for 30 day oral toxicity study (daily gavage) with in vitro data on mechanistic and neurological/behavior outcomes**

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|---|--|---------------------|------|-------|--|
| Study Citation: Genskow, KR; Bradner, JM; Hossain, MM; Richardson, JR; Caudle, WM (2015). Selective damage to dopaminergic transporters following exposure to the brominated flame retardant, HBCDD Neurotoxicology and Teratology, 52(Pt B), 162-169 | | | | | |
| Data Type: 30 day oral toxicity study (daily gavage); primarily mechanistic, also contains in vitro data | | | | | |
| HERO ID: 2919804 | | | | | |
| Domain 1: Test Substance | | | | | |
| Metric 1: | Test Substance Identity | Medium | × 2 | 4 | Test substance name was provided but CAS# was not provided |
| Metric 2: | Test Substance Source | Medium | × 1 | 2 | Test substance source was provide but batch or lot number was not reported |
| Metric 3: | Test Substance Purity | Low | × 1 | 3 | Purity of the test substance is not reported |
| Domain 2: Test Design | | | | | |
| Metric 4: | Negative and Vehicle Controls | High | × 2 | 2 | Vehicle control reported |
| Metric 5: | Positive Controls | Not Rated | NA | NA | A positive control was not necessary, but could have provided useful information in this study that would aid in the interpretation of the results |
| Metric 6: | Randomized Allocation | Medium | × 1 | 2 | The study does not indicate whether animals were randomized, the endpoints evaluated were more mechanistic in nature, and may not have been impacted greatly by randomization. |
| Domain 3: Exposure Characterization | | | | | |
| Metric 7: | Preparation and Storage of Test Substance | Low | × 1 | 3 | Details of preparation, frequency of preparation, and storage were lacking |
| Metric 8: | Consistency of Exposure Administration | High | × 1 | 1 | Control and treatment groups were treated consistently |
| Metric 9: | Reporting of Doses/Concentrations | Medium | × 2 | 4 | Dose concentrations were clearly reported, however, no validation of dose was performed by the study authors. |
| Metric 10: | Exposure Frequency and Duration | High | × 1 | 1 | Exposure frequency and duration were clearly reported |
| Metric 11: | Number of Exposure Groups and Dose Spacing | Medium | × 1 | 2 | Single dose exposure that did not induce effects for several endpoints measured. It is unclear whether HBCD indeed has no effect, or whether a dose-limit was not reached NK: Single dose exposure, daily for 30 days. Control had 4 mice and treatment group had 6 mice. |
| Metric 12: | Exposure Route and Method | High | × 1 | 1 | Exposure route and method were acceptable. |
| Domain 4: Test Organism | | | | | |

Continued on next page ...

... continued from previous page

| Study Citation: | Genskow, KR; Bradner, JM; Hossain, MM; Richardson, JR; Caudle, WM (2015). Selective damage to dopaminergic transporters following exposure to the brominated flame retardant, HBCDD Neurotoxicology and Teratology, 52(Pt B), 162-169 | | | | | |
|--|---|----------------------------|------|-------|--|--|
| Data Type: | 30 day oral toxicity study (daily gavage); primarily mechanistic, also contains in vitro data | | | | | |
| HERO ID: | 2919804 | | | | | |
| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} | |
| | Metric 13: Test Animal Characteristics | Medium | × 2 | 4 | Animals (C57BL/6 male mice) were purchased at 8 weeks old and the mice were treated when they were 3 months old (4 weeks later). Animals generally get acclimatized for a week but 4 weeks seem a bit odd. | |
| | Metric 14: Adequacy and Consistency of Animal Husbandry Conditions | Medium | × 1 | 2 | Animal husbandry details were not provided, but the study authors state that procedures were conducted in accordance with the guide for care and use of laboratory animals | |
| | Metric 15: Number per Group | Medium | × 1 | 2 | Four control animals and 6 treated animals of a single sex were used. OECD guidelines for 28-day toxicity studies recommends an n of 10 (5 animals of each sex). | |
| Domain 5: Outcome Assessment | | | | | | |
| | Metric 16: Outcome Assessment Methodology | High | × 2 | 2 | The outcome assessment methodology addressed or reported the intended outcome(s) of interest and was sensitive for the outcome(s) of interest. | |
| | Metric 17: Consistency of Outcome Assessment | High | × 1 | 1 | Details of the outcome assessment protocol were reported and outcomes were assessed consistently across study groups | |
| | Metric 18: Sampling Adequacy | High | × 1 | 1 | The study reported adequate sampling for the outcome(s) of interest | |
| | Metric 19: Blinding of Assessors | Not Rated | NA | NA | Blinding is not required for this methodology | |
| | Metric 20: Negative Control Response | High | × 1 | 1 | Control responses appear to be appropriate | |
| Domain 6: Confounding / Variable Control | | | | | | |
| | Metric 21: Confounding Variables in Test Design and Procedures | Medium | × 2 | 4 | No confounding variables were noted, however, data regarding other potential exposure-related effects (i.e., potential effects on body weight), were not included in the report. | |
| | Metric 22: Health Outcomes Unrelated to Exposure | Medium | × 1 | 2 | This information was not included in the study report or in the study design. | |
| Domain 7: Data Presentation and Analysis | | | | | | |
| | Metric 23: Statistical Methods | High | × 1 | 1 | Statistical analysis was acceptable | |
| | Metric 24: Reporting of Data | High | × 2 | 2 | Reporting of data (for the methods used) was acceptable. | |
| Overall Quality Determination [‡] | | High → Medium [§] | | 4.6 | | |
| Extracted | | Yes | | | | |
| Continued on next page ... | | | | | | |

...continued from previous page

Study Citation: Genskow, KR; Bradner, JM; Hossain, MM; Richardson, JR; Caudle, WM (2015). Selective damage to dopaminergic transporters following exposure to the brominated flame retardant, HBCDD Neurotoxicology and Teratology, 52(Pt B), 162-169
 Data Type: 30 day oral toxicity study (daily gavage); primarily mechanistic, also contains in vitro data
 HERO ID: 2919804

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|--------|--------|---------------------|------|-------|------------------------|
|--------|--------|---------------------|------|-------|------------------------|

* MWF = Metric Weighting Factor

[†] High = 1; Medium = 2; Low = 3; Unacceptable = 4; N/A has no value.

[‡] The overall rating is calculated as necessary. EPA may not always provide a comment for a metric that has been categorized as High.

$$\text{Overall rating} = \begin{cases} 4 & \text{if any metric is Unacceptable} \\ \left[\sum_i (\text{Metric Score}_i \times \text{MWF}_i) / \sum_j \text{MWF}_j \right]_{0.1} & \text{(round to the nearest tenth) otherwise} \end{cases}$$

where High $\Rightarrow \geq 1$ to < 1.7 ; Medium $\Rightarrow \geq 1.7$ to < 2.3 ; Low $\Rightarrow \geq 2.3$ to ≤ 3.0 . If the reviewer determines that the overall rating needs adjustment, the original rating is crossed out and an arrow points to the new rating.

^{††} This metric met the criteria for high confidence as expected for this type of study

[§] Evaluator's explanation for rating change: "Downgraded the study from 'high' to 'medium' because this is primarily a mechanistic study. The small part of the study that is animal toxicity study with just one dose and has fewer animals (n=4 for control) and n=6 for treatment group)"

Table 7: **Animal toxicity evaluation results of Song et al 2016 for acute and 14-day inhalation-systemic toxicity study on body weight, hematological and immune, clinical chemistry/biochemical, hepatic, renal, respiratory, and reproductive outcomes**

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|---|---|---------------------|------|-------|---|
| Study Citation: Song, N; Li, L; Li, H; Ai, W; Xie, W; Yu, W; Liu, W; Wang, C; Shen, G; Zhou, L; Wei, C; Li, D; Chen, H (2016). Single and 14-day repeated dose inhalation toxicity studies of hexabromocyclododecane in rats Food and Chemical Toxicology, 91 73-81 | | | | | |
| Data Type: acute and 14-day inhalation-systemic tox | | | | | |
| HERO ID: 3350482 | | | | | |
| Domain 1: Test Substance | | | | | |
| Metric 1: | Test Substance Identity | High | × 2 | 2 | Test substance was clearly identified by name and CASRN. |
| Metric 2: | Test Substance Source | Medium | × 1 | 2 | The test substance source/manufacturer was identified however the batch/lot number was not reported |
| Metric 3: | Test Substance Purity | High | × 1 | 1 | The test substance purity was identified |
| Domain 2: Test Design | | | | | |
| Metric 4: | Negative and Vehicle Controls | High | × 2 | 2 | Negative control animals were included in the 14 day. No negative control required for acute study. |
| Metric 5: | Positive Controls | Not Rated | NA | NA | Positive controls not applicable. |
| Metric 6: | Randomized Allocation | High | × 1 | 1 | Animals were randomly allocated to each group. |
| Domain 3: Exposure Characterization | | | | | |
| Metric 7: | Preparation and Storage of Test Substance | High | × 1 | 1 | The method and equipment used to generate the dust aerosol were reported and appropriate. |
| Metric 8: | Consistency of Exposure Administration | High | × 1 | 1 | Exposures were administered consistently. |
| Metric 9: | Reporting of Doses/Concentrations | High | × 2 | 2 | Target and measured concentrations, MMAD, and GSD were reported for all groups. |
| Metric 10: | Exposure Frequency and Duration | High | × 1 | 1 | Frequency and duration were reported. |
| Metric 11: | Number of Exposure Groups and Dose Spacing | High | × 1 | 1 | The number of groups and spacing were reported along with rationale for concentration selection. |
| Metric 12: | Exposure Route and Method | High | × 1 | 1 | The route and method were appropriate. |
| Domain 4: Test Organism | | | | | |
| Metric 13: | Test Animal Characteristics | Medium | × 2 | 4 | The source, health status, species, strain, age, and sex were reported. Initial body weight was not reported. |
| Metric 14: | Adequacy and Consistency of Animal Husbandry Conditions | High | × 1 | 1 | All husbandry conditions were reported and appropriate. |
| Metric 15: | Number per Group | High | × 1 | 1 | The number of animals per study group was appropriate. |
| Domain 5: Outcome Assessment | | | | | |
| Metric 16: | Outcome Assessment Methodology | High | × 2 | 2 | Outcome assessment methodology was reported and appropriate. |

Continued on next page ...

... continued from previous page

Study Citation: Song, N; Li, L; Li, H; Ai, W; Xie, W; Yu, W; Liu, W; Wang, C; Shen, G; Zhou, L; Wei, C; Li, D; Chen, H (2016). Single and 14-day repeated dose inhalation toxicity studies of hexabromocyclododecane in rats Food and Chemical Toxicology, 91 73-81
 Data Type: acute and 14-day inhalation-systemic tox
 HERO ID: 3350482

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|--|--|---------------------|------|-------|---|
| | Metric 17: Consistency of Outcome Assessment | High | × 1 | 1 | Outcomes were assessed consistently. |
| | Metric 18: Sampling Adequacy | High | × 1 | 1 | Sampling size was adequate. |
| | Metric 19: Blinding of Assessors | Not Rated | NA | NA | Blinding not required. |
| | Metric 20: Negative Control Response | High | × 1 | 1 | Negative control responses were appropriate. |
| Domain 6: Confounding / Variable Control | | | | | |
| | Metric 21: Confounding Variables in Test Design and Procedures | High | × 2 | 2 | No confounding variables in test design were observed. |
| | Metric 22: Health Outcomes Unrelated to Exposure | High | × 1 | 1 | No health outcomes unrelated to exposure were reported. |
| Domain 7: Data Presentation and Analysis | | | | | |
| | Metric 23: Statistical Methods | High | × 1 | 1 | Statistical methods were reported and appropriate. |
| | Metric 24: Reporting of Data | High | × 2 | 2 | Data were reported. |
| Overall Quality Determination [‡] | | High | | 1.1 | |
| Extracted | | Yes | | | |

* MWF = Metric Weighting Factor

[†] High = 1; Medium = 2; Low = 3; Unacceptable = 4; N/A has no value.

[‡] The overall rating is calculated as necessary. EPA may not always provide a comment for a metric that has been categorized as High.

$$\text{Overall rating} = \begin{cases} 4 & \text{if any metric is Unacceptable} \\ \left[\frac{\sum_i (\text{Metric Score}_i \times \text{MWF}_i)}{\sum_j \text{MWF}_j} \right]_{0.1} & \text{(round to the nearest tenth) otherwise} \end{cases}$$

where High = ≥ 1 to < 1.7 ; Medium = ≥ 1.7 to < 2.3 ; Low = ≥ 2.3 to ≤ 3.0 . If the reviewer determines that the overall rating needs adjustment, the original rating is crossed out and an arrow points to the new rating.

^{††} This metric met the criteria for high confidence as expected for this type of study

Table 8: **Animal toxicity evaluation results of Miller et al 2016 for mechanism of liver and thyroid toxicity study on hepatic, thyroid outcomes**

| Study Citation: | Miller, I; Serchi, T; Cambier, S; Diepenbroek, C; Renaut, J; Van der Berg, JH; Kwadijk, C; Gutleb, AC; Rijntjes, E; Murk, AJ (2016). Hexabromocyclododecane (HBCD) induced changes in the liver proteome of eu- and hypothyroid female rats Toxicology Letters, 245 40-51 | | | | | |
|-------------------------------------|---|---------------------|------|-------|--|--|
| Data Type: | Mechanism of liver and thyroid toxicity | | | | | |
| HERO ID: | 3350495 | | | | | |
| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} | |
| Domain 1: Test Substance | | | | | | |
| Metric 1: | Test Substance Identity | Medium | × 2 | 4 | Test substance identified by name. No CAS # or other details were provided | |
| Metric 2: | Test Substance Source | Low | × 1 | 3 | Source or manufacturer was not identified. | |
| Metric 3: | Test Substance Purity | Low | × 1 | 3 | Purity of the substance was not provided | |
| Domain 2: Test Design | | | | | | |
| Metric 4: | Negative and Vehicle Controls | High | × 2 | 2 | Concurrent negative controls were included. | |
| Metric 5: | Positive Controls | Not Rated | NA | NA | Positive controls were not required. | |
| Metric 6: | Randomized Allocation | Low | × 1 | 3 | Allocation methods were not reported. | |
| Domain 3: Exposure Characterization | | | | | | |
| Metric 7: | Preparation and Storage of Test Substance | Medium | × 1 | 2 | Preparation of the test substance was reported., but storage prior to administration was not reported.. | |
| Metric 8: | Consistency of Exposure Administration | High | × 1 | 1 | Exposures were administered consistently. | |
| Metric 9: | Reporting of Doses/Concentrations | High | × 2 | 2 | Appropriate doses were reported | |
| Metric 10: | Exposure Frequency and Duration | High | × 1 | 1 | Frequency and duration were reported. | |
| Metric 11: | Number of Exposure Groups and Dose Spacing | High | × 1 | 1 | The number of groups and spacing were reported | |
| Metric 12: | Exposure Route and Method | High | × 1 | 1 | The route and method were appropriate. | |
| Domain 4: Test Organism | | | | | | |
| Metric 13: | Test Animal Characteristics | Medium | × 2 | 4 | The source, species, strain, and age were reported. Initial body weight was not reported. Some animals were iodine depleted to create a hypothyroid state resulting in 2 groups, normal and hypothyroid. | |
| Metric 14: | Adequacy and Consistency of Animal Husbandry Conditions | Medium | × 1 | 2 | The temperature, humidity, lighting, water, and diet were reported. No other details were reported. | |
| Metric 15: | Number per Group | High | × 1 | 1 | The number of animals per group was appropriate. | |
| Domain 5: Outcome Assessment | | | | | | |
| Metric 16: | Outcome Assessment Methodology | High | × 2 | 2 | Outcome assessment methodology was reported and appropriate. | |
| Metric 17: | Consistency of Outcome Assessment | High | × 1 | 1 | Outcomes were assessed consistently. | |

Continued on next page ...

... continued from previous page

Study Citation: Miller, I; Serchi, T; Cambier, S; Diepenbroek, C; Renaut, J; Van der Berg, JH; Kwadijk, C; Gutleb, AC; Rijntjes, E; Murk, AJ (2016). Hexabromocyclododecane (HBCD) induced changes in the liver proteome of eu- and hypothyroid female rats Toxicology Letters, 245 40-51
 Data Type: Mechanism of liver and thyroid toxicity
 HERO ID: 3350495

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|--|--|----------------------------|------|-------|---|
| | Metric 18: Sampling Adequacy | High | × 1 | 1 | Sampling was adequate. |
| | Metric 19: Blinding of Assessors | Not Rated | NA | NA | Blinding was not required. |
| | Metric 20: Negative Control Response | High | × 1 | 1 | Negative control responses were appropriate. |
| Domain 6: Confounding / Variable Control | | | | | |
| | Metric 21: Confounding Variables in Test Design and Procedures | Medium | × 2 | 4 | Iodine depletion may have an effect on the results |
| | Metric 22: Health Outcomes Unrelated to Exposure | Medium | × 1 | 2 | One group of animals were exposed in a hypothyroid state. |
| Domain 7: Data Presentation and Analysis | | | | | |
| | Metric 23: Statistical Methods | High | × 1 | 1 | Statistical methods were reported and appropriate. |
| | Metric 24: Reporting of Data | High | × 2 | 2 | Data were reported. |
| Overall Quality Determination [‡] | | High → Medium [§] | | 1.5 | |
| Extracted | | Yes | | | |

* MWF = Metric Weighting Factor

[†] High = 1; Medium = 2; Low = 3; Unacceptable = 4; N/A has no value.

[‡] The overall rating is calculated as necessary. EPA may not always provide a comment for a metric that has been categorized as High.

$$\text{Overall rating} = \begin{cases} 4 & \text{if any metric is Unacceptable} \\ \left\lfloor \frac{\sum_i (\text{Metric Score}_i \times \text{MWF}_i)}{\sum_j \text{MWF}_j} \right\rfloor_{0.1} & \text{(round to the nearest tenth) otherwise} \end{cases}$$

where High = ≥ 1 to < 1.7 ; Medium = ≥ 1.7 to < 2.3 ; Low = ≥ 2.3 to ≤ 3.0 . If the reviewer determines that the overall rating needs adjustment, the original rating is crossed out and an arrow points to the new rating.

^{††} This metric met the criteria for high confidence as expected for this type of study

[§] Evaluator's explanation for rating change: "This seem to be a well conducted study, however, one major flaw is that the source of HBCD was not reported. Not sure if the chemical was prepared in the lab or purchased from a manufacturer. Left the rating for metric 2 as low, but could be changed to unacceptable since information on test material source, manufacturer, purity, other analytical details of HBCD was not provided. Other parts of the study was appropriately conducted."

Table 9: **Animal toxicity evaluation results of Wang et al 2016 for 28 day oral gavage metabolomic study in mice study on nutrition and metabolic/adult exposure body weight, and gene expression/omics outcomes**

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|---|---|---------------------|------|-------|--|
| Study Citation: Wang, D; Zhang, P; Wang, X; Wang, Y; Zhou, Z; Zhu, W (2016). NMR- and LC-MS/MS-based urine metabolomic investigation of the subacute effects of hexabromocyclododecane in mice Environmental Science and Pollution Research, 23(9), 8500-8507 | | | | | |
| Data Type: 28 day oral gavage metabolomic study in mice | | | | | |
| HERO ID: 3350496 | | | | | |
| Domain 1: Test Substance | | | | | |
| Metric 1: | Test Substance Identity | High | × 2 | 2 | Test substance identified as technical HBCD with 10% alpha, 10% beta, and 80% gamma stereoisomers. |
| Metric 2: | Test Substance Source | Medium | × 1 | 2 | Test substance obtained from manufacturer but without certification or analytical verification of identity. |
| Metric 3: | Test Substance Purity | High | × 1 | 1 | Test substance purity reported as 95% |
| Domain 2: Test Design | | | | | |
| Metric 4: | Negative and Vehicle Controls | High | × 2 | 2 | Sham-treated controls received vehicle |
| Metric 5: | Positive Controls | Not Rated | NA | NA | Positive controls not typical for study type |
| Metric 6: | Randomized Allocation | High | × 1 | 1 | Study reports random allocation to groups |
| Domain 3: Exposure Characterization | | | | | |
| Metric 7: | Preparation and Storage of Test Substance | Medium | × 1 | 2 | Test substance preparation was reported but storage was not reported |
| Metric 8: | Consistency of Exposure Administration | Medium | × 1 | 2 | Time of day of gavage administration was not reported. |
| Metric 9: | Reporting of Doses/Concentrations | High | × 2 | 2 | Details of exposure administration were reported and exposures were administered consistently across study groups in a scientifically sound manner |
| Metric 10: | Exposure Frequency and Duration | High | × 1 | 1 | Doses administered daily for 28 days |
| Metric 11: | Number of Exposure Groups and Dose Spacing | Medium | × 1 | 2 | 2 nonzero doses were administered ranging 5-fold. Doses were selected based on reported range of toxic doses |
| Metric 12: | Exposure Route and Method | High | × 1 | 1 | oral gavage exposure with appropriate vehicle reported |
| Domain 4: Test Organism | | | | | |
| Metric 13: | Test Animal Characteristics | High | × 2 | 2 | Test animal species, strain, sex, age, and body weight were reported. Females were chosen because they were reportedly more sensitive. |
| Metric 14: | Adequacy and Consistency of Animal Husbandry Conditions | Medium | × 1 | 2 | Relative humidity and diet were not reported. All other husbandry conditions were reported and adequate. |

Continued on next page ...

... continued from previous page

| Study Citation: | Wang, D; Zhang, P; Wang, X; Wang, Y; Zhou, Z; Zhu, W (2016). NMR- and LC-MS/MS-based urine metabolomic investigation of the subacute effects of hexabromocyclododecane in mice Environmental Science and Pollution Research, 23(9), 8500-8507 | | | | | |
|--|---|----------------------------|------|-------|--|--|
| Data Type: | 28 day oral gavage metabolomic study in mice | | | | | |
| HERO ID: | 3350496 | | | | | |
| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} | |
| | Metric 15: Number per Group | Medium | × 1 | 2 | 5 animals/dose tested. | |
| Domain 5: Outcome Assessment | | | | | | |
| | Metric 16: Outcome Assessment Methodology | Medium | × 2 | 4 | Body weight, organ weight and both targeted and untargeted metabolomics were evaluated. BW was measured weekly, but metabolomics only performed once on 24 hr urine samples collected after last dose. | |
| | Metric 17: Consistency of Outcome Assessment | High | × 1 | 1 | No inconsistencies in outcome assessment were noted | |
| | Metric 18: Sampling Adequacy | High | × 1 | 1 | Body weights and metabolomics assessed for individual animals | |
| | Metric 19: Blinding of Assessors | Not Rated | NA | NA | no subjective outcomes | |
| | Metric 20: Negative Control Response | High | × 1 | 1 | Control responses were reported and appeared to be appropriate | |
| Domain 6: Confounding / Variable Control | | | | | | |
| | Metric 21: Confounding Variables in Test Design and Procedures | Medium | × 2 | 4 | Food and water intake were not reported. | |
| | Metric 22: Health Outcomes Unrelated to Exposure | Medium | × 1 | 2 | One control mouse died during the study. | |
| Domain 7: Data Presentation and Analysis | | | | | | |
| | Metric 23: Statistical Methods | High | × 1 | 1 | Statistical analysis methods reported and appropriate. | |
| | Metric 24: Reporting of Data | Medium | × 2 | 4 | Body weights reported graphically without measure of variability in supplemental material. | |
| Overall Quality Determination [‡] | | High → Medium [§] | | 1.4 | | |
| Extracted | | No | | | | |

* MWF = Metric Weighting Factor

† High = 1; Medium = 2; Low = 3; Unacceptable = 4; N/A has no value.

‡ The overall rating is calculated as necessary. EPA may not always provide a comment for a metric that has been categorized as High.

$$\text{Overall rating} = \begin{cases} 4 & \text{if any metric is Unacceptable} \\ \left\lfloor \frac{\sum_i (\text{Metric Score}_i \times \text{MWF}_i)}{\sum_j \text{MWF}_j} \right\rfloor_{0.1} & \text{(round to the nearest tenth) otherwise} \end{cases}$$

where High = ≥ 1 to < 1.7 ; Medium = ≥ 1.7 to < 2.3 ; Low = ≥ 2.3 to ≤ 3.0 . If the reviewer determines that the overall rating needs adjustment, the original rating is crossed out and an arrow points to the new rating.

†† This metric met the criteria for high confidence as expected for this type of study

§ Evaluator's explanation for rating change: "Although body weight and organ weights were measured, only average body weight was provided in the supplemental material. the author reports organ weight data was not shown, but did not have any changes. This study mainly focus on metabolomics using urine samples and analyzing amino acids. Even though it is a 28-day study, no useful information is provided in terms of outcomes for toxicological endpoint. It possibly can be used as a mechanistic supporting study for understanding the metabolic pathway."

Table 10: **Animal toxicity evaluation results of Bernhard et al 2016 for 28-day dietary study on hematological and immune, hepatic, and adult body weight outcomes**

| Study Citation: | Bernhard, A; Berntssen, MH; Lundebye, A-K; Alvheim, AR; Myrnel, LS; Fjære, E; Torstensen, BE; Kristiansen, K; Madsen, L; Brattelid, T; Rasinger, JD (2016). Marine fatty acids aggravate hepatotoxicity of a-HBCD in juvenile female BALB/c mice Food and Chemical Toxicology, 97 411-423 | | | | |
|-------------------------------------|---|---------------------|------|-------|--|
| Data Type: | 28-day dietary study | | | | |
| HERO ID: | 3545918 | | | | |
| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
| Domain 1: Test Substance | | | | | |
| Metric 1: | Test Substance Identity | Medium | × 2 | 4 | The test substance was identified definitively and the specific form, however CAS# was not provided |
| Metric 2: | Test Substance Source | Low | × 1 | 3 | alpha-HBCD was prepared from gamma-HBCD; however the source of the alpha-HBCD was not reported |
| Metric 3: | Test Substance Purity | Low | × 1 | 3 | Purity was not reported. |
| Domain 2: Test Design | | | | | |
| Metric 4: | Negative and Vehicle Controls | High | × 2 | 2 | Vehicle (DMSO) dietary control. |
| Metric 5: | Positive Controls | Not Rated | NA | NA | Positive controls are not needed for repeat dose studies. |
| Metric 6: | Randomized Allocation | High | × 1 | 1 | Animals were randomly assigned to groups. |
| Domain 3: Exposure Characterization | | | | | |
| Metric 7: | Preparation and Storage of Test Substance | Low | × 1 | 3 | Although feed and water was changed three times per week and feed intake was recorded, the authors did not indicate how often the diets were freshly prepared. Storage of the test substance was also not provided |
| Metric 8: | Consistency of Exposure Administration | High | × 1 | 1 | 28-day repeat exposure according to OECD407 guidelines |
| Metric 9: | Reporting of Doses/Concentrations | High | × 2 | 2 | Diets were analyzed and daily doses were calculated based on body weights and estimate food intake (15% w/w). |
| Metric 10: | Exposure Frequency and Duration | High | × 1 | 1 | 28-day, continuous exposure. |
| Metric 11: | Number of Exposure Groups and Dose Spacing | High | × 1 | 1 | Dose levels and spacing were justified by the study authors. Selected dose produced a range of responses. |
| Metric 12: | Exposure Route and Method | High | × 1 | 1 | Oral - feeding study |
| Domain 4: Test Organism | | | | | |
| Metric 13: | Test Animal Characteristics | High | × 2 | 2 | Species, strain, sex and starting age were reported (commercial source0). |
| Continued on next page ... | | | | | |

... continued from previous page

| Study Citation: | Bernhard, A; Berntssen, MH; Lundebye, A-K; Alvheim, AR; Myrmel, LS; Fjære, E; Torstensen, BE; Kristiansen, K; Madsen, L; Brattelid, T; Rasinger, JD (2016). Marine fatty acids aggravate hepatotoxicity of a-HBCD in juvenile female BALB/c mice Food and Chemical Toxicology, 97 411-423 | | | | | |
|--|---|---------------------|------|-------|--|--|
| Data Type: | 28-day dietary study | | | | | |
| HERO ID: | 3545918 | | | | | |
| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} | |
| | Metric 14: Adequacy and Consistency of Animal Husbandry Conditions | High | × 1 | 1 | Husbandry conditions were reported and appropriate. | |
| | Metric 15: Number per Group | High | × 1 | 1 | Eight animals per experimental group | |
| Domain 5: Outcome Assessment | | | | | | |
| | Metric 16: Outcome Assessment Methodology | High | × 2 | 2 | Multiple measures of liver effects | |
| | Metric 17: Consistency of Outcome Assessment | High | × 1 | 1 | outcomes were assessed consistently across study groups | |
| | Metric 18: Sampling Adequacy | Medium | × 1 | 2 | Only 3-4 /group for histopathology and serum chemistry. | |
| | Metric 19: Blinding of Assessors | Low | × 1 | 3 | Blinding was not reported | |
| | Metric 20: Negative Control Response | High | × 1 | 1 | Vehicle control was used and appropriate | |
| Domain 6: Confounding / Variable Control | | | | | | |
| | Metric 21: Confounding Variables in Test Design and Procedures | High | × 2 | 2 | Food consumption did not differ among groups. | |
| | Metric 22: Health Outcomes Unrelated to Exposure | Low | × 1 | 3 | Data on attrition and/or health outcomes unrelated to exposure were not reported for each study group. | |
| Domain 7: Data Presentation and Analysis | | | | | | |
| | Metric 23: Statistical Methods | High | × 1 | 1 | Appropriate and detailed statistical methods were reported | |
| | Metric 24: Reporting of Data | Medium | × 2 | 4 | Incidence data were not provided for liver histopathology. | |
| Overall Quality Determination [‡] | | High | | 1.5 | | |
| Extracted | | Yes | | | | |

* MWF = Metric Weighting Factor

† High = 1; Medium = 2; Low = 3; Unacceptable = 4; N/A has no value.

‡ The overall rating is calculated as necessary. EPA may not always provide a comment for a metric that has been categorized as High.

$$\text{Overall rating} = \begin{cases} 4 & \text{if any metric is Unacceptable} \\ \left\lceil \frac{\sum_i (\text{Metric Score}_i \times \text{MWF}_i)}{\sum_j \text{MWF}_j} \right\rceil_{0.1} & \text{(round to the nearest tenth) otherwise} \end{cases}$$

where High $\Rightarrow 1$ to < 1.7 ; Medium $\Rightarrow 1.7$ to < 2.3 ; Low $\Rightarrow 2.3$ to ≤ 3.0 . If the reviewer determines that the overall rating needs adjustment, the original rating is crossed out and an arrow points to the new rating.

†† This metric met the criteria for high confidence as expected for this type of study

Table 11: **Animal toxicity evaluation results of Bernhard et al 2016 for 28-day oral exposure in mice via diet study on hepatic, and body weight outcomes**

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|---|---|---------------------|------|-------|---|
| Study Citation: Bernhard, A; Berntssen, MH; Lundebye, A-K; Alvheim, AR; Myrmel, LS; Fjære, E; Torstensen, BE; Kristiansen, K; Madsen, L; Brattelid, T; Rasinger, JD (2016). Marine fatty acids aggravate hepatotoxicity of a-HBCD in juvenile female BALB/c mice 97 411-423 | | | | | |
| Data Type: 28-day oral exposure in mice via diet | | | | | |
| HERO ID: 3588138 | | | | | |
| Domain 1: Test Substance | | | | | |
| Metric 1: | Test Substance Identity | High | × 2 | 2 | Identity and form are stated, no CAS# reported. |
| Metric 2: | Test Substance Source | Medium | × 1 | 2 | alpha-HBCD was synthesized from from gamma-HBCD. Analytical verification of the product was not done, however, concentrations in feed were analyzed by GC-MS. |
| Metric 3: | Test Substance Purity | Low | × 1 | 3 | After production, purity of the alpha isomer was described as "pure". alpha-HBCD was produced in the laboratory. Study report states that "purified alpha-HBCD" was used to dose animals but % purity or details on the purification methods were not provided. |
| Domain 2: Test Design | | | | | |
| Metric 4: | Negative and Vehicle Controls | High | × 2 | 2 | Study used an appropriate vehicle negative control diet. |
| Metric 5: | Positive Controls | Not Rated | NA | NA | Positive control not necessary |
| Metric 6: | Randomized Allocation | Medium | × 1 | 2 | It was stated that animals were randomly assigned, although the method for assignment was not described. |
| Domain 3: Exposure Characterization | | | | | |
| Metric 7: | Preparation and Storage of Test Substance | Medium | × 1 | 2 | The frequency of diet preparation and a statement about stability were not provided. Preparation of diets was acceptable. |
| Metric 8: | Consistency of Exposure Administration | High | × 1 | 1 | administration was consistent across groups. |
| Metric 9: | Reporting of Doses/Concentrations | Low | × 2 | 6 | Both nominal and measured concentrations in the diet were provided with corresponding daily exposures. However, these values were calculated using estimated (rather than actual) daily food intake. It can not be determined whether there was a difference in the intake across treatment groups. |
| Metric 10: | Exposure Frequency and Duration | High | × 1 | 1 | Appropriate; study design was based on OECD guideline 407 for short-term repeated dose toxicity study |
| Continued on next page ... | | | | | |

... continued from previous page

| Study Citation: | Bernhard, A; Berntssen, MH; Lundebye, A-K; Alvheim, AR; Myrnel, LS; Fjære, E; Torstensen, BE; Kristiansen, K; Madsen, L; Brattelid, T; Rasinger, JD (2016). Marine fatty acids aggravate hepatotoxicity of a-HBCD in juvenile female BALB/c mice 97 411-423 | | | | | |
|--|---|---------------------|------|-------|--|--|
| Data Type: | 28-day oral exposure in mice via diet | | | | | |
| HERO ID: | 3588138 | | | | | |
| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} | |
| | Metric 11: Number of Exposure Groups and Dose Spacing | High | × 1 | 1 | Number of exposure groups was appropriate. Authors state that "The high dose (HD) chosen was high enough to elicit molecular aberrations and the low dose (LD) was based on the potentially relevant Lowest Observed Adverse Effect Level (LOAEL) (Table 1; Yanagisawa et al., 2014)." | |
| | Metric 12: Exposure Route and Method | High | × 1 | 1 | Exposure route acceptable | |
| Domain 4: Test Organism | | | | | | |
| | Metric 13: Test Animal Characteristics | High | × 2 | 2 | Standard animal model was used. Age was appropriate for desired "juvenile" developmental time point. Only one sex evaluated. Animals were obtained from Taconic. | |
| | Metric 14: Adequacy and Consistency of Animal Husbandry Conditions | High | × 1 | 1 | Animal husbandry clearly reported and appropriate. | |
| | Metric 15: Number per Group | Medium | × 1 | 2 | n = 3-8 / group, depending on the outcome evaluated. Sample size is below the recommended minimum (n = 10) for OECD 407. | |
| Domain 5: Outcome Assessment | | | | | | |
| | Metric 16: Outcome Assessment Methodology | High | × 2 | 2 | Methodology of outcome assessments were clearly described and appropriate | |
| | Metric 17: Consistency of Outcome Assessment | High | × 1 | 1 | Consistent assessment across groups. | |
| | Metric 18: Sampling Adequacy | High | × 1 | 1 | Sampling was adequate. Histology was performed on a subset of animals (n=3-4) from each exposure group, including controls | |
| | Metric 19: Blinding of Assessors | Medium | × 1 | 2 | Histopathology evaluations were subjective. Study report does not indicate that the assessor was blinded during assessment or whether outcomes were evaluated independently by a second pathologist. | |
| | Metric 20: Negative Control Response | High | × 1 | 1 | No out of the ordinary control responses were noted. | |
| Domain 6: Confounding / Variable Control | | | | | | |
| | Metric 21: Confounding Variables in Test Design and Procedures | Low | × 2 | 6 | Initial body weights of animals were not reported. It is unclear whether there were differences in feed consumption because a default value (15% w/w) was used rather than the actual dietary intake | |
| | Metric 22: Health Outcomes Unrelated to Exposure | High | × 1 | 1 | No health outcomes unrelated to exposure were reported; animals were observed daily. | |
| Domain 7: Data Presentation and Analysis | | | | | | |

Continued on next page ...

...continued from previous page

Study Citation: Bernhard, A; Berntssen, MH; Lundebye, A-K; Alvheim, AR; Myrnel, LS; Fjære, E; Torstensen, BE; Kristiansen, K; Madsen, L; Brattelid, T; Rasinger, JD (2016). Marine fatty acids aggravate hepatotoxicity of a-HBCD in juvenile female BALB/c mice 97 411-423
 Data Type: 28-day oral exposure in mice via diet
 HERO ID: 3588138

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|--|--------------------------------|----------------------------|------|-------|--|
| | Metric 23: Statistical Methods | High | × 1 | 1 | Statistical analysis methodology were clearly reported and appropriate. |
| | Metric 24: Reporting of Data | High | × 2 | 2 | Reporting of data was appropriate for most outcomes. Confidence level for histopathology results is reduced to Medium because results are only presented qualitatively (representative histology images from each group were shown and text description of the effects). |
| Overall Quality Determination [‡] | | High → Medium [§] | | 1.5 | |
| Extracted | | Yes | | | |

* MWF = Metric Weighting Factor

[†] High = 1; Medium = 2; Low = 3; Unacceptable = 4; N/A has no value.

[‡] The overall rating is calculated as necessary. EPA may not always provide a comment for a metric that has been categorized as High.

$$\text{Overall rating} = \begin{cases} 4 & \text{if any metric is Unacceptable} \\ \left\lfloor \frac{\sum_i (\text{Metric Score}_i \times \text{MWF}_i)}{\sum_j \text{MWF}_j} \right\rfloor_{0.1} & \text{(round to the nearest tenth) otherwise} \end{cases},$$

where High = ≥ 1 to < 1.7 ; Medium = ≥ 1.7 to < 2.3 ; Low = ≥ 2.3 to ≤ 3.0 . If the reviewer determines that the overall rating needs adjustment, the original rating is crossed out and an arrow points to the new rating.

^{††} This metric met the criteria for high confidence as expected for this type of study

[§] Evaluator's explanation for rating change: "I would downgrade this study based on concerns related to the purity of the chemical and reporting of the doses/concentrations."

Table 12: **Animal toxicity evaluation results of American Chemistry Council 2003 for short term sensitization study in mice on ear swelling response**

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|---|---|---------------------|------|-------|--|
| Study Citation: ACC (American Chemistry Council) (2003). Hexabromocyclododecane: Contact sensitization potential via the local lymph node assay (including a primary irritancy screen) using CBA/J mice | | | | | |
| Data Type: Ear swelling response | | | | | |
| HERO ID: 4269880 | | | | | |
| Domain 1: Test Substance | | | | | |
| Metric 1: | Test Substance Identity | High | × 2 | 2 | The test substance was identified definitely and the diastereomers information reported. |
| Metric 2: | Test Substance Source | High | × 1 | 1 | The source of the test substance was reported. |
| Metric 3: | Test Substance Purity | High | × 1 | 1 | The purity of the test substance reported and adequate to identify its toxicological effects. |
| Domain 2: Test Design | | | | | |
| Metric 4: | Negative and Vehicle Controls | High | × 2 | 2 | Study authors reported using a concurrent negative control group. |
| Metric 5: | Positive Controls | Not Rated | NA | NA | Positive control is not necessary for pre-screen irritation test. |
| Metric 6: | Randomized Allocation | High | × 1 | 1 | The authors reported randomization of animals based on pre-exposure body weights using a computer program. |
| Domain 3: Exposure Characterization | | | | | |
| Metric 7: | Preparation and Storage of Test Substance | Low | × 1 | 3 | The study authors did not provide details of preparation and storage of the test compound. |
| Metric 8: | Consistency of Exposure Administration | High | × 1 | 1 | Study authors reported details of exposure administration which is uniform across dose groups. |
| Metric 9: | Reporting of Doses/Concentrations | High | × 2 | 2 | The exposure doses/concentrations or amounts of test substance were reported. |
| Metric 10: | Exposure Frequency and Duration | High | × 1 | 1 | The exposure duration and frequency were reported. |
| Metric 11: | Number of Exposure Groups and Dose Spacing | High | × 1 | 1 | The number of exposure groups and dose/concentration spacing were justified by study authors. |
| Metric 12: | Exposure Route and Method | High | × 1 | 1 | The route and method of exposure were reported and were suited to the test substance. |
| Domain 4: Test Organism | | | | | |
| Metric 13: | Test Animal Characteristics | High | × 2 | 2 | The test animal species, strain and sex were reported. Although starting body weights are not reported, it may not impact the study results. |
| Metric 14: | Adequacy and Consistency of Animal Husbandry Conditions | High | × 1 | 1 | The study authors report following the OECD 429 guidelines. |
| Continued on next page ... | | | | | |

... continued from previous page

| Study Citation: | ACC (American Chemistry Council) (2003). Hexabromocyclododecane: Contact sensitization potential via the local lymph node assay (including a primary irritancy screen) using CBA/J mice | | | | | |
|--|---|---------------------|------|-------|---|--|
| Data Type: | Ear swelling response | | | | | |
| HERO ID: | 4269880 | | | | | |
| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} | |
| | Metric 15: Number per Group | High | × 1 | 1 | Although the authors used only 1 animal/group, this is appropriate for a pre-screening test for irritation | |
| Domain 5: Outcome Assessment | | | | | | |
| | Metric 16: Outcome Assessment Methodology | Unacceptable | × 2 | 8 | Not a robust test for skin irritation; preliminary test to determine doses for LLNA, evaluates ear swelling only. | |
| | Metric 17: Consistency of Outcome Assessment | High | × 1 | 1 | None noted. | |
| | Metric 18: Sampling Adequacy | High | × 1 | 1 | The authors reported using both the ears of the animal per dose, which is adequate for the ear swelling response. | |
| | Metric 19: Blinding of Assessors | Not Rated | NA | NA | Not a necessary specification in OECD 429 guideline | |
| | Metric 20: Negative Control Response | High | × 1 | 1 | Ear swelling was minimal for the vehicle control. | |
| Domain 6: Confounding / Variable Control | | | | | | |
| | Metric 21: Confounding Variables in Test Design and Procedures | High | × 2 | 2 | No confounding variables were apparent. | |
| | Metric 22: Health Outcomes Unrelated to Exposure | Medium | × 1 | 2 | Other outcomes not evaluated during the pre-screen. | |
| Domain 7: Data Presentation and Analysis | | | | | | |
| | Metric 23: Statistical Methods | Not Rated | NA | NA | Limited sample number precluding ability to do statistical analysis. | |
| | Metric 24: Reporting of Data | High | × 2 | 2 | Quantitative data provided. | |
| Overall Quality Determination [‡] | | Unacceptable** | | 1.3 | | |
| Extracted | | No | | | | |

** Consistent with our *Application of Systematic Review in TSCARisk Evaluations* document, if a metric for a data source receives a score of Unacceptable (score = 4), EPA will determine the study to be unacceptable. In this case, one or more of the metrics were rated as unacceptable. As such, the study is considered unacceptable and the score is presented solely to increase transparency.

* MWF = Metric Weighting Factor

† High = 1; Medium = 2; Low = 3; Unacceptable = 4; N/A has no value.

‡ The overall rating is calculated as necessary. EPA may not always provide a comment for a metric that has been categorized as High.

$$\text{Overall rating} = \begin{cases} 4 & \text{if any metric is Unacceptable} \\ \left\lceil \frac{\sum_i (\text{Metric Score}_i \times \text{MWF}_i)}{\sum_j \text{MWF}_j} \right\rceil_{0.1} & \text{(round to the nearest tenth) otherwise} \end{cases}$$

where High = ≥ 1 to < 1.7 ; Medium = ≥ 1.7 to < 2.3 ; Low = ≥ 2.3 to ≤ 3.0 . If the reviewer determines that the overall rating needs adjustment, the original rating is crossed out and an arrow points to the new rating.

†† This metric met the criteria for high confidence as expected for this type of study

Table 13: **Animal toxicity evaluation results of American Chemistry Council 2003 for LLN assay for skin sensitization**

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|---|---|---------------------|------|-------|--|
| Study Citation: ACC (American Chemistry Council) (2003). Hexabromocyclododecane: Contact sensitization potential via the local lymph node assay (including a primary irritancy screen) using CBA/J mice | | | | | |
| Data Type: LLN assay for skin sensitization | | | | | |
| HERO ID: 4269880 | | | | | |
| Domain 1: Test Substance | | | | | |
| Metric 1: | Test Substance Identity | High | × 2 | 2 | The test substance was identified definitely and the diastereomers information reported. |
| Metric 2: | Test Substance Source | High | × 1 | 1 | The source of the test substance was reported. |
| Metric 3: | Test Substance Purity | High | × 1 | 1 | The purity of the test substance reported and adequate to identify its toxicological effects. |
| Domain 2: Test Design | | | | | |
| Metric 4: | Negative and Vehicle Controls | High | × 2 | 2 | Study authors reported using a concurrent negative control group. |
| Metric 5: | Positive Controls | High | × 1 | 1 | Study authors reported using a concurrent positive control group. |
| Metric 6: | Randomized Allocation | High | × 1 | 1 | The authors reported randomization of animals based on pre-exposure body weights using a computer program. |
| Domain 3: Exposure Characterization | | | | | |
| Metric 7: | Preparation and Storage of Test Substance | Low | × 1 | 3 | The study authors did not provide details of preparation and storage of the test compound. Study indicates that the test material was not adequately soluble in the preferred vehicle for LLNA assays. |
| Metric 8: | Consistency of Exposure Administration | High | × 1 | 1 | Study authors reported details of exposure administration which is uniform across dose groups. |
| Metric 9: | Reporting of Doses/Concentrations | High | × 2 | 2 | The exposure doses/concentrations or amounts of test substance were reported. |
| Metric 10: | Exposure Frequency and Duration | High | × 1 | 1 | The exposure duration and frequency were reported. |
| Metric 11: | Number of Exposure Groups and Dose Spacing | High | × 1 | 1 | The number of exposure groups and dose/concentration spacing were justified by study authors. |
| Metric 12: | Exposure Route and Method | High | × 1 | 1 | The route and method of exposure were reported and were suited to the test substance. |
| Domain 4: Test Organism | | | | | |
| Metric 13: | Test Animal Characteristics | High | × 2 | 2 | The test animal species, strain and sex were reported. Although starting body weights are not reported, it may not impact the study results. |
| Metric 14: | Adequacy and Consistency of Animal Husbandry Conditions | High | × 1 | 1 | The study authors report following the OECD 429 guidelines. |
| Continued on next page ... | | | | | |

... continued from previous page

Study Citation: ACC (American Chemistry Council) (2003). Hexabromocyclododecane: Contact sensitization potential via the local lymph node assay (including a primary irritancy screen) using CBA/J mice
 Data Type: LLN assay for skin sensitization
 HERO ID: 4269880

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|--|--|---------------------|------|-------|--|
| | Metric 15: Number per Group | High | × 1 | 1 | The number of animals per study group was reported which is appropriate for the study type and outcome analysis. |
| Domain 5: Outcome Assessment | | | | | |
| | Metric 16: Outcome Assessment Methodology | High | × 2 | 2 | The study authors followed OECD 429 guidelines. |
| | Metric 17: Consistency of Outcome Assessment | High | × 1 | 1 | The study authors did not note any inconsistencies. |
| | Metric 18: Sampling Adequacy | High | × 1 | 1 | Details regarding sampling for the outcome(s) of interest were reported and the study used adequate sampling for the outcome(s) of interest. |
| | Metric 19: Blinding of Assessors | Not Rated | NA | NA | Not specified as a requirement in OECD 429 guideline |
| | Metric 20: Negative Control Response | Medium | × 1 | 2 | The responses from vehicle control group was higher than other historical controls, but did not alter conclusions of the study. |
| Domain 6: Confounding / Variable Control | | | | | |
| | Metric 21: Confounding Variables in Test Design and Procedures | High | × 2 | 2 | No significant confounders were identified. |
| | Metric 22: Health Outcomes Unrelated to Exposure | High | × 1 | 1 | No unrelated health outcomes. |
| Domain 7: Data Presentation and Analysis | | | | | |
| | Metric 23: Statistical Methods | High | × 1 | 1 | Appropriate statistical methods utilized. |
| | Metric 24: Reporting of Data | High | × 2 | 2 | Quantitative data/results provided. |
| Overall Quality Determination [‡] | | High | | 1.1 | |
| Extracted | | Yes | | | |

* MWF = Metric Weighting Factor

[†] High = 1; Medium = 2; Low = 3; Unacceptable = 4; N/A has no value.

[‡] The overall rating is calculated as necessary. EPA may not always provide a comment for a metric that has been categorized as High.

$$\text{Overall rating} = \begin{cases} 4 & \text{if any metric is Unacceptable} \\ \left\lfloor \frac{\sum_i (\text{Metric Score}_i \times \text{MWF}_i)}{\sum_j \text{MWF}_j} \right\rfloor_{0.1} & \text{(round to the nearest tenth) otherwise} \end{cases}$$

where High = ≥ 1 to < 1.7 ; Medium = ≥ 1.7 to < 2.3 ; Low = ≥ 2.3 to ≤ 3.0 . If the reviewer determines that the overall rating needs adjustment, the original rating is crossed out and an arrow points to the new rating.

^{††} This metric met the criteria for high confidence as expected for this type of study

Table 14: **Animal toxicity evaluation results of W. I. L. Research 1997 for 28-day repeated oral study on mortality, nutrition and metabolic/adult exposure body weight, neurological/behavior, hematological and immune, clinical chemistry/biochemical, hepatic, renal, cardiovascular, reproductive, endocrine, gastrointestinal, and respiratory outcomes**

| Study Citation: | WIL Research Laboratories (1997). Twenty-eight day repeated dose oral toxicity study of HBCD in rats, with cover letter dated 3/18/1997 | | | | | |
|-------------------------------------|---|---------------------|------|-------|--|--|
| Data Type: | 28-Day Repeated Oral | | | | | |
| HERO ID: | 787758 | | | | | |
| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} | |
| Domain 1: Test Substance | | | | | | |
| Metric 1: | Test Substance Identity | High | × 2 | 2 | The test substance was identified definitively. | |
| Metric 2: | Test Substance Source | High | × 1 | 1 | The source of the test substance was reported, including manufacturer and lot number. | |
| Metric 3: | Test Substance Purity | Medium | × 1 | 2 | The study authors stated that the purity was "considered to be 100%", but no verification of this purity was reported. | |
| Domain 2: Test Design | | | | | | |
| Metric 4: | Negative and Vehicle Controls | High | × 2 | 2 | The study authors reported using an appropriate concurrent negative control group (administered the vehicle via gavage at the same dose volume). | |
| Metric 5: | Positive Controls | Not Rated | NA | NA | Positive control is not indicated by study type. | |
| Metric 6: | Randomized Allocation | Medium | × 1 | 2 | The study reported methods of allocation of animals to study groups, but there were minor limitations in the allocation method (method of distribution had a non-random component, including assignment to minimize differences in body weight across groups). | |
| Domain 3: Exposure Characterization | | | | | | |
| Metric 7: | Preparation and Storage of Test Substance | High | × 1 | 1 | The test substance preparation and storage conditions were reported and appropriate for the test substance (the test substance was prepared daily and stored at room temperature). Storage of the bulk test substance was also reported (sealed container at room temperature) and the bulk test substance was considered stable under the storage conditions. | |
| Metric 8: | Consistency of Exposure Administration | Medium | × 1 | 2 | Details of the administration were reported but minor limitations in administration of the exposures, including accidental mistakes in dosing, were identified that are unlikely to have a substantial impact on results. On one particular day, animals at higher dose levels were inadvertently dosed with lower doses, and a few lower dose animals were inadvertently dosed with higher doses. Lower doses were corrected so that the underdosed animals received the correct doses. | |

Continued on next page ...

... continued from previous page

Study Citation: WIL Research Laboratories (1997). Twenty-eight day repeated dose oral toxicity study of HBCD in rats, with cover letter dated 3/18/1997
 Data Type: 28-Day Repeated Oral
 HERO ID: 787758

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|------------------------------|--|---------------------|------|-------|---|
| | Metric 9: Reporting of Doses/Concentrations | Medium | × 2 | 4 | Administered doses were reported without ambiguity. Test concentrations were evaluated by gravimetric analysis each day prior to dosing and homogeneity was evaluated on three days during the administration period (d 0, 13, 27); however, the results were not reported. |
| | Metric 10: Exposure Frequency and Duration | High | × 1 | 1 | The exposure frequency and duration of exposure (daily exposure for 28 consecutive days) were reported and appropriate for the study type and outcomes of interest. |
| | Metric 11: Number of Exposure Groups and Dose Spacing | High | × 1 | 1 | The number of exposure groups and dose spacing (125, 350, 1000 mg/kg/day) were considered adequate to address the purpose of the study. Although the basis for selection of the doses was not reported, the range of doses was adequate. |
| | Metric 12: Exposure Route and Method | High | × 1 | 1 | The route and method of exposure (oral, gavage) were reported and were suited to the test substance. |
| Domain 4: Test Organism | | | | | |
| | Metric 13: Test Animal Characteristics | Medium | × 2 | 4 | The test animal source, species, strain, sex, age, and starting body weight (group means) were reported; however, health status was not reported. |
| | Metric 14: Adequacy and Consistency of Animal Husbandry Conditions | High | × 1 | 1 | All husbandry conditions (temperature, humidity, light-dark cycle) were reported and were adequate and the same for control and exposed populations. |
| | Metric 15: Number per Group | Medium | × 1 | 2 | The reported number of animals was lower than the typical number used in studies of the same or similar type for some groups; however, the number was sufficient for statistical analysis. The low- and mid-dose groups had only 6/sex/group, while the control and high-dose groups had 12/sex/group (6/sex/group sacrificed at the end of the 28-day administration period and the remaining 6/sex/group were maintained for an additional 14-day recovery period). |
| Domain 5: Outcome Assessment | | | | | |
| | Metric 16: Outcome Assessment Methodology | High | × 2 | 2 | The outcome assessment methodology addressed or reported the intended outcomes of interest and was sensitive for the outcomes of interest. |
| | Metric 17: Consistency of Outcome Assessment | High | × 1 | 1 | Details of the outcome assessment protocol were reported and outcomes were assessed consistently across study groups. |

Continued on next page ...

...continued from previous page

| Study Citation: | WIL Research Laboratories (1997). Twenty-eight day repeated dose oral toxicity study of HBCD in rats, with cover letter dated 3/18/1997 | | | | | |
|--|---|---------------------|------|-------|--|--|
| Data Type: | 28-Day Repeated Oral | | | | | |
| HERO ID: | 787758 | | | | | |
| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} | |
| | Metric 18: Sampling Adequacy | High | × 1 | 1 | Details regarding the sampling for the outcomes of interest were reported and the study used adequate sampling for the outcomes of interest. | |
| | Metric 19: Blinding of Assessors | High | × 1 | 1 | The study states that investigators were blinded for subjective outcomes in the neurological tests (For FOB parameters "testing was performed by the same technicians without knowledge of the animal group assignment"). No other subjective outcomes were reported in the study. | |
| | Metric 20: Negative Control Response | High | × 1 | 1 | The biological responses of the negative control groups were adequate. | |
| Domain 6: Confounding / Variable Control | | | | | | |
| | Metric 21: Confounding Variables in Test Design and Procedures | High | × 2 | 2 | There were no reported differences among the study groups related to confounding variables in test design or procedures and no significant differences in initial body weights. | |
| | Metric 22: Health Outcomes Unrelated to Exposure | Medium | × 1 | 2 | Data on attrition and health outcomes unrelated to exposure were reported. The authors report that "animal no. 50292 was replaced by animal no.50289 on study day -1 as animal no. 50292 died shortly after being handled for pretest clinical observations and weighing." The authors also stated that "Several animals weighed less than the protocol-specified minimum weight (175 g for males, 125 g for females) at the initiation of dosing. This deviation had no impact on the outcome of the study as all animals were within the protocol-specified age range (4-8 weeks) at the initiation of dosing. " | |
| Domain 7: Data Presentation and Analysis | | | | | | |
| | Metric 23: Statistical Methods | High | × 1 | 1 | Statistical methods were clearly described and appropriate for the datasets. | |
| | Metric 24: Reporting of Data | High | × 2 | 2 | Data for exposure-related findings were presented for all outcomes by exposure group and sex with quantal or continuous presentation and negative findings reported qualitatively or quantitatively. | |
| Overall Quality Determination [‡] | | High | | 1.3 | | |
| Extracted | | Yes | | | | |
| Continued on next page ... | | | | | | |

...continued from previous page

Study Citation: WIL Research Laboratories (1997). Twenty-eight day repeated dose oral toxicity study of HBCD in rats, with cover letter dated 3/18/1997
 Data Type: 28-Day Repeated Oral
 HERO ID: 787758

| Domain | Metric | Rating [†] | MWF [*] | Score | Comments ^{††} |
|--------|--------|---------------------|------------------|-------|------------------------|
|--------|--------|---------------------|------------------|-------|------------------------|

* MWF = Metric Weighting Factor

† High = 1; Medium = 2; Low = 3; Unacceptable = 4; N/A has no value.

‡ The overall rating is calculated as necessary. EPA may not always provide a comment for a metric that has been categorized as High.

$$\text{Overall rating} = \begin{cases} 4 & \text{if any metric is Unacceptable} \\ \left[\sum_i (\text{Metric Score}_i \times \text{MWF}_i) / \sum_j \text{MWF}_j \right]_{0.1} & \text{(round to the nearest tenth) otherwise} \end{cases}$$

where High $\Rightarrow \geq 1$ to < 1.7 ; Medium $\Rightarrow \geq 1.7$ to < 2.3 ; Low $\Rightarrow \geq 2.3$ to ≤ 3.0 . If the reviewer determines that the overall rating needs adjustment, the original rating is crossed out and an arrow points to the new rating.

†† This metric met the criteria for high confidence as expected for this type of study

3 Other

Table 15: Animal toxicity evaluation results of Miller et al 2016 for 7 day gavage study on proteomic endpoints

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|---|--|---------------------|------|-------|---|
| Study Citation: Miller, I; Renault, J; Cambier, S; Murk, AJ; Gutleb, AC; Serchi, T (2016). Dataset of liver proteins of eu- and hypothyroid rats affected in abundance by any of three factors: In vivo exposure to hexabromocyclododecane (HBCD), thyroid status, gender differences 8 1344-1347 | | | | | |
| Data Type: 7 day gavage study of proteomic endpoints | | | | | |
| HERO ID: 3546017 | | | | | |
| <hr/> | | | | | |
| Domain 1: Test Substance | | | | | |
| Metric 1: | Test Substance Identity | Medium | × 2 | 4 | Test substance was identified. The authors have provided two of their previous studies (Miller et al. 2016a,b) for experimental details. |
| Metric 2: | Test Substance Source | Low | × 1 | 3 | Test substance source not reported. |
| Metric 3: | Test Substance Purity | Low | × 1 | 3 | Test substance purity not reported. |
| <hr/> | | | | | |
| Domain 2: Test Design | | | | | |
| Metric 4: | Negative and Vehicle Controls | High | × 2 | 2 | The authors have provided two of their previous studies (Miller et al. 2016a,b) for experimental details. So it is assumed that they used concurrent negative controls. |
| Metric 5: | Positive Controls | Not Rated | NA | NA | Not typical for this experiment type. |
| Metric 6: | Randomized Allocation | Low | × 1 | 3 | The authors have provided two of their previous studies (Miller et al. 2016a,b) for experimental details. But animal allocation was not reported. |
| <hr/> | | | | | |
| Domain 3: Exposure Characterization | | | | | |
| Metric 7: | Preparation and Storage of Test Substance | Low | × 1 | 3 | The authors have provided two of their previous studies (Miller et al. 2016a,b) for experimental details. But preparation and storage of test substance not reported. |
| Metric 8: | Consistency of Exposure Administration | Low | × 1 | 3 | The authors have provided two of their previous studies (Miller et al. 2016a,b) for experimental details. However, these studies and the present one did not report the details of exposure administration. |
| Metric 9: | Reporting of Doses/Concentrations | Medium | × 2 | 4 | The study authors reported gavage doses but gavage volumes were not reported. |
| Metric 10: | Exposure Frequency and Duration | High | × 1 | 1 | The exposure frequency and duration of exposure were reported and appropriate for this study type and/or outcome(s) of interest. |
| Metric 11: | Number of Exposure Groups and Dose Spacing | High | × 1 | 1 | The number of exposure groups and dose/concentration were reported and spacing were justified. |
| <hr/> | | | | | |
| Continued on next page ... | | | | | |
| <hr/> | | | | | |

... continued from previous page

| Study Citation: | Miller, I; Renaut, J; Cambier, S; Murk, AJ; Gutleb, AC; Serchi, T (2016). Dataset of liver proteins of eu- and hypothyroid rats affected in abundance by any of three factors: In vivo exposure to hexabromocyclododecane (HBCD), thyroid status, gender differences 8 1344-1347 | | | | | |
|--|--|---------------------|------|-------|--|--|
| Data Type: | 7 day gavage study of proteomic endpoints | | | | | |
| HERO ID: | 3546017 | | | | | |
| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} | |
| | Metric 12: Exposure Route and Method | High | × 1 | 1 | The route and method of exposure were reported and were suited to the test substance. | |
| Domain 4: Test Organism | | | | | | |
| | Metric 13: Test Animal Characteristics | High | × 2 | 2 | Test species, strain, and sex were reported. The authors have provided two of their previous studies (Miller et al. 2016a,b) for experimental details. | |
| | Metric 14: Adequacy and Consistency of Animal Husbandry Conditions | High | × 1 | 1 | The authors have provided two of their previous studies (Miller et al. 2016) for experimental details which included animal husbandry conditions. | |
| | Metric 15: Number per Group | Medium | × 1 | 2 | The authors have provided two of their previous studies (Miller et al. 2016a,b) for experimental details which included animal husbandry conditions. It is assume that they used 6 rats per group which is not sufficient. | |
| Domain 5: Outcome Assessment | | | | | | |
| | Metric 16: Outcome Assessment Methodology | High | × 2 | 2 | The study authors reported outcome assessment methodology and was sensitive for the outcome of interest. | |
| | Metric 17: Consistency of Outcome Assessment | Low | × 1 | 3 | There is no information available in the publication to determine whether there were inconsistencies in outcome assessment. | |
| | Metric 18: Sampling Adequacy | Low | × 1 | 3 | The authors have provided two of their previous studies (Miller et al. 2016a,b) for experimental details. However, it is not clear how many animals exposed and/or samples analyzed. | |
| | Metric 19: Blinding of Assessors | Not Rated | NA | NA | No subjective outcomes | |
| | Metric 20: Negative Control Response | Low | × 1 | 3 | It is not clear from this study how the control responses differed from the test responses. | |
| Domain 6: Confounding / Variable Control | | | | | | |
| | Metric 21: Confounding Variables in Test Design and Procedures | Low | × 2 | 6 | It is not clear from this study whether or not there were any confounding variables. | |
| | Metric 22: Health Outcomes Unrelated to Exposure | Low | × 1 | 3 | The study authors haven't provided a discussion on the health outcomes unrelated to exposure. | |
| Domain 7: Data Presentation and Analysis | | | | | | |
| Continued on next page ... | | | | | | |

... continued from previous page

Study Citation: Miller, I; Renaut, J; Cambier, S; Murk, AJ; Gutleb, AC; Serchi, T (2016). Dataset of liver proteins of eu- and hypothyroid rats affected in abundance by any of three factors: In vivo exposure to hexabromocyclododecane (HBCD), thyroid status, gender differences 8 1344-1347
 Data Type: 7 day gavage study of proteomic endpoints
 HERO ID: 3546017

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|--|--------------------------------|--------------------------------------|------|-------|---|
| | Metric 23: Statistical Methods | Low | × 1 | 3 | Study authors provided data analysis in supplementary files. Statistical methods were described in their previous paper (Miller et al. 2016a,b). However, they haven't provided the conclusions of their analysis in the present study. |
| | Metric 24: Reporting of Data | High | × 2 | 2 | The study authors reported data in supplementary material. |
| Overall Quality Determination [‡] | | Medium → Low [§] | | 2.0 | |
| Extracted | | No | | | |

* MWF = Metric Weighting Factor

[†] High = 1; Medium = 2; Low = 3; Unacceptable = 4; N/A has no value.

[‡] The overall rating is calculated as necessary. EPA may not always provide a comment for a metric that has been categorized as High.

$$\text{Overall rating} = \begin{cases} 4 & \text{if any metric is Unacceptable} \\ \left\lfloor \frac{\sum_i (\text{Metric Score}_i \times \text{MWF}_i)}{\sum_j \text{MWF}_j} \right\rfloor_{0.1} & \text{(round to the nearest tenth) otherwise} \end{cases}$$

where High = ≥ 1 to < 1.7 ; Medium = ≥ 1.7 to < 2.3 ; Low = ≥ 2.3 to ≤ 3.0 . If the reviewer determines that the overall rating needs adjustment, the original rating is crossed out and an arrow points to the new rating.

^{††} This metric met the criteria for high confidence as expected for this type of study

[§] Evaluator's explanation for rating change: "The data is less amenable for further analysis."

4 Subchronic (30-90 days)

Table 16: Animal toxicity evaluation results of W. I. L. Research 2001 for 90-day gavage study on reproductive, hematological and immune, neurological/behavior, renal, hepatic, ocular and sensory, cardiovascular, clinical chemistry/biochemical, endocrine, gastrointestinal, body weight, and respiratory outcomes

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|---|---|---------------------|------|-------|--|
| Study Citation: WIL Research Laboratories (2001). 90-Day oral (gavage) toxicity study of HBCD in rats | | | | | |
| Data Type: 90-day gavage study | | | | | |
| HERO ID: 787787 | | | | | |
| Domain 1: Test Substance | | | | | |
| Metric 1: | Test Substance Identity | High | × 2 | 2 | Identified by name. |
| Metric 2: | Test Substance Source | High | × 1 | 1 | Manufacturer, lot no. and composite sample nos. |
| Metric 3: | Test Substance Purity | High | × 1 | 1 | Composite made from commercial HBCD products. A mix of HBCD, Alpha; HBCD, Beta; HBCD, Gamma; CAS number 3194-55-6. The standards had reported purities of 99.4%,100% and 98.7%. respectively, |
| Domain 2: Test Design | | | | | |
| Metric 4: | Negative and Vehicle Controls | High | × 2 | 2 | Sham gavage negative control with corn oil vehicle was used. |
| Metric 5: | Positive Controls | Not Rated | NA | NA | Positive controls are not used for 90-day studies. |
| Metric 6: | Randomized Allocation | High | × 1 | 1 | Computerized randomization. |
| Domain 3: Exposure Characterization | | | | | |
| Metric 7: | Preparation and Storage of Test Substance | High | × 1 | 1 | Stirred until uniform and continuously throughout used. Dosing formulations were prepared weekly. |
| Metric 8: | Consistency of Exposure Administration | High | × 1 | 1 | Dosed daily for 90 days, with 28 day recovery period |
| Metric 9: | Reporting of Doses/Concentrations | High | × 2 | 2 | Doses reported as mg/kg/day, based on most recent bw measurement, |
| Metric 10: | Exposure Frequency and Duration | High | × 1 | 1 | 90 consecutive days. |
| Metric 11: | Number of Exposure Groups and Dose Spacing | High | × 1 | 1 | 3 treatment groups plus control; not justified by authors, but did produce a range of response |
| Metric 12: | Exposure Route and Method | High | × 1 | 1 | Followed OECD Guidelines OECD Guideline 408 and OPPTS 870.3 100 - gavage |
| Domain 4: Test Organism | | | | | |
| Metric 13: | Test Animal Characteristics | High | × 2 | 2 | Species, strain, sex, age, and starting body weight were reported (commercial source). |
| Metric 14: | Adequacy and Consistency of Animal Husbandry Conditions | High | × 1 | 1 | Husbandry conditions were reported and appropriate. |
| Continued on next page ... | | | | | |

...continued from previous page

| Study Citation: | WIL Research Laboratories (2001). 90-Day oral (gavage) toxicity study of HBCD in rats | | | | | |
|--|---|---------------------|------|-------|--|--|
| Data Type: | 90-day gavage study | | | | | |
| HERO ID: | 787787 | | | | | |
| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} | |
| | Metric 15: Number per Group | Medium | × 1 | 2 | 15/sex/group, 1- animals/sex/group used for most outcomes at 13 weeks. FOB was only performed on 5 animals/group. 5 animals/sex/group for 3 weeks and 17 week (recovery) groups for all outcomes and for supplemental analyses (lipid staining). | |
| Domain 5: Outcome Assessment | | | | | | |
| | Metric 16: Outcome Assessment Methodology | High | × 2 | 2 | Thorough outcome assessments. | |
| | Metric 17: Consistency of Outcome Assessment | High | × 1 | 1 | | |
| | Metric 18: Sampling Adequacy | High | × 1 | 1 | | |
| | Metric 19: Blinding of Assessors | High | × 1 | 1 | FOB testing was performed without knowledge of the animal groups assignment. Other outcomes were objective. CK: Functional Observational Battery (FOB) evaluations | |
| | Metric 20: Negative Control Response | High | × 1 | 1 | Low incidence of histopath. lesions. | |
| Domain 6: Confounding / Variable Control | | | | | | |
| | Metric 21: Confounding Variables in Test Design and Procedures | High | × 2 | 2 | | |
| | Metric 22: Health Outcomes Unrelated to Exposure | High | × 1 | 1 | | |
| Domain 7: Data Presentation and Analysis | | | | | | |
| | Metric 23: Statistical Methods | High | × 1 | 1 | CK: Well described | |
| | Metric 24: Reporting of Data | High | × 2 | 2 | Summary and individual animals tables. | |
| Overall Quality Determination [‡] | | High | | 1.0 | | |
| Extracted | | Yes | | | | |

* MWF = Metric Weighting Factor

[†] High = 1; Medium = 2; Low = 3; Unacceptable = 4; N/A has no value.

[‡] The overall rating is calculated as necessary. EPA may not always provide a comment for a metric that has been categorized as High.

$$\text{Overall rating} = \begin{cases} 4 & \text{if any metric is Unacceptable} \\ \left\lceil \left[\frac{\sum_i (\text{Metric Score}_i \times \text{MWF}_i)}{\sum_j \text{MWF}_j} \right]_{0.1} \right\rceil & \text{(round to the nearest tenth) otherwise} \end{cases}$$

where High ≥ 1 to < 1.7 ; Medium ≥ 1.7 to < 2.3 ; Low ≥ 2.3 to ≤ 3.0 . If the reviewer determines that the overall rating needs adjustment, the original rating is crossed out and an arrow points to the new rating.

^{††} This metric met the criteria for high confidence as expected for this type of study

Table 17: **Animal toxicity evaluation results of W. I. L. Research 2001 for 90-day gavage study on thyroid outcomes**

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|---|---|---------------------|------|-------|--|
| Study Citation: WIL Research Laboratories (2001). 90-Day oral (gavage) toxicity study of HBCD in rats | | | | | |
| Data Type: 90-day gavage study | | | | | |
| HERO ID: 787787 | | | | | |
| Domain 1: Test Substance | | | | | |
| Metric 1: | Test Substance Identity | High | × 2 | 2 | Identified by name. |
| Metric 2: | Test Substance Source | High | × 1 | 1 | Manufacturer, lot no. and composite sample nos. |
| Metric 3: | Test Substance Purity | High | × 1 | 1 | Composite made from commercial HBCD products. A mix of HBCD, Alpha; HBCD, Beta; HBCD, Gamma; CAS number 3194-55-6. The standards had reported purities of 99.4%,100% and 98.7%. respectively, |
| Domain 2: Test Design | | | | | |
| Metric 4: | Negative and Vehicle Controls | High | × 2 | 2 | Sham gavage negative control with corn oil vehicle was used. |
| Metric 5: | Positive Controls | Not Rated | NA | NA | Positive controls are not used for 90-day studies. |
| Metric 6: | Randomized Allocation | High | × 1 | 1 | Computerized randomization. |
| Domain 3: Exposure Characterization | | | | | |
| Metric 7: | Preparation and Storage of Test Substance | High | × 1 | 1 | Stirred until uniform and continuously throughout used. Dosing formulations were prepared weekly. |
| Metric 8: | Consistency of Exposure Administration | High | × 1 | 1 | Dosed daily for 90 days, with 28 day recovery period |
| Metric 9: | Reporting of Doses/Concentrations | High | × 2 | 2 | Doses reported as mg/kg/day, based on most recent bw measurement, |
| Metric 10: | Exposure Frequency and Duration | High | × 1 | 1 | 90 consecutive days. |
| Metric 11: | Number of Exposure Groups and Dose Spacing | High | × 1 | 1 | 3 treatment groups plus control; not justified by authors, but did produce a range of response (i.e., thyroid). |
| Metric 12: | Exposure Route and Method | High | × 1 | 1 | Followed OECD Guidelines OECD Guideline 408 and OPPTS 870.3 100 - gavage |
| Domain 4: Test Organism | | | | | |
| Metric 13: | Test Animal Characteristics | High | × 2 | 2 | Species, strain, sex, age, and starting body weight were reported (commercial source). |
| Metric 14: | Adequacy and Consistency of Animal Husbandry Conditions | High | × 1 | 1 | Husbandry conditions were reported and appropriate. |
| Continued on next page ... | | | | | |

...continued from previous page

| Study Citation: | WIL Research Laboratories (2001). 90-Day oral (gavage) toxicity study of HBCD in rats | | | | | |
|--|---|-------------------------|------|-------|---|--|
| Data Type: | 90-day gavage study | | | | | |
| HERO ID: | 787787 | | | | | |
| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} | |
| | Metric 15: Number per Group | Low | × 1 | 3 | Only 10/sex/group at each timepoint for organ weights and histopathology. Only 5 animals/sex/group or less (as low as 1) for all TSH controls and week 3/ week 17 measurements (10 for week 13 treatment groups). For T3,T4, 10/sex/group for all week 13 groups (control and treatment) and 5/group for week 3/ week 17. | |
| Domain 5: Outcome Assessment | | | | | | |
| | Metric 16: Outcome Assessment Methodology | High | × 2 | 2 | Thorough outcome assessments. | |
| | Metric 17: Consistency of Outcome Assessment | High | × 1 | 1 | | |
| | Metric 18: Sampling Adequacy | High | × 1 | 1 | | |
| | Metric 19: Blinding of Assessors | Not Rated | NA | NA | Objective measurements | |
| | Metric 20: Negative Control Response | Low | × 1 | 3 | TSH levels in controls were unrealistically low (10-25x below other studies) for the 13-week group in both males and females, with several individual rats below the detection limit. Negative control data was adequate for thyroid weight and pathology. | |
| Domain 6: Confounding / Variable Control | | | | | | |
| | Metric 21: Confounding Variables in Test Design and Procedures | High | × 2 | 2 | | |
| | Metric 22: Health Outcomes Unrelated to Exposure | High | × 1 | 1 | | |
| Domain 7: Data Presentation and Analysis | | | | | | |
| | Metric 23: Statistical Methods | High | × 1 | 1 | | |
| | Metric 24: Reporting of Data | Low | × 2 | 6 | Summary and individual animal tables are included, however results for thyroid weight differ between summary tables and the text tables in the results section. The text tables show statistically significant increases in females while the summary tables do not. | |
| Overall Quality Determination [‡] | | High → Low [§] | | 4.3 | | |
| Extracted | | Yes | | | | |

Continued on next page ...

...continued from previous page

Study Citation: WIL Research Laboratories (2001). 90-Day oral (gavage) toxicity study of HBCD in rats
 Data Type: 90-day gavage study
 HERO ID: 787787

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|--------|--------|---------------------|------|-------|------------------------|
|--------|--------|---------------------|------|-------|------------------------|

* MWF = Metric Weighting Factor

[†] High = 1; Medium = 2; Low = 3; Unacceptable = 4; N/A has no value.

[‡] The overall rating is calculated as necessary. EPA may not always provide a comment for a metric that has been categorized as High.

$$\text{Overall rating} = \begin{cases} 4 & \text{if any metric is Unacceptable} \\ \left\lfloor \frac{\sum_i (\text{Metric Score}_i \times \text{MWF}_i)}{\sum_j \text{MWF}_j} \right\rfloor_{0.1} & \text{(round to the nearest tenth) otherwise} \end{cases}$$

where High $\Rightarrow 1$ to < 1.7 ; Medium $\Rightarrow 1.7$ to < 2.3 ; Low $\Rightarrow 2.3$ to ≤ 3.0 . If the reviewer determines that the overall rating needs adjustment, the original rating is crossed out and an arrow points to the new rating.

^{††} This metric met the criteria for high confidence as expected for this type of study

[§] Evaluator's explanation for rating change: "While the study is of good quality for other outcomes, the study has several important flaws for interpreting effects on thyroid measurement including: unrealistically low control TSH measurements that were occasionally below the limit of detection, small sample size for thyroid hormone controls, and inconsistent data reporting among tables. The study can contribute to a weight of evidence but is unreliable for use in thyroid dose-response analysis."

Table 18: **Animal toxicity evaluation results of BASF et al 1990 for 28-day and 90-day dietary studies study on reproductive, hematological and immune, neurological, renal, hepatic, endocrine, gastrointestinal, respiratory, and thyroid outcomes**

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|--|---|---------------------|------|-------|--|
| Study Citation: BASF, (1990). Hexabromocyclododecane 28-day feeding trials with rats with test data and cover letter 900000274 #86-900000274 | | | | | |
| Data Type: 28-day and 90-day dietary studies | | | | | |
| HERO ID: 787638 | | | | | |
| Domain 1: Test Substance | | | | | |
| Metric 1: | Test Substance Identity | High | × 2 | 2 | Identified by trade name and isomer designation. |
| Metric 2: | Test Substance Source | Medium | × 1 | 2 | Source and lot no. were not reported. Manufacturer was assumed to be BASF. |
| Metric 3: | Test Substance Purity | Low | × 1 | 3 | Purity was not reported. |
| Domain 2: Test Design | | | | | |
| Metric 4: | Negative and Vehicle Controls | High | × 2 | 2 | A negative dietary control group was used. |
| Metric 5: | Positive Controls | Not Rated | NA | NA | Positive controls are not necessary for a 28-day study. |
| Metric 6: | Randomized Allocation | Low | × 1 | 3 | The study did not report how animals were allocated to study groups. |
| Domain 3: Exposure Characterization | | | | | |
| Metric 7: | Preparation and Storage of Test Substance | High | × 1 | 1 | Analysis showed that concentrations remained stable over the week. |
| Metric 8: | Consistency of Exposure Administration | High | × 1 | 1 | Details of exposure administration were reported. |
| Metric 9: | Reporting of Doses/Concentrations | Medium | × 2 | 4 | Dietary concentrations were not measured analytically, but bw and food consumption were reported for each group. |
| Metric 10: | Exposure Frequency and Duration | High | × 1 | 1 | Diet was administered over 13 weeks (daily was assumed). |
| Metric 11: | Number of Exposure Groups and Dose Spacing | High | × 1 | 1 | 4 treatment groups plus control; dose response relationships were apparent. |
| Metric 12: | Exposure Route and Method | High | × 1 | 1 | The route and method of exposure were reported and were suited to the test substance. |
| Domain 4: Test Organism | | | | | |
| Metric 13: | Test Animal Characteristics | High | × 2 | 2 | Species, strain and starting bw was reported. Not a commercial source, but a laboratory maintained colony. |
| Metric 14: | Adequacy and Consistency of Animal Husbandry Conditions | Low | × 1 | 3 | Husbandry conditions were not reported. |
| Metric 15: | Number per Group | High | × 1 | 1 | 10/sex/group |
| Domain 5: Outcome Assessment | | | | | |
| Metric 16: | Outcome Assessment Methodology | High | × 2 | 2 | The outcome assessment methodology was reported. |

Continued on next page ...

... continued from previous page

| Study Citation: | BASF, (1990). Hexabromocyclododecane 28-day feeding trials with rats with test data and cover letter 900000274 #86-900000274 | | | | | |
|--|--|---------------------|------|-------|---|--|
| Data Type: | 28-day and 90-day dietary studies | | | | | |
| HERO ID: | 787638 | | | | | |
| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} | |
| | Metric 17: Consistency of Outcome Assessment | High | × 1 | 1 | | |
| | Metric 18: Sampling Adequacy | Medium | × 1 | 2 | Data tables are difficult to read, but sampling appears adequate. | |
| | Metric 19: Blinding of Assessors | Medium | × 1 | 2 | Blinding was not reported; however, outcomes were objective. | |
| | Metric 20: Negative Control Response | Low | × 1 | 3 | Data tables are difficult to read; however, several lesions are noted for controls. | |
| Domain 6: Confounding / Variable Control | | | | | | |
| | Metric 21: Confounding Variables in Test Design and Procedures | Medium | × 2 | 4 | The study reported (in the text) minor differences among the study groups (<20% difference from control) with respect to initial body weight, drinking water and/or food consumption. But the information in the tables is difficult to read. | |
| | Metric 22: Health Outcomes Unrelated to Exposure | Unacceptable | × 1 | 4 | A large proportion of rats showed signs of respiratory inflammation (47% of controls, 26% of all other rats). | |
| Domain 7: Data Presentation and Analysis | | | | | | |
| | Metric 23: Statistical Methods | Low | × 1 | 3 | Statistical analysis was not described clearly, and this deficiency is likely to have a substantial impact on results. | |
| | Metric 24: Reporting of Data | Low | × 2 | 6 | Data tables are provided for all outcomes by exposure group and sex; however, data are in German and mostly illegible. | |
| Overall Quality Determination [‡] | | Unacceptable** | | 1.8 | | |
| Extracted | | No | | | | |

** Consistent with our *Application of Systematic Review in TSCARisk Evaluations* document, if a metric for a data source receives a score of Unacceptable (score = 4), EPA will determine the study to be unacceptable. In this case, one or more of the metrics were rated as unacceptable. As such, the study is considered unacceptable and the score is presented solely to increase transparency.

* MWF = Metric Weighting Factor

† High = 1; Medium = 2; Low = 3; Unacceptable = 4; N/A has no value.

‡ The overall rating is calculated as necessary. EPA may not always provide a comment for a metric that has been categorized as High.

$$\text{Overall rating} = \begin{cases} 4 & \text{if any metric is Unacceptable} \\ \left\lceil \frac{\sum_i (\text{Metric Score}_i \times \text{MWF}_i)}{\sum_j \text{MWF}_j} \right\rceil_{0.1} & \text{(round to the nearest tenth) otherwise} \end{cases}$$

where High \Rightarrow 1 to < 1.7; Medium \Rightarrow 1.7 to < 2.3; Low \Rightarrow 2.3 to \leq 3.0. If the reviewer determines that the overall rating needs adjustment, the original rating is crossed out and an arrow points to the new rating.

†† This metric met the criteria for high confidence as expected for this type of study

Table 19: Animal toxicity evaluation results of Acc et al 2002 for 90-day gavage-systemic with sperm evaluations and neurobehavior, same as (2990994) study on reproductive, hematological, neurological/behavior, renal, hepatic, clinical chemistry/biochemical , body weight, ocular and sensory, and thyroid outcomes

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|--|--|---------------------|------|-------|--|
| Study Citation: ACC (American Chemistry Council) (2002). A 90-day oral (gavage) toxicity study of HBCD in rats | | | | | |
| Data Type: 90-day gavage-systemic with sperm evaluations and neurobehavior, same as (2990994) | | | | | |
| HERO ID: 4269953 | | | | | |
| Domain 1: Test Substance | | | | | |
| Metric 1: | Test Substance Identity | High | × 2 | 2 | Identified by name, CARSN, structure, molecular formula, and isomer distribution (pp. 1235-1236) |
| Metric 2: | Test Substance Source | High | × 1 | 1 | Source and analytical verification were included in the study report. |
| Metric 3: | Test Substance Purity | Medium | × 1 | 2 | The test substance composition was such that any observed effects were highly likely to be due to the test substance. Although the test chemical was analyzed to determine the isomer composition analysis does not appear to address the purity of the chemical. |
| Domain 2: Test Design | | | | | |
| Metric 4: | Negative and Vehicle Controls | High | × 2 | 2 | Concurrent vehicle control groups were included in the main and satellite studies. |
| Metric 5: | Positive Controls | Not Rated | NA | NA | This metric not applicable. |
| Metric 6: | Randomized Allocation | Medium | × 1 | 2 | Animals were allocated by a computerized randomization procedure based on body weight stratification in a block design. |
| Domain 3: Exposure Characterization | | | | | |
| Metric 7: | Preparation and Storage of Test Substance | High | × 1 | 1 | Preparation and storage conditions were reported and appropriate based on stability and homogeneity testing (pp. 1242-1268). |
| Metric 8: | Consistency of Exposure Administration | Medium | × 1 | 2 | Details were reported and administered consistently across groups. Dosing volume was appropriate. A dosing error was reported (pp. 65) but this is unlikely to have substantial impact on results. |
| Metric 9: | Reporting of Doses/Concentrations | High | × 2 | 2 | Doses reported without ambiguity. |
| Metric 10: | Exposure Frequency and Duration | High | × 1 | 1 | Duration of study and frequency of dosing were reported and appropriate for this study |
| Metric 11: | Number of Exposure Groups and Dose Spacing | Medium | × 1 | 2 | The selected doses were not justified by study authors, but the doses were adequate to show results relevant to the outcomes of interest. |
| Metric 12: | Exposure Route and Method | High | × 1 | 1 | Exposure route and method were suitable. |

Continued on next page ...

...continued from previous page

Study Citation: ACC (American Chemistry Council) (2002). A 90-day oral (gavage) toxicity study of HBCD in rats
 Data Type: 90-day gavage-systemic with sperm evaluations and neurobehavior, same as (2990994)
 HERO ID: 4269953

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|------------------------------|---|---------------------|------|-------|--|
| Domain 4: Test Organism | | | | | |
| Metric 13: | Test Animal Characteristics | High | × 2 | 2 | The test animal species, strain, sex, health status, age, and starting body weight were reported. Animals obtained from commercial supplier (Charles River). |
| Metric 14: | Adequacy and Consistency of Animal Husbandry Conditions | High | × 1 | 1 | Temperature, relative humidity, light/day cycle were reported. |
| Metric 15: | Number per Group | High | × 1 | 1 | In general, the number of animals assigned per group was appropriate for the study type and outcome analysis. Group sizes conformed to OECD 408. |
| Domain 5: Outcome Assessment | | | | | |
| Metric 16: | Outcome Assessment Methodology | High | × 2 | 2 | In general, outcome assessment methodology was described in detail and sensitive for outcomes of interest. Serious concerns were identified for serum hormone data. Specifically, the confidence rating for TSH data is low because of a high incidence of samples in the control group below the limit of detection, indicating insensitivity of the method. In one instance data were reported for a single control animal (278-281; 916-939) |
| Metric 17: | Consistency of Outcome Assessment | High | × 1 | 1 | Details of the protocols used for outcome assessment were reported and outcomes were assessed consistently across study groups. |
| Metric 18: | Sampling Adequacy | High | × 1 | 1 | Sampling details were well described and adequate. |
| Metric 19: | Blinding of Assessors | High | × 1 | 1 | Two subjective outcomes were evaluated: functional observational battery and histopathology. Functional Observational Battery : High - the study report indicates that assessors were blinded to treatment group during observations. Histopathology: Medium - Blinding was not reported in the study and no indication that tissues were subjected to a secondary independent evaluation. |

Continued on next page ...

...continued from previous page

Study Citation: ACC (American Chemistry Council) (2002). A 90-day oral (gavage) toxicity study of HBCD in rats
 Data Type: 90-day gavage-systemic with sperm evaluations and neurobehavior, same as (2990994)
 HERO ID: 4269953

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|--|--|---------------------|------|-------|---|
| | Metric 20: Negative Control Response | High | × 1 | 1 | In general, biological response of negative controls was adequate. Serious concerns were identified for the serum hormone data. Specifically, the confidence rating for TSH data is low because of a high variability in the biological responses between control replicates such that, in some cases, the SD > mean and there were as much as two orders of magnitude difference across individual controls (pp. 278-281; 916-939). |
| Domain 6: Confounding / Variable Control | | | | | |
| | Metric 21: Confounding Variables in Test Design and Procedures | High | × 2 | 2 | No reported differences among the groups were observed. |
| | Metric 22: Health Outcomes Unrelated to Exposure | High | × 1 | 1 | There were no health outcomes unrelated to exposure that would influence outcome assessment. |
| Domain 7: Data Presentation and Analysis | | | | | |
| | Metric 23: Statistical Methods | High | × 1 | 1 | Statistical methods were clearly described and appropriate. |
| | Metric 24: Reporting of Data | High | × 2 | 2 | Data were reported in tables and in the text for all outcomes. |
| Overall Quality Determination [‡] | | High | | 1.1 | |
| Extracted | | Yes | | | |

* MWF = Metric Weighting Factor

† High = 1; Medium = 2; Low = 3; Unacceptable = 4; N/A has no value.

‡ The overall rating is calculated as necessary. EPA may not always provide a comment for a metric that has been categorized as High.

$$\text{Overall rating} = \begin{cases} 4 & \text{if any metric is Unacceptable} \\ \left\lceil \frac{\sum_i (\text{Metric Score}_i \times \text{MWF}_i)}{\sum_j \text{MWF}_j} \right\rceil_{0.1} & \text{(round to the nearest tenth) otherwise} \end{cases}$$

where High = ≥ 1 to < 1.7 ; Medium = ≥ 1.7 to < 2.3 ; Low = ≥ 2.3 to ≤ 3.0 . If the reviewer determines that the overall rating needs adjustment, the original rating is crossed out and an arrow points to the new rating.

†† This metric met the criteria for high confidence as expected for this type of study

5 Chronic (>90 days)

Table 20: Animal toxicity evaluation results of Yanagisawa et al 2014 for 14-week study (animals dosed by gavage 1x per week) study on hepatic, body weight, and nutrition and metabolic/adult exposure body weight outcomes

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|--|--|---------------------|------|-------|--|
| Study Citation: Yanagisawa, R; Koike, E; Win-Shwe, TT; Yamamoto, M; Takano, H (2014). Impaired lipid and glucose homeostasis in hexabromocyclododecane-exposed mice fed a high-fat diet Environmental Health Perspectives, 122(3), 277-283 | | | | | |
| Data Type: 14-week study (animals dosed by gavage 1x per week) | | | | | |
| HERO ID: 2343717 | | | | | |
| Domain 1: Test Substance | | | | | |
| Metric 1: | Test Substance Identity | Medium | × 2 | 4 | Test substance described as HBCD, study did not indicate whether the test substance was composed of different isomers (as other studies have). |
| Metric 2: | Test Substance Source | High | × 1 | 1 | Sigma Aldrich - no catalog # |
| Metric 3: | Test Substance Purity | Medium | × 1 | 2 | Purity was not reported, however, products purchased from Sigma for experimental use are generally >95% pure. |
| Domain 2: Test Design | | | | | |
| Metric 4: | Negative and Vehicle Controls | High | × 2 | 2 | an appropriate vehicle control was used |
| Metric 5: | Positive Controls | Not Rated | NA | NA | Positive control was not necessary |
| Metric 6: | Randomized Allocation | High | × 1 | 1 | Mice were randomly allocated. There were no differences in initial BWs |
| Domain 3: Exposure Characterization | | | | | |
| Metric 7: | Preparation and Storage of Test Substance | Medium | × 1 | 2 | Preparation of the test substance was described, but the frequency of preparation and storage were not reported. |
| Metric 8: | Consistency of Exposure Administration | High | × 1 | 1 | All groups appeared to be treated consistently |
| Metric 9: | Reporting of Doses/Concentrations | High | × 2 | 2 | Dosing was clearly reported, although reported as mg/kg/week CK: Dosing was reported as µg/kg BW/week, not as mg/kg/week |
| Metric 10: | Exposure Frequency and Duration | Unacceptable | × 1 | 4 | Animals were only given the test substance 1x/week via oral gavage. This is not a standard frequency of administration, and there is no discussion in the text indicating reasoning for the chosen dosing frequency. It is an unusual frequency to evaluate the toxicological effects of the test substance on mice fed different diets. |
| Metric 11: | Number of Exposure Groups and Dose Spacing | High | × 1 | 1 | Three exposure groups and a control.. Justification for exposure levels was provided. |
| Continued on next page ... | | | | | |

... continued from previous page

| Study Citation: | Yanagisawa, R; Koike, E; Win-Shwe, TT; Yamamoto, M; Takano, H (2014). Impaired lipid and glucose homeostasis in hexabromocyclododecane-exposed mice fed a high-fat diet Environmental Health Perspectives, 122(3), 277-283 | | | | | |
|--|--|---------------------|------|-------|--|--|
| Data Type: | 14-week study (animals dosed by gavage 1x per week) | | | | | |
| HERO ID: | 2343717 | | | | | |
| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} | |
| | Metric 12: Exposure Route and Method | High | × 1 | 1 | Method of gavage is acceptable, although it is unclear in this case, why a spiked dietary administration wasn't used instead. | |
| Domain 4: Test Organism | | | | | | |
| | Metric 13: Test Animal Characteristics | Medium | × 2 | 4 | Animals, and animal characteristics were all reported, however, only a males were used, for an ~90-day repeated dose study, OECD guideline recommends testing on both sexes | |
| | Metric 14: Adequacy and Consistency of Animal Husbandry Conditions | High | × 1 | 1 | Animal husbandry conditions were appropriate | |
| | Metric 15: Number per Group | Medium | × 1 | 2 | Only 5-6 animals/group; OECD guideline for 90-day repeated dose study recommends a minimum of 8 animals/group (4 males and 4 females) | |
| Domain 5: Outcome Assessment | | | | | | |
| | Metric 16: Outcome Assessment Methodology | High | × 2 | 2 | Methods used to assess outcomes were appropriate | |
| | Metric 17: Consistency of Outcome Assessment | High | × 1 | 1 | There was consistency across the groups that were tested | |
| | Metric 18: Sampling Adequacy | Medium | × 1 | 2 | A number of endpoints were only done using controls and high-dose groups, even though significant changes were supposedly observed in the medium-dose group for other endpoints.. This precludes the ability to evaluate dose-response for these endpoints | |
| | Metric 19: Blinding of Assessors | High | × 1 | 1 | Study indicates histology was done in a blinded fashion. | |
| | Metric 20: Negative Control Response | High | × 1 | 1 | No unexpected negative control responses were reported | |
| Domain 6: Confounding / Variable Control | | | | | | |
| | Metric 21: Confounding Variables in Test Design and Procedures | High | × 2 | 2 | No confounding variables were identified. | |
| | Metric 22: Health Outcomes Unrelated to Exposure | High | × 1 | 1 | No unusual health outcomes un-related to the exposure were identified | |
| Domain 7: Data Presentation and Analysis | | | | | | |
| | Metric 23: Statistical Methods | High | × 1 | 1 | Statistical analysis was clearly described and appropriate | |
| | Metric 24: Reporting of Data | Medium | × 2 | 4 | Data presentation was adequate; histological data was presented as images only | |
| Overall Quality Determination [‡] | | Unacceptable** | | 1.4 | | |

Continued on next page ...

...continued from previous page

Study Citation: Yanagisawa, R; Koike, E; Win-Shwe, TT; Yamamoto, M; Takano, H (2014). Impaired lipid and glucose homeostasis in hexabromocyclododecane-exposed mice fed a high-fat diet Environmental Health Perspectives, 122(3), 277-283
 Data Type: 14-week study (animals dosed by gavage 1x per week)
 HERO ID: 2343717

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|-----------|--------|---------------------|------|-------|------------------------|
| Extracted | | No | | | |

** Consistent with our *Application of Systematic Review in TSCARisk Evaluations* document, if a metric for a data source receives a score of Unacceptable (score = 4), EPA will determine the study to be unacceptable. In this case, one or more of the metrics were rated as unacceptable. As such, the study is considered unacceptable and the score is presented solely to increase transparency.

* MWF = Metric Weighting Factor

[†] High = 1; Medium = 2; Low = 3; Unacceptable = 4; N/A has no value.

[‡] The overall rating is calculated as necessary. EPA may not always provide a comment for a metric that has been categorized as High.

$$\text{Overall rating} = \begin{cases} 4 & \text{if any metric is Unacceptable} \\ \left\lfloor \frac{\sum_i (\text{Metric Score}_i \times \text{MWF}_i)}{\sum_j \text{MWF}_j} \right\rfloor_{0.1} & \text{(round to the nearest tenth) otherwise} \end{cases},$$

where High $\Rightarrow \geq 1$ to < 1.7 ; Medium $\Rightarrow \geq 1.7$ to < 2.3 ; Low $\Rightarrow \geq 2.3$ to ≤ 3.0 . If the reviewer determines that the overall rating needs adjustment, the original rating is crossed out and an arrow points to the new rating.

^{††} This metric met the criteria for high confidence as expected for this type of study

Table 21: **Animal toxicity evaluation results of van der Ven et al 2006 for 280day oral toxicity study (gavage) study on hepatic, clinical chemistry/biochemical, endocrine, musculoskeletal/motor function, ADME/PBPK, thyroid, nutrition and metabolic/adult exposure body weight, hematological and immune, reproductive outcomes**

| Study Citation: | van der Ven, L.T., Verhoef, A., van de Kuil, T., Slob, W., Leonards, P.E., Visser, T.J., Hamers, T., Herlin, M., Hakansson, H., Olausson, H., Piersma, A.H., Vos, J.G. (2006). A 28-day oral dose toxicity study enhanced to detect endocrine effects of hexabromocyclododecane in Wistar rats <i>Toxicological Sciences</i> , 94(2), 281-292 | | | | | |
|----------------------------|---|---------------------|------|-------|---|--|
| Data Type: | 280Day Oral Toxicity Study (gavage) | | | | | |
| HERO ID: | 787745 | | | | | |
| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} | |
| Domain 1: Test Substance | | | | | | |
| Metric 1: | Test Substance Identity | High | × 2 | 2 | The test substance was identified definitively and characterized. HBCD technical preparation is a mixture of three enantiomers, HBCD-alpha- beta-, and gamma, and their respective proportion in the used batch was 10.28, 8.72, and 81.01%, respectively. | |
| Metric 2: | Test Substance Source | Medium | × 1 | 2 | The source (manufacturer) of the test substance was reported, but the batch/lot numbers were omitted; this omission is unlikely to have a substantial impact on results. | |
| Metric 3: | Test Substance Purity | High | × 1 | 1 | The test substance was noted to be technical HBCD as a mixture of three enantiomers, HBCD-alpha-beta-, and gamma, with respective proportions as 10.28, 8.72, and 81.01%, respectively. Trace impurities were identified as traces of tetra- and pentabromocyclododecane. | |
| Domain 2: Test Design | | | | | | |
| Metric 4: | Negative and Vehicle Controls | High | × 2 | 2 | An appropriate concurrent negative control group was included. | |
| Metric 5: | Positive Controls | Medium | × 1 | 2 | The use of a positive control was reported for the UDP-glucuronosyltransferase assay. This metric was not rated/applicable for the other evaluations in the study. | |
| Continued on next page ... | | | | | | |

... continued from previous page

Study Citation: van der Ven, L.T., Verhoef, A., van de Kuil, T., Slob, W., Leonards, P.E., Visser, T.J., Hamers, T., Herlin, M., Hakansson, H., Olausson, H., Piersma, A.H., Vos, J.G. (2006). A 28-day oral dose toxicity study enhanced to detect endocrine effects of hexabromocyclododecane in Wistar rats *Toxicological Sciences*, 94(2), 281-292
 Data Type: 280Day Oral Toxicity Study (gavage)
 HERO ID: 787745

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|-------------------------------------|---|---------------------|------|-------|--|
| | Metric 6: Randomized Allocation | Medium | × 1 | 2 | "The experimental protocol followed the OECD407 28-day sub-acute toxicity guideline, which was enhanced for endocrine and immunological endpoints (Andrews et al., 2001). However, in contrast to the published protocol, the animals were distributed among more dose groups each with fewer animals, that is, five rats per sex per dose group, for improved assessment of dose response relationships (Kavlock et al., 1996; Slob, 2002)." It is unclear if this would have a substantial impact on results. |
| Domain 3: Exposure Characterization | | | | | |
| | Metric 7: Preparation and Storage of Test Substance | Medium | × 1 | 2 | Test substance preparation was reported, but with limitations in reporting. HBCD was reported to be dissolved in corn oil. It is not reported how often the test solution was prepared or how it was stored. This omission is unlikely to have a substantial impact on results. |
| | Metric 8: Consistency of Exposure Administration | High | × 1 | 1 | Details of exposure administration were reported and administration was consistent across study groups. |
| | Metric 9: Reporting of Doses/Concentrations | High | × 2 | 2 | Administered doses were reported without ambiguity. |
| | Metric 10: Exposure Frequency and Duration | High | × 1 | 1 | The exposure frequency and duration of exposure were reported and appropriate for this study type and/or outcome(s) of interest. |
| | Metric 11: Number of Exposure Groups and Dose Spacing | High | × 1 | 1 | The number of exposure groups and spacing was reported. It was reported that a larger number of dose groups was used (than recommended in OECD 407) for improved assessment of the dose-response relationship. |
| | Metric 12: Exposure Route and Method | High | × 1 | 1 | The route and method of exposure were reported and were suited to the test substance. |
| Domain 4: Test Organism | | | | | |
| | Metric 13: Test Animal Characteristics | High | × 2 | 2 | The test animal species, strain, sex, and age was reported. It was noted that the animals were inspected daily for general condition and clinical abnormalities. The animals were obtained from a commercial breeding facility. |

Continued on next page ...

... continued from previous page

Study Citation: van der Ven, L.T., Verhoef, A., van de Kuil, T., Slob, W., Leonards, P.E., Visser, T.J., Hamers, T., Herlin, M., Hakansson, H., Olausson, H., Piersma, A.H., Vos, J.G. (2006). A 28-day oral dose toxicity study enhanced to detect endocrine effects of hexabromocyclododecane in Wistar rats *Toxicological Sciences*, 94(2), 281-292
 Data Type: 280Day Oral Toxicity Study (gavage)
 HERO ID: 787745

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|--|--|---------------------|------|-------|--|
| | Metric 14: Adequacy and Consistency of Animal Husbandry Conditions | Medium | × 1 | 2 | Most animal husbandry conditions were reported and adequate. Humidity and temperature was not reported, however, this limitation in reporting is unlikely to have a substantial impact on results. |
| | Metric 15: Number per Group | Medium | × 1 | 2 | The number of animals per study group was reported (5/sex/dose). OECD 407 requires at least 10 animals (5/sex) for each dose level. Hence, the confidence is selected as 'medium'. |
| Domain 5: Outcome Assessment | | | | | |
| | Metric 16: Outcome Assessment Methodology | High | × 2 | 2 | The outcome assessment methodology reported and sensitive to the intended outcomes of interest. |
| | Metric 17: Consistency of Outcome Assessment | High | × 1 | 1 | Details of the outcome assessment methodology were reported and consistent across study groups for the outcomes of interest. |
| | Metric 18: Sampling Adequacy | High | × 1 | 1 | Details regarding the sampling for the outcomes of interest were reported and adequate for assessment. |
| | Metric 19: Blinding of Assessors | Not Rated | NA | NA | This metric is not rated when outcomes are not subjective or for initial histopathology review. |
| | Metric 20: Negative Control Response | High | × 1 | 1 | The biological response of the negative control group was adequate. As shown in Data tables and in Supplemental tables (ID2919527) |
| Domain 6: Confounding / Variable Control | | | | | |
| | Metric 21: Confounding Variables in Test Design and Procedures | Medium | × 2 | 4 | There were no reported differences among the study groups that could influence the outcome of the assessment. Food consumption was reported, but initial body weights were not. The lack of reporting is not likely to have a significant impact on results. |
| | Metric 22: Health Outcomes Unrelated to Exposure | Medium | × 1 | 2 | Data on attrition unrelated to exposure was reported. No other health outcomes unrelated to exposure were reported. The incidence of attrition is unlikely to have a substantial impact on results. |
| Domain 7: Data Presentation and Analysis | | | | | |
| | Metric 23: Statistical Methods | High | × 1 | 1 | Statistical analysis was shown for all datasets included in the published report and for supplemental data tables (ID2919527). BMD methodology was clearly described and appropriate. |

Continued on next page ...

...continued from previous page

Study Citation: van der Ven, L.T., Verhoef, A., van de Kuil, T., Slob, W., Leonards, P.E., Visser, T.J., Hamers, T., Herlin, M., Hakansson, H., Olausson, H., Piersma, A.H., Vos, J.G. (2006). A 28-day oral dose toxicity study enhanced to detect endocrine effects of hexabromocyclododecane in Wistar rats *Toxicological Sciences*, 94(2), 281-292
 Data Type: 280Day Oral Toxicity Study (gavage)
 HERO ID: 787745

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|--|-------------------|---------------------|------|-------|--|
| Metric 24: | Reporting of Data | High | × 2 | 2 | Data for exposure-related findings were presented for all outcomes by exposure group and sex as evaluated for this reference and the supplemental data tables (ID2919527). |
| Overall Quality Determination [‡] | | High | | 1.3 | |
| Extracted | | Yes | | | |

* MWF = Metric Weighting Factor

[†] High = 1; Medium = 2; Low = 3; Unacceptable = 4; N/A has no value.

[‡] The overall rating is calculated as necessary. EPA may not always provide a comment for a metric that has been categorized as High.

$$\text{Overall rating} = \begin{cases} 4 & \text{if any metric is Unacceptable} \\ \left\lceil \frac{\sum_i (\text{Metric Score}_i \times \text{MWF}_i)}{\sum_j \text{MWF}_j} \right\rceil_{0.1} & \text{(round to the nearest tenth) otherwise} \end{cases}$$

where High = ≥ 1 to < 1.7 ; Medium = ≥ 1.7 to < 2.3 ; Low = ≥ 2.3 to ≤ 3.0 . If the reviewer determines that the overall rating needs adjustment, the original rating is crossed out and an arrow points to the new rating.

^{††} This metric met the criteria for high confidence as expected for this type of study

6 Genetic toxicity studies

Table 22: In vitro evaluation results of Zeiger et al 1987 for Salmonella mutagenicity assay

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|---|---|---------------------|------|-------|--|
| Study Citation: E. Zeiger, B. Anderson, S. Haworth, T. Lawlor, K. Mortelmans, W. Speck (1987). Salmonella mutagenicity tests: III. Results from the testing of 255 chemicals Environmental Mutagenesis, 9(Suppl. 9,Suppl. 9), 1-109 | | | | | |
| Data Type: Salmonella mutagenicity assay | | | | | |
| HERO ID: 699386 | | | | | |
| <hr/> | | | | | |
| Domain 1: Test Substance | | | | | |
| Metric 1: | Test Substance Identity | High | × 2 | 2 | Reported as “hexabromocyclododecane, mixed isomers”; CASRN 25637-99-4 |
| Metric 2: | Test Substance Source | High | × 1 | 1 | Manufacturer was reported. |
| Metric 3: | Test Substance Purity | Low | × 1 | 3 | Purity not reported |
| <hr/> | | | | | |
| Domain 2: Test Design | | | | | |
| Metric 4: | Negative and Vehicle Controls | High | × 2 | 2 | Solvent control used (DMSO); author stated that experiments in which the control chemical did not produce a mutagenic response or in which the solvent control values were higher (or lower in the case of TA100 and TA97) than their expected values were rejected. |
| Metric 5: | Positive Controls | Medium | × 2 | 4 | Positive controls were run with each trial. Positive control substances are identified by name in the study. The study author notes that experiments were rejected if the positive control did not produce a mutagenic response. |
| Metric 6: | Assay Procedures | Medium | × 1 | 2 | Study authors cite another study but also provide a general description of the method. |
| Metric 7: | Standards for Tests | Not Rated | NA | NA | This metric does not apply for genotoxicity studies. |
| <hr/> | | | | | |
| Domain 3: Exposure Characterization | | | | | |
| Metric 8: | Preparation and Storage of Test Substance | High | × 1 | 1 | Study notes that chemicals known or suspected to be volatile were incubated in capped tubes. |
| Metric 9: | Consistency of Exposure Administration | High | × 1 | 1 | Each experiment followed a consistent protocol. |
| Metric 10: | Reporting of Doses/Concentrations | High | × 2 | 2 | Exposure concentrations reported in Table 123 in Appendix 2. |
| Metric 11: | Number of Exposure Groups and Concentration Spacing | High | × 2 | 2 | 48-hour incubation |
| Metric 12: | Exposure Route and Method | High | × 1 | 1 | Five concentrations tested; initial testing was done in a toxicity assay to determine the appropriate dose range. |
| <hr/> | | | | | |
| Continued on next page ... | | | | | |
| <hr/> | | | | | |

...continued from previous page

| Study Citation: | E. Zeiger, B. Anderson, S. Haworth, T. Lawlor, K. Mortelmans, W. Speck (1987). Salmonella mutagenicity tests: III. Results from the testing of 255 chemicals Environmental Mutagenesis, 9(Suppl. 9,Suppl. 9), 1-109 | | | | | |
|--|---|---------------------|------|-------|---|--|
| Data Type: | Salmonella mutagenicity assay | | | | | |
| HERO ID: | 699386 | | | | | |
| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} | |
| | Metric 13: Metabolic Activation | High | × 1 | 1 | Although the study author cites another source for this method, the study includes enough detail on source, method of preparation and concentration in culture. | |
| Domain 4: Test Model | | | | | | |
| | Metric 14: Test Model | High | × 2 | 2 | Test strains described and source was reported. | |
| | Metric 15: Number per Group | High | × 1 | 1 | Mutagenicity assay tested in triplicate for each strain. | |
| Domain 5: Outcome Assessment | | | | | | |
| | Metric 16: Outcome Assessment Methodology | High | × 2 | 2 | Negative results reported; mean and SEM reported for each test concentration. | |
| | Metric 17: Consistency of Outcome Assessment | High | × 1 | 1 | Outcome assessment followed a standard protocol. | |
| | Metric 18: Sampling Adequacy | Not Rated | NA | NA | Not applicable for mutagenicity studies. | |
| | Metric 19: Blinding of Assessors | Not Rated | NA | NA | Not applicable for mutagenicity studies. | |
| Domain 6: Confounding / Variable Control | | | | | | |
| | Metric 20: Confounding Variables in Test Design and Procedures | High | × 2 | 2 | Consistency was maintained across exposure groups. | |
| | Metric 21: Confounding Variables in Outcomes Unrelated to Exposure | Medium | × 1 | 2 | No information on disproportionate outcomes unrelated to exposure, but this is not expected to impact the study results. | |
| Domain 7: Data Presentation and Analysis | | | | | | |
| | Metric 22: Data Analysis | High | × 1 | 1 | No statistical analysis, but mean and SEM reported for each group. | |
| | Metric 23: Data Interpretation | High | × 2 | 2 | Data evaluation protocol described in the text. | |
| | Metric 24: Cytotoxicity Data | High | × 1 | 1 | Toxicity was evaluated as a decrease in the number of his+ colonies or clearing in the density of the background lawn. | |
| | Metric 25: Reporting of Data | High | × 2 | 2 | Data were reported for each exposure group, strain and replicate. | |
| Overall Quality Determination [‡] | | High | | 1.2 | | |
| Extracted | | Yes | | | | |

Continued on next page ...

...continued from previous page

Study Citation: E. Zeiger, B. Anderson, S. Haworth, T. Lawlor, K. Mortelmans, W. Speck (1987). Salmonella mutagenicity tests: III. Results from the testing of 255 chemicals Environmental Mutagenesis, 9(Suppl. 9,Suppl. 9), 1-109
 Data Type: Salmonella mutagenicity assay
 HERO ID: 699386

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|--------|--------|---------------------|------|-------|------------------------|
|--------|--------|---------------------|------|-------|------------------------|

* MWF = Metric Weighting Factor

† High = 1; Medium = 2; Low = 3; Unacceptable = 4; N/A has no value.

‡ The overall rating is calculated as necessary. EPA may not always provide a comment for a metric that has been categorized as High.

$$\text{Overall rating} = \begin{cases} 4 & \text{if any metric is Unacceptable} \\ \left[\sum_i (\text{Metric Score}_i \times \text{MWF}_i) / \sum_j \text{MWF}_j \right]_{0.1} & \text{(round to the nearest tenth) otherwise} \end{cases}$$

where High $\Rightarrow \geq 1$ to < 1.7 ; Medium $\Rightarrow \geq 1.7$ to < 2.3 ; Low $\Rightarrow \geq 2.3$ to ≤ 3.0 . If the reviewer determines that the overall rating needs adjustment, the original rating is crossed out and an arrow points to the new rating.

†† This metric met the criteria for high confidence as expected for this type of study

Table 23: **In vitro** evaluation results of Ethyl Corporation 1990 for Salmonella/microsomal assay for HBCD

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|---|---|---------------------|------|-------|--|
| Study Citation: Ethyl Corporation (1990). Genetic toxicology salmonella/microsomal assay on hexabromocyclododecane with cover letter dated 030890 | | | | | |
| Data Type: Salmonella/microsomal assay for HBCD | | | | | |
| HERO ID: 787661 | | | | | |
| <hr/> | | | | | |
| Domain 1: Test Substance | | | | | |
| Metric 1: | Test Substance Identity | Medium | × 2 | 4 | The test substance was identified by name and CASRN (3194-55-6) in the submission. In the study itself, the test substance was referred to as "HBCD Bottoms" without additional information. |
| Metric 2: | Test Substance Source | Low | × 1 | 3 | The source (manufacturer) of the test substance was not reported; it was not clear if information provided with the test substance (PU-85121 and G.T.# 083) corresponded to batch/lot numbers. |
| Metric 3: | Test Substance Purity | Low | × 1 | 3 | The purity of the test substance was not reported. |
| <hr/> | | | | | |
| Domain 2: Test Design | | | | | |
| Metric 4: | Negative and Vehicle Controls | High | × 2 | 2 | Negative (untreated) and solvent controls (acetone) were reported; however, data were shown for the solvent control group only. |
| Metric 5: | Positive Controls | Medium | × 2 | 4 | Positive controls were included and induced, but were not identified. |
| Metric 6: | Assay Procedures | Low | × 1 | 3 | Methods and procedures were described in minimal detail; methods were cited to several company SOPs. The study indicated that OECD requirements were met (presumably for the Ames assay). |
| Metric 7: | Standards for Tests | Not Rated | NA | NA | This metric is not applicable to the study type. |
| <hr/> | | | | | |
| Domain 3: Exposure Characterization | | | | | |
| Metric 8: | Preparation and Storage of Test Substance | Not Rated | NA | NA | No details regarding test substance preparation were reported (cited to company SOPs). The only available information indicates that acetone was used as the solvent for HBCD. |
| Metric 9: | Consistency of Exposure Administration | Not Rated | NA | NA | No details regarding exposure methods were reported (cited to company SOPs). |
| Metric 10: | Reporting of Doses/Concentrations | High | × 2 | 2 | Concentrations were reported without ambiguity. |
| Metric 11: | Number of Exposure Groups and Concentration Spacing | Not Rated | NA | NA | No details regarding exposure duration were reported (cited to company SOPs). |
| Metric 12: | Exposure Route and Method | High | × 1 | 1 | The number of groups (5 plus controls) and spacing were reported. A rationale for the selection of exposure concentrations was not provided; however, the highest tested dose (5 mg/plate) was in line with recommendations for studies of this type. The exposure concentrations used were considered adequate to evaluate the dose-response. |
| <hr/> | | | | | |
| Continued on next page ... | | | | | |
| <hr/> | | | | | |

...continued from previous page

| Study Citation: | Ethyl Corporation (1990). Genetic toxicology salmonella/microsomal assay on hexabromocyclododecane with cover letter dated 030890 | | | | |
|--|---|---------------------|------|-------|--|
| Data Type: | Salmonella/microsomal assay for HBCD | | | | |
| HERO ID: | 787661 | | | | |
| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
| | Metric 13: Metabolic Activation | Low | × 1 | 3 | The presence of a metabolic system was reported in the study, but details were not provided (i.e., identification of system used, concentration). |
| Domain 4: Test Model | | | | | |
| | Metric 14: Test Model | Medium | × 2 | 4 | The test model (<i>Salmonella typhimurium</i>) was reported. Limited descriptive details were provided, but this test model is routinely used for the outcome of interest. |
| | Metric 15: Number per Group | High | × 1 | 1 | Each dose was tested in triplicate. |
| Domain 5: Outcome Assessment | | | | | |
| | Metric 16: Outcome Assessment Methodology | Not Rated | NA | NA | No details regarding outcome assessment methods were reported (cited to company SOPs). |
| | Metric 17: Consistency of Outcome Assessment | Not Rated | NA | NA | No details regarding the consistency of the outcome assessment methods were reported (cited to company SOPs). |
| | Metric 18: Sampling Adequacy | Not Rated | NA | NA | This metric is not applicable to the study type. |
| | Metric 19: Blinding of Assessors | Not Rated | NA | NA | This metric is not applicable to the study type. |
| Domain 6: Confounding / Variable Control | | | | | |
| | Metric 20: Confounding Variables in Test Design and Procedures | Low | × 2 | 6 | Initial information was not reported. |
| | Metric 21: Confounding Variables in Outcomes Unrelated to Exposure | Low | × 1 | 3 | Data on outcome differences unrelated to exposure were not reported for each study replicate or group. It was indicated that precipitate (which was observed at all dose levels) interfered with the automatic colony counter at "high dose level;" these levels were counted by hand. |
| Domain 7: Data Presentation and Analysis | | | | | |
| | Metric 22: Data Analysis | Low | × 1 | 3 | Statistical analysis was not conducted and standard deviations were not reported, so independent statistical analysis is not possible. However, statistical analysis is not necessarily required for the bacterial reverse mutation assay. |
| | Metric 23: Data Interpretation | Medium | × 2 | 4 | It was inferred from the data table that a 3-fold change compared to the solvent control was considered a positive response. |
| | Metric 24: Cytotoxicity Data | Not Rated | NA | NA | Cytotoxicity analyses are not strictly required by the study type. |
| | Metric 25: Reporting of Data | High | × 2 | 2 | Data were reported by exposure group. |
| Overall Quality Determination [‡] | | Medium | | 2.0 | |

Continued on next page ...

...continued from previous page

Study Citation: Ethyl Corporation (1990). Genetic toxicology salmonella/microsomal assay on hexabromocyclododecane with cover letter dated 030890
 Data Type: Salmonella/microsomal assay for HBCD
 HERO ID: 787661

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|-----------|--------|---------------------|------|-------|------------------------|
| Extracted | | Yes | | | |

* MWF = Metric Weighting Factor

† High = 1; Medium = 2; Low = 3; Unacceptable = 4; N/A has no value.

‡ The overall rating is calculated as necessary. EPA may not always provide a comment for a metric that has been categorized as High.

$$\text{Overall rating} = \begin{cases} 4 & \text{if any metric is Unacceptable} \\ \left\lfloor \frac{\sum_i (\text{Metric Score}_i \times \text{MWF}_i)}{\sum_j \text{MWF}_j} \right\rfloor_{0.1} & \text{(round to the nearest tenth) otherwise} \end{cases}$$

where High $\Rightarrow \geq 1$ to < 1.7 ; Medium $\Rightarrow \geq 1.7$ to < 2.3 ; Low $\Rightarrow \geq 2.3$ to ≤ 3.0 . If the reviewer determines that the overall rating needs adjustment, the original rating is crossed out and an arrow points to the new rating.

†† This metric met the criteria for high confidence as expected for this type of study

Table 24: **In vitro** evaluation results of Helleday et al 1999 for hprt recombination spd8 and sp5 cells

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|---|---|---------------------|------|-------|---|
| Study Citation: T. Helleday, K. L. Tuominen, A. Bergman, D. Jenssen (1999). Brominated flame retardants induce intragenic recombination in mammalian cells Mutation Research, 439(2,2), 137-147 | | | | | |
| Data Type: hprt recombination spd8 and sp5 cells | | | | | |
| HERO ID: 787680 | | | | | |
| Domain 1: Test Substance | | | | | |
| Metric 1: | Test Substance Identity | High | × 2 | 2 | Test substance was identified by name and structure. |
| Metric 2: | Test Substance Source | Medium | × 1 | 2 | The test substance source manufacturer was reported, but lot or batch was not reported. |
| Metric 3: | Test Substance Purity | Low | × 1 | 3 | Test substance purity was not reported. |
| Domain 2: Test Design | | | | | |
| Metric 4: | Negative and Vehicle Controls | High | × 2 | 2 | Concurrent negative (solvent) controls were reported. |
| Metric 5: | Positive Controls | Medium | × 2 | 4 | Concurrent positive control (camptothecin) was reported in text, but results were not reported. |
| Metric 6: | Assay Procedures | High | × 1 | 1 | Assay methods and procedures were described and were applicable for the study type. |
| Metric 7: | Standards for Tests | Not Rated | NA | NA | Not applicable to this study type. |
| Domain 3: Exposure Characterization | | | | | |
| Metric 8: | Preparation and Storage of Test Substance | Medium | × 1 | 2 | Test substance preparation was described, but storage conditions were not reported. |
| Metric 9: | Consistency of Exposure Administration | High | × 1 | 1 | Exposure administration is reported and consistency of administration across groups is inferred from the text |
| Metric 10: | Reporting of Doses/Concentrations | High | × 2 | 2 | Exposure concentrations were reported clearly. |
| Metric 11: | Number of Exposure Groups and Concentration Spacing | High | × 2 | 2 | Exposure duration was reported and appropriate for the study type. |
| Metric 12: | Exposure Route and Method | High | × 1 | 1 | The number of exposure concentrations was reported and appropriate. The spacing was not justified but appeared to be based on growth reduction and colony forming inhibition. |
| Metric 13: | Metabolic Activation | Not Rated | NA | NA | Metabolic activation was not applicable for this study type. |
| Domain 4: Test Model | | | | | |
| Metric 14: | Test Model | Medium | × 2 | 4 | Test model was briefly described and previously cited and appeared appropriate for the outcome of interest. |
| Continued on next page ... | | | | | |

... continued from previous page

| Study Citation: | T. Helleday, K. L. Tuominen, A. Bergman, D. Jenssen (1999). Brominated flame retardants induce intragenic recombination in mammalian cells Mutation Research, 439(2,2), 137-147 | | | | | |
|--|---|---------------------|------|-------|--|--|
| Data Type: | hprt recombination spd8 and sp5 cells | | | | | |
| HERO ID: | 787680 | | | | | |
| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} | |
| | Metric 15: Number per Group | High | × 1 | 1 | The number of cells was reported and appropriate for each group and each concentration was run in 2 independent experiments. | |
| Domain 5: Outcome Assessment | | | | | | |
| | Metric 16: Outcome Assessment Methodology | High | × 2 | 2 | The assessment methodology was appropriate for the outcome of interest. | |
| | Metric 17: Consistency of Outcome Assessment | High | × 1 | 1 | The outcome assessment was carried out consistently across study groups. | |
| | Metric 18: Sampling Adequacy | Not Rated | NA | NA | Not applicable to this study type | |
| | Metric 19: Blinding of Assessors | Not Rated | NA | NA | Not applicable to this study type | |
| Domain 6: Confounding / Variable Control | | | | | | |
| | Metric 20: Confounding Variables in Test Design and Procedures | Low | × 2 | 6 | Initial conditions were not reported for each group or experiment. | |
| | Metric 21: Confounding Variables in Outcomes Unrelated to Exposure | Medium | × 1 | 2 | Data on experienced disproportionate outcomes unrelated to exposure were not reported, but unlikely to affect the results. | |
| Domain 7: Data Presentation and Analysis | | | | | | |
| | Metric 22: Data Analysis | High | × 1 | 1 | Statistical methods were reported and appropriate for the data. | |
| | Metric 23: Data Interpretation | High | × 2 | 2 | Criteria were reported and consistent with standards. | |
| | Metric 24: Cytotoxicity Data | High | × 1 | 1 | Cytotoxicity data were reported and methods are commonly used. | |
| | Metric 25: Reporting of Data | High | × 2 | 2 | Data were reported for all outcomes and groups. | |
| Overall Quality Determination [‡] | | High | | 1.4 | | |
| Extracted | | Yes | | | | |

* MWF = Metric Weighting Factor

[†] High = 1; Medium = 2; Low = 3; Unacceptable = 4; N/A has no value.

[‡] The overall rating is calculated as necessary. EPA may not always provide a comment for a metric that has been categorized as High.

$$\text{Overall rating} = \begin{cases} 4 & \text{if any metric is Unacceptable} \\ \left\lceil \frac{\sum_i (\text{Metric Score}_i \times \text{MWF}_i)}{\sum_j \text{MWF}_j} \right\rceil_{0.1} & \text{(round to the nearest tenth) otherwise} \end{cases}$$

where High = ≥ 1 to < 1.7 ; Medium = ≥ 1.7 to < 2.3 ; Low = ≥ 2.3 to ≤ 3.0 . If the reviewer determines that the overall rating needs adjustment, the original rating is crossed out and an arrow points to the new rating.

^{††} This metric met the criteria for high confidence as expected for this type of study

Table 25: **In vitro** evaluation results of Huntingdon Research Center 1990 for bacterial reverse mutation

| Study Citation: | Huntingdon Research, Center (1990). Ames metabolic activation test to assess the potential mutagenic effect of und no. 49 with cover letter dated 031290 | | | | | |
|-------------------------------------|--|---------------------|------|-------|--|--|
| Data Type: | bacterial reverse mutation assay | | | | | |
| HERO ID: | 787683 | | | | | |
| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} | |
| Domain 1: Test Substance | | | | | | |
| Metric 1: | Test Substance Identity | High | × 2 | 2 | HBCD identified on the cover page with a reference to the full name and CASRN | |
| Metric 2: | Test Substance Source | Low | × 1 | 3 | No information on source of the test substance provided | |
| Metric 3: | Test Substance Purity | Low | × 1 | 3 | Purity not reported | |
| Domain 2: Test Design | | | | | | |
| Metric 4: | Negative and Vehicle Controls | High | × 2 | 2 | Solvent control included | |
| Metric 5: | Positive Controls | High | × 2 | 2 | Positive control included | |
| Metric 6: | Assay Procedures | Low | × 1 | 3 | No information was reported on incubation time or details of bacterial cell growth. | |
| Metric 7: | Standards for Tests | Not Rated | NA | NA | | |
| Domain 3: Exposure Characterization | | | | | | |
| Metric 8: | Preparation and Storage of Test Substance | Low | × 1 | 3 | Details were not provided on test substance storage or preparation, although this is less of a concern for a stable powdered compound that would not be expected to easily degrade or vaporize | |
| Metric 9: | Consistency of Exposure Administration | High | × 1 | 1 | There is no indication that any treatment groups received inconsistent HBCD administration | |
| Metric 10: | Reporting of Doses/Concentrations | High | × 2 | 2 | Doses were reported | |
| Metric 11: | Number of Exposure Groups and Concentration Spacing | Unacceptable | × 2 | 8 | Exposure duration was not reported | |
| Metric 12: | Exposure Route and Method | High | × 1 | 1 | 3 dose groups of 1log spacing is acceptable | |
| Metric 13: | Metabolic Activation | Medium | × 1 | 2 | Liver microsomal fraction was used for metabolic activation, however no details on concentration or other details were provided | |
| Domain 4: Test Model | | | | | | |
| Metric 14: | Test Model | Medium | × 2 | 4 | Strains TA 1535, 1537, 1538, TA 98, and TA 100 are typical and appropriate for an Ames assay but no details were provided and data was not shown for 1537 and 1538. | |
| Metric 15: | Number per Group | Unacceptable | × 1 | 4 | Number of cells/replicates per group were not reported | |
| Domain 5: Outcome Assessment | | | | | | |

Continued on next page ...

... continued from previous page

| Study Citation: | Huntingdon Research, Center (1990). Ames metabolic activation test to assess the potential mutagenic effect of und no. 49 with cover letter dated 031290 | | | | | |
|--|--|---------------------|------|-------|---|--|
| Data Type: | bacterial reverse mutation assay | | | | | |
| HERO ID: | 787683 | | | | | |
| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} | |
| | Metric 16: Outcome Assessment Methodology | High | × 2 | 2 | Assesment addressed the intended outcome of interest | |
| | Metric 17: Consistency of Outcome Assessment | Low | × 1 | 3 | Details of study protocol execution were not reported | |
| | Metric 18: Sampling Adequacy | Low | × 2 | 6 | Details on sampling was not reported | |
| | Metric 19: Blinding of Assessors | Not Rated | NA | NA | | |
| Domain 6: Confounding / Variable Control | | | | | | |
| | Metric 20: Confounding Variables in Test Design and Procedures | Low | × 2 | 6 | Potential confounders not discussed | |
| | Metric 21: Confounding Variables in Outcomes Unrelated to Exposure | Low | × 1 | 3 | Potential confounders not discussed | |
| Domain 7: Data Presentation and Analysis | | | | | | |
| | Metric 22: Data Analysis | Low | × 1 | 3 | Statistical analysis was not described | |
| | Metric 23: Data Interpretation | Medium | × 2 | 4 | Scoring criteria were not reported but are standard for Ames assays | |
| | Metric 24: Cytotoxicity Data | Unacceptable | × 1 | 4 | Cytotoxicity appears to have been performed based on the cover letter but data was not provided | |
| | Metric 25: Reporting of Data | Medium | × 2 | 4 | Basic revertant number was reported, however only one replication without dose-finding or other details | |
| Overall Quality Determination [‡] | | Unacceptable** | | 2.2 | | |
| Extracted | | No | | | | |

** Consistent with our *Application of Systematic Review in TSCARisk Evaluations* document, if a metric for a data source receives a score of Unacceptable (score = 4), EPA will determine the study to be unacceptable. In this case, one or more of the metrics were rated as unacceptable. As such, the study is considered unacceptable and the score is presented solely to increase transparency.

* MWF = Metric Weighting Factor

† High = 1; Medium = 2; Low = 3; Unacceptable = 4; N/A has no value.

‡ The overall rating is calculated as necessary. EPA may not always provide a comment for a metric that has been categorized as High.

$$\text{Overall rating} = \begin{cases} 4 & \text{if any metric is Unacceptable} \\ \left\lfloor \frac{\sum_i (\text{Metric Score}_i \times \text{MWF}_i)}{\sum_j \text{MWF}_j} \right\rfloor_{0.1} & \text{(round to the nearest tenth) otherwise} \end{cases}$$

where High = ≥ 1 to < 1.7 ; Medium = ≥ 1.7 to < 2.3 ; Low = ≥ 2.3 to ≤ 3.0 . If the reviewer determines that the overall rating needs adjustment, the original rating is crossed out and an arrow points to the new rating.

†† This metric met the criteria for high confidence as expected for this type of study

Table 26: **In vitro** evaluation results of IBT Labs 1990 for **in vitro** Ames assay in *S. typhimurium*

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|--|---|---------------------|------|-------|---|
| Study Citation: IBT Labs (1990). Mutagenicity of two lots of FM-100 lot 53 and residue of lot 3322 in the absence and presence of metabolic activation with test data and cover letter 900000267 #86-900000267 | | | | | |
| Data Type: in vitro Ames assay in <i>S. typhimurium</i> - HBCD (3194-55-6) | | | | | |
| HERO ID: 787688 | | | | | |
| Domain 1: Test Substance | | | | | |
| Metric 1: | Test Substance Identity | Medium | × 2 | 4 | The study only refers to formula names of 'Firemaster 100 and residue of FM-100', although both are associated with HBCD and the correct CASRN. Details for the residue form are not provided. |
| Metric 2: | Test Substance Source | High | × 1 | 1 | The source of the test substance was reported (Great Lakes Chemical Corporation). FM-100 Lot 53 |
| Metric 3: | Test Substance Purity | Low | × 1 | 3 | The purity and/or grade of the test substance was not reported |
| Domain 2: Test Design | | | | | |
| Metric 4: | Negative and Vehicle Controls | High | × 2 | 2 | Study authors report using a negative and solvent control (DMSO) for each strain |
| Metric 5: | Positive Controls | High | × 2 | 2 | A positive control was tested (N-methyl-N-nitrosoguanidine - MNNG) without metabolic activation and 2-aminofluorene with metabolic activation |
| Metric 6: | Assay Procedures | Medium | × 1 | 2 | Assay methods and procedures for the Ames assay were described and was noted to conform to published procedure (Ames et al., 1975) |
| Metric 7: | Standards for Tests | Not Rated | NA | NA | Not applicable for this study |
| Domain 3: Exposure Characterization | | | | | |
| Metric 8: | Preparation and Storage of Test Substance | Medium | × 1 | 2 | Test substance preparation was described as diluted in DMSO; storage was not indicated. |
| Metric 9: | Consistency of Exposure Administration | High | × 1 | 1 | Exposures were reported to be administered consistently across treated and control groups. |
| Metric 10: | Reporting of Doses/Concentrations | High | × 2 | 2 | The test concentration was reported in the results without ambiguity; 25, 50, 100, and 250 ug/10 ml with and without metabolic activation |
| Metric 11: | Number of Exposure Groups and Concentration Spacing | Not Rated | NA | NA | The exposure duration was not reported in the study; however, the test method conformed to the published procedure (Ames et al., 1975) |
| Metric 12: | Exposure Route and Method | High | × 1 | 1 | The number of exposure concentrations were reported. The concentrations tested were based on the absence of cytotoxicity. The highest concentration tested was limited by its solubility in dimethylsulfoxide (250 ug/10ul) |
| Continued on next page ... | | | | | |

...continued from previous page

| Study Citation: | IBT Labs (1990). Mutagenicity of two lots of FM-100 lot 53 and residue of lot 3322 in the absence and presence of metabolic activation with test data and cover letter 900000267 #86-900000267 | | | | | |
|--|--|---------------------|------|-------|---|--|
| Data Type: | in vitro Ames assay in <i>S. typhimurium</i> - HBCD (3194-55-6) | | | | | |
| HERO ID: | 787688 | | | | | |
| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} | |
| | Metric 13: Metabolic Activation | High | × 1 | 1 | S. typhimurium TA-98, TA-100, TA-1535, TA-1537, and TA 1538 were tested with metabolic activation (rat liver microsomes); all but TA 1538 were tested without metabolic activation. The method of preparation and concentrations were reported. | |
| Domain 4: Test Model | | | | | | |
| | Metric 14: Test Model | High | × 2 | 2 | The test models were reported and appropriate for the outcome of interest: <i>S. typhimurium</i> TA-98, TA-100, TA-1535, TA-1537, and TA 1538 The source of the bacteria was not reported. Test species were checked for its genetic characteristics in accordance with the Ames protocol. | |
| | Metric 15: Number per Group | High | × 1 | 1 | The number of organisms were not reported; it was noted that the sample to be tested is 10 ul. 3 replicates per study group were reported. The study was noted to be conducted according to Ames et al., 1975) | |
| Domain 5: Outcome Assessment | | | | | | |
| | Metric 16: Outcome Assessment Methodology | High | × 2 | 2 | The outcome assessment methodologies were appropriate for the endpoints of interest. | |
| | Metric 17: Consistency of Outcome Assessment | High | × 1 | 1 | The outcome assessment was carried out consistently across the controls and treated groups. | |
| | Metric 18: Sampling Adequacy | Not Rated | NA | NA | Not applicable | |
| | Metric 19: Blinding of Assessors | Not Rated | NA | NA | This metric is not applicable to the outcome. | |
| Domain 6: Confounding / Variable Control | | | | | | |
| | Metric 20: Confounding Variables in Test Design and Procedures | Low | × 2 | 6 | Initial conditions were not reported for each study replicate or group. | |
| | Metric 21: Confounding Variables in Outcomes Unrelated to Exposure | Medium | × 1 | 2 | Data on experienced disproportionate outcomes unrelated to exposure were not reported, but this was unlikely to have a substantial effect on results. | |
| Domain 7: Data Presentation and Analysis | | | | | | |
| | Metric 22: Data Analysis | High | × 1 | 1 | Statistical methods were described and appropriate. | |
| | Metric 23: Data Interpretation | Medium | × 2 | 4 | Tests regarded as mutagenic if the test material is statistically significantly different (significance at the 1% level) from the control and mutations related linearly to dosage. | |
| | Metric 24: Cytotoxicity Data | High | × 1 | 1 | Cytotoxicity endpoints were described (inhibition of growth) | |
| Continued on next page ... | | | | | | |

...continued from previous page

Study Citation: IBT Labs (1990). Mutagenicity of two lots of FM-100 lot 53 and residue of lot 3322 in the absence and presence of metabolic activation with test data and cover letter 900000267 #86-900000267
 Data Type: in vitro Ames assay in *S. typhimurium* - HBCD (3194-55-6)
 HERO ID: 787688

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|--|------------------------------|---------------------|------|-------|---|
| | Metric 25: Reporting of Data | | × 2 | NA | The reporting of data in studies conducted by IBT during 1960-1978 is considered unacceptable due to concerns about the integrity of the lab (i.e., discrepancies between raw data and study report, and gross deficiencies in study conduct were identified during an inspection by the FDA in 1976 and a follow-up audit by EPA and in collaboration with the Canadian Health and Welfare Department). Guidance for review of IBT studies is provided in EPA's Manual for Investigation of HPV Chemicals, based on agreements reached in the OECD Existing Chemicals Programme. |
| Overall Quality Determination [‡] | | Unacceptable** | | 1.6 | |
| Extracted | | No | | | |

** Consistent with our *Application of Systematic Review in TSCARisk Evaluations* document, if a metric for a data source receives a score of Unacceptable (score = 4), EPA will determine the study to be unacceptable. In this case, one or more of the metrics were rated as unacceptable. As such, the study is considered unacceptable and the score is presented solely to increase transparency.

* MWF = Metric Weighting Factor

† High = 1; Medium = 2; Low = 3; Unacceptable = 4; N/A has no value.

‡ The overall rating is calculated as necessary. EPA may not always provide a comment for a metric that has been categorized as High.

$$\text{Overall rating} = \begin{cases} 4 & \text{if any metric is Unacceptable} \\ \left[\frac{\sum_i (\text{Metric Score}_i \times \text{MWF}_i)}{\sum_j \text{MWF}_j} \right]_{0.1} & \text{(round to the nearest tenth) otherwise} \end{cases},$$

where High = ≥ 1 to < 1.7 ; Medium = ≥ 1.7 to < 2.3 ; Low = ≥ 2.3 to ≤ 3.0 . If the reviewer determines that the overall rating needs adjustment, the original rating is crossed out and an arrow points to the new rating.

†† This metric met the criteria for high confidence as expected for this type of study

Table 27: **In vitro** evaluation results of Litton Bionetics 1990 for mutagenicity evaluation

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|--|---|---------------------|------|-------|--|
| Study Citation: Litton Bionetics (1990). Mutagenicity evaluation of 421-32B (final report) with test data and cover letter | | | | | |
| Data Type: Mutagenicity evaluation for HBCD | | | | | |
| HERO ID: 787698 | | | | | |
| Domain 1: Test Substance | | | | | |
| Metric 1: | Test Substance Identity | Medium | × 2 | 4 | The test substance was identified by name and CASRN (3194-55-6) in the submission. In the study itself, the test substance was referred to as 421-32B or "hexabromocyclododecane dispersion" without additional information. |
| Metric 2: | Test Substance Source | Low | × 1 | 3 | The source of the test substance was not reported; it was not clear if the manufacturer was the submitting organization (Great Lakes Chemical Corporation) cited in the submission. |
| Metric 3: | Test Substance Purity | Low | × 1 | 3 | The purity of the test substance was not reported. The study indicates that there were no known additives to the test substance(s). |
| Domain 2: Test Design | | | | | |
| Metric 4: | Negative and Vehicle Controls | Medium | × 2 | 4 | The study authors reported using a concurrent negative (solvent) control group; however, the identity of the solvent was not specified. |
| Metric 5: | Positive Controls | High | × 2 | 2 | Concurrent positive controls were used and the intended positive responses were induced. It is noted that a volatile positive control was not used. |
| Metric 6: | Assay Procedures | High | × 1 | 1 | Assay procedures were reported in adequate detail (including final concentrations of components in the reaction mixture, initial cell density, temperature). |
| Metric 7: | Standards for Tests | Not Rated | NA | NA | This metric is not applicable to the study type. |
| Domain 3: Exposure Characterization | | | | | |
| Metric 8: | Preparation and Storage of Test Substance | Low | × 1 | 3 | Preparation of the test substance was reported with missing details (i.e., solvent used). |
| Metric 9: | Consistency of Exposure Administration | High | × 1 | 1 | Exposures were administered consistently across study groups. |
| Metric 10: | Reporting of Doses/Concentrations | High | × 2 | 2 | Concentrations were reported without ambiguity. |
| Metric 11: | Number of Exposure Groups and Concentration Spacing | High | × 2 | 2 | The exposure duration was reported and applicable to the study type. |
| Metric 12: | Exposure Route and Method | High | × 1 | 1 | The number of exposure groups (4 plus controls) was reported (slightly lower than 5 recommended number of analyzable concentrations). A rationale for the selection of doses was provided; there was no evidence of toxicity at the lowest dose, and there was evidence of effects at the high dose level. |

Continued on next page ...

... continued from previous page

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|--|--|---------------------|------|-------|--|
| Study Citation: Litton Bionetics (1990). Mutagenicity evaluation of 421-32B (final report) with test data and cover letter | | | | | |
| Data Type: Mutagenicity evaluation for HBCD | | | | | |
| HERO ID: 787698 | | | | | |
| | Metric 13: Metabolic Activation | Medium | × 1 | 2 | The study authors reported the type, source, and methods of preparation of the metabolic activation system. The concentration of rat liver S9 used in the assays was not specified. |
| Domain 4: Test Model | | | | | |
| | Metric 14: Test Model | Low | × 2 | 6 | The test models (5 strains of Salmonella and Saccharomyces cerevisiae strain D4) were reported and are routinely used for studies of this type. However, the source of these strains (and other descriptive information) was not reported. |
| | Metric 15: Number per Group | Low | × 1 | 3 | The number of replicates used were not reported (it is not clear if there was more than 1 plate per dose level). Data were presented as summary data and measured as revertants per plate (therefore, it is possible that multiple plates were used). |
| Domain 5: Outcome Assessment | | | | | |
| | Metric 16: Outcome Assessment Methodology | High | × 2 | 2 | The outcome assessment methodology was reported and appropriate for the study type. |
| | Metric 17: Consistency of Outcome Assessment | High | × 1 | 1 | Outcomes were assessed consistently across study groups. |
| | Metric 18: Sampling Adequacy | Not Rated | NA | NA | This metric is not applicable to the study type. |
| | Metric 19: Blinding of Assessors | Not Rated | NA | NA | This metric is not applicable to the study type. |
| Domain 6: Confounding / Variable Control | | | | | |
| | Metric 20: Confounding Variables in Test Design and Procedures | High | × 2 | 2 | No confounding variables were identified. |
| | Metric 21: Confounding Variables in Outcomes Unrelated to Exposure | Low | × 1 | 3 | Data on outcome differences unrelated to exposure were not reported for each study replicate or group. |
| Domain 7: Data Presentation and Analysis | | | | | |
| | Metric 22: Data Analysis | Low | × 1 | 3 | Statistical analysis was not conducted, not required by study type, and may not have been possible (if only one plate was used per dose). Data were provided with respect to numbers of revertants/plate (without information with respect to sample size, or measure of variance, if applicable). |
| | Metric 23: Data Interpretation | High | × 2 | 2 | The study indicates that a dose-related increased number of revertants would be considered a positive response. It is also inferred from the text that a >3-fold increase in the number of revertants could be considered positive (the study states that 2 to 3-fold increases in mutant counts might be within the spontaneous range). |

Continued on next page ...

...continued from previous page

Study Citation: Litton Bionetics (1990). Mutagenicity evaluation of 421-32B (final report) with test data and cover letter
 Data Type: Mutagenicity evaluation for HBCD
 HERO ID: 787698

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|--|------------------------------|---------------------|------|-------|--|
| | Metric 24: Cytotoxicity Data | Low | × 1 | 3 | The study indicated that cytotoxicity was evaluated, but cytotoxicity and the methods used to determine it were not well-defined. It is stated that toxicity was evaluated at higher doses by assessing background growth. However, it was also indicated that cell survival could not be quantified using plate test procedures (but rather, subjective criteria were applied). |
| | Metric 25: Reporting of Data | High | × 2 | 2 | Data were reported by exposure group. |
| Overall Quality Determination [‡] | | Medium | | 1.7 | |
| Extracted | | Yes | | | |

* MWF = Metric Weighting Factor

† High = 1; Medium = 2; Low = 3; Unacceptable = 4; N/A has no value.

‡ The overall rating is calculated as necessary. EPA may not always provide a comment for a metric that has been categorized as High.

$$\text{Overall rating} = \begin{cases} 4 & \text{if any metric is Unacceptable} \\ \left\lfloor \frac{\sum_i (\text{Metric Score}_i \times \text{MWF}_i)}{\sum_j \text{MWF}_j} \right\rfloor_{0.1} & \text{(round to the nearest tenth) otherwise} \end{cases}$$

where High $\Rightarrow \geq 1$ to < 1.7 ; Medium $\Rightarrow \geq 1.7$ to < 2.3 ; Low $\Rightarrow \geq 2.3$ to ≤ 3.0 . If the reviewer determines that the overall rating needs adjustment, the original rating is crossed out and an arrow points to the new rating.

†† This metric met the criteria for high confidence as expected for this type of study

Table 28: **In vitro** evaluation results of Microbiological Associates 1996 for CAs in human PBLs

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|---|---|---------------------|------|-------|---|
| Study Citation: Microbiological Associates (1996). Hexabromocyclododecane (HBCD): Chromosome aberrations in human peripheral blood lymphocytes with cover letter dated 12/12/1996 | | | | | |
| Data Type: CAs in human PBLs | | | | | |
| HERO ID: 787699 | | | | | |
| Domain 1: Test Substance | | | | | |
| Metric 1: | Test Substance Identity | High | × 2 | 2 | Test substance was identified by name and CAS 25637-99-4 |
| Metric 2: | Test Substance Source | Low | × 1 | 3 | The test substance source was not reported. Three industry submitters were identified, but no single source of them test substance was given. |
| Metric 3: | Test Substance Purity | Low | × 1 | 3 | Purity of the test substance was not reported. |
| Domain 2: Test Design | | | | | |
| Metric 4: | Negative and Vehicle Controls | High | × 2 | 2 | Concurrent solvent and cell media controls were reported. |
| Metric 5: | Positive Controls | High | × 2 | 2 | Concurrent positive controls were used +/- S9 and had appropriate responses. |
| Metric 6: | Assay Procedures | High | × 1 | 1 | Assay procedures were well described and appropriate. |
| Metric 7: | Standards for Tests | Not Rated | NA | NA | Not applicable for the study type. |
| Domain 3: Exposure Characterization | | | | | |
| Metric 8: | Preparation and Storage of Test Substance | High | × 1 | 1 | Preparation and storage of the test substance was reported. |
| Metric 9: | Consistency of Exposure Administration | High | × 1 | 1 | Consistency of exposure administration across groups was inferred from the text. |
| Metric 10: | Reporting of Doses/Concentrations | High | × 2 | 2 | Concentrations were reported clearly in tables. |
| Metric 11: | Number of Exposure Groups and Concentration Spacing | High | × 2 | 2 | Exposure duration was reported and was longer than guidance values but appears to be appropriate. |
| Metric 12: | Exposure Route and Method | High | × 1 | 1 | Exposure groups spacing were justified based on the high dose solubility, number of groups was reported and appropriate. |
| Metric 13: | Metabolic Activation | High | × 1 | 1 | Metabolic activation was well described and is commonly used. |
| Domain 4: Test Model | | | | | |
| Metric 14: | Test Model | High | × 2 | 2 | Test model was reported and is commonly used for the outcome of interest. |
| Metric 15: | Number per Group | Low | × 1 | 3 | Number per group was not reported, but study was done in duplicate. |
| Domain 5: Outcome Assessment | | | | | |

Continued on next page ...

... continued from previous page

Study Citation: Microbiological Associates (1996). Hexabromocyclododecane (HBCD): Chromosome aberrations in human peripheral blood lymphocytes with cover letter dated 12/12/1996
 Data Type: CAs in human PBLs
 HERO ID: 787699

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|--|--|---------------------|------|-------|--|
| | Metric 16: Outcome Assessment Methodology | High | × 2 | 2 | Outcome assessment methodology was appropriate for the outcome of interest. |
| | Metric 17: Consistency of Outcome Assessment | High | × 1 | 1 | Outcome assessment was carried out consistently across groups. |
| | Metric 18: Sampling Adequacy | Medium | × 2 | 4 | Number of cells samples is 100/replicate and is less than recommended. |
| | Metric 19: Blinding of Assessors | High | × 1 | 1 | Blinding of assessors was reported. |
| Domain 6: Confounding / Variable Control | | | | | |
| | Metric 20: Confounding Variables in Test Design and Procedures | Low | × 2 | 6 | Initial conditions were not reported for each group and replicate. |
| | Metric 21: Confounding Variables in Outcomes Unrelated to Exposure | Medium | × 1 | 2 | Data on experienced disproportionate outcomes unrelated to exposure were not reported, but this is unlikely to have a substantial impact on results. |
| Domain 7: Data Presentation and Analysis | | | | | |
| | Metric 22: Data Analysis | High | × 1 | 1 | Statistical analysis was reported and was appropriate for the study type. |
| | Metric 23: Data Interpretation | High | × 2 | 2 | Evaluation criteria were reported and consistent with guideline. |
| | Metric 24: Cytotoxicity Data | High | × 1 | 1 | Cytotoxicity was evaluated based on mitotic inhibition and is commonly used. |
| | Metric 25: Reporting of Data | High | × 2 | 2 | Data were reported for all groups and outcomes. |
| Overall Quality Determination [‡] | | High | | 1.4 | |
| Extracted | | Yes | | | |

* MWF = Metric Weighting Factor

[†] High = 1; Medium = 2; Low = 3; Unacceptable = 4; N/A has no value.

[‡] The overall rating is calculated as necessary. EPA may not always provide a comment for a metric that has been categorized as High.

$$\text{Overall rating} = \begin{cases} 4 & \text{if any metric is Unacceptable} \\ \left[\frac{\sum_i (\text{Metric Score}_i \times \text{MWF}_i)}{\sum_j \text{MWF}_j} \right]_{0.1} & \text{(round to the nearest tenth) otherwise} \end{cases}$$

where High = ≥ 1 to < 1.7 ; Medium = ≥ 1.7 to < 2.3 ; Low = ≥ 2.3 to ≤ 3.0 . If the reviewer determines that the overall rating needs adjustment, the original rating is crossed out and an arrow points to the new rating.

^{††} This metric met the criteria for high confidence as expected for this type of study

Table 29: In vitro evaluation results of Pharmakologisches Institut 1990 for Ames test

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|---|---|---------------------|------|-------|---|
| Study Citation: Pharmakologisches Institut (1990). Ames test with hexabromides with cover letter dated 031290 | | | | | |
| Data Type: Ames test for HBCD | | | | | |
| HERO ID: 787701 | | | | | |
| <hr/> | | | | | |
| Domain 1: Test Substance | | | | | |
| Metric 1: | Test Substance Identity | High | × 2 | 2 | The test substance was identified by chemical name, CASRN (3194-55-6), and structure in the submission. In the study itself, the test substance was referred to as "Hexabromid S" without additional information. |
| Metric 2: | Test Substance Source | Low | × 1 | 3 | The source of the test substance was not reported (unclear if the source was the submitting organization). |
| Metric 3: | Test Substance Purity | High | × 1 | 1 | The reported purity of the test substance (approximately 95%) is such that effects likely due to test substance. |
| <hr/> | | | | | |
| Domain 2: Test Design | | | | | |
| Metric 4: | Negative and Vehicle Controls | High | × 2 | 2 | Negative (DMSO-only) controls were included; all conditions except exposure to the test substance appeared to be equal. |
| Metric 5: | Positive Controls | High | × 2 | 2 | Concurrent positive controls were used, and the intended positive response was induced. |
| Metric 6: | Assay Procedures | Medium | × 1 | 2 | Assay procedures (namely modifications) were briefly reported; methods were partially cited to another publication. |
| Metric 7: | Standards for Tests | Not Rated | NA | NA | This metric is not applicable to the study type. |
| <hr/> | | | | | |
| Domain 3: Exposure Characterization | | | | | |
| Metric 8: | Preparation and Storage of Test Substance | High | × 1 | 1 | The study indicates that the test substance was stored at 4C in the dark and dissolved in the solvent on the day of the mutagenicity experiment. |
| Metric 9: | Consistency of Exposure Administration | High | × 1 | 1 | Exposures were administered consistently across study groups. |
| Metric 10: | Reporting of Doses/Concentrations | High | × 2 | 2 | Exposure concentrations were reported without ambiguity. |
| Metric 11: | Number of Exposure Groups and Concentration Spacing | High | × 2 | 2 | Exposure duration was reported and appropriate for the study type. |
| <hr/> | | | | | |
| Continued on next page ... | | | | | |
| <hr/> | | | | | |

... continued from previous page

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|---|--|---------------------|------|-------|---|
| Study Citation: Pharmakologisches Institut (1990). Ames test with hexabromides with cover letter dated 031290 | | | | | |
| Data Type: Ames test for HBCD | | | | | |
| HERO ID: 787701 | | | | | |
| | Metric 12: Exposure Route and Method | Medium | × 1 | 2 | The number of exposure groups was reported (5 plus controls in the absence of activation and 7 plus controls in the presence of activation). The number of exposure groups aligns with the number recommended for studies of this type; however, no rationale for dose selection (other than indications of precipitation at 1000 ug/plate) was provided. |
| | Metric 13: Metabolic Activation | High | × 1 | 1 | The study authors reported exposures were conducted in the presence of metabolic activation and the type and source, method of preparation, and volume in final culture of the metabolic activation system were described. |
| Domain 4: Test Model | | | | | |
| | Metric 14: Test Model | Medium | × 2 | 4 | The test models (Salmonella strains) were described in detail in the Introduction of the study and are routinely for the outcome of interest. The source of the bacterial strains was not specified. |
| | Metric 15: Number per Group | High | × 1 | 1 | The number of replicates (two plates) was reported and appropriate for the study type. It is noted that one plate was available for the 315 ug/plate dose with activation; no explanation was provided. |
| Domain 5: Outcome Assessment | | | | | |
| | Metric 16: Outcome Assessment Methodology | High | × 2 | 2 | The outcome assessment methodology was reported and appropriate for the study type. |
| | Metric 17: Consistency of Outcome Assessment | High | × 1 | 1 | Outcomes were assessed consistently across study groups. |
| | Metric 18: Sampling Adequacy | Not Rated | NA | NA | This metric is not applicable to the study type. |
| | Metric 19: Blinding of Assessors | High | × 1 | 1 | The study indicated that the person that counted colonies did not know the specifications of the plates. |
| Domain 6: Confounding / Variable Control | | | | | |
| | Metric 20: Confounding Variables in Test Design and Procedures | High | × 2 | 2 | No confounding variables were identified. |
| | Metric 21: Confounding Variables in Outcomes Unrelated to Exposure | Medium | × 1 | 2 | The test material interfered in the assay (i.e., precipitation at 1000 ug/plate and above). The study authors indicated that this was not expected to be a study limitation, since mutagenicity is expected at lower doses. |
| Domain 7: Data Presentation and Analysis | | | | | |
| | Metric 22: Data Analysis | High | × 1 | 1 | Data were not analyzed statistically, but were raw data were presented so that analyses could be conducted independently. |

Continued on next page ...

...continued from previous page

Study Citation: Pharmakologisches Institut (1990). Ames test with hexabromides with cover letter dated 031290
 Data Type: Ames test for HBCD
 HERO ID: 787701

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|--|--------------------------------|---------------------|------|-------|---|
| | Metric 23: Data Interpretation | Medium | × 2 | 4 | The criteria for a positive response was not clearly specified; however, this omission is not expected to substantially impact the study results. |
| | Metric 24: Cytotoxicity Data | Not Rated | NA | NA | Cytotoxicity was not included in the study and are not strictly required by study type. |
| | Metric 25: Reporting of Data | High | × 2 | 2 | Data were reported by exposure group. |
| Overall Quality Determination [‡] | | High | | 1.3 | |
| Extracted | | Yes | | | |

* MWF = Metric Weighting Factor

† High = 1; Medium = 2; Low = 3; Unacceptable = 4; N/A has no value.

‡ The overall rating is calculated as necessary. EPA may not always provide a comment for a metric that has been categorized as High.

$$\text{Overall rating} = \begin{cases} 4 & \text{if any metric is Unacceptable} \\ \left\lfloor \frac{\sum_i (\text{Metric Score}_i \times \text{MWF}_i)}{\sum_j \text{MWF}_j} \right\rfloor_{0.1} & \text{(round to the nearest tenth) otherwise} \end{cases}$$

where High ≥ 1 to < 1.7 ; Medium ≥ 1.7 to < 2.3 ; Low ≥ 2.3 to ≤ 3.0 . If the reviewer determines that the overall rating needs adjustment, the original rating is crossed out and an arrow points to the new rating.

†† This metric met the criteria for high confidence as expected for this type of study

Table 30: In vitro evaluation results of SRI International 1990 for mutagenicity studies

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|---|---|---------------------|------|-------|---|
| Study Citation: SRI International (1990). In vitro microbiological mutagenicity studies of four Ciba-Geigy Corporation compounds (final report) with test data and cover letter | | | | | |
| Data Type: Mutagenicity studies for HBCD | | | | | |
| HERO ID: 787716 | | | | | |
| Domain 1: Test Substance | | | | | |
| Metric 1: | Test Substance Identity | Medium | × 2 | 4 | The test substance was identified by name and CASRN (3146-5-6) in the submission. In the study itself, the test substance was referred to as 421-3B "hexabromocyclododecane dispersion" without further information. |
| Metric 2: | Test Substance Source | Low | × 1 | 3 | The source of the test substance was not reported; it was not clear if the source was the submitting organization (Great Lakes Chemical Corporation) or corporation for which the report was prepared (as this test substance and others were called "Ciby-Geigy Corporation compounds"). |
| Metric 3: | Test Substance Purity | Low | × 1 | 3 | The purity of the test substance was not reported. the study indicated that there were no known additives to the test substance(s). |
| Domain 2: Test Design | | | | | |
| Metric 4: | Negative and Vehicle Controls | High | × 2 | 2 | The study reported using concurrent negative (solvent only) controls. |
| Metric 5: | Positive Controls | Medium | × 2 | 4 | Concurrent positive controls were used and the intended positive response was induced. The study indicated that each culture was tested using specific mutagens (positive controls); however, it appears from the data tables that only two of five strains were tested with activation (all were tested without activation). |
| Metric 6: | Assay Procedures | High | × 1 | 1 | Methods and procedures were adequately described (including reaction mix, temperature, and media). |
| Metric 7: | Standards for Tests | Not Rated | NA | NA | This metric is not applicable to the study type. |
| Domain 3: Exposure Characterization | | | | | |
| Metric 8: | Preparation and Storage of Test Substance | Medium | × 1 | 2 | The study indicated that the test substance was dissolved in the solvent immediately before use. Storage conditions were not reported. |
| Metric 9: | Consistency of Exposure Administration | High | × 1 | 1 | Exposures were administered consistently across study groups. |
| Metric 10: | Reporting of Doses/Concentrations | High | × 2 | 2 | Exposure concentrations were reported without ambiguity. |
| Continued on next page ... | | | | | |

... continued from previous page

| Study Citation: | SRI International (1990). In vitro microbiological mutagenicity studies of four Ciba-Geigy Corporation compounds (final report) with test data and cover letter | | | | | |
|--|---|---------------------|------|-------|---|--|
| Data Type: | Mutagenicity studies for HBCD | | | | | |
| HERO ID: | 787716 | | | | | |
| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} | |
| | Metric 11: Number of Exposure Groups and Concentration Spacing | High | × 2 | 2 | The exposure duration was reported and adequate for the study type. | |
| | Metric 12: Exposure Route and Method | Medium | × 1 | 2 | The number of exposure groups (7 plus controls) was reported. A rationale for the selection of dose groups was not provided other than a statement indicating that the test substance was tested over a wide range of doses for toxicity and mutagenicity determinations. | |
| | Metric 13: Metabolic Activation | High | × 1 | 1 | The study authors reported exposures were conducted in the presence of metabolic activation and the type and source, method of preparation, and volume in final culture of the metabolic activation system were described. | |
| Domain 4: Test Model | | | | | | |
| | Metric 14: Test Model | High | × 2 | 2 | The test model (Salmonella typhimurium strains) and descriptive information were reported. The source of the model was a laboratory-maintained culture, and this test model is routinely used for assays of this type. | |
| | Metric 15: Number per Group | Medium | × 1 | 2 | The study indicated that results were the average of at least two experiments (conducted on two separate days). The results are presented as the average number of revertants per plate, indicating that there were multiple plates per exposure group (number not explicitly specified). | |
| Domain 5: Outcome Assessment | | | | | | |
| | Metric 16: Outcome Assessment Methodology | High | × 2 | 2 | The outcome methodology assessment was reported and appropriate for the study type. | |
| | Metric 17: Consistency of Outcome Assessment | High | × 1 | 1 | Outcomes were assessed consistently across study groups. | |
| | Metric 18: Sampling Adequacy | Not Rated | NA | NA | This metric is not applicable to the study type. | |
| | Metric 19: Blinding of Assessors | Not Rated | NA | NA | This metric is not applicable to the study type. | |
| Domain 6: Confounding / Variable Control | | | | | | |
| | Metric 20: Confounding Variables in Test Design and Procedures | High | × 2 | 2 | No confounding variables were identified. | |
| | Metric 21: Confounding Variables in Outcomes Unrelated to Exposure | Low | × 1 | 3 | No data were reported for outcomes unrelated to exposure. | |
| Domain 7: Data Presentation and Analysis | | | | | | |

Continued on next page ...

...continued from previous page

Study Citation: SRI International (1990). In vitro microbiological mutagenicity studies of four Ciba-Geigy Corporation compounds (final report) with test data and cover letter
 Data Type: Mutagenicity studies for HBCD
 HERO ID: 787716

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|--|---------------------|---------------------|------|-------|--|
| Metric 22: | Data Analysis | Low | × 1 | 3 | Statistical analysis was not conducted and standard deviations were not reported, so independent statistical analysis is not possible. However, statistical analysis is not necessarily required for the bacterial reverse mutation assay. |
| Metric 23: | Data Interpretation | Low | × 2 | 6 | The criteria for a positive response was not explicitly specified. |
| Metric 24: | Cytotoxicity Data | Not Rated | NA | NA | Cytotoxicity analyses are not strictly required by study type. |
| Metric 25: | Reporting of Data | High | × 2 | 2 | Data were reported by exposure group. |
| Overall Quality Determination [‡] | | High | | 1.6 | |
| Extracted | | Yes | | | |

* MWF = Metric Weighting Factor

[†] High = 1; Medium = 2; Low = 3; Unacceptable = 4; N/A has no value.

[‡] The overall rating is calculated as necessary. EPA may not always provide a comment for a metric that has been categorized as High.

$$\text{Overall rating} = \begin{cases} 4 & \text{if any metric is Unacceptable} \\ \left\lfloor \frac{\sum_i (\text{Metric Score}_i \times \text{MWF}_i)}{\sum_j \text{MWF}_j} \right\rfloor_{0.1} & \text{(round to the nearest tenth) otherwise} \end{cases}$$

where High = ≥ 1 to < 1.7 ; Medium = ≥ 1.7 to < 2.3 ; Low = ≥ 2.3 to ≤ 3.0 . If the reviewer determines that the overall rating needs adjustment, the original rating is crossed out and an arrow points to the new rating.

^{††} This metric met the criteria for high confidence as expected for this type of study

Table 31: **In vitro** evaluation results of An et al 2013 for Comet assay on L02 cell line

| Study Citation: | J. An, W. Zou, C. Chen, F. Y. Zhong, Q. Z. Yu, Q. J. Wang (2013). The cytological effects of HBCDs on human hepatocyte L02 and the potential molecular mechanism Journal of Environmental Science and Health, Part A: Toxic/Hazardous Substances & Environmental Engineering, 48(11,11), 1333-1342 | | | | | |
|-------------------------------------|--|---------------------|------|-------|--|--|
| Data Type: | Comet assay on L02 cell line | | | | | |
| HERO ID: | 1927550 | | | | | |
| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} | |
| Domain 1: Test Substance | | | | | | |
| Metric 1: | Test Substance Identity | High | × 2 | 2 | Test substance was identified as hexabromocyclodecanes. | |
| Metric 2: | Test Substance Source | High | × 1 | 1 | Test substance was purchased from TCI (Tokyo, Japan). | |
| Metric 3: | Test Substance Purity | Low | × 1 | 3 | Purity or grade of test substance was not reported. | |
| Domain 2: Test Design | | | | | | |
| Metric 4: | Negative and Vehicle Controls | Low | × 2 | 6 | Concurrent negative controls were included in assays; however, it is not clear whether the controls were treated with DMSO (media or solvent/vehicle controls). | |
| Metric 5: | Positive Controls | Not Rated | NA | NA | Positive controls were not used, but may not have been needed in the mechanistic context of the study. A clear dose-response relationship was demonstrated for DNA damage. | |
| Metric 6: | Assay Procedures | High | × 1 | 1 | Assay methods were well described. | |
| Metric 7: | Standards for Tests | Not Rated | NA | NA | Not applicable | |
| Domain 3: Exposure Characterization | | | | | | |
| Metric 8: | Preparation and Storage of Test Substance | Medium | × 1 | 2 | Preparation of test substance was reported; however, storage conditions, or if substance was made immediately prior to use, were not given. | |
| Metric 9: | Consistency of Exposure Administration | High | × 1 | 1 | Exposures were administered consistently across groups. | |
| Metric 10: | Reporting of Doses/Concentrations | High | × 2 | 2 | Concentrations were reported without ambiguity. | |
| Metric 11: | Number of Exposure Groups and Concentration Spacing | High | × 2 | 2 | Exposure duration were reported and appropriate. | |
| Metric 12: | Exposure Route and Method | High | × 1 | 1 | The number of exposure groups were appropriate to establish dose-response relationships. | |
| Metric 13: | Metabolic Activation | Not Rated | NA | NA | It was assumed that the human hepatocyte cell line does not require exogenous metabolic activation. | |
| Domain 4: Test Model | | | | | | |
| Continued on next page ... | | | | | | |

... continued from previous page

| Study Citation: | J. An, W. Zou, C. Chen, F. Y. Zhong, Q. Z. Yu, Q. J. Wang (2013). The cytological effects of HBCDs on human hepatocyte L02 and the potential molecular mechanism Journal of Environmental Science and Health, Part A: Toxic/Hazardous Substances & Environmental Engineering, 48(11,11), 1333-1342 | | | | | |
|--|--|---------------------|------|-------|---|--|
| Data Type: | Comet assay on L02 cell line | | | | | |
| HERO ID: | 1927550 | | | | | |
| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} | |
| | Metric 14: Test Model | High | × 2 | 2 | Test model was identified as an immortalized human hepatocyte (L02) cell line obtained from Ping Zhou (Beijing Institute of Radiation Medicine, Beijing China). | |
| | Metric 15: Number per Group | High | × 1 | 1 | All experiments were performed in at least triplicate. | |
| Domain 5: Outcome Assessment | | | | | | |
| | Metric 16: Outcome Assessment Methodology | High | × 2 | 2 | Outcome assessment methodology was reported and is sensitive for the outcome or interest. | |
| | Metric 17: Consistency of Outcome Assessment | High | × 1 | 1 | Outcome assessments were carried out consistently. | |
| | Metric 18: Sampling Adequacy | High | × 2 | 2 | Sampling was adequate for the outcome of interest (100 cells/sample). | |
| | Metric 19: Blinding of Assessors | Not Rated | NA | NA | Automated measurements were made using fluorescence analysis. | |
| Domain 6: Confounding / Variable Control | | | | | | |
| | Metric 20: Confounding Variables in Test Design and Procedures | Low | × 2 | 6 | Initial conditions were not reported by group or replicate. | |
| | Metric 21: Confounding Variables in Outcomes Unrelated to Exposure | Medium | × 1 | 2 | Data on outcome differences unrelated to exposure were not reported for each study replicate or group. | |
| Domain 7: Data Presentation and Analysis | | | | | | |
| | Metric 22: Data Analysis | High | × 1 | 1 | ANOVA and a post hoc Tukey test were performed. | |
| | Metric 23: Data Interpretation | High | × 2 | 2 | Data scoring and evaluations were appropriate. | |
| | Metric 24: Cytotoxicity Data | High | × 1 | 1 | Cytotoxic endpoints were clearly defined. | |
| | Metric 25: Reporting of Data | High | × 2 | 2 | Data were presented clearly in figures and in the text. | |
| Overall Quality Determination [‡] | | High | | 1.4 | | |
| Extracted | | Yes | | | | |

* MWF = Metric Weighting Factor

[†] High = 1; Medium = 2; Low = 3; Unacceptable = 4; N/A has no value.

[‡] The overall rating is calculated as necessary. EPA may not always provide a comment for a metric that has been categorized as High.

$$\text{Overall rating} = \begin{cases} 4 & \text{if any metric is Unacceptable} \\ \left\lceil \left[\frac{\sum_i (\text{Metric Score}_i \times \text{MWF}_i)}{\sum_j \text{MWF}_j} \right]_{0.1} \right\rceil & \text{(round to the nearest tenth) otherwise} \end{cases}$$

where High = ≥ 1 to < 1.7 ; Medium = ≥ 1.7 to < 2.3 ; Low = ≥ 2.3 to ≤ 3.0 . If the reviewer determines that the overall rating needs adjustment, the original rating is crossed out and an arrow points to the new rating.

^{††} This metric met the criteria for high confidence as expected for this type of study

Table 32: **In vitro** evaluation results of Ethyl Corporation 1990 for DNA repair in rat hepatocytes

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|--|---|---------------------|------|-------|---|
| Study Citation: Ethyl Corporation (1990). Genetic toxicology rat hepatocyte primary culture/DNA repair test on hexabromocyclododecane with cover letter dated 030890 | | | | | |
| Data Type: DNA repair in rat hepatocytes for HBCD | | | | | |
| HERO ID: 1928253 | | | | | |
| Domain 1: Test Substance | | | | | |
| Metric 1: | Test Substance Identity | Medium | × 2 | 4 | The test substance was identified by name and CASRN (3194-55-6) in the submission. In the study itself, the test substance was referred to as "HBCD Bottoms" without additional information. |
| Metric 2: | Test Substance Source | Low | × 1 | 3 | The source (manufacturer) of the test substance was not reported; it was not clear if information provided with the test substance (PU-85121 or G.T.# 083) corresponded to batch/lot numbers. |
| Metric 3: | Test Substance Purity | Low | × 1 | 3 | The purity of the test substance was not reported. |
| Domain 2: Test Design | | | | | |
| Metric 4: | Negative and Vehicle Controls | High | × 2 | 2 | Negative (untreated) and solvent controls (acetone) were reported; however, data were shown for the solvent control group only. The response of the vehicle-only controls was acceptable. |
| Metric 5: | Positive Controls | High | × 2 | 2 | A concurrent positive control group was used (2-AAF) and the intended positive response was induced. |
| Metric 6: | Assay Procedures | Low | × 1 | 3 | Methods and procedures were described in minimal detail; methods were cited primarily to company SOPs. An SOP entitled "Rat Hepatocyte Primary Culture/DNA Repair Test" was included with the study (but is not specific to the study). |
| Metric 7: | Standards for Tests | Not Rated | NA | NA | This metric is not applicable to the study type. |
| Domain 3: Exposure Characterization | | | | | |
| Metric 8: | Preparation and Storage of Test Substance | Medium | × 1 | 2 | The study indicates that the color and appearance of the test substance did not change from the time of receipt until the time of use. Acetone was identified as the solvent used in the experiment. The company SOP provided with the study (but not specific to the study) indicated that solvent selection is based on the solubility and/or suspendability of the test substance. There was no information on storage conditions. |
| Continued on next page ... | | | | | |

...continued from previous page

| Study Citation: | Ethyl Corporation (1990). Genetic toxicology rat hepatocyte primary culture/DNA repair test on hexabromocyclododecane with cover letter dated 030890 | | | | | |
|------------------------------|--|---------------------|------|-------|--|--|
| Data Type: | DNA repair in rat hepatocytes for HBCD | | | | | |
| HERO ID: | 1928253 | | | | | |
| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} | |
| | Metric 9: Consistency of Exposure Administration | Medium | × 1 | 2 | Limited data were provided; however, the study indicated that application volumes were consistent (i.e., 20 uL HBCD bottoms added to 2 mL of media). It is inferred from the text that exposures were administered consistently across study groups. | |
| | Metric 10: Reporting of Doses/Concentrations | High | × 2 | 2 | Exposure concentrations were reported without ambiguity. | |
| | Metric 11: Number of Exposure Groups and Concentration Spacing | Not Rated | NA | NA | The exposure duration (and details) were cited to a company SOP (ETTOX 029). | |
| | Metric 12: Exposure Route and Method | High | × 1 | 1 | The study used 10 concentrations plus controls; cytotoxicity was reported at the highest dose. The SOP provided for the study type (but not specific to the study) indicated that highest doses would be 5% or the highest soluble concentration and remaining doses would be half-log dilutions. | |
| | Metric 13: Metabolic Activation | Not Rated | NA | NA | This metric is not applicable to the study type. | |
| Domain 4: Test Model | | | | | | |
| | Metric 14: Test Model | Medium | × 2 | 4 | The test model (rat hepatocytes) was reported with limited descriptive information. This test model is routinely used to evaluate the outcome of interest. The SOP provided with the study (but not specific to the study) indicated that rat hepatocytes are used in this assay because they have been shown to incorporate 3H-thymidine into DNA due to unscheduled DNA synthesis. Some details regarding the test model were cited to other company SOPs. | |
| | Metric 15: Number per Group | Not Rated | NA | NA | The number of replicates was not reported; detailed methods were cited to company SOPs. | |
| Domain 5: Outcome Assessment | | | | | | |
| | Metric 16: Outcome Assessment Methodology | Medium | × 2 | 4 | Outcome assessment methods were partially described (UDS as measured as a net nuclear increase in grain count) and partially cited to company SOPs. | |
| | Metric 17: Consistency of Outcome Assessment | Medium | × 1 | 2 | Outcome assessment methods were cited to company SOPs, but some details were partially described and consistency of evaluations appeared appropriate. | |
| Continued on next page ... | | | | | | |

...continued from previous page

| Study Citation: | Ethyl Corporation (1990). Genetic toxicology rat hepatocyte primary culture/DNA repair test on hexabromocyclododecane with cover letter dated 030890 | | | | | |
|--|--|---------------------|------|-------|--|--|
| Data Type: | DNA repair in rat hepatocytes for HBCD | | | | | |
| HERO ID: | 1928253 | | | | | |
| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} | |
| | Metric 18: Sampling Adequacy | High | × 2 | 2 | The SOP provided with the study (but not specific to the study) stated that nuclear and background grain counts should be quantified in 25 cells/slide or as many cells as possible per slide (up to 25) in the presence of cytotoxicity. The data table indicates that 25 cells were counted on one slide (unclear which group(s) this refers to). | |
| | Metric 19: Blinding of Assessors | Not Rated | NA | NA | This metric is not applicable to the study type. | |
| Domain 6: Confounding / Variable Control | | | | | | |
| | Metric 20: Confounding Variables in Test Design and Procedures | Low | × 2 | 6 | Initial conditions for each study group were not reported. | |
| | Metric 21: Confounding Variables in Outcomes Unrelated to Exposure | Low | × 1 | 3 | Data on outcomes unrelated to exposure were not reported for each study group. | |
| Domain 7: Data Presentation and Analysis | | | | | | |
| | Metric 22: Data Analysis | Medium | × 1 | 2 | Statistical methods were reported with omissions. The study stated that a Chi square analysis was done to compare treated cells to untreated cells, and that statistical significance was achieved at the top 4 concentrations (not indicated as positive in the accompanying data table). | |
| | Metric 23: Data Interpretation | High | × 2 | 2 | The criteria for a positive response was explicitly specified. The study indicated that the result for HBCD was considered positive because it produced a mean grain count of 5 or greater than the negative control mean grain count and a statistically significant change between HBCD-treated cells and the controls in the number of cells with grain counts > 0. | |
| | Metric 24: Cytotoxicity Data | Low | × 1 | 3 | It is reported that cytotoxicity was assessed (as cytotoxicity was noted at 1000 ug/well); however, the endpoint was not well-defined and the methods of measurement were not reported. | |
| | Metric 25: Reporting of Data | High | × 2 | 2 | Data were reported by exposure group. | |
| Overall Quality Determination [‡] | | Medium | | 1.8 | | |
| Extracted | | Yes | | | | |
| Continued on next page ... | | | | | | |

...continued from previous page

Study Citation: Ethyl Corporation (1990). Genetic toxicology rat hepatocyte primary culture/DNA repair test on hexabromocyclododecane with cover letter dated 030890
 Data Type: DNA repair in rat hepatocytes for HBCD
 HERO ID: 1928253

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|--------|--------|---------------------|------|-------|------------------------|
|--------|--------|---------------------|------|-------|------------------------|

* MWF = Metric Weighting Factor

† High = 1; Medium = 2; Low = 3; Unacceptable = 4; N/A has no value.

‡ The overall rating is calculated as necessary. EPA may not always provide a comment for a metric that has been categorized as High.

$$\text{Overall rating} = \begin{cases} 4 & \text{if any metric is Unacceptable} \\ \left\lceil \sum_i (\text{Metric Score}_i \times \text{MWF}_i) / \sum_j \text{MWF}_j \right\rceil_{0.1} & \text{(round to the nearest tenth) otherwise} \end{cases}$$

where High $\Rightarrow \geq 1$ to < 1.7 ; Medium $\Rightarrow \geq 1.7$ to < 2.3 ; Low $\Rightarrow \geq 2.3$ to ≤ 3.0 . If the reviewer determines that the overall rating needs adjustment, the original rating is crossed out and an arrow points to the new rating.

†† This metric met the criteria for high confidence as expected for this type of study

Table 33: **In vitro** evaluation results of Ameribrom Inc 1990 for bacterial reverse mutation

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|---|---|---------------------|------|-------|---|
| Study Citation: (1990). Letter from Ameribrom Inc to US EPA regarding 8D submission for hexabromocyclododecane with attachments | | | | | |
| Data Type: Bacterial reverse mutation | | | | | |
| HERO ID: 1928284 | | | | | |
| <hr/> | | | | | |
| Domain 1: Test Substance | | | | | |
| Metric 1: | Test Substance Identity | High | × 2 | 2 | Test substance identified by name, chemical formula, and physical chemical properties. |
| Metric 2: | Test Substance Source | Medium | × 1 | 2 | Source was identified as Bromine Compounds Ltd; batch/lot number was not given. |
| Metric 3: | Test Substance Purity | Low | × 1 | 3 | Purity not reported. |
| <hr/> | | | | | |
| Domain 2: Test Design | | | | | |
| Metric 4: | Negative and Vehicle Controls | High | × 2 | 2 | Negative controls were included. |
| Metric 5: | Positive Controls | High | × 2 | 2 | Positive controls were included. |
| Metric 6: | Assay Procedures | High | × 1 | 1 | Assay procedures were described. |
| Metric 7: | Standards for Tests | Not Rated | NA | NA | Criteria not required. |
| <hr/> | | | | | |
| Domain 3: Exposure Characterization | | | | | |
| Metric 8: | Preparation and Storage of Test Substance | High | × 1 | 1 | Preparation details were described. |
| Metric 9: | Consistency of Exposure Administration | High | × 1 | 1 | Exposures were administered consistently. |
| Metric 10: | Reporting of Doses/Concentrations | High | × 2 | 2 | Concentrations were reported. |
| Metric 11: | Number of Exposure Groups and Concentration Spacing | High | × 2 | 2 | Duration was reported and appropriate. |
| Metric 12: | Exposure Route and Method | High | × 1 | 1 | The number of groups and spacing were reported with justification. |
| Metric 13: | Metabolic Activation | High | × 1 | 1 | Activation system and mix were described. |
| <hr/> | | | | | |
| Domain 4: Test Model | | | | | |
| Metric 14: | Test Model | High | × 2 | 2 | Test models were well described. |
| Metric 15: | Number per Group | Medium | × 1 | 2 | An overnight culture was used for experiments, but exact number of cells not reported. The number of replicates was reported. |
| <hr/> | | | | | |
| Domain 5: Outcome Assessment | | | | | |
| Metric 16: | Outcome Assessment Methodology | High | × 2 | 2 | Outcome assessment methodology was described. |
| Metric 17: | Consistency of Outcome Assessment | High | × 1 | 1 | Outcomes were assessed consistently. |
| Metric 18: | Sampling Adequacy | Not Rated | NA | NA | This metric is not applicable to the outcome. |
| Metric 19: | Blinding of Assessors | Not Rated | NA | NA | Blinding was not required. |
| <hr/> | | | | | |
| Domain 6: Confounding / Variable Control | | | | | |
| Metric 20: | Confounding Variables in Test Design and Procedures | Low | × 2 | 6 | Initial conditions were not reported for each study replicate or group. |
| <hr/> | | | | | |
| Continued on next page ... | | | | | |

... continued from previous page

Study Citation: (1990). Letter from Ameribrom Inc to US EPA regarding 8D submission for hexabromocyclododecane with attachments
 Data Type: Bacterial reverse mutation
 HERO ID: 1928284

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|--|--|---------------------|------|-------|--|
| | Metric 21: Confounding Variables in Outcomes Unrelated to Exposure | Medium | × 1 | 2 | Sterility check plates were used to show that the test material and S9 mix were free of microbial contamination. |
| Domain 7: Data Presentation and Analysis | | | | | |
| | Metric 22: Data Analysis | High | × 1 | 1 | Statistical methods were described. |
| | Metric 23: Data Interpretation | High | × 2 | 2 | Criteria for positive finding was described. |
| | Metric 24: Cytotoxicity Data | High | × 1 | 1 | A preliminary cytotoxicity assay was conducted. |
| | Metric 25: Reporting of Data | High | × 2 | 2 | Data were reported. |
| Overall Quality Determination [‡] | | High | | 1.3 | |
| Extracted | | Yes | | | |

* MWF = Metric Weighting Factor

† High = 1; Medium = 2; Low = 3; Unacceptable = 4; N/A has no value.

‡ The overall rating is calculated as necessary. EPA may not always provide a comment for a metric that has been categorized as High.

$$\text{Overall rating} = \begin{cases} 4 & \text{if any metric is Unacceptable} \\ \left\lfloor \frac{\sum_i (\text{Metric Score}_i \times \text{MWF}_i)}{\sum_j \text{MWF}_j} \right\rfloor_{0.1} & \text{(round to the nearest tenth) otherwise} \end{cases}$$

where High $\Rightarrow 1$ to < 1.7 ; Medium $\Rightarrow 1.7$ to < 2.3 ; Low $\Rightarrow 2.3$ to ≤ 3.0 . If the reviewer determines that the overall rating needs adjustment, the original rating is crossed out and an arrow points to the new rating.

†† This metric met the criteria for high confidence as expected for this type of study

Table 34: **In vitro** evaluation results of GSRI 1978 for Ames assay in *S. typhimurium*

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|--|---|---------------------|------|-------|--|
| Study Citation: GSRI (1978). Mutagenicity test of GLS-S6-41A (not published) | | | | | |
| Data Type: in vitro mutation Ames assay in <i>S. typhimurium</i> | | | | | |
| HERO ID: 1937197 | | | | | |
| Domain 1: Test Substance | | | | | |
| Metric 1: | Test Substance Identity | Low | × 2 | 6 | The test substance was identified as GLS-S6-41A in the study report. A hand-written notation on the cover page of the study identifies this substance as hexabromocyclododecane; specific form was not reported. |
| Metric 2: | Test Substance Source | Low | × 1 | 3 | The source of the test substance was not reported. A hand-written notation on the cover page of the study identifies Ethyl Corp., but it is not clear if this is the source of the test substance. |
| Metric 3: | Test Substance Purity | Low | × 1 | 3 | The purity and/or grade of the test substance was not reported |
| Domain 2: Test Design | | | | | |
| Metric 4: | Negative and Vehicle Controls | High | × 2 | 2 | Study results report using a solvent control (DMSO 0.1 ml) for each strain |
| Metric 5: | Positive Controls | High | × 2 | 2 | Positive controls were tested (Benzo(a)pyrene (TA98 and TA100, N-methyl-N-nitroso N-nitroguanidine (TA1535), 9-aminoacridine (TA 1537) |
| Metric 6: | Assay Procedures | Not Rated | NA | NA | Assay methods and procedures for the Ames assay were not described, but was noted to conform to published procedure (Ames et al., 1975) |
| Metric 7: | Standards for Tests | Not Rated | NA | NA | Not applicable for this study |
| Domain 3: Exposure Characterization | | | | | |
| Metric 8: | Preparation and Storage of Test Substance | Medium | × 1 | 2 | Test substance preparation was not described but can be assumed to be prepared by dilution in DMSO as this is noted to be the solvent control. |
| Metric 9: | Consistency of Exposure Administration | Medium | × 1 | 2 | Exposures can be inferred to be administered consistently across treated and control groups; application methods were not described. |
| Metric 10: | Reporting of Doses/Concentrations | High | × 2 | 2 | The test concentration was reported in the results without ambiguity; 2, 40, 200, and 1000 ug/plate with and without metabolic activation |
| Metric 11: | Number of Exposure Groups and Concentration Spacing | Not Rated | NA | NA | The exposure duration was not reported in the study; however, the test method was noted to be conducted according to the published procedure (Ames et al., 1975) |
| Continued on next page ... | | | | | |

... continued from previous page

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|--|--|---------------------|------|-------|---|
| Study Citation: GSRI (1978). Mutagenicity test of GLS-S6-41A (not published) | | | | | |
| Data Type: in vitro mutation Ames assay in <i>S. typhimurium</i> | | | | | |
| HERO ID: 1937197 | | | | | |
| | Metric 12: Exposure Route and Method | High | × 1 | 1 | The number of exposure concentrations and spacing were reported in the results. the number of exposure groups and spacing of exposure levels appear to be adequate to show results relevant to the outcome of interest. |
| | Metric 13: Metabolic Activation | Medium | × 1 | 2 | The presence of a metabolic activation system was reported in the study. Details regarding type, composition mix, concentration, or quality control information were not described. The activity of the liver homogenate was noted to be validated by its ability to convert the positive controls to mutagenic products. |
| Domain 4: Test Model | | | | | |
| | Metric 14: Test Model | Low | × 2 | 6 | The test model was reported but no additional details were reported: <i>S. typhimurium</i> TA-98, TA-100, TA-1535, TA-1537. The source of the bacteria was not reported. |
| | Metric 15: Number per Group | Unacceptable | × 1 | 4 | The number of organisms or tissues per study group and replicates per study group were not reported |
| Domain 5: Outcome Assessment | | | | | |
| | Metric 16: Outcome Assessment Methodology | Medium | × 2 | 4 | The outcome assessment methodology used only partially addressed or reported the intended outcomes of interest (mutation frequency evaluated in the absence of cytotoxicity in a gene mutation test). |
| | Metric 17: Consistency of Outcome Assessment | Medium | × 1 | 2 | There was incomplete reporting of minor details of outcome assessment protocol execution; however, the study was noted to be conducted according to the published protocol (Ames et al. 1975) |
| | Metric 18: Sampling Adequacy | Not Rated | NA | NA | Not applicable |
| | Metric 19: Blinding of Assessors | Not Rated | NA | NA | This method is not applicable to the outcome. |
| Domain 6: Confounding / Variable Control | | | | | |
| | Metric 20: Confounding Variables in Test Design and Procedures | High | × 2 | 2 | There were no confounding variables noted in the study |
| | Metric 21: Confounding Variables in Outcomes Unrelated to Exposure | Low | × 1 | 3 | <i>S. typhimurium</i> TA100 and TA98 were noted to have intrinsically high spontaneous mutation frequency, and therefore comparison to background levels should be interpreted cautiously. It appears there were no replicates to the assay. |
| Domain 7: Data Presentation and Analysis | | | | | |

Continued on next page ...

... continued from previous page

| Study Citation: | GSRI (1978). Mutagenicity test of GLS-S6-41A (not published) | | | | | |
|--|--|---------------------|------|-------|---|--|
| Data Type: | in vitro mutation Ames assay in <i>S. typhimurium</i> | | | | | |
| HERO ID: | 1937197 | | | | | |
| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} | |
| | Metric 22: Data Analysis | Low | × 1 | 3 | Statistics were not used to assess increased revertants/plate, either from control or comparing with/without metabolic activation. A positive result was not specifically defined, but it was suggested that it was related to increased revertants and dose-dependency. Statistical analysis is not necessarily required for the bacterial reverse mutation assay, so the data analysis is considered acceptable.” | |
| | Metric 23: Data Interpretation | Low | × 2 | 6 | Scoring and/or evaluation criteria were not reported | |
| | Metric 24: Cytotoxicity Data | Unacceptable | × 1 | 4 | Cytotoxicity endpoints were not defined, methods were not described, and it could not be determined that cytotoxicity was accounted for in the interpretation of study results | |
| | Metric 25: Reporting of Data | High | × 2 | 2 | Data for the outcome were presented for each study group. | |
| Overall Quality Determination [‡] | | Unacceptable** | | 2.1 | | |
| Extracted | | No | | | | |

** Consistent with our *Application of Systematic Review in TSCARisk Evaluations* document, if a metric for a data source receives a score of Unacceptable (score = 4), EPA will determine the study to be unacceptable. In this case, one or more of the metrics were rated as unacceptable. As such, the study is considered unacceptable and the score is presented solely to increase transparency.

* MWF = Metric Weighting Factor

† High = 1; Medium = 2; Low = 3; Unacceptable = 4; N/A has no value.

‡ The overall rating is calculated as necessary. EPA may not always provide a comment for a metric that has been categorized as High.

$$\text{Overall rating} = \begin{cases} 4 & \text{if any metric is Unacceptable} \\ \left\lfloor \frac{\sum_i (\text{Metric Score}_i \times \text{MWF}_i)}{\sum_j \text{MWF}_j} \right\rfloor_{0.1} & \text{(round to the nearest tenth) otherwise} \end{cases},$$

where High \Rightarrow 1 to $<$ 1.7; Medium \Rightarrow 1.7 to $<$ 2.3; Low \Rightarrow 2.3 to \leq 3.0. If the reviewer determines that the overall rating needs adjustment, the original rating is crossed out and an arrow points to the new rating.

†† This metric met the criteria for high confidence as expected for this type of study

Table 35: **In vitro** evaluation results of An et al 2016 for Comet assay

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|--|---|---------------------|------|-------|--|
| Study Citation: An, J; Guo, P; Shang, Y; Zhong, Y; Zhang, X; Yu, Y; Yu, Z (2016). The "adaptive responses" of low concentrations of HBCD in L02 cells and the underlying molecular mechanisms <i>Chemosphere</i> , 145 68-76 | | | | | |
| Data Type: Comet assay for HBCD | | | | | |
| HERO ID: 3350502 | | | | | |
| Domain 1: Test Substance | | | | | |
| Metric 1: | Test Substance Identity | High | × 2 | 2 | The test substance was clearly identified by name. |
| Metric 2: | Test Substance Source | Medium | × 1 | 2 | The source of the test substance (a manufacturer) was reported; no information on a batch/lot number was provided. |
| Metric 3: | Test Substance Purity | Medium | × 1 | 2 | The purity of the test substance was not reported. The study indicates that HBCD was from a manufacturer and "all other chemicals were analytical reagents." |
| Domain 2: Test Design | | | | | |
| Metric 4: | Negative and Vehicle Controls | High | × 2 | 2 | The study used concurrent negative (vehicle-only) control groups. The study evaluated DNA breaks after low +/- high exposures to HBCD; appropriate control groups were used (i.e., no treatment, only high-dose treatment). |
| Metric 5: | Positive Controls | Not Rated | NA | NA | This metric is not applicable to the study type. However, test substances used in the assay showed positive dose-related responses. |
| Metric 6: | Assay Procedures | High | × 1 | 1 | Comet assay procedures were described in adequate detail (e.g., cell density, volumes, temperature). |
| Metric 7: | Standards for Tests | Not Rated | NA | NA | This metric is not applicable to the study type. |
| Domain 3: Exposure Characterization | | | | | |
| Metric 8: | Preparation and Storage of Test Substance | Low | × 1 | 3 | information related to the preparation, storage, and stability of the test substance (in solvent) were not reported. |
| Metric 9: | Consistency of Exposure Administration | High | × 1 | 1 | Exposures appeared to be administered consistently across study groups. |
| Metric 10: | Reporting of Doses/Concentrations | High | × 2 | 2 | Exposure concentrations were reported without ambiguity. |
| Metric 11: | Number of Exposure Groups and Concentration Spacing | Medium | × 2 | 4 | The duration of exposures were reported. The typical duration of exposure for an in vitro comet assay is 3 to 6 hours. This study evaluated the low dose HBCD exposures +/- subsequent high-dose HBCD exposure; in each case, exposures were 48 hours (presumably based on earlier studies). |
| Continued on next page ... | | | | | |

... continued from previous page

| Study Citation: | An, J; Guo, P; Shang, Y; Zhong, Y; Zhang, X; Yu, Y; Yu, Z (2016). The "adaptive responses" of low concentrations of HBCD in L02 cells and the underlying molecular mechanisms Chemosphere, 145 68-76 | | | | | |
|--|--|---------------------|------|-------|---|--|
| Data Type: | Comet assay for HBCD | | | | | |
| HERO ID: | 3350502 | | | | | |
| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} | |
| | Metric 12: Exposure Route and Method | Low | × 1 | 3 | The number of exposure groups was reported. Two HBCD low exposure conditions were used (10 ⁻¹³ and 10 ⁻¹¹ M; three are recommended), and one high dose of HBCD (50 uM) was used thereafter. The low doses were selected because they were considered environmentally-relevant. A rationale for the high dose was not provided; and the high dose induced significant toxicity (survival as low as 60% of controls). | |
| | Metric 13: Metabolic Activation | Not Rated | NA | NA | This metric is not applicable to the study type. | |
| Domain 4: Test Model | | | | | | |
| | Metric 14: Test Model | Medium | × 2 | 4 | The test model was described with limited details, and the source was not reported. The study indicated that the cell line was selected because the liver is a primary target of xenobiotics, and the cell line is routinely used to investigate cell signaling pathways (the focus of the study). | |
| | Metric 15: Number per Group | High | × 1 | 1 | The study indicated that each experiment was performed in triplicate using three replicates per sample. | |
| Domain 5: Outcome Assessment | | | | | | |
| | Metric 16: Outcome Assessment Methodology | High | × 2 | 2 | Outcome assessment methodology was reported. | |
| | Metric 17: Consistency of Outcome Assessment | High | × 1 | 1 | Outcomes were assessed consistently across study groups. | |
| | Metric 18: Sampling Adequacy | Not Rated | NA | NA | This metric is not applicable to the study type. | |
| | Metric 19: Blinding of Assessors | Not Rated | NA | NA | This metric is not applicable to the study type. | |
| Domain 6: Confounding / Variable Control | | | | | | |
| | Metric 20: Confounding Variables in Test Design and Procedures | High | × 2 | 2 | No confounding variables in test design were identified. | |
| | Metric 21: Confounding Variables in Outcomes Unrelated to Exposure | Medium | × 1 | 2 | No outcomes unrelated to exposure were reported (and are not expected to impact the study results). | |
| Domain 7: Data Presentation and Analysis | | | | | | |
| | Metric 22: Data Analysis | High | × 1 | 1 | Statistical methods were reported and appropriate for the study type. | |
| | Metric 23: Data Interpretation | Medium | × 2 | 4 | Statistical significance appears to have been the criteria for a positive response (recommended as an aid in determining positive responses). | |

Continued on next page ...

...continued from previous page

Study Citation: An, J; Guo, P; Shang, Y; Zhong, Y; Zhang, X; Yu, Y; Yu, Z (2016). The "adaptive responses" of low concentrations of HBCD in L02 cells and the underlying molecular mechanisms Chemosphere, 145 68-76
 Data Type: Comet assay for HBCD
 HERO ID: 3350502

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|--|------------------------------|---------------------|------|-------|--|
| | Metric 24: Cytotoxicity Data | Medium | × 1 | 2 | Cytotoxicity was defined. Methods were briefly described and partially cited to manufacturer's instructions. Sampling was adequate; cell viability was measured indirectly (spectrophotometrically). |
| | Metric 25: Reporting of Data | High | × 2 | 2 | Data were reported by exposure group. |
| Overall Quality Determination [‡] | | High | | 1.5 | |
| Extracted | | Yes | | | |

* MWF = Metric Weighting Factor

[†] High = 1; Medium = 2; Low = 3; Unacceptable = 4; N/A has no value.

[‡] The overall rating is calculated as necessary. EPA may not always provide a comment for a metric that has been categorized as High.

$$\text{Overall rating} = \begin{cases} 4 & \text{if any metric is Unacceptable} \\ \left\lfloor \frac{\sum_i (\text{Metric Score}_i \times \text{MWF}_i)}{\sum_j \text{MWF}_j} \right\rfloor_{0.1} & \text{(round to the nearest tenth) otherwise} \end{cases}$$

where High ≥ 1 to < 1.7 ; Medium ≥ 1.7 to < 2.3 ; Low ≥ 2.3 to ≤ 3.0 . If the reviewer determines that the overall rating needs adjustment, the original rating is crossed out and an arrow points to the new rating.

^{††} This metric met the criteria for high confidence as expected for this type of study

Table 36: **In vitro** evaluation results of Huang et al 2016 for DNA damage

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|---|---|---------------------|------|-------|---|
| Study Citation: Huang, X; Chen, C; Shang, Y; Zhong, Y; Ren, G; Yu, Z; An, J (2016). In vitro study on the biotransformation and cytotoxicity of three hexabromocyclododecane diastereoisomers in liver cells Chemosphere, 161 251-258 | | | | | |
| Data Type: DNA damage for HBCD diastereomers | | | | | |
| HERO ID: 3545979 | | | | | |
| Domain 1: Test Substance | | | | | |
| Metric 1: | Test Substance Identity | High | × 2 | 2 | The test substances were identified by name (alpha-, beta-, and gamma-HBCD). |
| Metric 2: | Test Substance Source | High | × 1 | 1 | The source of the test substances (a manufacturer) was reported. |
| Metric 3: | Test Substance Purity | Low | × 1 | 3 | The purity of the test substance was not reported. |
| Domain 2: Test Design | | | | | |
| Metric 4: | Negative and Vehicle Controls | High | × 2 | 2 | The study authors reported using a concurrent negative control group (DMSO-only) in which all conditions equal except exposure to test substance. |
| Metric 5: | Positive Controls | Not Rated | NA | NA | This metric is not applicable to the study type. |
| Metric 6: | Assay Procedures | Medium | × 1 | 2 | Methods and procedures were partially described (and appear appropriate), and partially cited to another publication (i.e., Tice et al. 2000 for the comet assay). |
| Metric 7: | Standards for Tests | Not Rated | NA | NA | This metric is not applicable to the study type. |
| Domain 3: Exposure Characterization | | | | | |
| Metric 8: | Preparation and Storage of Test Substance | Medium | × 1 | 2 | The study indicates that working solutions were freshly prepared. Storage conditions were not reported, but are not expected to substantially impact the study results owing to the short duration of the experiments (i.e., 24 and 48 hours for cell viability, 24 hours for comet assay). |
| Metric 9: | Consistency of Exposure Administration | High | × 1 | 1 | Exposures were administered consistently across study groups. |
| Metric 10: | Reporting of Doses/Concentrations | High | × 2 | 2 | Concentrations were reported without ambiguity. |
| Metric 11: | Number of Exposure Groups and Concentration Spacing | High | × 2 | 2 | Exposure duration was reported and appeared to be appropriate for the study type (e.g., 24 hours for comet assay). |
| Metric 12: | Exposure Route and Method | Medium | × 1 | 2 | The number of groups (3 doses plus controls for cell viability and comet assays) was reported. Although a rationale for dose selection was not provided, the highest dose used in the comet assay did not induce excessive cytotoxicity (as recommended). |
| Metric 13: | Metabolic Activation | Not Rated | NA | NA | This metric is not applicable to the study type. |

Continued on next page ...

... continued from previous page

| Study Citation: | Huang, X; Chen, C; Shang, Y; Zhong, Y; Ren, G; Yu, Z; An, J (2016). In vitro study on the biotransformation and cytotoxicity of three hexabromocyclododecane diastereoisomers in liver cells <i>Chemosphere</i> , 161 251-258 | | | | |
|--|---|---------------------|------|-------|---|
| Data Type: | DNA damage for HBCD diastereomers | | | | |
| HERO ID: | 3545979 | | | | |
| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
| Domain 4: Test Model | | | | | |
| | Metric 14: Test Model | High | × 2 | 2 | The cell types used were appropriate for the intended outcomes. The source of the cells was reported, and information such as media and number of passages was provided. |
| | Metric 15: Number per Group | High | × 1 | 1 | An adequate number of replicates was reported (i.e., at least triplicate experiments/replicates for cell viability and comet assays). |
| Domain 5: Outcome Assessment | | | | | |
| | Metric 16: Outcome Assessment Methodology | High | × 2 | 2 | Outcome assessment methodologies were described in detail. |
| | Metric 17: Consistency of Outcome Assessment | High | × 1 | 1 | Outcomes assessments were conducted consistently across study groups. |
| | Metric 18: Sampling Adequacy | High | × 2 | 2 | The study indicates that three hundred cells per sample were evaluated (comet assay). |
| | Metric 19: Blinding of Assessors | High | × 1 | 1 | It was indicated that cells used for analysis of DNA migration (comet assay) were randomly captured. |
| Domain 6: Confounding / Variable Control | | | | | |
| | Metric 20: Confounding Variables in Test Design and Procedures | High | × 2 | 2 | No confounding variables were identified. |
| | Metric 21: Confounding Variables in Outcomes Unrelated to Exposure | Low | × 1 | 3 | Data on outcome differences unrelated to exposure were not reported for each study group. |
| Domain 7: Data Presentation and Analysis | | | | | |
| | Metric 22: Data Analysis | High | × 1 | 1 | Statistical analyses were performed and appropriate for the study type. |
| | Metric 23: Data Interpretation | High | × 2 | 2 | The study used statistical analyses to evaluate differences among study groups (and identify positive responses). It can also be inferred from the text that the time- and dose-relatedness of the response was considered (e.g., for cell viability and comet assays). |
| | Metric 24: Cytotoxicity Data | High | × 1 | 1 | Cytotoxicity was defined and methods were adequately described. |
| | Metric 25: Reporting of Data | High | × 2 | 2 | Outcome data were reported by exposure group (means +/- standard deviations). |
| Overall Quality Determination [‡] | | High | | 1.2 | |
| Extracted | | Yes | | | |
| Continued on next page ... | | | | | |

... continued from previous page

Study Citation: Huang, X; Chen, C; Shang, Y; Zhong, Y; Ren, G; Yu, Z; An, J (2016). In vitro study on the biotransformation and cytotoxicity of three hexabromocyclododecane diastereoisomers in liver cells Chemosphere, 161 251-258
 Data Type: DNA damage for HBCD diastereoisomers
 HERO ID: 3545979

| Domain | Metric | Rating [†] | MWF [*] | Score | Comments ^{††} |
|--------|--------|---------------------|------------------|-------|------------------------|
|--------|--------|---------------------|------------------|-------|------------------------|

* MWF = Metric Weighting Factor

† High = 1; Medium = 2; Low = 3; Unacceptable = 4; N/A has no value.

‡ The overall rating is calculated as necessary. EPA may not always provide a comment for a metric that has been categorized as High.

$$\text{Overall rating} = \begin{cases} 4 & \text{if any metric is Unacceptable} \\ \left\lceil \sum_i (\text{Metric Score}_i \times \text{MWF}_i) / \sum_j \text{MWF}_j \right\rceil_{0.1} & \text{(round to the nearest tenth) otherwise} \end{cases}$$

where High $\Rightarrow \geq 1$ to < 1.7 ; Medium $\Rightarrow \geq 1.7$ to < 2.3 ; Low $\Rightarrow \geq 2.3$ to ≤ 3.0 . If the reviewer determines that the overall rating needs adjustment, the original rating is crossed out and an arrow points to the new rating.

†† This metric met the criteria for high confidence as expected for this type of study

7 Developmental and Reproductive

Table 37: Animal toxicity evaluation results of van der Ven et al 2009 for 1-generation reproduction study, oral dietary study on endocrine, reproductive, hematological and immune, thyroid, growth (early life) and development, musculoskeletal/motor function, clinical chemistry/biochemical, nutrition and metabolic/adult exposure body weight, and hepatic outcomes

| Study Citation: | van der Ven, LTM; van de Kuil, T; Leonards, PEG; Slob, W; Lilienthal, H; Litens, S; Herlin, M; Håkansson, H; Cantón, RF; van den Berg, M; Visser, TJ; van Loveren, H; Vos, JG; Piersma, AH (2009). Endocrine effects of hexabromocyclododecane (HBCD) in a one-generation reproduction study in Wistar rats Toxicology Letters, 185(1), 51-62 | | | | |
|-------------------------------------|---|---------------------|------|-------|---|
| Data Type: | 1-generation reproduction study, oral dietary | | | | |
| HERO ID: | 589273 | | | | |
| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
| Domain 1: Test Substance | | | | | |
| Metric 1: | Test Substance Identity | High | × 2 | 2 | The test substance was identified definitively as HBCD a mixture of three diastereoisomers, H alpha-, beta-, and gamma- HBCD and their respective proportion in the used batch was 10.3–8.7–81.0%. |
| Metric 2: | Test Substance Source | Medium | × 1 | 2 | The test substance manufacturer and source was reported; however, the batch/lot number was not specified. |
| Metric 3: | Test Substance Purity | High | × 1 | 1 | The test substance was said to be technical grade (technical mixture containing traces of tetra- and pentabromocyclododecane) it was noted; the test substance composition is such that any observed effects are likely due to the nominal test substance. |
| Domain 2: Test Design | | | | | |
| Metric 4: | Negative and Vehicle Controls | High | × 2 | 2 | Study authors reported using an appropriate concurrent negative control group. An additional group was included to monitor effects of the carrier oil contents in the feed. |
| Metric 5: | Positive Controls | Not Rated | NA | NA | This metric is not rated/applicable for this study type |
| Metric 6: | Randomized Allocation | Low | × 1 | 3 | The study noted that the protocol was based on OECD415 (one-generation reproduction toxicity study) guideline and that the animals were distributed among a larger number of dose groups than advised in guideline. The study did not explicitly report how animals were allocated to study groups. It is unclear if this would have a substantial impact on results. |
| Domain 3: Exposure Characterization | | | | | |
| Continued on next page ... | | | | | |

... continued from previous page

Study Citation: van der Ven, LTM; van de Kuil, T; Leonards, PEG; Slob, W; Lilienthal, H; Litens, S; Herlin, M; Håkansson, H; Cantón, RF; van den Berg, M; Visser, TJ; van Loveren, H; Vos, JG; Piersma, AH (2009). Endocrine effects of hexabromocyclododecane (HBCD) in a one-generation reproduction study in Wistar rats Toxicology Letters, 185(1), 51-62

Data Type: 1-generation reproduction study, oral dietary

HERO ID: 589273

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|------------------------------|--|---------------------|------|-------|---|
| | Metric 7: Preparation and Storage of Test Substance | Medium | × 1 | 2 | Test substance preparation was reported, but with limitations in reporting. HBCD was reported to be mixed with corn-based oil and pelleted for feed. It is not reported how often feed was mixed or how it was stored. This omission is unlikely to have a substantial impact on results. |
| | Metric 8: Consistency of Exposure Administration | High | × 1 | 1 | Details of exposure administration were reported and administration was consistent between across study groups. |
| | Metric 9: Reporting of Doses/Concentrations | High | × 2 | 2 | The targeted dietary exposure was reported to be 0–0.1–0.3–1–3–10–30–100 mg/kg bodyweight/day. |
| | Metric 10: Exposure Frequency and Duration | High | × 1 | 1 | Exposure frequency (ad libitum) and duration of exposure were reported and appropriate. |
| | Metric 11: Number of Exposure Groups and Dose Spacing | High | × 1 | 1 | The number of exposure groups and spacing was reported and was justified based on a preceding subacute repeated oral dose study. |
| | Metric 12: Exposure Route and Method | High | × 1 | 1 | The route (oral, dietary) was reported and suited to the test substance. |
| Domain 4: Test Organism | | | | | |
| | Metric 13: Test Animal Characteristics | High | × 2 | 2 | The test animal species, strain, sex, and age was reported. It was noted that the animals were of weighed and that animals were inspected daily for general condition and clinical abnormalities. The animals were obtained from a commercial breeding facility. |
| | Metric 14: Adequacy and Consistency of Animal Husbandry Conditions | High | × 1 | 1 | Animal husbandry conditions were reported and included temperature, humidity, and light-dark cycle. Husbandry conditions were adequate and the same for all animals. |
| | Metric 15: Number per Group | High | × 1 | 1 | The number of animals per group was reported and appropriate for the study type and outcome analysis. |
| Domain 5: Outcome Assessment | | | | | |
| | Metric 16: Outcome Assessment Methodology | High | × 2 | 2 | The outcome assessment methodology reported and sensitive to the intended outcomes of interest. |
| | Metric 17: Consistency of Outcome Assessment | High | × 1 | 1 | Details of the outcome assessment methodology were reported and consistent across study groups for the outcomes of interest. |
| | Metric 18: Sampling Adequacy | High | × 1 | 1 | Details regarding the sampling for the outcomes of interest were reported and adequate for assessment. |

Continued on next page ...

... continued from previous page

| Study Citation: | van der Ven, LTM; van de Kuil, T; Leonards, PEG; Slob, W; Lilienthal, H; Litens, S; Herlin, M; Håkansson, H; Cantón, RF; van den Berg, M; Visser, TJ; van Loveren, H; Vos, JG; Piersma, AH (2009). Endocrine effects of hexabromocyclododecane (HBDC) in a one-generation reproduction study in Wistar rats Toxicology Letters, 185(1), 51-62 | | | | | |
|--|---|---------------------|------|-------|--|--|
| Data Type: | 1-generation reproduction study, oral dietary | | | | | |
| HERO ID: | 589273 | | | | | |
| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} | |
| | Metric 19: Blinding of Assessors | Not Rated | NA | NA | This metric is not rated when outcomes are not subjective or for initial histopathology review. | |
| | Metric 20: Negative Control Response | High | × 1 | 1 | The biological response of the negative control group was adequate. As shown in Supplemental tables 1-16 (ID2919529) | |
| Domain 6: Confounding / Variable Control | | | | | | |
| | Metric 21: Confounding Variables in Test Design and Procedures | Medium | × 2 | 4 | There were no reported differences among the study groups that could influence the outcome assessment. | |
| | Metric 22: Health Outcomes Unrelated to Exposure | Medium | × 1 | 2 | Data on attrition or health outcomes not related to exposure were not reported. The carrier oil control group experienced increased mortality of F1 pups during lactation and several other health outcomes. While not related to HBDC exposure, these effects were influenced by the carrier oil in the feed. | |
| Domain 7: Data Presentation and Analysis | | | | | | |
| | Metric 23: Statistical Methods | High | × 1 | 1 | Statistical analysis was shown for all datasets as evaluated for Supplemental tables 1-16 (ID2919529). BMD methodology was clearly described and appropriate. | |
| | Metric 24: Reporting of Data | High | × 2 | 2 | Data for exposure-related findings were presented for all outcomes by exposure group and sex - as evaluated for Supplemental tables 1-16 (ID2919529). | |
| Overall Quality Determination [‡] | | High | | 1.2 | | |
| Extracted | | Yes | | | | |

* MWF = Metric Weighting Factor

[†] High = 1; Medium = 2; Low = 3; Unacceptable = 4; N/A has no value.

[‡] The overall rating is calculated as necessary. EPA may not always provide a comment for a metric that has been categorized as High.

$$\text{Overall rating} = \begin{cases} 4 & \text{if any metric is Unacceptable} \\ \left\lfloor \frac{\sum_i (\text{Metric Score}_i \times \text{MWF}_i)}{\sum_j \text{MWF}_j} \right\rfloor_{0.1} & \text{(round to the nearest tenth) otherwise} \end{cases}$$

where High = ≥ 1 to < 1.7 ; Medium = ≥ 1.7 to < 2.3 ; Low = ≥ 2.3 to ≤ 3.0 . If the reviewer determines that the overall rating needs adjustment, the original rating is crossed out and an arrow points to the new rating.

^{††} This metric met the criteria for high confidence as expected for this type of study

Table 38: **Animal toxicity evaluation results of Hachisuka et al 2010 for oral developmental immunotoxicity study on hematological and immune outcomes**

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|--|---|---------------------|------|-------|---|
| Study Citation: Hachisuka, A., Nakamura, R., Sato, Y., Nakamura, R., Shibutani, M., Teshima, R. (2010). Effects of perinatal exposure to the brominated flame-retardant hexabromocyclododecane (HBCD) on the developing immune system in rats Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku, [2010](128), 58-64 | | | | | |
| Data Type: Oral developmental immunotoxicity | | | | | |
| HERO ID: 1403765 | | | | | |
| Domain 1: Test Substance | | | | | |
| Metric 1: | Test Substance Identity | Medium | × 2 | 4 | Test substance identified by name. |
| Metric 2: | Test Substance Source | Low | × 1 | 3 | Source not identified. |
| Metric 3: | Test Substance Purity | Low | × 1 | 3 | Composition and purity not reported. |
| Domain 2: Test Design | | | | | |
| Metric 4: | Negative and Vehicle Controls | High | × 2 | 2 | Concurrent negative control animals are included. |
| Metric 5: | Positive Controls | Not Rated | NA | NA | Positive controls not required. |
| Metric 6: | Randomized Allocation | Low | × 1 | 3 | Allocation methods were not reported. |
| Domain 3: Exposure Characterization | | | | | |
| Metric 7: | Preparation and Storage of Test Substance | Low | × 1 | 3 | Limited details on preparation (mixed into the food) and no information on storage and stability were reported. |
| Metric 8: | Consistency of Exposure Administration | Medium | × 1 | 2 | Animals were allowed to feed freely on the diet, but no details on the amount of diet provided was reported. |
| Metric 9: | Reporting of Doses/Concentrations | High | × 2 | 2 | Concentrations were reported. |
| Metric 10: | Exposure Frequency and Duration | High | × 1 | 1 | Exposure duration was reported. |
| Metric 11: | Number of Exposure Groups and Dose Spacing | Medium | × 1 | 2 | The number of exposure groups and spacing were reported, but not justified. |
| Metric 12: | Exposure Route and Method | High | × 1 | 1 | The exposure route and method were appropriate. |
| Domain 4: Test Organism | | | | | |
| Metric 13: | Test Animal Characteristics | Low | × 2 | 6 | The species, strain, and sex were reported. The source and starting body weight of dams were not reported. |
| Metric 14: | Adequacy and Consistency of Animal Husbandry Conditions | Low | × 1 | 3 | Details were not reported. |
| Metric 15: | Number per Group | High | × 1 | 1 | The number of animals per group was appropriate. |
| Domain 5: Outcome Assessment | | | | | |

Continued on next page ...

... continued from previous page

Study Citation: Hachisuka, A., Nakamura, R., Sato, Y., Nakamura, R., Shibutani, M., Teshima, R. (2010). Effects of perinatal exposure to the brominated flame-retardant hexabromocyclododecane (HBCD) on the developing immune system in rats Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku, [2010](128), 58-64
 Data Type: Oral developmental immunotoxicity
 HERO ID: 1403765

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|--|--|---------------------|------|-------|---|
| | Metric 16: Outcome Assessment Methodology | Medium | × 2 | 4 | Outcome assessment methodology was reported for some outcomes- hematology, thymus and spleen weight and pathology, and immunity. Other outcomes assessment methodology, including body weight and weight gain, were not reported. |
| | Metric 17: Consistency of Outcome Assessment | High | × 1 | 1 | Outcomes were assessed consistently. |
| | Metric 18: Sampling Adequacy | Medium | × 1 | 2 | Sampling for some outcomes was not reported or illegible. |
| | Metric 19: Blinding of Assessors | Not Rated | NA | NA | Blinding not required. |
| | Metric 20: Negative Control Response | High | × 1 | 1 | Negative control responses were appropriate. |
| Domain 6: Confounding / Variable Control | | | | | |
| | Metric 21: Confounding Variables in Test Design and Procedures | Low | × 2 | 6 | Initial body weight and food/water intake of same were not reported and appear not to have been measured. |
| | Metric 22: Health Outcomes Unrelated to Exposure | High | × 1 | 1 | There were not reported differences among the groups in health outcomes unrelated to exposures. |
| Domain 7: Data Presentation and Analysis | | | | | |
| | Metric 23: Statistical Methods | Medium | × 1 | 2 | Statistical methods were not described but were conducted, and data were provided to conduct an independent analysis. |
| | Metric 24: Reporting of Data | Medium | × 2 | 4 | Data were reported by groups, however it appears that not all outcomes were reported by sex. |
| Overall Quality Determination [‡] | | Medium | | 2.0 | |
| Extracted | | Yes | | | |

* MWF = Metric Weighting Factor

† High = 1; Medium = 2; Low = 3; Unacceptable = 4; N/A has no value.

‡ The overall rating is calculated as necessary. EPA may not always provide a comment for a metric that has been categorized as High.

$$\text{Overall rating} = \begin{cases} 4 & \text{if any metric is Unacceptable} \\ \left\lceil \frac{\sum_i (\text{Metric Score}_i \times \text{MWF}_i)}{\sum_j \text{MWF}_j} \right\rceil_{0.1} & \text{(round to the nearest tenth) otherwise} \end{cases}$$

where High = ≥ 1 to < 1.7 ; Medium = ≥ 1.7 to < 2.3 ; Low = ≥ 2.3 to ≤ 3.0 . If the reviewer determines that the overall rating needs adjustment, the original rating is crossed out and an arrow points to the new rating.

†† This metric met the criteria for high confidence as expected for this type of study

Table 39: **Animal toxicity evaluation results of Miller-Rhodes et al 2014 for developmental study and gestation day 1-parturition study on growth (early life) and development, and neurological/behavior outcomes**

| Study Citation: | Miller-Rhodes, P; Popescu, M; Goeke, C; Tirabassi, T; Johnson, L; Markowski, VP (2014). Prenatal exposure to the brominated flame retardant hexabromocyclododecane (HBCD) impairs measures of sustained attention and increases age-related morbidity in the Long-Evans rat <i>Neurotoxicology and Teratology</i> , 45 34-43 | | | | | |
|-------------------------------------|--|---------------------|------|-------|--|--|
| Data Type: | Developmental study; GD 1-parturition | | | | | |
| HERO ID: | 2528337 | | | | | |
| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} | |
| Domain 1: Test Substance | | | | | | |
| Metric 1: | Test Substance Identity | High | × 2 | 2 | Name and product number provided | |
| Metric 2: | Test Substance Source | High | × 1 | 1 | Commercial source | |
| Metric 3: | Test Substance Purity | High | × 1 | 1 | Purity >95% | |
| Domain 2: Test Design | | | | | | |
| Metric 4: | Negative and Vehicle Controls | High | × 2 | 2 | Use of vehicle control | |
| Metric 5: | Positive Controls | Not Rated | NA | NA | Positive control not necessary | |
| Metric 6: | Randomized Allocation | High | × 1 | 1 | Randomized block design | |
| Domain 3: Exposure Characterization | | | | | | |
| Metric 7: | Preparation and Storage of Test Substance | High | × 1 | 1 | Prepared fresh daily, properly mixed. | |
| Metric 8: | Consistency of Exposure Administration | High | × 1 | 1 | Exposure consistent across groups | |
| Metric 9: | Reporting of Doses/Concentrations | High | × 2 | 2 | concentrations were reported | |
| Metric 10: | Exposure Frequency and Duration | High | × 1 | 1 | Daily gavage | |
| Metric 11: | Number of Exposure Groups and Dose Spacing | High | × 1 | 1 | Three dose groups and a control | |
| Metric 12: | Exposure Route and Method | High | × 1 | 1 | Gavage | |
| Domain 4: Test Organism | | | | | | |
| Metric 13: | Test Animal Characteristics | High | × 2 | 2 | Standard animal model used (Long Evans rats) | |
| Metric 14: | Adequacy and Consistency of Animal Husbandry Conditions | High | × 1 | 1 | Animal husbandry was reported and acceptable | |
| Metric 15: | Number per Group | High | × 1 | 1 | 10-11 pregnant dams/treatment group. (litters culled to 8 pups using randomized selection procedure) | |
| Domain 5: Outcome Assessment | | | | | | |
| Metric 16: | Outcome Assessment Methodology | High | × 2 | 2 | Outcome assessment methods were appropriate | |
| Metric 17: | Consistency of Outcome Assessment | High | × 1 | 1 | Outcomes were assessed consistently across groups | |
| Continued on next page ... | | | | | | |

... continued from previous page

Study Citation: Miller-Rhodes, P; Popescu, M; Goeke, C; Tirabassi, T; Johnson, L; Markowski, VP (2014). Prenatal exposure to the brominated flame retardant hexabromocyclododecane (HBCD) impairs measures of sustained attention and increases age-related morbidity in the Long-Evans rat Neurotoxicology and Teratology, 45 34-43
 Data Type: Developmental study; GD 1-parturition
 HERO ID: 2528337

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|--|--|---------------------|------|-------|---|
| | Metric 18: Sampling Adequacy | Low | × 1 | 3 | It is unclear the number of animals evaluated for each outcome. The "n" is consistently stated. Although it was mentioned that litters were culled to 8 pups, there were a number of deaths, so it is not clear how many were left for further analysis. It is stated that every pup in each litter was examined, for example, for FOB tests, but it is not known what differences in n there is between exposure groups, or if there are any. In some cases, it is mentioned that one male and one female from each litter were used for some endpoints, but it is not clear this was always the case. |
| | Metric 19: Blinding of Assessors | High | × 1 | 1 | Stated that observers were blind to the exposure group |
| | Metric 20: Negative Control Response | Medium | × 1 | 2 | Study authors indicate that the mean gestation length of the control group was shorter than typically expected for these rats, which may be the reason why HBCD treated rats appeared to have a longer gestation period. |
| Domain 6: Confounding / Variable Control | | | | | |
| | Metric 21: Confounding Variables in Test Design and Procedures | Medium | × 2 | 4 | Study authors mention that the ability to detect an exposure effect for locomotor activity could have been confounded by different body size to chamber size ratios. It was also mentioned that paw sizes were not taken into account for the grip strength tests |
| | Metric 22: Health Outcomes Unrelated to Exposure | Low | × 1 | 3 | There were a number of animals that disproportionately died unexpectedly or became ill. The authors indicate that data from these animals were not used for several of the analyses. Since the actual numbers of animals affected were not reported, it is unclear how this impacted the analyses or the actual number of animals evaluated for each endpoint. The timing of when these animals died, or became ill is also not reported. |
| Domain 7: Data Presentation and Analysis | | | | | |
| | Metric 23: Statistical Methods | Medium | × 1 | 2 | The described statistical analysis was appropriate, and the litter was used as the unit of analysis for offspring endpoints, however, results from statistical analysis were not shown in any of the figures making it difficult to easily interpret the data. In most instances, p-values were provided within the text. |

Continued on next page ...

... continued from previous page

Study Citation: Miller-Rhodes, P; Popescu, M; Goeke, C; Tirabassi, T; Johnson, L; Markowski, VP (2014). Prenatal exposure to the brominated flame retardant hexabromocyclododecane (HBCD) impairs measures of sustained attention and increases age-related morbidity in the Long-Evans rat Neurotoxicology and Teratology, 45 34-43
 Data Type: Developmental study; GD 1-parturition
 HERO ID: 2528337

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|--|-------------------|---------------------|------|---------------------|--|
| Metric 24: | Reporting of Data | Low | × 2 | 6 | No individual offspring animal data were reported, therefore the data cannot be independently reviewed. Additionally, most data is reported in the form of bar graphs, and text does not provide the quantal values. Data from males and females were often pooled and averaged, and therefore not reported independently. |
| Overall Quality Determination [‡] | | High | → | Medium [§] | 1.4 |
| Extracted | | Yes | | | |

* MWF = Metric Weighting Factor

[†] High = 1; Medium = 2; Low = 3; Unacceptable = 4; N/A has no value.

[‡] The overall rating is calculated as necessary. EPA may not always provide a comment for a metric that has been categorized as High.

$$\text{Overall rating} = \begin{cases} 4 & \text{if any metric is Unacceptable} \\ \left\lfloor \frac{\sum_i (\text{Metric Score}_i \times \text{MWF}_i)}{\sum_j \text{MWF}_j} \right\rfloor_{0.1} & \text{(round to the nearest tenth) otherwise} \end{cases},$$

where High = ≥ 1 to < 1.7 ; Medium = ≥ 1.7 to < 2.3 ; Low = ≥ 2.3 to ≤ 3.0 . If the reviewer determines that the overall rating needs adjustment, the original rating is crossed out and an arrow points to the new rating.

^{††} This metric met the criteria for high confidence as expected for this type of study

[§] Evaluator's explanation for rating change: "The lack of individual animal data, and the way the data is presented, make it difficult to interpret the data. Additionally, the lack of clarity regarding the number of animals evaluated should be considered. There was also a large number of animals that became ill. Without further transparency or information, it is difficult to know how this could have impacted the various results with the data provided"

Table 40: **Animal toxicity evaluation results of Szabo et al 2016 for single dose gavage (PND 10) study in mice on metabolomics outcomes**

| Study Citation: | Szabo, DT; Pathmasiri, W; Sumner, S; Birnbaum, LS (2016). Serum metabolomic profiles in neonatal mice following oral brominated flame retardant exposures to hexabromocyclododecane (HBCD) alpha, gamma, and commercial mixture Environmental Health Perspectives, 125(4), 651-659 | | | | | |
|-------------------------------------|--|---------------------|------|-------|---|--|
| Data Type: | Single gavage in mice on PND 10; metabolomics evaluation only | | | | | |
| HERO ID: | 3546063 | | | | | |
| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} | |
| Domain 1: Test Substance | | | | | | |
| Metric 1: | Test Substance Identity | High | × 2 | 2 | Chemical identity is clear; CAS #. provided Test substance is a commercial mixture of three stereoisomers. Percentages of each isomer are provided. | |
| Metric 2: | Test Substance Source | High | × 1 | 1 | Sourced from Sigma-Aldrich | |
| Metric 3: | Test Substance Purity | Medium | × 1 | 2 | Percentages of isomers in commercial mixture were provided.; it is not indicated whether other impurities are present, but the study authors indicate that chemicals were purchased at the highest purity level available. The authors did, however, go through a stereoisomer separation and thermal conversion process and it is not clear how pure the samples were after this process. Additionally, dosing solutions were made using corn oil and toluene that was evaporated under vacuum. Whether there was any remaining toluene is unknown, although all samples, including controls were treated equally. | |
| Domain 2: Test Design | | | | | | |
| Metric 4: | Negative and Vehicle Controls | High | × 2 | 2 | Appropriate negative (vehicle) control was used. | |
| Metric 5: | Positive Controls | Not Rated | NA | NA | Positive control was not required. | |
| Metric 6: | Randomized Allocation | Low | × 1 | 3 | Study does not indicate how dams and corresponding pups were allocated into treatment groups. Given the small number of total dams/litters (n = 7), and the fact that no statements are made indicating, for example, that dams and pup weights were equivalent, this introduces uncertainty that could impact results. | |
| Domain 3: Exposure Characterization | | | | | | |
| Metric 7: | Preparation and Storage of Test Substance | High | × 1 | 1 | Study references previous publications for methods used for stereoisomer separation. Preparation of dosing solutions were appropriate. Since animals only received a single dose, storage of the dosing solutions were not necessary. | |

Continued on next page ...

... continued from previous page

| Study Citation: | Szabo, DT; Pathmasiri, W; Sumner, S; Birnbaum, LS (2016). Serum metabolomic profiles in neonatal mice following oral brominated flame retardant exposures to hexabromocyclododecane (HBCD) alpha, gamma, and commercial mixture Environmental Health Perspectives, 125(4), 651-659 | | | | | |
|------------------------------|--|---|--------|-------|------------------------|--|
| Data Type: | Single gavage in mice on PND 10; metabolomics evaluation only | | | | | |
| HERO ID: | 3546063 | | | | | |
| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} | |
| | Metric 8: | Consistency of Exposure Administration | High | × 1 | 1 | Dosing was equivalent across treatment groups (all animals given 10 mL/kg gavage of appropriate treatment) |
| | Metric 9: | Reporting of Doses/Concentrations | High | × 2 | 2 | Doses were clearly stated |
| | Metric 10: | Exposure Frequency and Duration | High | × 1 | 1 | Single exposure via gavage |
| | Metric 11: | Number of Exposure Groups and Dose Spacing | High | × 1 | 1 | An explanation of chosen doses was provided |
| | Metric 12: | Exposure Route and Method | High | × 1 | 1 | Gavage was appropriate for pups that were still lactating. |
| Domain 4: Test Organism | | | | | | |
| | Metric 13: | Test Animal Characteristics | High | × 2 | 2 | Study clearly explains reasoning for choosing mice at this stage of development. |
| | Metric 14: | Adequacy and Consistency of Animal Husbandry Conditions | High | × 1 | 1 | Animal husbandry conditions were appropriate. |
| | Metric 15: | Number per Group | Low | × 1 | 3 | Study indicates that 6 female pups per litter (n = 7 litters total) were used for the experiment. Including the control, there is a total of 7 dose groups (control, 3-doses of alpha-HBCD, 2-doses of gamma HBCD, and a single dose of the commercial mixture). It is unclear how this would work, unless one litter was used exclusively as a control, and then 1 pup per litter (out of 6 remaining litters) received each treatment.? Overall, the total number of pups per treatment group is not explicitly stated and cannot be accurately inferred given the available data. |
| Domain 5: Outcome Assessment | | | | | | |
| | Metric 16: | Outcome Assessment Methodology | Medium | × 2 | 4 | Metabolomic assessment of the blood was done via NMR at a single time-point (4-days post-exposure), which generally could miss key transitional changes. However, the study authors indicate that this time point was chosen to coincide with previous data collected from various tissues, and therefore seems appropriate. - NMR has relatively low sensitivity compared with other analytical tools for metabolomics, and no power analysis was done to determine an appropriate sample size. It is not clear whether technical replicates were included in the methodology. |
| | Metric 17: | Consistency of Outcome Assessment | High | × 1 | 1 | Outcome assessment appeared to be consistent across groups |
| Continued on next page ... | | | | | | |

...continued from previous page

| Study Citation: | Szabo, DT; Pathmasiri, W; Sumner, S; Birnbaum, LS (2016). Serum metabolomic profiles in neonatal mice following oral brominated flame retardant exposures to hexabromocyclododecane (HBCD) alpha, gamma, and commercial mixture Environmental Health Perspectives, 125(4), 651-659 | | | | | |
|--|--|----------------------------|------|-------|--|--|
| Data Type: | Single gavage in mice on PND 10; metabolomics evaluation only | | | | | |
| HERO ID: | 3546063 | | | | | |
| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} | |
| | Metric 18: Sampling Adequacy | Low | × 1 | 3 | Analysis was done on samples taken from 3 -6 pups/ treatment group. The number of control samples were not stated. It is unclear whether the differences in sample numbers across treatment groups was because those were the total number of animals treated, or whether for some reason, in some cases, samples were only collected from three out of 6 treated animals. Three biological replicates for an omics-based study is an absolute minimum and greatly reduces statistical power and has increased noise. | |
| | Metric 19: Blinding of Assessors | Not Rated | NA | NA | Blinding was not indicated, but not necessarily applicable to NMR analysis | |
| | Metric 20: Negative Control Response | High | × 1 | 1 | The responses of the controls are presumed to be appropriate | |
| Domain 6: Confounding / Variable Control | | | | | | |
| | Metric 21: Confounding Variables in Test Design and Procedures | Low | × 2 | 6 | The study authors did not discuss potential confounding variables. It is mentioned that there were no changes in body weights between treated and controls following treatment, but no statements were made indicating that the initial health and weights of treated pups were equivalent across litters leaving the potential for unknown confounding variables. There is also a potential for litter effects,, however, this was presumably were taken into account in the study design by treating across litters. | |
| | Metric 22: Health Outcomes Unrelated to Exposure | Low | × 1 | 3 | The study does not include observations (clinical or otherwise) of pups during or after dosing. It is still unclear why some treatment groups had three samples evaluated, and others had 6 samples evaluated, and whether this could potentially be due to problems with some of the animals, or if only three animals were treated. | |
| Domain 7: Data Presentation and Analysis | | | | | | |
| | Metric 23: Statistical Methods | High | × 1 | 1 | Statistical analysis was appropriate. | |
| | Metric 24: Reporting of Data | High | × 2 | 2 | Data presentation was adequate and appropriate for omics reporting. - Some data was presented in supplementary tables that were not available to view | |
| Overall Quality Determination [‡] | | High → Medium [§] | | 4.5 | | |

Continued on next page ...

... continued from previous page

Study Citation: Szabo, DT; Pathmasiri, W; Sumner, S; Birnbaum, LS (2016). Serum metabolomic profiles in neonatal mice following oral brominated flame retardant exposures to hexabromocyclododecane (HBCD) alpha, gamma, and commercial mixture Environmental Health Perspectives, 125(4), 651-659
 Data Type: Single gavage in mice on PND 10; metabolomics evaluation only
 HERO ID: 3546063

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|-----------|--------|---------------------|------|-------|------------------------|
| Extracted | | Yes | | | |

* MWF = Metric Weighting Factor

[†] High = 1; Medium = 2; Low = 3; Unacceptable = 4; N/A has no value.

[‡] The overall rating is calculated as necessary. EPA may not always provide a comment for a metric that has been categorized as High.

$$\text{Overall rating} = \begin{cases} 4 & \text{if any metric is Unacceptable} \\ \left[\sum_i (\text{Metric Score}_i \times \text{MWF}_i) / \sum_j \text{MWF}_j \right]_{0.1} & \text{(round to the nearest tenth) otherwise} \end{cases}$$

where High = ≥ 1 to < 1.7 ; Medium = ≥ 1.7 to < 2.3 ; Low = ≥ 2.3 to ≤ 3.0 . If the reviewer determines that the overall rating needs adjustment, the original rating is crossed out and an arrow points to the new rating.

^{††} This metric met the criteria for high confidence as expected for this type of study

[§] Evaluator's explanation for rating change: "Problems with methods reporting (specifically the number of animals exposed/treatment group), as well as data indicating animals were of equivalent health and body weight at study initiation decrease confidence in the study results."

Table 41: **Animal toxicity evaluation results of Ema et al 2008 study on reproductive, growth (early life) and development, hepatic, neurological/behavior, and thyroid outcomes**

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|--|---|---------------------|------|-------|--|
| Study Citation: Ema, M., Fujii, S., Hirata-Koizumi, M., Matsumoto, M. (2008). Two-generation reproductive toxicity study of the flame retardant hexabromocyclododecane in rats <i>Reproductive Toxicology</i> , 25(3), 335-351 | | | | | |
| Data Type: | | | | | |
| HERO ID: 787657 | | | | | |
| Domain 1: Test Substance | | | | | |
| Metric 1: | Test Substance Identity | High | × 2 | 2 | The CASRN, purity, mixture components, and ratios were explicitly specified. |
| Metric 2: | Test Substance Source | High | × 1 | 1 | The manufacturer was specified; test substance number was reported. It was indicated that the purity and stability of the test chemical were verified using liquid chromatography. |
| Metric 3: | Test Substance Purity | High | × 1 | 1 | The test substance was 99.7% pure; therefore, effects in the study were highly likely to be due to the test substance itself (rather than any unspecified impurities). |
| Domain 2: Test Design | | | | | |
| Metric 4: | Negative and Vehicle Controls | High | × 2 | 2 | An appropriate concurrent control group was used (all of the conditions the same except exposure). |
| Metric 5: | Positive Controls | Not Rated | NA | NA | Positive control not indicated by study type. |
| Metric 6: | Randomized Allocation | High | × 1 | 1 | The study indicates that rats were randomly assigned into study groups. |
| Domain 3: Exposure Characterization | | | | | |
| Metric 7: | Preparation and Storage of Test Substance | High | × 1 | 1 | It was indicated that the test substance was stored in a sealed container under cool and dark conditions. The test substance was well-mixed in the diet (homogeneous and stable for at least 21 days). |
| Metric 8: | Consistency of Exposure Administration | High | × 1 | 1 | Analysis of the diet indicated that the test substance was administered at the desired feed concentrations throughout the study. Animals were fed ad libitum. |
| Metric 9: | Reporting of Doses/Concentrations | High | × 2 | 2 | Food consumption data were recorded (provided in the supplemental data). Mean daily intakes of the test substance for various generations and life stages (i.e. F0 and F1 males and females during pre-mating, mating, gestation, lactation, and for the whole period of administration) were reported without ambiguity.. |
| Metric 10: | Exposure Frequency and Duration | High | × 1 | 1 | The exposure frequency and duration were appropriate for the study type (and consistent with OECD guidelines). Mating was 3 weeks (rather than 2 weeks outlined by guideline). |
| Continued on next page ... | | | | | |

...continued from previous page

Study Citation: Ema, M., Fujii, S., Hirata-Koizumi, M., Matsumoto, M. (2008). Two-generation reproductive toxicity study of the flame retardant hexabromocyclododecane in rats *Reproductive Toxicology*, 25(3), 335-351

Data Type:

HERO ID: 787657

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|------------------------------|--|---------------------|------|-------|---|
| | Metric 11: Number of Exposure Groups and Dose Spacing | High | × 1 | 1 | Three dose groups and a concurrent control group were used. Dosage levels were based on the results of a 90-day repeated-dose toxicity study. |
| | Metric 12: Exposure Route and Method | High | × 1 | 1 | The test substance was administered in the diet (oral route is recommended by guideline). |
| Domain 4: Test Organism | | | | | |
| | Metric 13: Test Animal Characteristics | High | × 2 | 2 | The animal species, strain, sex, health, age, and starting body weights were reported. Animals were purchased from a commercial laboratory. CrI:CD(SD) rats were used because they are the most commonly used in reproductive and developmental toxicity studies; historical control data are available. The rat is the preferred species for testing (according to guideline). |
| | Metric 14: Adequacy and Consistency of Animal Husbandry Conditions | High | × 1 | 1 | Animals were housed under the same conditions (at the temperature and humidity recommended by guideline). Animals were housed individually except during acclimation, mating, and nursing periods. |
| | Metric 15: Number per Group | High | × 1 | 1 | No less than 20 pregnant females per group is preferred (but not always possible). The study utilized 24 rats/sex/group. Although the number of pregnant animals was only 19 for high-dose F0 females, the number of pregnant females was adequate for meaningful analyses of the desired outcomes. |
| Domain 5: Outcome Assessment | | | | | |
| | Metric 16: Outcome Assessment Methodology | High | × 2 | 2 | The outcome assessment methodology addressed the intended outcomes (mirrored guideline recommendations for a two-generation reproductive toxicity assay). |
| | Metric 17: Consistency of Outcome Assessment | High | × 1 | 1 | The outcomes were measured consistently across study groups. |
| | Metric 18: Sampling Adequacy | High | × 1 | 1 | Reporting details were provided; litter data were recorded. Sampling was adequate for the outcomes of interest. |
| | Metric 19: Blinding of Assessors | High | × 1 | 1 | Although the study does not indicate that investigators were blinded to treatment group, the study cited various quality control methods that were followed. |
| | Metric 20: Negative Control Response | High | × 1 | 1 | The response of the negative controls was reported and were adequate (e.g. there were no histological findings in the thyroid of control rats). |

Continued on next page ...

... continued from previous page

Study Citation: Ema, M., Fujii, S., Hirata-Koizumi, M., Matsumoto, M. (2008). Two-generation reproductive toxicity study of the flame retardant hexabromocyclododecane in rats *Reproductive Toxicology*, 25(3), 335-351

Data Type:

HERO ID: 787657

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|--|--|---------------------|------|-------|---|
| Domain 6: Confounding / Variable Control | | | | | |
| | Metric 21: Confounding Variables in Test Design and Procedures | High | × 2 | 2 | There were no differences in initial body weights or intake that could influence the outcome assessment. |
| | Metric 22: Health Outcomes Unrelated to Exposure | High | × 1 | 1 | Details regarding animal outcomes unrelated to exposure (i.e. accidental injury in the home cage) were reported, but these differences would not influence the outcome assessment. |
| Domain 7: Data Presentation and Analysis | | | | | |
| | Metric 23: Statistical Methods | High | × 1 | 1 | Statistical methods were clearly described. |
| | Metric 24: Reporting of Data | High | × 2 | 2 | Data were provided for all exposure-related findings by dose group. The cutoff value for decreased thyroid follicle size was not reported, but this is not likely to affect the outcome of the study. Additional data are provided in the supplemental document (for example, data for primordial follicles are presented graphically in the primary report; quantitative data are available in the supplemental document). |
| Overall Quality Determination [‡] | | High | | 1.0 | |
| Extracted | | Yes | | | |

* MWF = Metric Weighting Factor

[†] High = 1; Medium = 2; Low = 3; Unacceptable = 4; N/A has no value.

[‡] The overall rating is calculated as necessary. EPA may not always provide a comment for a metric that has been categorized as High.

$$\text{Overall rating} = \begin{cases} 4 & \text{if any metric is Unacceptable} \\ \left\lfloor \frac{\sum_i (\text{Metric Score}_i \times \text{MWF}_i)}{\sum_j \text{MWF}_j} \right\rfloor_{0.1} & \text{(round to the nearest tenth) otherwise} \end{cases}$$

where High = ≥ 1 to < 1.7 ; Medium = ≥ 1.7 to < 2.3 ; Low = ≥ 2.3 to ≤ 3.0 . If the reviewer determines that the overall rating needs adjustment, the original rating is crossed out and an arrow points to the new rating.

^{††} This metric met the criteria for high confidence as expected for this type of study

Table 42: **Animal toxicity evaluation results of Eriksson et al 2006 for oral neurodevelopmental study (single dose PND 10) study on neurological/behavior, and growth (early life) and development outcomes**

| Study Citation: | Eriksson, P., Fischer, C., Wallin, M., Jakobsson, E., Fredriksson, A. (2006). Impaired behaviour, learning and memory, in adult mice neonatally exposed to hexabromocyclododecane (HBCDD) <i>Environmental Toxicology and Pharmacology</i> , 21(3), 317-322 | | | | | |
|-------------------------------------|---|---------------------|------|-------|---|--|
| Data Type: | Oral neurodevelopmental study (single dose PND10) | | | | | |
| HERO ID: | 787660 | | | | | |
| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} | |
| Domain 1: Test Substance | | | | | | |
| Metric 1: | Test Substance Identity | High | × 2 | 2 | Characterized as a mixture containing three diastereo-isomers alpha-, beta-, and gamma-HBCD. | |
| Metric 2: | Test Substance Source | Low | × 1 | 3 | Prepared from a commercial mixture, but the manufacturer and lot/batch number were not given. Analytical verification is not described. | |
| Metric 3: | Test Substance Purity | High | × 1 | 1 | >98% | |
| Domain 2: Test Design | | | | | | |
| Metric 4: | Negative and Vehicle Controls | High | × 2 | 2 | Negative vehicle controls were used. | |
| Metric 5: | Positive Controls | Not Rated | NA | NA | Positive controls were not needed for neurodevelopmental studies. | |
| Metric 6: | Randomized Allocation | High | × 1 | 1 | Randomly selected from 3-4 different litters from each treatment group. | |
| Domain 3: Exposure Characterization | | | | | | |
| Metric 7: | Preparation and Storage of Test Substance | High | × 1 | 1 | Preparation was well described and appropriate. Single dose study, therefore prolonged storage is not a concern. | |
| Metric 8: | Consistency of Exposure Administration | High | × 1 | 1 | Details of exposure administration were reported and exposures were administered consistently across study groups in a scientifically sound manner (dose given via a PVC tube). | |
| Metric 9: | Reporting of Doses/Concentrations | High | × 2 | 2 | Gavage doses were reported as both mg/kg and umol/kg. | |
| Metric 10: | Exposure Frequency and Duration | High | × 1 | 1 | Administered as single dose during a critical period (on PND 10) in neonatal development of the mouse brain. | |
| Metric 11: | Number of Exposure Groups and Dose Spacing | Medium | × 1 | 2 | 2 doses plus control. A justification was not provided for the doses selected, but the results suggest they were appropriate.. | |
| Metric 12: | Exposure Route and Method | High | × 1 | 1 | The route and method of exposure were reported and were suited to the test substance. | |
| Domain 4: Test Organism | | | | | | |
| Metric 13: | Test Animal Characteristics | High | × 2 | 2 | Species, strain and age of neonatal mice was specified. | |

Continued on next page ...

...continued from previous page

| Study Citation: | Eriksson, P., Fischer, C., Wallin, M., Jakobsson, E., Fredriksson, A. (2006). Impaired behaviour, learning and memory, in adult mice neonatally exposed to hexabromocyclododecane (HBCDD) <i>Environmental Toxicology and Pharmacology</i> , 21(3), 317-322 | | | | | |
|--|---|---------------------|------|-------|--|--|
| Data Type: | Oral neurodevelopmental study (single dose PND10) | | | | | |
| HERO ID: | 787660 | | | | | |
| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} | |
| | Metric 14: Adequacy and Consistency of Animal Husbandry Conditions | Medium | × 1 | 2 | Most husbandry conditions were reported and were adequate and similar for all groups. Humidity was not reported. But this is unlikely to have a substantial impact on the results. | |
| | Metric 15: Number per Group | High | × 1 | 1 | The number of animals per study group was reported, appropriate for the study type and outcome analysis, and consistent with studies of the same or similar type (10/group or 12-17/group) | |
| Domain 5: Outcome Assessment | | | | | | |
| | Metric 16: Outcome Assessment Methodology | High | × 2 | 2 | Standard tests of spontaneous behavior and learning and memory. | |
| | Metric 17: Consistency of Outcome Assessment | High | × 1 | 1 | Details of the outcome assessment protocol were reported and outcomes were assessed consistently across study groups (e.g., at the same time after initial exposure) using the same protocol in all study groups. | |
| | Metric 18: Sampling Adequacy | Low | × 1 | 3 | It is difficult to discern definitively but based on the methods description and a statistical paper published explaining the methods used (Eriksson 2005, <i>The Toxicologist</i>) it appears that the pup was used as a statistical unit. While this is less important because the mice were not exposed in utero, it still ignores known litter effects, as documented in (Holsen et al, 2008). Additionally, Holson et al 2008 recommends examining both sexes, while this study only examines males. | |
| | Metric 19: Blinding of Assessors | Medium | × 1 | 2 | If litters were assessed, then metric 15 (number of animals per group) would be insufficient. Blinding was not reported; however, outcomes were objective. | |
| | Metric 20: Negative Control Response | High | × 1 | 1 | The biological responses of the negative control group(s) were adequate. | |
| Domain 6: Confounding / Variable Control | | | | | | |
| | Metric 21: Confounding Variables in Test Design and Procedures | High | × 2 | 2 | There were no significant deviations in body weight gain in HBCDD-treated mice compared with the vehicle-treated mice. | |
| | Metric 22: Health Outcomes Unrelated to Exposure | Low | × 1 | 3 | Data on attrition and/or health outcomes unrelated to exposure were not reported for each study group | |
| Domain 7: Data Presentation and Analysis | | | | | | |

Continued on next page ...

...continued from previous page

Study Citation: Eriksson, P., Fischer, C., Wallin, M., Jakobsson, E., Fredriksson, A. (2006). Impaired behaviour, learning and memory, in adult mice neonatally exposed to hexabromocyclododecane (HBCDD) *Environmental Toxicology and Pharmacology*, 21(3), 317-322
 Data Type: Oral neurodevelopmental study (single dose PND10)
 HERO ID: 787660

| Domain | Metric | Rating [†] | MWF [*] | Score | Comments ^{††} |
|--|--------------------------------|----------------------------|------------------|-------|--|
| | Metric 23: Statistical Methods | Low | × 1 | 3 | The specifics of analyzing pups as opposed to litters were not explicitly explained, and failing to account for litter effects could have a large statistical impact on results. |
| | Metric 24: Reporting of Data | High | × 2 | 2 | Data for exposure-related findings were presented for all outcomes by exposure group and sex. |
| Overall Quality Determination [‡] | | High → Medium [§] | | 1.4 | |
| Extracted | | No | | | |

* MWF = Metric Weighting Factor

† High = 1; Medium = 2; Low = 3; Unacceptable = 4; N/A has no value.

‡ The overall rating is calculated as necessary. EPA may not always provide a comment for a metric that has been categorized as High.

$$\text{Overall rating} = \begin{cases} 4 & \text{if any metric is Unacceptable} \\ \left\lfloor \frac{\sum_i (\text{Metric Score}_i \times \text{MWF}_i)}{\sum_j \text{MWF}_j} \right\rfloor_{0.1} & \text{(round to the nearest tenth) otherwise} \end{cases}$$

where High = ≥ 1 to < 1.7 ; Medium = ≥ 1.7 to < 2.3 ; Low = ≥ 2.3 to ≤ 3.0 . If the reviewer determines that the overall rating needs adjustment, the original rating is crossed out and an arrow points to the new rating.

†† This metric met the criteria for high confidence as expected for this type of study

§ Evaluator's explanation for rating change: "Downgraded because the statistical methods are inappropriate based on proper methods for DNT studies according to other publications (e.g. Holman et al, 2008, *Neurotoxicology and Teratology*)"

Table 43: **Animal toxicity evaluation results of Lilienthal et al 2009 for 1-generation reproductive study, dietary exposure study on neurological/behavior outcomes**

| Study Citation: | Lilienthal, H., van der Ven, L.T., Piersma, A.H., Vos, J.G. (2009). Effects of the brominated flame retardant hexabromocyclododecane (HBCD) on dopamine-dependent behavior and brainstem auditory evoked potentials in a one-generation reproduction study in Wistar rats Toxicology Letters, 185(1), 63-72 | | | | | |
|-------------------------------------|---|---------------------|------|-------|---|--|
| Data Type: | 1-generation reproductive study, dietary exposure | | | | | |
| HERO ID: | 787693 | | | | | |
| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} | |
| Domain 1: Test Substance | | | | | | |
| Metric 1: | Test Substance Identity | High | × 2 | 2 | Isomer composition of HBCD was reported. | |
| Metric 2: | Test Substance Source | Medium | × 1 | 2 | Supplier was Bromine Science and Environmental Forum. No information on lot or batch and no analytical verification was described. | |
| Metric 3: | Test Substance Purity | High | × 1 | 1 | HBCD was a technical mixture of three diastereoisomers, alpha-, beta-, and gamma-HBCD at respective proportions of 10.28%, 8.72%, and 81.02% with traces of tetra- and pentabromocyclododecane. | |
| Domain 2: Test Design | | | | | | |
| Metric 4: | Negative and Vehicle Controls | High | × 2 | 2 | Untreated and vehicle controls. | |
| Metric 5: | Positive Controls | Not Rated | NA | NA | Positive controls were not needed for neurobehavioral studies. | |
| Metric 6: | Randomized Allocation | Low | × 1 | 3 | The study did not report how animals were allocated to study groups. | |
| Domain 3: Exposure Characterization | | | | | | |
| Metric 7: | Preparation and Storage of Test Substance | Medium | × 1 | 2 | Preparation of test diets was described; however, the frequency of preparation and store was not indicated. | |
| Metric 8: | Consistency of Exposure Administration | High | × 1 | 1 | Details of exposure administration were reported and exposures were administered consistently across study groups in a scientifically sound manner. | |
| Metric 9: | Reporting of Doses/Concentrations | High | × 2 | 2 | Dose in mg/kg/day were calculated by study authors. | |
| Metric 10: | Exposure Frequency and Duration | High | × 1 | 1 | Continuous paternal and maternal exposure during premating, mating, gestation, lactation and after weaning in offspring was reported. | |
| Metric 11: | Number of Exposure Groups and Dose Spacing | High | × 1 | 1 | The number of exposure groups and dose/concentration spacing were justified by study authors and considered adequate to address the purpose of the study. | |
| Metric 12: | Exposure Route and Method | High | × 1 | 1 | The route and method of exposure were reported and were suited to the test substance. | |

Continued on next page ...

... continued from previous page

| Study Citation: | Lilienthal, H., van der Ven, L.T., Piersma, A.H., Vos, J.G. (2009). Effects of the brominated flame retardant hexabromocyclododecane (HBCD) on dopamine-dependent behavior and brainstem auditory evoked potentials in a one-generation reproduction study in Wistar rats Toxicology Letters, 185(1), 63-72 | | | | |
|--|---|---------------------|------|-------|---|
| Data Type: | 1-generation reproductive study, dietary exposure | | | | |
| HERO ID: | 787693 | | | | |
| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
| Domain 4: Test Organism | | | | | |
| Metric 13: | Test Animal Characteristics | High | × 2 | 2 | Species, strain, sex and starting age were provided (commercial source). |
| Metric 14: | Adequacy and Consistency of Animal Husbandry Conditions | Medium | × 1 | 2 | Husbandry conditions were reported and appropriate. |
| Metric 15: | Number per Group | High | × 1 | 1 | 6/sex/group |
| Domain 5: Outcome Assessment | | | | | |
| Metric 16: | Outcome Assessment Methodology | High | × 2 | 2 | The outcome assessment methodology addressed or reported the intended outcome(s) of interest and was sensitive for the outcomes(s) of interest. |
| Metric 17: | Consistency of Outcome Assessment | High | × 1 | 1 | Details of the outcome assessment protocol were reported and outcomes were assessed consistently across study groups. |
| Metric 18: | Sampling Adequacy | High | × 1 | 1 | Details regarding sampling for the outcome(s) of interest were reported. |
| Metric 19: | Blinding of Assessors | High | × 1 | 1 | The authors report that "personnel conducting the measurements were unaware of the exposure conditions" suggesting the assessors were blinded. |
| Metric 20: | Negative Control Response | High | × 1 | 1 | The biological responses of the negative control group(s) were adequate. |
| Domain 6: Confounding / Variable Control | | | | | |
| Metric 21: | Confounding Variables in Test Design and Procedures | Low | × 2 | 6 | Initial body weight and food/water intake were not reported. |
| Metric 22: | Health Outcomes Unrelated to Exposure | Low | × 1 | 3 | Data on attrition and/or health outcomes unrelated to exposure were not reported for each study group. |
| Domain 7: Data Presentation and Analysis | | | | | |
| Metric 23: | Statistical Methods | High | × 1 | 1 | Statistics and BMD modeling was reported. |
| Metric 24: | Reporting of Data | High | × 2 | 2 | Test data and BMD results were reported. |
| Overall Quality Determination [‡] | | High | | 1.4 | |
| Extracted | | Yes | | | |

Continued on next page ...

...continued from previous page

Study Citation: Lilienthal, H., van der Ven, L.T., Piersma, A.H., Vos, J.G. (2009). Effects of the brominated flame retardant hexabromocyclododecane (HBCD) on dopamine-dependent behavior and brainstem auditory evoked potentials in a one-generation reproduction study in Wistar rats *Toxicology Letters*, 185(1), 63-72
 Data Type: 1-generation reproductive study, dietary exposure
 HERO ID: 787693

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|--------|--------|---------------------|------|-------|------------------------|
|--------|--------|---------------------|------|-------|------------------------|

* MWF = Metric Weighting Factor

[†] High = 1; Medium = 2; Low = 3; Unacceptable = 4; N/A has no value.

[‡] The overall rating is calculated as necessary. EPA may not always provide a comment for a metric that has been categorized as High.

$$\text{Overall rating} = \begin{cases} 4 & \text{if any metric is Unacceptable} \\ \left\lceil \left[\frac{\sum_i (\text{Metric Score}_i \times \text{MWF}_i)}{\sum_j \text{MWF}_j} \right]_{0.1} \right\rceil & \text{(round to the nearest tenth) otherwise} \end{cases}$$

where High $\Rightarrow \geq 1$ to < 1.7 ; Medium $\Rightarrow \geq 1.7$ to < 2.3 ; Low $\Rightarrow \geq 2.3$ to ≤ 3.0 . If the reviewer determines that the overall rating needs adjustment, the original rating is crossed out and an arrow points to the new rating.

^{††} This metric met the criteria for high confidence as expected for this type of study

Table 44: **Animal toxicity evaluation results of Saegusa et al 2009 for 1-generation developmental toxicity (dietary exposure) study on reproductive, growth (early life) and development, neurological, hepatic, endocrine, thyroid, nutrition and metabolic/adult exposure body weight outcomes**

| Study Citation: | Saegusa, Y., Fujimoto, H., Woo, G.H., Inoue, K., Takahashi, M., Mitsumori, K., Hirose, M., Nishikawa, A. (2009). Developmental toxicity of brominated flame retardants, tetrabromobisphenol A and 1,2,5,6,9,10-hexabromocyclododecane, in rat offspring after maternal exposure from mid-gestation through lactation <i>Reproductive Toxicology</i> , 28(4), 456-467 | | | | | |
|-------------------------------------|--|---------------------|------|-------|---|--|
| Data Type: | 1-Generation Developmental Toxicity (Dietary Exposure) | | | | | |
| HERO ID: | 787721 | | | | | |
| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} | |
| Domain 1: Test Substance | | | | | | |
| Metric 1: | Test Substance Identity | High | × 2 | 2 | Identified by chemical name and CASRN. | |
| Metric 2: | Test Substance Source | High | × 1 | 1 | Manufacturer and lot no. were reported.. | |
| Metric 3: | Test Substance Purity | High | × 1 | 1 | >95% | |
| Domain 2: Test Design | | | | | | |
| Metric 4: | Negative and Vehicle Controls | High | × 2 | 2 | Concurrent negative control. | |
| Metric 5: | Positive Controls | Not Rated | NA | NA | Positive control not needed developmental studies. | |
| Metric 6: | Randomized Allocation | High | × 1 | 1 | Randomized allocation. | |
| Domain 3: Exposure Characterization | | | | | | |
| Metric 7: | Preparation and Storage of Test Substance | Low | × 1 | 3 | Test substance preparation and storage were not described. | |
| Metric 8: | Consistency of Exposure Administration | High | × 1 | 1 | Details of exposure administration were reported. | |
| Metric 9: | Reporting of Doses/Concentrations | High | × 2 | 2 | Doses were reported as mg/kg-day (mean +/- SD) for 3 time periods (GD 10-20, PND 1-9 and PND 10-20) | |
| Metric 10: | Exposure Frequency and Duration | High | × 1 | 1 | Daily exposure during critical developmental periods. | |
| Metric 11: | Number of Exposure Groups and Dose Spacing | High | × 1 | 1 | Range-finding study was used to set doses.. 3 treatment groups plus controls. | |
| Metric 12: | Exposure Route and Method | High | × 1 | 1 | The route and method of exposure were reported and were suited to the test substance. | |
| Domain 4: Test Organism | | | | | | |
| Metric 13: | Test Animal Characteristics | High | × 2 | 2 | Test animals were obtained from a commercial source. Species, strain, and pregnancy status were reported. | |
| Metric 14: | Adequacy and Consistency of Animal Husbandry Conditions | High | × 1 | 1 | Husbandry conditions were reported and appropriate. | |
| Continued on next page ... | | | | | | |

... continued from previous page

| Study Citation: | Saeguas, Y., Fujimoto, H., Woo, G.H., Inoue, K., Takahashi, M., Mitsumori, K., Hirose, M., Nishikawa, A. (2009). Developmental toxicity of brominated flame retardants, tetrabromobisphenol A and 1,2,5,6,9,10-hexabromocyclododecane, in rat offspring after maternal exposure from mid-gestation through lactation <i>Reproductive Toxicology</i> , 28(4), 456-467 | | | | | |
|--|--|---------------------|------|-------|--|--|
| Data Type: | 1-Generation Developmental Toxicity (Dietary Exposure) | | | | | |
| HERO ID: | 787721 | | | | | |
| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} | |
| | Metric 15: Number per Group | High | × 1 | 1 | The number of animals per study group was reported, appropriate for the study type and outcome analysis, and consistent with studies of the same or similar type (10/group). | |
| Domain 5: Outcome Assessment | | | | | | |
| | Metric 16: Outcome Assessment Methodology | High | × 2 | 2 | Thorough outcome examinations pubertal and adult necropsies). | |
| | Metric 17: Consistency of Outcome Assessment | High | × 1 | 1 | Details of the outcome assessment protocol were reported and outcomes were assessed consistently across study groups. | |
| | Metric 18: Sampling Adequacy | High | × 1 | 1 | Details regarding sampling for the outcome(s) of interest were reported and the study used adequate sampling for the outcome(s) of interest (e.g., litter data provided for developmental studies; endpoints were evaluated in an adequate number of animals in each group). | |
| | Metric 19: Blinding of Assessors | Medium | × 1 | 2 | Blinding was not reported, but outcomes were objective. | |
| | Metric 20: Negative Control Response | High | × 1 | 1 | No histopathology lesion in controls. | |
| Domain 6: Confounding / Variable Control | | | | | | |
| | Metric 21: Confounding Variables in Test Design and Procedures | High | × 2 | 2 | No differences among groups in food consumption and body weight. | |
| | Metric 22: Health Outcomes Unrelated to Exposure | Low | × 1 | 3 | Data on attrition and/or health outcomes unrelated to exposure were not reported for each study group | |
| Domain 7: Data Presentation and Analysis | | | | | | |
| | Metric 23: Statistical Methods | High | × 1 | 1 | Statistical methods were clearly described and appropriate for dataset(s). | |
| | Metric 24: Reporting of Data | Medium | × 2 | 4 | HBCD caused a dose-dependent decrease in Cingulate deep cortex CNPase (+) cell count, which was significantly lower at the highest dose exposed. | |
| Overall Quality Determination [‡] | | High | | 1.2 | | |
| Extracted | | Yes | | | | |

Continued on next page ...

... continued from previous page

Study Citation: Saeguas, Y., Fujimoto, H., Woo, G.H., Inoue, K., Takahashi, M., Mitsumori, K., Hirose, M., Nishikawa, A. (2009). Developmental toxicity of brominated flame retardants, tetrabromobisphenol A and 1,2,5,6,9,10-hexabromocyclododecane, in rat offspring after maternal exposure from mid-gestation through lactation *Reproductive Toxicology*, 28(4), 456-467

Data Type: 1-Generation Developmental Toxicity (Dietary Exposure)

HERO ID: 787721

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|--------|--------|---------------------|------|-------|------------------------|
|--------|--------|---------------------|------|-------|------------------------|

* MWF = Metric Weighting Factor

[†] High = 1; Medium = 2; Low = 3; Unacceptable = 4; N/A has no value.

[‡] The overall rating is calculated as necessary. EPA may not always provide a comment for a metric that has been categorized as High.

$$\text{Overall rating} = \begin{cases} 4 & \text{if any metric is Unacceptable} \\ \left[\sum_i (\text{Metric Score}_i \times \text{MWF}_i) / \sum_j \text{MWF}_j \right]_{0.1} & \text{(round to the nearest tenth) otherwise} \end{cases}$$

where High $\Rightarrow \geq 1$ to < 1.7 ; Medium $\Rightarrow \geq 1.7$ to < 2.3 ; Low $\Rightarrow \geq 2.3$ to ≤ 3.0 . If the reviewer determines that the overall rating needs adjustment, the original rating is crossed out and an arrow points to the new rating.

^{††} This metric met the criteria for high confidence as expected for this type of study

8 Mechanistic

Table 45: In vitro evaluation results of Anisuzzaman and Whalen 2016 for secretion of IL-1beta

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|--|---|---------------------|------|-------|---|
| Study Citation: Anisuzzaman, S; Whalen, MM (2016). Tetrabromobisphenol A and hexabromocyclododecane alter secretion of IL-1β from human immune cells Journal of Immunotoxicology, 13(3), 403-416 | | | | | |
| Data Type: Secretion of IL-1beta for HBCD | | | | | |
| HERO ID: 3350463 | | | | | |
| Domain 1: Test Substance | | | | | |
| Metric 1: | Test Substance Identity | High | × 2 | 2 | The test substance was clearly identified by name. |
| Metric 2: | Test Substance Source | Medium | × 1 | 2 | The source of the test substance (a manufacturer) was identified; not information on batch/lot number was provided. |
| Metric 3: | Test Substance Purity | Low | × 1 | 3 | The purity of the test substance was not reported. |
| Domain 2: Test Design | | | | | |
| Metric 4: | Negative and Vehicle Controls | High | × 2 | 2 | Concurrent negative (vehicle-only) controls were included for each cell type/study condition. |
| Metric 5: | Positive Controls | Not Rated | NA | NA | Positive controls not required. However, treatment-related positive responses were observed (i.e., demonstrating the test is capable of detecting a positive response). |
| Metric 6: | Assay Procedures | High | × 1 | 1 | The study authors described the methods and procedures (e.g., test conditions, cell density, culture media, temperatures) used for the test in detail and they were applicable for the study type. |
| Metric 7: | Standards for Tests | Not Rated | NA | NA | This metric is not applicable to the study type. |
| Domain 3: Exposure Characterization | | | | | |
| Metric 8: | Preparation and Storage of Test Substance | Low | × 1 | 3 | The study indicates that stock solutions were made by dissolving the test substance in DMSO; concentrations used in the assays were prepared by diluting the stock solution, Information about stability and storage were not reported (for studies as long as 6 days in duration). |
| Metric 9: | Consistency of Exposure Administration | High | × 1 | 1 | Exposures were administered consistently across study groups. |
| Metric 10: | Reporting of Doses/Concentrations | High | × 2 | 2 | Concentrations were reported without ambiguity. |
| Metric 11: | Number of Exposure Groups and Concentration Spacing | High | × 2 | 2 | The study used varying duration of exposures (24 hours, 48 hours, 6 days). |
| Continued on next page ... | | | | | |

... continued from previous page

| Study Citation: | Anisuzzaman, S; Whalen, MM (2016). Tetrabromobisphenol A and hexabromocyclododecane alter secretion of IL-1 β from human immune cells Journal of Immunotoxicology, 13(3), 403-416 | | | | | |
|--|---|---------------------|------|-------|--|--|
| Data Type: | Secretion of IL-1beta for HBCD | | | | | |
| HERO ID: | 3350463 | | | | | |
| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} | |
| | Metric 12: Exposure Route and Method | High | × 1 | 1 | The number of exposure groups was reported (as many as 7 groups plus controls), and the rationale for selected doses was reported (i.e., ranges tested were based those that had caused effects on NK lytic function, cell-surface protein expression, and MAPK activity). | |
| | Metric 13: Metabolic Activation | Not Rated | NA | NA | This metric is not applicable to the study type. | |
| Domain 4: Test Model | | | | | | |
| | Metric 14: Test Model | Medium | × 2 | 4 | The test models (natural killer cells, monocyte-depleted peripheral blood mononuclear cells [PMBC], and PBMC) was reported along with limited descriptive information. The sources of cells was reported. The cell types were appropriate for the outcome of interest because they secrete pro-inflammatory cytokines. | |
| | Metric 15: Number per Group | High | × 1 | 1 | The study indicates that experiments were performed in triplicate. | |
| Domain 5: Outcome Assessment | | | | | | |
| | Metric 16: Outcome Assessment Methodology | High | × 2 | 2 | The outcome assessment methodology was reported in adequate detail. | |
| | Metric 17: Consistency of Outcome Assessment | High | × 1 | 1 | Outcomes were assessed consistently across study groups. | |
| | Metric 18: Sampling Adequacy | High | × 2 | 2 | This metric is not applicable to the study type. | |
| | Metric 19: Blinding of Assessors | Not Rated | NA | NA | This metric is not applicable to the study type. | |
| Domain 6: Confounding / Variable Control | | | | | | |
| | Metric 20: Confounding Variables in Test Design and Procedures | High | × 2 | 2 | The study authors acknowledged differences in the response of cells to HBCD for various donors; data were shown for individual donors. | |
| | Metric 21: Confounding Variables in Outcomes Unrelated to Exposure | Medium | × 1 | 2 | No reported outcome differences among study groups unrelated to exposure were reported (not expected to impact the study results). | |
| Domain 7: Data Presentation and Analysis | | | | | | |
| | Metric 22: Data Analysis | High | × 1 | 1 | Statistical methods were clearly described and presented for datasets of interest (i.e., ANOVA and Student's t-tests). | |
| | Metric 23: Data Interpretation | Medium | × 2 | 4 | Statistical significance served as the primary criteria for a positive response. | |
| | Metric 24: Cytotoxicity Data | High | × 1 | 1 | Cell viability was defined and methods were described. | |

Continued on next page ...

...continued from previous page

Study Citation: Anisuzzaman, S; Whalen, MM (2016). Tetrabromobisphenol A and hexabromocyclododecane alter secretion of IL-1 β from human immune cells Journal of Immunotoxicology, 13(3), 403-416
 Data Type: Secretion of IL-1beta for HBCD
 HERO ID: 3350463

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|--|------------------------------|---------------------|------|-------|---|
| | Metric 25: Reporting of Data | High | × 2 | 2 | All data were reported by exposure group. |
| Overall Quality Determination [‡] | | High | | 1.3 | |
| Extracted | | Yes | | | |

* MWF = Metric Weighting Factor

† High = 1; Medium = 2; Low = 3; Unacceptable = 4; N/A has no value.

‡ The overall rating is calculated as necessary. EPA may not always provide a comment for a metric that has been categorized as High.

$$\text{Overall rating} = \begin{cases} 4 & \text{if any metric is Unacceptable} \\ \left\lfloor \frac{\sum_i (\text{Metric Score}_i \times \text{MWF}_i)}{\sum_j \text{MWF}_j} \right\rfloor_{0.1} & \text{(round to the nearest tenth) otherwise} \end{cases}$$

where High \Rightarrow 1 to < 1.7; Medium \Rightarrow 1.7 to < 2.3; Low \Rightarrow 2.3 to \leq 3.0. If the reviewer determines that the overall rating needs adjustment, the original rating is crossed out and an arrow points to the new rating.

†† This metric met the criteria for high confidence as expected for this type of study

Table 46: **In vitro** evaluation results of Wang et al 2016 for metabolic pathways for mechanism of toxicity

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|--|---|---------------------|------|-------|--|
| Study Citation: Wang, F; Zhang, H; Geng, N; Zhang, B; Ren, X; Chen, J (2016). New insights into the cytotoxic mechanism of hexabromocyclododecane from a metabolomic approach Environmental Science and Technology, 50(6), 3145-3153 | | | | | |
| Data Type: Metabolic pathways for mechanism of toxicity for HBCD | | | | | |
| HERO ID: 3350479 | | | | | |
| Domain 1: Test Substance | | | | | |
| Metric 1: | Test Substance Identity | Medium | × 2 | 4 | The test substance was clearly identified by name. |
| Metric 2: | Test Substance Source | Medium | × 1 | 2 | The source of the test substance was reported (without information regarding batch/lot number). |
| Metric 3: | Test Substance Purity | High | × 1 | 1 | Reported purity and grade (reagent-grade; >95% pure) were such that effects likely due to test substance. |
| Domain 2: Test Design | | | | | |
| Metric 4: | Negative and Vehicle Controls | High | × 2 | 2 | Negative control (vehicle-only) groups were included; the only difference among groups was exposure to the test substance. |
| Metric 5: | Positive Controls | Not Rated | NA | NA | This metric is not applicable to the study type. However, treatment-related positive responses were observed (i.e., demonstrating the test is capable of detecting a positive response). |
| Metric 6: | Assay Procedures | High | × 1 | 1 | The study authors described the methods and procedures (e.g., test conditions, culture media and volumes, temperatures) used for the test in detail and they were applicable for the study type. Some methodological information was provided in the Supporting Information. Although a non-traditional method was used for metabolomic analysis (psuedotargeted approach rather than Q-TOF MS untargeted method), the authors showed that their method produced results that were repeatable. |
| Metric 7: | Standards for Tests | Not Rated | NA | NA | This metric is not applicable to the study type. |
| Domain 3: Exposure Characterization | | | | | |
| Metric 8: | Preparation and Storage of Test Substance | Medium | × 1 | 2 | The study indicates that HBCD stock solutions were prepared in DMSO and incorporated into the cell culture medium. Information on stability and storage were not reported (but are not expected to impact the study results owing to the short duration of the study [24 hours for the metabolomic portion of the study]). |
| Metric 9: | Consistency of Exposure Administration | High | × 1 | 1 | Exposures were administered consistently across study groups. |
| Metric 10: | Reporting of Doses/Concentrations | High | × 2 | 2 | Concentrations were reported without ambiguity. |
| Continued on next page ... | | | | | |

... continued from previous page

| Study Citation: | Wang, F; Zhang, H; Geng, N; Zhang, B; Ren, X; Chen, J (2016). New insights into the cytotoxic mechanism of hexabromocyclododecane from a metabolomic approach Environmental Science and Technology, 50(6), 3145-3153 | | | | | |
|--|--|---------------------|------|-------|--|--|
| Data Type: | Metabolic pathways for mechanism of toxicity for HBCD | | | | | |
| HERO ID: | 3350479 | | | | | |
| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} | |
| | Metric 11: Number of Exposure Groups and Concentration Spacing | High | × 2 | 2 | Durations were reported and adequate for the study type. The duration of the metabolomic study was based on results for the cell viability assay. | |
| | Metric 12: Exposure Route and Method | High | × 1 | 1 | The number of groups (3 groups plus controls) was reported and based on cell viability testing (lowest dose with observable inhibition effect, middle dose without observable effect, and highest dose with observable stimulation effect). The lowest dose was also comparable with the maximum serum concentration of HBCD in occupationally exposed individuals. | |
| | Metric 13: Metabolic Activation | Not Rated | NA | NA | This metric is not applicable to the study type. | |
| Domain 4: Test Model | | | | | | |
| | Metric 14: Test Model | High | × 2 | 2 | The test model (HepG2 cells) and descriptive information were reported, the test model was obtained from a commercial source (China Infrastructure of Cell Line Resources). The study indicates that this test system was used as a model because the cells are stable, have an unlimited lifespan, and retains liver-specific functions. In addition, its molecular expression and biological phenotypes have been extensively characterized. | |
| | Metric 15: Number per Group | High | × 1 | 1 | The number of replicates (n = 6 for metabolomic analyses) was appropriate for the study type. | |
| Domain 5: Outcome Assessment | | | | | | |
| | Metric 16: Outcome Assessment Methodology | High | × 2 | 2 | Outcome assessment methodologies were described in adequate detail. Some of this information is reported in the Supplemental Information. | |
| | Metric 17: Consistency of Outcome Assessment | High | × 1 | 1 | Exposures were administered consistently across study groups. | |
| | Metric 18: Sampling Adequacy | Not Rated | NA | NA | This metric is not applicable to the study type. | |
| | Metric 19: Blinding of Assessors | Not Rated | NA | NA | This metric is not applicable to the study type. | |
| Domain 6: Confounding / Variable Control | | | | | | |
| | Metric 20: Confounding Variables in Test Design and Procedures | High | × 2 | 2 | No confounding variables in test design and procedures were identified. | |
| | Metric 21: Confounding Variables in Outcomes Unrelated to Exposure | Medium | × 1 | 2 | No confounding variables in outcomes unrelated to exposure were reported (none are expected to impact the study results). | |
| Domain 7: Data Presentation and Analysis | | | | | | |

Continued on next page ...

... continued from previous page

Study Citation: Wang, F; Zhang, H; Geng, N; Zhang, B; Ren, X; Chen, J (2016). New insights into the cytotoxic mechanism of hexabromocyclododecane from a metabolomic approach *Environmental Science and Technology*, 50(6), 3145-3153
 Data Type: Metabolic pathways for mechanism of toxicity for HBCD
 HERO ID: 3350479

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|--|---------------------|---------------------|------|-------|--|
| Metric 22: | Data Analysis | High | × 1 | 1 | Statistical methods (e.g., ANOVA using statistics software) and data manipulation (with respect to metabolomic analyses) were reported and appropriate for the study type. |
| Metric 23: | Data Interpretation | High | × 2 | 2 | The study indicated the criteria for positive responses (e.g., based on statistical significance or dose-response). |
| Metric 24: | Cytotoxicity Data | High | × 1 | 1 | Cytotoxicity endpoints were defined and methods were reported in adequate detail. |
| Metric 25: | Reporting of Data | High | × 2 | 2 | Data were reported for outcomes by exposure group. |
| Overall Quality Determination [‡] | | High | | 1.2 | |
| Extracted | | Yes | | | |

* MWF = Metric Weighting Factor

[†] High = 1; Medium = 2; Low = 3; Unacceptable = 4; N/A has no value.

[‡] The overall rating is calculated as necessary. EPA may not always provide a comment for a metric that has been categorized as High.

$$\text{Overall rating} = \begin{cases} 4 & \text{if any metric is Unacceptable} \\ \left\lfloor \frac{\sum_i (\text{Metric Score}_i \times \text{MWF}_i)}{\sum_j \text{MWF}_j} \right\rfloor_{0.1} & \text{(round to the nearest tenth) otherwise} \end{cases}$$

where High = ≥ 1 to < 1.7 ; Medium = ≥ 1.7 to < 2.3 ; Low = ≥ 2.3 to ≤ 3.0 . If the reviewer determines that the overall rating needs adjustment, the original rating is crossed out and an arrow points to the new rating.

^{††} This metric met the criteria for high confidence as expected for this type of study

Table 47: **In vitro** evaluation results of Kim et al 2016 for cancer progression (cell growth, apoptosis, migration, gene expression)

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|---|---|---------------------|------|-------|---|
| Study Citation: Kim, SH; Nam, KH; Hwang, KA; Choi, KC (2016). Influence of hexabromocyclododecane and 4-nonylphenol on the regulation of cell growth, apoptosis and migration in prostatic cancer cells Toxicology In Vitro, 32 240-247 | | | | | |
| Data Type: Cancer progression (cell growth, apoptosis, migration, gene expression) for HBCD | | | | | |
| HERO ID: 3350494 | | | | | |
| Domain 1: Test Substance | | | | | |
| Metric 1: | Test Substance Identity | High | × 2 | 2 | The test substance was clearly identified by name. |
| Metric 2: | Test Substance Source | Medium | × 1 | 2 | The source of the test substance (a manufacturer) was identified (no batch/lot numbers provided). |
| Metric 3: | Test Substance Purity | High | × 1 | 1 | Purity was reported (>99% or analytical standard); therefore, effects observed are likely due to test substance itself. |
| Domain 2: Test Design | | | | | |
| Metric 4: | Negative and Vehicle Controls | High | × 2 | 2 | Concurrent vehicle-only control groups were used; conditions appeared to be equal other than addition of the test substance. |
| Metric 5: | Positive Controls | High | × 2 | 2 | Dihydrotestosterone was used as a positive control (as a potent androgen that binds strongly to the androgen receptor [AR]). The study aimed to evaluate whether HBCD enhances prostate cancer progression via AR in vitro. |
| Metric 6: | Assay Procedures | High | × 1 | 1 | Methods and procedures were described in adequate detail (e.g., cell density, culture media and volumes, temperature). |
| Metric 7: | Standards for Tests | Not Rated | NA | NA | This metric is not applicable to the study type. |
| Domain 3: Exposure Characterization | | | | | |
| Metric 8: | Preparation and Storage of Test Substance | Low | × 1 | 3 | Test substance was dissolved in solvent (DMSO) but no other details (e.g., storage) were provided. The absence of details is considered a deficiency owing to the duration of experiments conducted in this study (i.e., up to 5 days in duration for the migration assay). |
| Metric 9: | Consistency of Exposure Administration | High | × 1 | 1 | Exposures were administered consistently across study groups. |
| Metric 10: | Reporting of Doses/Concentrations | High | × 2 | 2 | Exposure concentrations were reported without ambiguity. |
| Metric 11: | Number of Exposure Groups and Concentration Spacing | High | × 2 | 2 | Exposure duration is listed for all experiments (and are considered appropriate for the study type(s)). |
| Continued on next page ... | | | | | |

... continued from previous page

| Study Citation: | Kim, SH; Nam, KH; Hwang, KA; Choi, KC (2016). Influence of hexabromocyclododecane and 4-nonylphenol on the regulation of cell growth, apoptosis and migration in prostatic cancer cells Toxicology In Vitro, 32 240-247 | | | | | |
|--|---|---------------------|------|-------|---|--|
| Data Type: | Cancer progression (cell growth, apoptosis, migration, gene expression) for HBCD | | | | | |
| HERO ID: | 3350494 | | | | | |
| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} | |
| | Metric 12: Exposure Route and Method | Low | × 1 | 3 | The number of exposure groups was reported (as many as 4 dose groups plus controls for viability, as few as 1 dose group for migration and gene expression assays). It was indicated that doses were in the range of human/environmental exposure levels. The doses used did not generate a dose-related effect (viability assay); and dose-relatedness could not be evaluated for experiments using only one dose. | |
| | Metric 13: Metabolic Activation | Not Rated | NA | NA | This metric is not applicable to the study type. | |
| Domain 4: Test Model | | | | | | |
| | Metric 14: Test Model | Medium | × 2 | 4 | The test model was appropriate for the outcomes of interest (i.e., cancer progression endpoints via androgen receptor endpoints in prostatic cancer cells). The number of passages were indicated; however, the source of the cells was not specified. | |
| | Metric 15: Number per Group | High | × 1 | 1 | The study indicated that each experiment was repeated three times. | |
| Domain 5: Outcome Assessment | | | | | | |
| | Metric 16: Outcome Assessment Methodology | Medium | × 2 | 4 | Outcome assessment methodologies were reported in adequate detail. However, it is noted that the approach used to evaluate gene expression was semi-quantitative (based on band intensity). | |
| | Metric 17: Consistency of Outcome Assessment | High | × 1 | 1 | Outcomes were assessed consistently across groups. | |
| | Metric 18: Sampling Adequacy | High | × 2 | 2 | This metric is not applicable to the study type. | |
| | Metric 19: Blinding of Assessors | Not Rated | NA | NA | This metric is not applicable to the study type. | |
| Domain 6: Confounding / Variable Control | | | | | | |
| | Metric 20: Confounding Variables in Test Design and Procedures | High | × 2 | 2 | No confounding variables were identified. | |
| | Metric 21: Confounding Variables in Outcomes Unrelated to Exposure | Low | × 1 | 3 | Outcomes unrelated to exposure were not reported. | |
| Domain 7: Data Presentation and Analysis | | | | | | |
| | Metric 22: Data Analysis | High | × 1 | 1 | Statistical analyses used in the analyses were reported. In the figure legends, it is indicated when Dunnett's comparison test was used (unclear if Student's t-test was applied to the dataset(s)). | |
| Continued on next page ... | | | | | | |

... continued from previous page

Study Citation: Kim, SH; Nam, KH; Hwang, KA; Choi, KC (2016). Influence of hexabromocyclododecane and 4-nonylphenol on the regulation of cell growth, apoptosis and migration in prostatic cancer cells *Toxicology In Vitro*, 32 240-247
 Data Type: Cancer progression (cell growth, apoptosis, migration, gene expression) for HBCD
 HERO ID: 3350494

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|--|--------------------------------|---------------------|------|-------|---|
| | Metric 23: Data Interpretation | Medium | × 2 | 4 | Statistical analyses were used as the basis for positive results. Dose-relatedness could only be assessed for the cell viability assay (the only experiment that utilized multiple dose levels); effects on cell viability were not dose-related. |
| | Metric 24: Cytotoxicity Data | High | × 1 | 1 | Methods to determine cell viability were described in adequate detail. |
| | Metric 25: Reporting of Data | High | × 2 | 2 | Data were reported for all outcomes by exposure group. |
| Overall Quality Determination [‡] | | High | | 1.4 | |
| Extracted | | Yes | | | |

* MWF = Metric Weighting Factor

[†] High = 1; Medium = 2; Low = 3; Unacceptable = 4; N/A has no value.

[‡] The overall rating is calculated as necessary. EPA may not always provide a comment for a metric that has been categorized as High.

$$\text{Overall rating} = \begin{cases} 4 & \text{if any metric is Unacceptable} \\ \left\lfloor \frac{\sum_i (\text{Metric Score}_i \times \text{MWF}_i)}{\sum_j \text{MWF}_j} \right\rfloor_{0.1} & \text{(round to the nearest tenth) otherwise} \end{cases}$$

where High = ≥ 1 to < 1.7 ; Medium = ≥ 1.7 to < 2.3 ; Low = ≥ 2.3 to ≤ 3.0 . If the reviewer determines that the overall rating needs adjustment, the original rating is crossed out and an arrow points to the new rating.

^{††} This metric met the criteria for high confidence as expected for this type of study

Table 48: **In vitro** evaluation results of Koike et al 2016 for immune response in respiratory cells

| Study Citation: | Koike, E; Yanagisawa, R; Takano, H (2016). Brominated flame retardants, hexabromocyclododecane and tetrabromobisphenol A, affect proinflammatory protein expression in human bronchial epithelial cells via disruption of intracellular signaling Toxicology In Vitro, 32 212-219 | | | | | |
|-------------------------------------|---|---------------------|------|-------|---|--|
| Data Type: | Immune response in respiratory cells for HBCD | | | | | |
| HERO ID: | 3350501 | | | | | |
| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} | |
| Domain 1: Test Substance | | | | | | |
| Metric 1: | Test Substance Identity | High | × 2 | 2 | The test substance identified by name, structure, and molecular weight. | |
| Metric 2: | Test Substance Source | Medium | × 1 | 2 | The source of the test substance (a manufacturer) was reported (without information on a batch/lot number). | |
| Metric 3: | Test Substance Purity | High | × 1 | 1 | The reported purity of the test substance (>95%) was such that observed effects are likely due to the test substance. | |
| Domain 2: Test Design | | | | | | |
| Metric 4: | Negative and Vehicle Controls | High | × 2 | 2 | Concurrent negative (vehicle-only) controls were included. | |
| Metric 5: | Positive Controls | Not Rated | NA | NA | This metric is not applicable to the study type. Treatment with then substances used in the study induced positive responses (indicative of the efficacy of the test system). For the nuclear receptor-ligand binding assay, 3,3',5-triiodo-L-thyronine (T3) was used as a positive control for the thyroid receptor and beta-estradiol was used as a positive control for the estrogen receptor. | |
| Metric 6: | Assay Procedures | Medium | × 1 | 2 | Assay procedures were partially reported (immunoassay for EGFR phosphorylation, transcription factor assay) and partially cited to other publications and/or protocols (measurement of the expression of pro-inflammatory proteins, nuclear receptor-ligand binding assay). | |
| Metric 7: | Standards for Tests | Not Rated | NA | NA | This metric is not applicable to the study type. | |
| Domain 3: Exposure Characterization | | | | | | |
| Metric 8: | Preparation and Storage of Test Substance | Medium | × 1 | 2 | Preparation details were reported (i.e., test substance was diluted in DMSO), but storage and stability conditions were not reported (not expected to impact the study results owing to the short duration of the experiments [up to 24 hours]). | |
| Metric 9: | Consistency of Exposure Administration | High | × 1 | 1 | Exposures were administered consistently across study groups. | |
| Continued on next page ... | | | | | | |

... continued from previous page

| Study Citation: | Koike, E; Yanagisawa, R; Takano, H (2016). Brominated flame retardants, hexabromocyclododecane and tetrabromobisphenol A, affect proinflammatory protein expression in human bronchial epithelial cells via disruption of intracellular signaling Toxicology In Vitro, 32 212-219 | | | | | |
|--|---|---------------------|------|-------|--|--|
| Data Type: | Immune response in respiratory cells for HBCD | | | | | |
| HERO ID: | 3350501 | | | | | |
| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} | |
| | Metric 10: Reporting of Doses/Concentrations | High | × 2 | 2 | Exposure concentrations were reported. The range of concentrations was reported in the methods; individual concentrations were shown or could be estimated from graphs and/or figure legends. | |
| | Metric 11: Number of Exposure Groups and Concentration Spacing | Medium | × 2 | 4 | The duration of exposures was clearly reported for most assays; however, the duration of the ligand-binding assay was not explicitly specified. | |
| | Metric 12: Exposure Route and Method | Low | × 1 | 3 | The number of groups (1 to 3 dose groups plus controls depending on assay type) was reported. A rationale for the selected doses was not provided, and it was not clear how exposure concentrations were selected when only one dose group was used. The dose used in the assays evaluating the expression of pro-inflammatory proteins and activation of transcription factors also statistically significantly induced toxicity (albeit < viability was >80% of controls). | |
| | Metric 13: Metabolic Activation | Not Rated | NA | NA | Metabolic activation was not required. | |
| Domain 4: Test Model | Metric 14: Test Model | Medium | × 2 | 4 | The test model was reported with minimal descriptive information. Human respiratory cells were used because inhalation is expected to be a relevant route of exposure. The bronchial epithelial BEAS-2B cells were obtained from a cell culture collection. These cells are not routinely used for the outcomes of interest. | |
| | Metric 15: Number per Group | High | × 1 | 1 | The study indicates that results were from triplicate cultures and experiments were repeated 2 or 3 times. | |
| Domain 5: Outcome Assessment | Metric 16: Outcome Assessment Methodology | Medium | × 2 | 4 | Outcome assessment methodologies were described for some assays, but some of the information for others (e.g., EGFR phosphorylation, transcription factor assay, nuclear-receptor-ligand binding) was cited to manufacturer's protocols. | |
| | Metric 17: Consistency of Outcome Assessment | High | × 1 | 1 | Outcomes were assessed consistently among study groups. | |
| | Metric 18: Sampling Adequacy | Not Rated | NA | NA | This metric is not applicable to the study type. | |
| | Metric 19: Blinding of Assessors | Not Rated | NA | NA | This metric is not applicable to the study type. | |
| Domain 6: Confounding / Variable Control | | | | | | |

Continued on next page ...

... continued from previous page

| Study Citation: | Koike, E; Yanagisawa, R; Takano, H (2016). Brominated flame retardants, hexabromocyclododecane and tetrabromobisphenol A, affect proinflammatory protein expression in human bronchial epithelial cells via disruption of intracellular signaling Toxicology In Vitro, 32 212-219 | | | | | |
|--|---|---------------------|------|-------|--|--|
| Data Type: | Immune response in respiratory cells for HBCD | | | | | |
| HERO ID: | 3350501 | | | | | |
| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} | |
| | Metric 20: Confounding Variables in Test Design and Procedures | High | × 2 | 2 | No confounding variable in assay design were identified. | |
| | Metric 21: Confounding Variables in Outcomes Unrelated to Exposure | Medium | × 1 | 2 | No confounding variables in outcomes were reported (and none are expected to impact the study results). | |
| Domain 7: Data Presentation and Analysis | | | | | | |
| | Metric 22: Data Analysis | High | × 1 | 1 | The statistical methods used were reported and appeared to be appropriate for the study types. | |
| | Metric 23: Data Interpretation | Medium | × 2 | 4 | It appeared that statistical significance was the primary determinant of a positive response. Some of the assays only used one dose (therefore, the dose-relatedness of responses could not be evaluated). | |
| | Metric 24: Cytotoxicity Data | High | × 1 | 1 | Cell viability endpoints were defined, described, and appropriate for the study type. | |
| | Metric 25: Reporting of Data | High | × 2 | 2 | Data were reported by exposure group. Negative findings were reported qualitatively (e.g., nuclear receptor-ligand binding assay). | |
| Overall Quality Determination [‡] | | High | | 1.5 | | |
| Extracted | | Yes | | | | |

* MWF = Metric Weighting Factor

[†] High = 1; Medium = 2; Low = 3; Unacceptable = 4; N/A has no value.

[‡] The overall rating is calculated as necessary. EPA may not always provide a comment for a metric that has been categorized as High.

$$\text{Overall rating} = \begin{cases} 4 & \text{if any metric is Unacceptable} \\ \left\lfloor \frac{\sum_i (\text{Metric Score}_i \times \text{MWF}_i)}{\sum_j \text{MWF}_j} \right\rfloor_{0.1} & \text{(round to the nearest tenth) otherwise} \end{cases},$$

where High = ≥ 1 to < 1.7 ; Medium = ≥ 1.7 to < 2.3 ; Low = ≥ 2.3 to ≤ 3.0 . If the reviewer determines that the overall rating needs adjustment, the original rating is crossed out and an arrow points to the new rating.

^{††} This metric met the criteria for high confidence as expected for this type of study

Table 49: **In vitro** evaluation results of Wu et al 2016 for cardiac toxicity

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|--|---|---------------------|------|-------|--|
| Study Citation: Wu, M; Wu, D; Wang, C; Guo, Z; Li, B; Zuo, Z (2016). Hexabromocyclododecane exposure induces cardiac hypertrophy and arrhythmia by inhibiting miR-1 expression via up-regulation of the homeobox gene Nkx2.5 Journal of Hazardous Materials, 302 304-313 | | | | | |
| Data Type: Cardiac toxicity for HBCD | | | | | |
| HERO ID: 3350515 | | | | | |
| Domain 1: Test Substance | | | | | |
| Metric 1: | Test Substance Identity | High | × 2 | 2 | The test substance was identified clearly by name. A structure was also provided (in the graphical abstract). |
| Metric 2: | Test Substance Source | Medium | × 1 | 2 | The source of the test substance (a manufacturer) was reported (no batch/lot number was provided). |
| Metric 3: | Test Substance Purity | High | × 1 | 1 | The reported purity (95%) was such that effects likely due to the test substance. |
| Domain 2: Test Design | | | | | |
| Metric 4: | Negative and Vehicle Controls | High | × 2 | 2 | Concurrent negative (vehicle-only) control groups were included. |
| Metric 5: | Positive Controls | Not Rated | NA | NA | This metric is not applicable to the study type. Treatment-related positive responses were observed for the test substance (i.e., demonstrating the test is capable of detecting a positive response). |
| Metric 6: | Assay Procedures | High | × 1 | 1 | Assay procedures (measurement of calcium transients, gene expression analyses) were described and appropriate. Minor details were cited to manufacturer's instructions. |
| Metric 7: | Standards for Tests | Not Rated | NA | NA | This metric is not applicable to the study type. |
| Domain 3: Exposure Characterization | | | | | |
| Metric 8: | Preparation and Storage of Test Substance | Medium | × 1 | 2 | Preparation of the test substance was described (i.e., dissolved in DMSO), but storage and/or stability was not adequately reported. |
| Metric 9: | Consistency of Exposure Administration | High | × 1 | 1 | Exposures were administered consistently across study groups. |
| Metric 10: | Reporting of Doses/Concentrations | High | × 2 | 2 | Exposure concentrations were reported without ambiguity. |
| Metric 11: | Number of Exposure Groups and Concentration Spacing | High | × 2 | 2 | The duration of exposure was reported (24 hours for Ca ²⁺ handling, and 24 to 36 hours for gene expression studies) and appeared to be appropriate for the study type(s). |
| Metric 12: | Exposure Route and Method | Medium | × 1 | 2 | The number of exposure groups was reported (three groups plus controls for Ca ²⁺ handling, one for gene expression analyses). The rationale for dose selection was not provided; however, it was inferred that doses were based on earlier studies. |
| Continued on next page ... | | | | | |

... continued from previous page

| Study Citation: | Wu, M; Wu, D; Wang, C; Guo, Z; Li, B; Zuo, Z (2016). Hexabromocyclododecane exposure induces cardiac hypertrophy and arrhythmia by inhibiting miR-1 expression via up-regulation of the homeobox gene Nkx2.5 Journal of Hazardous Materials, 302 304-313 | | | | | |
|--|--|---------------------|------|-------|---|--|
| Data Type: | Cardiac toxicity for HBCD | | | | | |
| HERO ID: | 3350515 | | | | | |
| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} | |
| | Metric 13: Metabolic Activation | Not Rated | NA | NA | This metric is not applicable to the study type. | |
| Domain 4: Test Model | | | | | | |
| | Metric 14: Test Model | High | × 2 | 2 | The test model (rat cardiomyocyte cell line H9C2) and source were reported and were appropriate for the study type (i.e., evaluating cardiac toxicity). | |
| | Metric 15: Number per Group | High | × 1 | 1 | The number of replicates (n =6) was reported in the figure legends (see Figures 2 and 5). | |
| Domain 5: Outcome Assessment | | | | | | |
| | Metric 16: Outcome Assessment Methodology | High | × 2 | 2 | Outcome assessment methodologies were reported and appropriate. Minor details were cited to manufacturer's instructions. | |
| | Metric 17: Consistency of Outcome Assessment | High | × 1 | 1 | Outcomes were assessed consistently across study groups. | |
| | Metric 18: Sampling Adequacy | Not Rated | NA | NA | This metric is not applicable to the study type. | |
| | Metric 19: Blinding of Assessors | Not Rated | NA | NA | This metric is not applicable to the study type. | |
| Domain 6: Confounding / Variable Control | | | | | | |
| | Metric 20: Confounding Variables in Test Design and Procedures | High | × 2 | 2 | No confounding variables in test design were reported. | |
| | Metric 21: Confounding Variables in Outcomes Unrelated to Exposure | Medium | × 1 | 2 | No confounding variables in outcomes unrelated to exposure were reported (and not expected to impact the study results). | |
| Domain 7: Data Presentation and Analysis | | | | | | |
| | Metric 22: Data Analysis | High | × 1 | 1 | Statistical methods were reported and appropriate for the study types. | |
| | Metric 23: Data Interpretation | Not Rated | NA | NA | The dose-relatedness and statistical significance of effects on Ca ²⁺ handling were considered. For gene expression, statistical analyses and fold-changes were evaluated. | |
| | Metric 24: Cytotoxicity Data | Not Rated | NA | NA | This metric not applicable to the study type. | |
| | Metric 25: Reporting of Data | High | × 2 | 2 | Data were reported by exposure group. | |
| Overall Quality Determination [‡] | | High | | 1.2 | | |
| Extracted | | Yes | | | | |

Continued on next page ...

... continued from previous page

Study Citation: Wu, M; Wu, D; Wang, C; Guo, Z; Li, B; Zuo, Z (2016). Hexabromocyclododecane exposure induces cardiac hypertrophy and arrhythmia by inhibiting miR-1 expression via up-regulation of the homeobox gene Nkx2.5 Journal of Hazardous Materials, 302 304-313
 Data Type: Cardiac toxicity for HBCD
 HERO ID: 3350515

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|--------|--------|---------------------|------|-------|------------------------|
|--------|--------|---------------------|------|-------|------------------------|

* MWF = Metric Weighting Factor

[†] High = 1; Medium = 2; Low = 3; Unacceptable = 4; N/A has no value.

[‡] The overall rating is calculated as necessary. EPA may not always provide a comment for a metric that has been categorized as High.

$$\text{Overall rating} = \begin{cases} 4 & \text{if any metric is Unacceptable} \\ \left\lceil \sum_i (\text{Metric Score}_i \times \text{MWF}_i) / \sum_j \text{MWF}_j \right\rceil_{0.1} & \text{(round to the nearest tenth) otherwise} \end{cases}$$

where High $\Rightarrow \geq 1$ to < 1.7 ; Medium $\Rightarrow \geq 1.7$ to < 2.3 ; Low $\Rightarrow \geq 2.3$ to ≤ 3.0 . If the reviewer determines that the overall rating needs adjustment, the original rating is crossed out and an arrow points to the new rating.

^{††} This metric met the criteria for high confidence as expected for this type of study

Table 50: **In vitro** evaluation results of Almughamsi and Whalen 2016 for altered inflammatory cytokine in human cells

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|--|---|---------------------|------|-------|--|
| Study Citation: Almughamsi, H; Whalen, MM (2016). Hexabromocyclododecane and tetrabromobisphenol A alter secretion of interferon gamma (IFN- γ) from human immune cells Archives of Toxicology, 90(7), 1695-1707 | | | | | |
| Data Type: Altered inflammatory cytokine in human cells | | | | | |
| HERO ID: 3350524 | | | | | |
| Domain 1: Test Substance | | | | | |
| Metric 1: | Test Substance Identity | High | × 2 | 2 | Test substance identified by name. |
| Metric 2: | Test Substance Source | High | × 1 | 1 | Source was identified. |
| Metric 3: | Test Substance Purity | Low | × 1 | 3 | Purity/grade and/or composition were not reported. |
| Domain 2: Test Design | | | | | |
| Metric 4: | Negative and Vehicle Controls | High | × 2 | 2 | Concurrent controls were included. |
| Metric 5: | Positive Controls | Not Rated | NA | NA | Positive controls not required. |
| Metric 6: | Assay Procedures | High | × 1 | 1 | Assay procedures were reported. |
| Metric 7: | Standards for Tests | Not Rated | NA | NA | No standards were required for the assays. |
| Domain 3: Exposure Characterization | | | | | |
| Metric 8: | Preparation and Storage of Test Substance | Medium | × 1 | 2 | Limited preparation details were provided and not storage or stability data were reported. |
| Metric 9: | Consistency of Exposure Administration | High | × 1 | 1 | Exposures were administered consistently. |
| Metric 10: | Reporting of Doses/Concentrations | High | × 2 | 2 | Concentrations were reported. |
| Metric 11: | Number of Exposure Groups and Concentration Spacing | High | × 2 | 2 | Durations were reported. |
| Metric 12: | Exposure Route and Method | Medium | × 1 | 2 | The number of groups and spacing were reported but not justified. |
| Metric 13: | Metabolic Activation | Not Rated | NA | NA | Not required for the assay. |
| Domain 4: Test Model | | | | | |
| Metric 14: | Test Model | High | × 2 | 2 | The test models and sources were identified and appropriate. |
| Metric 15: | Number per Group | High | × 1 | 1 | The number of cells exposure were reported. |
| Domain 5: Outcome Assessment | | | | | |
| Metric 16: | Outcome Assessment Methodology | High | × 2 | 2 | Outcome assessment methodology was reported. |
| Metric 17: | Consistency of Outcome Assessment | High | × 1 | 1 | Outcomes were assessed consistently. |
| Metric 18: | Sampling Adequacy | High | × 2 | 2 | Sampling was adequate. |
| Metric 19: | Blinding of Assessors | Not Rated | NA | NA | Blinding not required. |
| Domain 6: Confounding / Variable Control | | | | | |
| Metric 20: | Confounding Variables in Test Design and Procedures | Low | × 2 | 6 | Initial conditions were not reported for each study replicate or group. |

Continued on next page ...

... continued from previous page

Study Citation: Almughamsi, H; Whalen, MM (2016). Hexabromocyclododecane and tetrabromobisphenol A alter secretion of interferon gamma (IFN- γ) from human immune cells Archives of Toxicology, 90(7), 1695-1707
 Data Type: Altered inflammatory cytokine in human cells
 HERO ID: 3350524

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|--|--|---------------------|------|-------|--|
| | Metric 21: Confounding Variables in Outcomes Unrelated to Exposure | Medium | × 1 | 2 | No confounding variables in outcomes unrelated to exposures were reported. |
| Domain 7: Data Presentation and Analysis | | | | | |
| | Metric 22: Data Analysis | High | × 1 | 1 | Statistical methods were reported and appropriate. |
| | Metric 23: Data Interpretation | Not Rated | NA | NA | Metric not required. |
| | Metric 24: Cytotoxicity Data | High | × 1 | 1 | Cell viability methods were defined and described. |
| | Metric 25: Reporting of Data | High | × 2 | 2 | Data were reported. |
| Overall Quality Determination [‡] | | High | | 1.3 | |
| Extracted | | Yes | | | |

* MWF = Metric Weighting Factor

† High = 1; Medium = 2; Low = 3; Unacceptable = 4; N/A has no value.

‡ The overall rating is calculated as necessary. EPA may not always provide a comment for a metric that has been categorized as High.

$$\text{Overall rating} = \begin{cases} 4 & \text{if any metric is Unacceptable} \\ \left\lfloor \frac{\sum_i (\text{Metric Score}_i \times \text{MWF}_i)}{\sum_j \text{MWF}_j} \right\rfloor_{0.1} & \text{(round to the nearest tenth) otherwise} \end{cases}$$

where High \Rightarrow 1 to < 1.7; Medium \Rightarrow 1.7 to < 2.3; Low \Rightarrow 2.3 to \leq 3.0. If the reviewer determines that the overall rating needs adjustment, the original rating is crossed out and an arrow points to the new rating.

†† This metric met the criteria for high confidence as expected for this type of study

Table 51: In vitro evaluation results of Canbaz et al 2016 for immune effects

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|---|---|---------------------|------|-------|--|
| Study Citation: Canbaz, D; Lebre, MC; Logiantara, A; van Ree, R; van Rijt, LS (2016). Indoor pollutant hexabromocyclododecane enhances house dust mite-induced activation of human monocyte-derived dendritic cells Journal of Immunotoxicology, 13(6), 1-7 | | | | | |
| Data Type: Immune effects | | | | | |
| HERO ID: 3355511 | | | | | |
| Domain 1: Test Substance | | | | | |
| Metric 1: | Test Substance Identity | High | × 2 | 2 | Test substance identified by name. |
| Metric 2: | Test Substance Source | High | × 1 | 1 | Source identified. |
| Metric 3: | Test Substance Purity | Low | × 1 | 3 | Test substance described as technical mixture, but purity/grade and/or composition were not reported. |
| Domain 2: Test Design | | | | | |
| Metric 4: | Negative and Vehicle Controls | High | × 2 | 2 | Concurrent negative controls were used. |
| Metric 5: | Positive Controls | Not Rated | NA | NA | Positive controls not required. |
| Metric 6: | Assay Procedures | High | × 1 | 1 | Assay procedures were reported.. |
| Metric 7: | Standards for Tests | Not Rated | NA | NA | Standards not required for assays. |
| Domain 3: Exposure Characterization | | | | | |
| Metric 8: | Preparation and Storage of Test Substance | Medium | × 1 | 2 | Limited preparation details were reported, but stability and storage were not. |
| Metric 9: | Consistency of Exposure Administration | High | × 1 | 1 | Exposures were administered consistently. |
| Metric 10: | Reporting of Doses/Concentrations | High | × 2 | 2 | Concentrations were administered consistently. |
| Metric 11: | Number of Exposure Groups and Concentration Spacing | High | × 2 | 2 | Durations were reported and appropriate. |
| Metric 12: | Exposure Route and Method | Medium | × 1 | 2 | The number of groups and spacing were reported nut not justified. |
| Metric 13: | Metabolic Activation | Not Rated | NA | NA | Activation not required. |
| Domain 4: Test Model | | | | | |
| Metric 14: | Test Model | High | × 2 | 2 | Test model and donor information were provided. |
| Metric 15: | Number per Group | Medium | × 1 | 2 | The number of cells per group in the initial exposure assay was not reported, but was reported for the cytokine assay. |
| Domain 5: Outcome Assessment | | | | | |
| Metric 16: | Outcome Assessment Methodology | High | × 2 | 2 | Outcome assessment methodology was . |
| Metric 17: | Consistency of Outcome Assessment | High | × 1 | 1 | Outcomes were assessed consistently. |
| Metric 18: | Sampling Adequacy | High | × 2 | 2 | Sampling was adequate. |
| Metric 19: | Blinding of Assessors | Not Rated | NA | NA | Blinding was not required. |
| Domain 6: Confounding / Variable Control | | | | | |

Continued on next page ...

... continued from previous page

Study Citation: Canbaz, D; Lebre, MC; Logiantara, A; van Ree, R; van Rijt, LS (2016). Indoor pollutant hexabromocyclododecane enhances house dust mite-induced activation of human monocyte-derived dendritic cells *Journal of Immunotoxicology*, 13(6), 1-7

Data Type: Immune effects

HERO ID: 3355511

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|--|--|---------------------|------|-------|---|
| | Metric 20: Confounding Variables in Test Design and Procedures | Low | × 2 | 6 | Initial conditions were not reported for each study replicate or group. |
| | Metric 21: Confounding Variables in Outcomes Unrelated to Exposure | Medium | × 1 | 2 | Two donors did not yield sufficient cells to perform all experiments. |
| Domain 7: Data Presentation and Analysis | | | | | |
| | Metric 22: Data Analysis | High | × 1 | 1 | Statistical methods were reported and appropriate. |
| | Metric 23: Data Interpretation | Not Rated | NA | NA | Data interpretation criteria not required. |
| | Metric 24: Cytotoxicity Data | Low | × 1 | 3 | Methods were not reported but the data were provided. |
| | Metric 25: Reporting of Data | High | × 2 | 2 | Data were reported. |
| Overall Quality Determination [‡] | | High | | 1.4 | |
| Extracted | | Yes | | | |

* MWF = Metric Weighting Factor

† High = 1; Medium = 2; Low = 3; Unacceptable = 4; N/A has no value.

‡ The overall rating is calculated as necessary. EPA may not always provide a comment for a metric that has been categorized as High.

$$\text{Overall rating} = \begin{cases} 4 & \text{if any metric is Unacceptable} \\ \left\lfloor \frac{\sum_i (\text{Metric Score}_i \times \text{MWF}_i)}{\sum_j \text{MWF}_j} \right\rfloor_{0.1} & \text{(round to the nearest tenth) otherwise} \end{cases}$$

where High $\Rightarrow 1 < 1.7$; Medium $\Rightarrow 1.7 < 2.3$; Low $\Rightarrow 2.3 < 3.0$. If the reviewer determines that the overall rating needs adjustment, the original rating is crossed out and an arrow points to the new rating.

†† This metric met the criteria for high confidence as expected for this type of study

Epidemiological Studies

Table Listing

| | | |
|---|---|----|
| 1 | Roze et al. 2009: Evaluation of Neurological/Behavior Outcomes | 2 |
| 2 | Eggesbø et al., 2011: Evaluation of Thyroid Outcomes | 6 |
| 3 | Meijer et al. 2012: Evaluation of Reproductive for sex hormone outcomes Outcomes | 10 |
| 4 | Meijer et al. 2012: Evaluation of Reproductive for male sexual development outcomes Outcomes | 14 |
| 5 | Johnson et al. 2013: Evaluation of Reproductive Outcomes | 18 |
| 6 | Kicinski et al. 2012: Evaluation of Neurological/Behavior Outcomes | 20 |
| 7 | Kicinski et al. 2012: Evaluation of Thyroid Outcomes | 24 |
| 8 | Kim and Oh 2014: Evaluation of Thyroid Outcomes | 28 |

Table 1: **Roze et al. 2009: Evaluation of Neurological/Behavior Outcomes**

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|---|-------------------------|---------------------|-------|-------|--|
| Study Citation: Roze, E., Meijer, L., Bakker, A., van Braeckel, K.N.J.A., Sauer, P.J.J., Bos, A.F (2009). Prenatal exposure to organohalogens, including brominated flame retardants, influences motor, cognitive, and behavioral performance at school age Environmental Health Perspectives, 117(12), 1953-1958 | | | | | |
| Data Type: GIC cohort HBCD_coordination outcome-Neurological/Behavior | | | | | |
| HERO ID: 758049 | | | | | |
| Domain 1: Study Participation | | | | | |
| Metric 1: | Participant selection | Medium | × 0.4 | 0.8 | The GIC cohort consisted of 90 white, healthy pregnant women who were randomly selected from those who had given birth to a healthy, full-term, singleton infant. Subjects were selected from the same general population during the same time frame using the same methods. Participation rates and number eligible were not reported. It was noted that all women who had registered with midwives between October 2001 and November 2002 were invited. |
| Metric 2: | Attrition | High | × 0.4 | 0.4 | HBCD was only measured in 69 of the 90 women due to financial constraints, but samples were randomly selected. 62 of these actually participated in the follow-up programs. The OHC concentrations of the seven children not followed up were not different from those who did participate. Some results were only available in 57 of the children. Any exclusion of subjects from analyses was adequately addressed and reasons were documented when subjects were removed from the study or excluded from analyses (NTP, 2015a). |
| Metric 3: | Comparison Group | Medium | × 0.2 | 0.4 | There is only indirect evidence (e.g., stated by the authors without providing a description of methods) that groups are similar with regard to exposure. Some differences in baseline characteristics of groups (such as SES, HOME scores, and sex) were considered as potential confounding and were adjusted for in the analyses. |
| Domain 2: Exposure Characterization | | | | | |
| Metric 4: | Measurement of Exposure | High | × 0.4 | 0.4 | Maternal serum levels obtained at the 35th week of pregnancy were measured for HBCD levels. Noted to be described in Meijer et al., 2008 (HERO ID 787696). Cited reference provides complete details including quality control. Therefore, exposure was consistently assessed using well established methods of compound in the serum. |
| Continued on next page ... | | | | | |

... continued from previous page

Study Citation: Roze, E., Meijer, L., Bakker, A., van Braeckel, K.N.J.A., Sauer, P.J.J., Bos, A.F (2009). Prenatal exposure to organohalogens, including brominated flame retardants, influences motor, cognitive, and behavioral performance at school age Environmental Health Perspectives, 117(12), 1953-1958

Data Type: GIC cohort HBCD_coordination outcome-Neurological/Behavior

HERO ID: 758049

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|--|---|---------------------|---------|-------|--|
| | Metric 5: Exposure levels | Medium | × 0.2 | 0.4 | Range (0.3-7.5 ng/g lipid) and distribution (continuous) of exposure is sufficient to establish an exposure response estimate. |
| | Metric 6: Temporality | Medium | × 0.4 | 0.8 | Temporality is established. However, it isn't clear if the levels at 35 weeks of gestation cover the time window relevant to the outcome of interest. |
| Domain 3: Outcome Assessment | | | | | |
| | Metric 7: Outcome measurement or characterization | High | × 0.667 | 0.67 | Children were assessed at 5-6 years of age for motor performance, cognition, and behavior. Standardized tests of motor skills for children 4-12 years of age were used for motor outcome. WPPSI-R was used for cognitive outcomes, Touwen's age-specific neurological examination was used to test coordination, balance, and fine manipulative abilities These are standard methods and are considered to be validated and well-established. The Dutch version of the Developmental Coordination Disorder Questionnaire was also filled out by the parents. |
| | Metric 8: Reporting Bias | Low | × 0.333 | 1.0 | All of the study's measured outcomes (primary and secondary) outlined in the methods, abstract, and/or introduction (that are relevant for the evaluation) have not been reported. Although Table 4 provides correlation coefficients for a list of outcomes, it appears that only the significant (less than or equal to a p value of 0.05) or borderline significant effects (less than a p value of 0.10) were reported. For HBCD correlation coefficients were reported for only 3 outcomes. |
| Domain 4: Potential Confounding/Variable Control | | | | | |
| | Metric 9: Covariate Adjustment | Medium | × 0.5 | 1 | Results were adjusted for some covariates (such as SES, HOME, and sex) without providing a description of methods. |
| | Metric 10: Covariate Characterization | Medium | × 0.25 | 0.5 | Information was obtained from a questionnaire during the first year after birth. The validity and reliability of this questionnaire was not discussed by the authors. |

Continued on next page ...

... continued from previous page

| Study Citation: | Roze, E., Meijer, L., Bakker, A., van Braeckel, K.N.J.A., Sauer, P.J.J., Bos, A.F (2009). Prenatal exposure to organohalogens, including brominated flame retardants, influences motor, cognitive, and behavioral performance at school age Environmental Health Perspectives, 117(12), 1953-1958 | | | | | |
|--|---|---------------------|--------|-------|---|--|
| Data Type: | GIC cohort HBCD_coordination outcome-Neurological/Behavior | | | | | |
| HERO ID: | 758049 | | | | | |
| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} | |
| | Metric 11: Co-exposure Confounding | Medium | × 0.25 | 0.5 | The study measured several compounds in the serum. There is no indication that there is a correlation among any of the compounds. This is a general population study with no reason to believe there would be other differential co-exposures that would influence the results. | |
| Domain 5: Analysis | Metric 12: Study Design and Methods | Medium | × 0.4 | 0.8 | The prospective cohort study design is appropriate and uses acceptable statistical method (i.e., correlations or Mann-Whitney U test) to address the research question. | |
| | Metric 13: Statistical power | Medium | × 0.2 | 0.4 | The number of participants (i.e., 62) seem adequate to detect an effect in the exposed population. | |
| | Metric 14: Reproducibility of analyses | Low | × 0.2 | 0.6 | The description of the analysis is insufficient to understand what has been done and to be reproducible. Table 4 indicates adjustments for SES, HOME, and sex, but the method description for this was not complete enough to be reproducible. | |
| | Metric 15: Statistical models | Medium | × 0.2 | 0.4 | As described, it appears that the method is appropriate and that assumptions were met (or data were transformed). | |
| Domain 6: Other Considerations for Biomarker Selection and Measurement | Metric 16: Use of Biomarker of Exposure | High | × 0.2 | 0.2 | Maternal serum levels of HBCD is a biomarker in a specified matrix that has accurate and precise relationship with external exposure. | |
| | Metric 17: Effect biomarker | Not Rated | NA | NA | No biomarker of effect was measured. | |
| | Metric 18: Method Sensitivity | Medium | × 0.2 | 0.4 | Limits of detection are low enough to detect chemicals in a sufficient percentage of the samples to address the research question. Analytical methods measuring biomarkers are adequately reported. LOD/LOQ (value or %) are reported. | |
| | Metric 19: Biomarker stability | Low | × 0.2 | 0.6 | No information was provided on storage history or stability. | |
| | Metric 20: Sample contamination | Medium | × 0.2 | 0.4 | There is incomplete documentation of the steps taken to provide necessary assurance that the study data are reliable. | |
| | Metric 21: Method requirements | Medium | × 0.2 | 0.4 | Instrumentation provides unambiguous identification and quantification of the biomarker at the require sensitivity (GC-MS). | |

Continued on next page ...

...continued from previous page

Study Citation: Roze, E., Meijer, L., Bakker, A., van Braeckel, K.N.J.A., Sauer, P.J.J., Bos, A.F (2009). Prenatal exposure to organohalogens, including brominated flame retardants, influences motor, cognitive, and behavioral performance at school age Environmental Health Perspectives, 117(12), 1953-1958
 Data Type: GIC cohort HBCD_coordination outcome-Neurological/Behavior
 HERO ID: 758049

| Domain | Metric | Rating [†] | MWF [*] | Score | Comments ^{††} |
|--|------------------------------|---------------------|------------------|-------|---|
| | Metric 22: Matrix adjustment | Not Rated | NA | NA | I don't think any adjustment is needed. |
| Overall Quality Determination [‡] | | Medium | | 1.8 | |
| Extracted | | Yes | | | |

* MWF = Metric Weighting Factor

[†] High = 1; Medium = 2; Low = 3; Unacceptable = 4; N/A has no value.

[‡] The overall rating is calculated as necessary. EPA may not always provide a comment for a metric that has been categorized as High.

$$\text{Overall rating} = \begin{cases} 4 & \text{if any metric is Unacceptable} \\ \left[\sum_i (\text{Metric Score}_i \times \text{MWF}_i) / \sum_j \text{MWF}_j \right]_{0.1} & \text{(round to the nearest tenth) otherwise} \end{cases},$$

where High ≥ 1 to < 1.7 ; Medium ≥ 1.7 to < 2.3 ; Low ≥ 2.3 to ≤ 3.0 . If the reviewer determines that the overall rating needs adjustment, the original rating is crossed out and an arrow points to the new rating.

^{††} This metric met the criteria for high confidence as expected for this type of study

Table 2: Eggesbø et al., 2011: Evaluation of Thyroid Outcomes

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|---|-------------------------|---------------------|-------|-------|--|
| Study Citation: Eggesbø, M., Thomsen, C., Jørgensen, J. V., Becher, G., Odland, J. Ø., Longnecker, M. P. (2011). Associations between brominated flame retardants in human milk and thyroid-stimulating hormone (TSH) in neonates Environmental Research, 111(6), 737-743 | | | | | |
| Data Type: Q3 vs Q1 HBCD and neonatal TSH levels-Thyroid | | | | | |
| HERO ID: 787656 | | | | | |
| Domain 1: Study Participation | | | | | |
| Metric 1: | Participant selection | High | × 0.4 | 0.4 | High rating: key elements of study design were reported (such as setting, participation rate described at all steps of the study, inclusion and exclusion criteria, and methods of participant selection), and the reported information indicates selection in or out of the study and participation is not likely to be biased. |
| Metric 2: | Attrition | Medium | × 0.4 | 0.8 | Medium rating: 31% of women that agreed to participate in the study did not provide milk samples (authors explained this was partly due to lack of milk); 40% of the 396 babies selected for the study were excluded from analysis due to inaccessible TSH values. Attrition was acceptably handled. Supplemental Fig A1 provides a description of characteristics between participants and non-participants. No significant differences were reported between these 2 groups. Missing values for “age at which TSH was measured” were replaced by mean values for 80 (33%) participants. |
| Metric 3: | Comparison Group | High | × 0.2 | 0.2 | High rating: differences in baseline characteristics of groups were considered as potential confounding or stratification variables and were thereby controlled by statistical analysis. Covariates included age at which TSH was measured(continuously in hours), county of residence and pre-pregnancy maternal body mass index. The following potential confounders: maternal education as a socioeconomic index (<12, 12, 13–16 and >16 years of education), Norwegian nationality, season, parity, smoking, maternal age at delivery, sex, pregnancy hypertension and/or preeclampsia based on maternal reports (yes/no) and type of delivery (spontaneous, induced, assisted or cesarean); and continuous variables: gestational age, HCB, b-HCH,p,p0-DDE,oxychlordane and the sum of all PCB congeners. |
| Domain 2: Exposure Characterization | | | | | |
| Metric 4: | Measurement of Exposure | High | × 0.4 | 0.4 | High rating: exposure was assessed using the same well-established methods that directly measure HBCD in breast milk, a frequently used biomarker of exposure. |
| Continued on next page ... | | | | | |

... continued from previous page

| Domain | Metric | Rating [†] | MWF [*] | Score | Comments ^{††} |
|---|---|---------------------|------------------|-------|---|
| Study Citation: Eggesbø, M., Thomsen, C., Jørgensen, J. V., Becher, G., Odland, J. Ø., Longnecker, M. P. (2011). Associations between brominated flame retardants in human milk and thyroid-stimulating hormone (TSH) in neonates Environmental Research, 111(6), 737-743 | | | | | |
| Data Type: Q3 vs Q1 HBCD and neonatal TSH levels-Thyroid | | | | | |
| HERO ID: 787656 | | | | | |
| | Metric 5: Exposure levels | Medium | × 0.2 | 0.4 | Medium rating: range and distribution of exposure was sufficient to develop an exposure-response estimate; 3 or more levels of exposure were reported. |
| | Metric 6: Temporality | High | × 0.4 | 0.4 | High rating: temporality is established and the interval between the exposure and the outcome has an appropriate consideration of relevant exposure windows. |
| Domain 3: Outcome Assessment | | | | | |
| | Metric 7: Outcome measurement or characterization | High | × 0.667 | 0.67 | High rating: TSH levels were measured using well-established methods (i.e., on dried filter paper bloodspots by an immunoassay) (Auto Delfias neonatal TSH kits; Perkin Elmer). |
| | Metric 8: Reporting Bias | High | × 0.333 | 0.33 | High rating: all of the study's measured outcomes are reported, effect estimates reported with confidence interval; number of exposed reported for each analysis. |
| Domain 4: Potential Confounding/Variable Control | | | | | |
| | Metric 9: Covariate Adjustment | High | × 0.5 | 0.5 | High rating: appropriate adjustments or explicit considerations were made for potential confounders in the final analyses through the use of statistical models for covariate adjustment. See discussion in metric 3. |
| | Metric 10: Covariate Characterization | Medium | × 0.25 | 0.5 | Medium rating: Primary confounders (excluding co-exposures) were assessed. The paper did not describe if the survey to gather demographic characteristics, the amount of breastfeeding/month, etc. was validated. |
| | Metric 11: Co-exposure Confounding | Medium | × 0.25 | 0.5 | Medium rating: HBCD models were adjusted for some co-pollutants (PCBs, HCB, DDE, etc); however, separate models were run for PBDEs and HBCD, and it difficult to distinguish which contaminant might have caused an association with a disease. However, there does not appear to be direct evidence of an unbalanced provision of additional co-exposures across the primary study groups, |
| Domain 5: Analysis | | | | | |
| | Metric 12: Study Design and Methods | Medium | × 0.4 | 0.8 | Medium rating: appropriate design (i.e., prospective cohort for assessment of TSH levels in relation to HBCD exposure), and appropriate statistical methods (i.e., linear and logistic regression analyses) were employed to analyze data. |
| Continued on next page ... | | | | | |

... continued from previous page

| Study Citation: | Eggesbø, M., Thomsen, C., Jørgensen, J. V., Becher, G., Odland, J. Ø., Longnecker, M. P. (2011). Associations between brominated flame retardants in human milk and thyroid-stimulating hormone (TSH) in neonates Environmental Research, 111(6), 737-743 | | | | | |
|--|---|---------------------|------------------|-------|--|--|
| Data Type: | Q3 vs Q1 HBCD and neonatal TSH levels-Thyroid | | | | | |
| HERO ID: | 787656 | | | | | |
| Domain | Metric | Rating [†] | MWF [*] | Score | Comments ^{††} | |
| | Metric 13: Statistical power | Medium | × 0.2 | 0.4 | Medium rating: the number of participants were adequate to detect an effect in the exposed population for HBCD and for most BFRs except BDE- 209. | |
| | Metric 14: Reproducibility of analyses | Medium | × 0.2 | 0.4 | Medium rating: description of the analyses is sufficient to understand what has been done and to be reproducible with access to the data. | |
| | Metric 15: Statistical models | Medium | × 0.2 | 0.4 | Medium rating: linear regression models were used to generate beta coefficients and logistic regression models were used to generate Odds Ratios. Rationale for variable selection is stated. Model assumptions are met. | |
| Domain 6: Other Considerations for Biomarker Selection and Measurement | | | | | | |
| | Metric 16: Use of Biomarker of Exposure | High | × 0.143 | 0.14 | High rating: Evidence exists for a relationship between HBCD in breast milk and external exposure. | |
| | Metric 17: Effect biomarker | High | × 0.143 | 0.14 | High rating: Effect biomarker measured is an indicator of a key event in an AOP. | |
| | Metric 18: Method Sensitivity | Medium | × 0.143 | 0.29 | Medium rating: LOD is low enough to detect HBCD in a sufficient percentage of the samples to address the research question. Analytical methods measuring biomarker are adequately reported. LOD/LOQ (value or %) are reported. | |
| | Metric 19: Biomarker stability | High | NA | NA | High rating: samples with a known storage history (Supplement-03 document) | |
| | Metric 20: Sample contamination | Low | × 0.143 | 0.43 | Low rating: No known sampling contamination issues are discussed in the paper, but there is no documentation of the steps taken to provide the necessary assurance that the study data are reliable. | |
| | Metric 21: Method requirements | High | × 0.143 | 0.14 | High rating: instrumentation that provides unambiguous identification and quantitation of the biomarker at the required sensitivity were used. Specifically, the extracts were analyzed by gas chromatography coupled to a mass spectrometer using electron capture negative ionization (GC- EC/MS) and an internal standard calibration as described by Thomsen et al., 2007. | |
| | Metric 22: Matrix adjustment | Medium | × 0.143 | 0.29 | Medium rating: study only provides results using one method (lipid-adjusted). | |
| Overall Quality Determination [‡] | | High | | 1.4 | | |
| Extracted | | Yes | | | | |
| Continued on next page ... | | | | | | |

...continued from previous page

Study Citation: Eggesbø, M., Thomsen, C., Jørgensen, J. V., Becher, G., Odland, J. Ø., Longnecker, M. P. (2011). Associations between brominated flame retardants in human milk and thyroid-stimulating hormone (TSH) in neonates Environmental Research, 111(6), 737-743
 Data Type: Q3 vs Q1 HBCD and neonatal TSH levels-Thyroid
 HERO ID: 787656

| Domain | Metric | Rating [†] | MWF [*] | Score | Comments ^{††} |
|--------|--------|---------------------|------------------|-------|------------------------|
|--------|--------|---------------------|------------------|-------|------------------------|

* MWF = Metric Weighting Factor

[†] High = 1; Medium = 2; Low = 3; Unacceptable = 4; N/A has no value.

[‡] The overall rating is calculated as necessary. EPA may not always provide a comment for a metric that has been categorized as High.

$$\text{Overall rating} = \begin{cases} 4 & \text{if any metric is Unacceptable} \\ \left[\sum_i (\text{Metric Score}_i \times \text{MWF}_i) / \sum_j \text{MWF}_j \right]_{0.1} & \text{(round to the nearest tenth) otherwise} \end{cases}$$

where High = ≥ 1 to < 1.7 ; Medium = ≥ 1.7 to < 2.3 ; Low = ≥ 2.3 to ≤ 3.0 . If the reviewer determines that the overall rating needs adjustment, the original rating is crossed out and an arrow points to the new rating.

^{††} This metric met the criteria for high confidence as expected for this type of study

Table 3: Meijer et al. 2012: Evaluation of Reproductive for sex hormone outcomes Outcomes

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|--|-----------------------------------|---------------------|-------|-------|---|
| Study Citation: Meijer, L., Martijn, A., Melessen, J., Brouwer, A., Weiss, J., de Jong, F. H., Sauer, P. J. (2012). Influence of prenatal organohalogen levels on infant male sexual development: Sex hormone levels, testes volume and penile length Human Reproduction, 27(3), 867-872 | | | | | |
| Data Type: GIC cohort HBCD_sex hormones-Reproductive | | | | | |
| HERO ID: 1401499 | | | | | |
| Domain 1: Study Participation | | | | | |
| | Metric 1: Participant selection | Medium | × 0.4 | 0.8 | Subjects were part of the Groningen-infant-compare cohort (GIC). Cohort consisted of 90 healthy pregnant women, living in the norther provinces of the Netherlands, who delivered a single, term, health infant. This study only focused on the 56 boys born in the cohort; one boy was excluded after ICSI (intracytoplasmic sperm injection) pregnancy, which may predispose to aberrations of sexual development (Wennerholm et al., 2000). How the initial cohort was selected was not determined nor do the study authors provide a citation. However, there is no indication that this sample would not be representative of the exposure-outcome distribution. |
| | Metric 2: Attrition | High | × 0.4 | 0.4 | There was minimal subject loss to follow up during the study. One boy was excluded because he was born after ICSI pregnancy, which they indicated could predispose the boy to aberrations of sexual development. HBCD was only measured in 44 of the samples, which were randomly selected, due to financial restraints. |
| | Metric 3: Comparison Group | Medium | × 0.2 | 0.4 | HBCD was evaluated on a continuous basis and there is no indication that there was anything different about the exposure in this cohort. |
| Domain 2: Exposure Characterization | | | | | |
| | Metric 4: Measurement of Exposure | High | × 0.4 | 0.4 | Maternal serum levels obtained at the 35th week of pregnancy were measured for HBCD levels at the Department of Environmental Chemistry, Stockholm University, Sweden and noted to be described in Meijer et al., 2008 (HERO ID 787696). Cited reference provides complete details including quality control. Therefore, exposure was consistently assessed using well established methods of compound in serum. |
| | Metric 5: Exposure levels | Medium | × 0.2 | 0.4 | Range (not detected to 7.4 ng/g lipid) and distribution (continuous) of exposure is sufficient to establish an exposure response estimate. |
| Continued on next page ... | | | | | |

... continued from previous page

| Study Citation: | Meijer, L., Martijn, A., Melessen, J., Brouwer, A., Weiss, J., de Jong, F. H., Sauer, P. J. (2012). Influence of prenatal organohalogen levels on infant male sexual development: Sex hormone levels, testes volume and penile length Human Reproduction, 27(3), 867-872 | | | | | |
|---|--|---------------------|---------|-------|---|--|
| Data Type: | GIC cohort HBCD_sex hormones-Reproductive | | | | | |
| HERO ID: | 1401499 | | | | | |
| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} | |
| | Metric 6: Temporality | Medium | × 0.4 | 0.8 | Temporality is established, however, it isn't clear if the levels at 35 weeks of gestation cover the time window relevant to the outcome of interest (male sexual development). | |
| Domain 3: Outcome Assessment | | | | | | |
| | Metric 7: Outcome measurement or characterization | Medium | × 0.667 | 1.33 | Sex hormones were measured using acceptable methods and measured at the Endocrine Laboratory, Department of Internal Medicine, Erasmus Medical Centre, Rotterdam, The Netherlands as described elsewhere (Laven et al., 2004). Sex hormones were measured in a specific order due to insufficient amounts of the hormone in some infants. | |
| | Metric 8: Reporting Bias | Low | × 0.333 | 1.0 | All of the study's measured outcomes (primary and secondary) outlined in the methods, abstract, and/or introduction (that are relevant for the evaluation) have not been reported. There are some very general comments for most of the data relevant to the assessment and very little of the HBCD data was actually provided. | |
| Domain 4: Potential Counfounding/Variable Control | | | | | | |
| | Metric 9: Covariate Adjustment | Low | × 0.667 | 2 | No consideration was made for any possible covariates. However, there is no information provided to indicate that there was a significant differential distribution that would have affected the results. | |
| | Metric 10: Covariate Characterization | Not Rated | NA | NA | Covariates were not assessed. | |
| | Metric 11: Co-exposure Counfounding | Medium | × 0.333 | 0.67 | The study measured several OHC compounds in the serum. There is no indication that there is a correlation between any of these compounds. This is a general population study with no reason to believe there would be other differential co-exposures that would affect the results. However, in this cohort, compounds, such as phthalates, that also might be related to sexual development (Hannas et al.,2011) were not analyzed for. | |
| Domain 5: Analysis | | | | | | |
| | Metric 12: Study Design and Methods | Medium | × 0.4 | 0.8 | The study design chosen was appropriate for the research question. The study used an appropriate statistical method to address the research question. | |
| | Metric 13: Statistical power | Medium | × 0.2 | 0.4 | The number of participants (i.e., 55) seem adequate to detect an effect in the exposed population. | |
| Continued on next page ... | | | | | | |

... continued from previous page

| Study Citation: | Meijer, L., Martijn, A., Melessen, J., Brouwer, A., Weiss, J., de Jong, F. H., Sauer, P. J. (2012). Influence of prenatal organohalogen levels on infant male sexual development: Sex hormone levels, testes volume and penile length Human Reproduction, 27(3), 867-872 | | | | | |
|--|--|---------------------|---------|-------|---|--|
| Data Type: | GIC cohort HBCD_sex hormones-Reproductive | | | | | |
| HERO ID: | 1401499 | | | | | |
| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} | |
| | Metric 14: Reproducibility of analyses | Medium | × 0.2 | 0.4 | The description of the analysis is sufficient to understand precisely what was done and to be conceptually reproducible with access to the analytic data. | |
| | Metric 15: Statistical models | Medium | × 0.2 | 0.4 | There is a clear description of the analyses. | |
| Domain 6: Other | Considerations for Biomarker Selection and Measurement | | | | | |
| | Metric 16: Use of Biomarker of Exposure | High | × 0.167 | 0.17 | Maternal serum level of HBCD is the biomarker of exposure and its use is thought to have an accurate and precise quantitative relationship with external exposure. | |
| | Metric 17: Effect biomarker | Medium | × 0.167 | 0.33 | Sex hormones levels are an acceptable biomarker of effect and they were determined at the Endocrine Laboratory, Department of Internal Medicine, Erasmus Medical Centre, Rotterdam, The Netherlands as described elsewhere (Laven et al., 2004). | |
| | Metric 18: Method Sensitivity | Medium | × 0.167 | 0.33 | Limits of detection are low enough to detect chemicals in a sufficient percentage of the samples to address the research question. Analytical methods measuring biomarker are adequately reported. LOD/LOQ (value or %) are reported. The limit of detection (LOD = three times the standard deviation of the blank values) was 9 pg/g serum for HBCDD. Background levels were subtracted from reported results. HBCDD levels were below LOD in 1/44 samples. | |
| | Metric 19: Biomarker stability | Medium | × 0.167 | 0.33 | Although the infant serum was stated to be stored at -20 degrees C until analysis, there is no information on how long that was or if there might be any stability issues. No information was provided on the storage or stability of the serum samples for HBCD. | |
| | Metric 20: Sample contamination | Medium | × 0.167 | 0.33 | There is incomplete documentation of the steps taken to provide the necessary assurance that the study data are reliable. | |
| | Metric 21: Method requirements | High | × 0.167 | 0.17 | Instrumentation that provides unambiguous identification and quantitation of the biomarker at the required sensitivity (GC-MS) was used. | |
| | Metric 22: Matrix adjustment | Not Rated | NA | NA | I don't think this is applicable to either matrix measured. | |
| Overall Quality Determination [‡] | | Medium | | 2.0 | | |
| Extracted | | Yes | | | | |
| Continued on next page ... | | | | | | |

...continued from previous page

Study Citation: Meijer, L., Martijn, A., Melessen, J., Brouwer, A., Weiss, J., de Jong, F. H., Sauer, P. J. (2012). Influence of prenatal organohalogen levels on infant male sexual development: Sex hormone levels, testes volume and penile length Human Reproduction, 27(3), 867-872
 Data Type: GIC cohort HBCD_sex hormones-Reproductive
 HERO ID: 1401499

| Domain | Metric | Rating [†] | MWF [*] | Score | Comments ^{††} |
|--------|--------|---------------------|------------------|-------|------------------------|
|--------|--------|---------------------|------------------|-------|------------------------|

* MWF = Metric Weighting Factor

[†] High = 1; Medium = 2; Low = 3; Unacceptable = 4; N/A has no value.

[‡] The overall rating is calculated as necessary. EPA may not always provide a comment for a metric that has been categorized as High.

$$\text{Overall rating} = \begin{cases} 4 & \text{if any metric is Unacceptable} \\ \left\lceil \sum_i (\text{Metric Score}_i \times \text{MWF}_i) / \sum_j \text{MWF}_j \right\rceil_{0,1} & \text{(round to the nearest tenth) otherwise} \end{cases}$$

where High $\Rightarrow \geq 1$ to < 1.7 ; Medium $\Rightarrow \geq 1.7$ to < 2.3 ; Low $\Rightarrow \geq 2.3$ to ≤ 3.0 . If the reviewer determines that the overall rating needs adjustment, the original rating is crossed out and an arrow points to the new rating.

^{††} This metric met the criteria for high confidence as expected for this type of study

Table 4: Meijer et al. 2012: Evaluation of Reproductive for male sexual development outcomes Outcomes

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|--|-----------------------------------|---------------------|-------|-------|---|
| Study Citation: Meijer, L., Martijn, A., Melessen, J., Brouwer, A., Weiss, J., de Jong, F. H., Sauer, P. J. (2012). Influence of prenatal organohalogen levels on infant male sexual development: Sex hormone levels, testes volume and penile length Human Reproduction, 27(3), 867-872 | | | | | |
| Data Type: GIC cohort HBCD_male sexual development-Reproductive | | | | | |
| HERO ID: 1401499 | | | | | |
| Domain 1: Study Participation | | | | | |
| | Metric 1: Participant selection | Medium | × 0.4 | 0.8 | Subjects were part of the Groningen-infant-compare cohort (GIC). Cohort consisted of 90 healthy pregnant women, living in the norther provinces of the Netherlands, who delivered a single, term, health infant. This study only focused on the 56 boys born in the cohort; one boy was excluded after ICSI (intracytoplasmic sperm injection) pregnancy, which may predispose to aberrations of sexual development (Wennerholm et al., 2000). How the initial cohort was selected was not determined nor do the study authors provide a citation. However, there is no indication that this sample would not be representative of the exposure-outcome distribution. |
| | Metric 2: Attrition | High | × 0.4 | 0.4 | There was minimal subject loss to follow up during the study. One boy was excluded because he was born after ICSI pregnancy, which they indicated could predispose the boy to aberrations of sexual development. HBCD was only measured in 44 of the samples, which were randomly selected, due to financial restraints. Penile length was missing in 8 infants at 18 months due to non-cooperative behavior or loss to follow-up. There is no indication how many of these were from the 44 with measurements for HBCD. |
| | Metric 3: Comparison Group | Medium | × 0.2 | 0.4 | HBCD was evaluated on a continuous basis and there is no indication that there was anything different about the exposure in this cohort. |
| Domain 2: Exposure Characterization | | | | | |
| | Metric 4: Measurement of Exposure | High | × 0.4 | 0.4 | Maternal serum levels obtained at the 35th week of pregnancy were measured for HBCD levels at the Department of Environmental Chemistry, Stockholm University, Sweden and noted to be described in Meijer et al., 2008 (HERO ID 787696). Cited reference provides complete details including quality control. Therefore, exposure was consistently assessed using well established methods of compound in serum. |
| Continued on next page ... | | | | | |

... continued from previous page

| Study Citation: | Meijer, L., Martijn, A., Melessen, J., Brouwer, A., Weiss, J., de Jong, F. H., Sauer, P. J. (2012). Influence of prenatal organohalogen levels on infant male sexual development: Sex hormone levels, testes volume and penile length Human Reproduction, 27(3), 867-872 | | | | | |
|---|--|---------------------|---------|-------|--|--|
| Data Type: | GIC cohort HBCD_male sexual development-Reproductive | | | | | |
| HERO ID: | 1401499 | | | | | |
| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} | |
| | Metric 5: Exposure levels | Medium | × 0.2 | 0.4 | Range (not detected to 7.4 ng/g lipid) and distribution (continuous) of exposure is sufficient to establish an exposure response estimate. | |
| | Metric 6: Temporality | Medium | × 0.4 | 0.8 | Temporality is established, however, it isn't clear if the levels at 35 weeks of gestation cover the time window relevant to the outcome of interest (male sexual development). | |
| Domain 3: Outcome Assessment | | | | | | |
| | Metric 7: Outcome measurement or characterization | High | × 0.667 | 0.67 | Testes volume was measured by ultrasound. Measurements were performed by three pediatric radiologists trained for the examination on the same Antares ultrasound machine (Siemens, Erlangen, Germany). Penile length was measured with a standardized tapeline by the same investigator throughout the entire study. A detailed description of how the penile length measurement was made was included. Thus, these outcomes were objectively measured with diagnostic methods and by trained interviewers. There is no reason to believe that the evaluators would be aware of the child's exposure status. | |
| | Metric 8: Reporting Bias | Low | × 0.333 | 1.0 | All of the study's measured outcomes (primary and secondary) outlined in the methods, abstract, and/or introduction (that are relevant for the evaluation) have not been reported. There are some very general comments for most of the data relevant to the assessment and very little of the HBCD data was actually provided. | |
| Domain 4: Potential Counfounding/Variable Control | | | | | | |
| | Metric 9: Covariate Adjustment | Low | × 0.667 | 2 | No consideration was made for any possible covariates. However, there is no information provided to indicate that there was a significant differential distribution that would have affected the results. | |
| | Metric 10: Covariate Characterization | Not Rated | NA | NA | Covariates were not assessed. | |
| Continued on next page ... | | | | | | |

... continued from previous page

| Study Citation: | Meijer, L., Martijn, A., Melessen, J., Brouwer, A., Weiss, J., de Jong, F. H., Sauer, P. J. (2012). Influence of prenatal organohalogen levels on infant male sexual development: Sex hormone levels, testes volume and penile length Human Reproduction, 27(3), 867-872 | | | | | |
|--|--|---------------------|---------|-------|---|--|
| Data Type: | GIC cohort HBCD_male sexual development-Reproductive | | | | | |
| HERO ID: | 1401499 | | | | | |
| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} | |
| | Metric 11: Co-exposure Confounding | Medium | × 0.333 | 0.67 | The study measured several OHC compounds in the serum. There is no indication that there is a correlation between any of these compounds. This is a general population study with no reason to believe there would be other differential co-exposures that would affect the results. However, in this cohort, compounds, such as phthalates, that also might be related to sexual development (Hannas et al.,2011) were not analyzed for. | |
| Domain 5: Analysis | | | | | | |
| | Metric 12: Study Design and Methods | Medium | × 0.4 | 0.8 | The study design chosen was appropriate for the research question. The study used an appropriate statistical method to address the research question. | |
| | Metric 13: Statistical power | Medium | × 0.2 | 0.4 | The number of participants (i.e., 55) seem adequate to detect an effect in the exposed population. | |
| | Metric 14: Reproducibility of analyses | Medium | × 0.2 | 0.4 | The description of the analysis is sufficient to understand precisely what was done and to be conceptually reproducible with access to the analytic data. | |
| | Metric 15: Statistical models | Medium | × 0.2 | 0.4 | There is a clear description of the analyses. | |
| Domain 6: Other Considerations for Biomarker Selection and Measurement | | | | | | |
| | Metric 16: Use of Biomarker of Exposure | High | × 0.167 | 0.17 | Maternal serum level of HBCD is the biomarker of exposure and its use is thought to have an accurate and precise quantitative relationship with external exposure. | |
| | Metric 17: Effect biomarker | Medium | × 0.167 | 0.33 | Sex hormones levels are an acceptable biomarker of effect and they were determined at the Endocrine Laboratory, Department of Internal Medicine, Erasmus Medical Centre, Rotterdam, The Netherlands as described elsewhere (Laven et al., 2004). | |
| | Metric 18: Method Sensitivity | Medium | × 0.167 | 0.33 | Limits of detection are low enough to detect chemicals in a sufficient percentage of the samples to address the research question. Analytical methods measuring biomarker are adequately reported. LOD/LOQ (value or %) are reported. The limit of detection (LOD = three times the standard deviation of the blank values) was 9 pg/g serum for HBCDD. Background levels were subtracted from reported results. HBCDD levels were below LOD in 1/44 samples. | |

Continued on next page ...

... continued from previous page

Study Citation: Meijer, L., Martijn, A., Melessen, J., Brouwer, A., Weiss, J., de Jong, F. H., Sauer, P. J. (2012). Influence of prenatal organohalogen levels on infant male sexual development: Sex hormone levels, testes volume and penile length Human Reproduction, 27(3), 867-872
 Data Type: GIC cohort HBCD_male sexual development-Reproductive
 HERO ID: 1401499

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|--|----------------------|---------------------|---------|-------|---|
| Metric 19: | Biomarker stability | Medium | × 0.167 | 0.33 | Although the infant serum was stated to be stored at -20 degrees C until analysis, there is no information on how long that was or if there might be any stability issues. No information was provided on the storage or stability of the serum samples for HBCD. |
| Metric 20: | Sample contamination | Medium | × 0.167 | 0.33 | There is incomplete documentation of the steps taken to provide the necessary assurance that the study data are reliable. |
| Metric 21: | Method requirements | High | × 0.167 | 0.17 | Instrumentation that provides unambiguous identification and quantitation of the biomarker at the required sensitivity (GC-MS) was used. |
| Metric 22: | Matrix adjustment | Not Rated | NA | NA | I don't think this is applicable to either matrix measured. |
| Overall Quality Determination [‡] | | Medium | | 1.9 | |
| Extracted | | Yes | | | |

* MWF = Metric Weighting Factor

[†] High = 1; Medium = 2; Low = 3; Unacceptable = 4; N/A has no value.

[‡] The overall rating is calculated as necessary. EPA may not always provide a comment for a metric that has been categorized as High.

$$\text{Overall rating} = \begin{cases} 4 & \text{if any metric is Unacceptable} \\ \left\lfloor \frac{\sum_i (\text{Metric Score}_i \times \text{MWF}_i)}{\sum_j \text{MWF}_j} \right\rfloor_{0.1} & \text{(round to the nearest tenth) otherwise} \end{cases}$$

where High = ≥ 1 to < 1.7 ; Medium = ≥ 1.7 to < 2.3 ; Low = ≥ 2.3 to ≤ 3.0 . If the reviewer determines that the overall rating needs adjustment, the original rating is crossed out and an arrow points to the new rating.

^{††} This metric met the criteria for high confidence as expected for this type of study

Table 5: **Johnson et al. 2013: Evaluation of Reproductive Outcomes**

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|--|---|---------------------|---------|-------|---|
| Study Citation: Johnson, P. I., Stapleton, H. M., Mukherjee, B., Hauser, R., Meeker, J. D. (2013). Associations between brominated flame retardants in house dust and hormone levels in men <i>Science of the Total Environment</i> , 445-446(Supplement C), 177-184 | | | | | |
| Data Type: Cross-sectional, HBCD Exposed males house dust, endpoint sex hormone binding globulin-Reproductive | | | | | |
| HERO ID: 1676758 | | | | | |
| Domain 1: Study Participation | | | | | |
| Metric 1: | Participant selection | High | × 0.25 | 0.25 | No explanation for participation rate of 65% provided; only male subjects. Information on participation selection, inclusion and exclusion criteria are provided in cited publications. |
| Metric 2: | Attrition | Low | × 0.4 | 1.2 | Attrition is not reported, and n values do not equal 62 in all results presented. (e.g. T3 has n=38 which is ~40% missing samples). No information on how missing data is handled. |
| Metric 3: | Comparison Group | Unacceptable | × 0.2 | 0.04 | There is no information on a comparison group. However correlation analysis performed looking for trend on a continuum of exposure. |
| Domain 2: Exposure Characterization | | | | | |
| Metric 4: | Measurement of Exposure | Medium | × 0.4 | 0.8 | Dust samples were collected from used vacuum badge from home. It is unclear if this is an established method to determine levels of exposure. HBCD detected in 97% of samples. |
| Metric 5: | Exposure levels | Low | × 0.2 | 0.6 | The range of exposure is limited but based on the analysis it does allow limited exploration in the exposure-response relationship. |
| Metric 6: | Temporality | Medium | × 0.4 | 0.8 | Dust samples and serum hormone levels are sampled in the same year for participants. The temporality of exposure and outcome is uncertain. |
| Domain 3: Outcome Assessment | | | | | |
| Metric 7: | Outcome measurement or characterization | High | × 0.667 | 0.67 | QA/QC methods described in another paper. The outcome was assessed using established methods. |
| Metric 8: | Reporting Bias | Medium | × 0.333 | 0.67 | Author's discuss results in text for significant results only |
| Domain 4: Potential Counfounding/Variable Control | | | | | |
| Metric 9: | Covariate Adjustment | High | × 0.5 | 0.5 | Although models were adjusted for age and BMI for some flame retardants, there is no mention of covariate consideration for HBCD. |
| Metric 10: | Covariate Characterization | High | × 0.25 | 0.25 | There is no information to suggest that the questionnaire used was validated; however there is no evidence that the method had poor validity. |
| Continued on next page ... | | | | | |

... continued from previous page

| Study Citation: | Johnson, P. I., Stapleton, H. M., Mukherjee, B., Hauser, R., Meeker, J. D. (2013). Associations between brominated flame retardants in house dust and hormone levels in men <i>Science of the Total Environment</i> , 445-446(Supplement C), 177-184 | | | | |
|--|--|---------------------|--------|-------|--|
| Data Type: | Cross-sectional, HBCD Exposed males house dust, endpoint sex hormone binding globulin-Reproductive | | | | |
| HERO ID: | 1676758 | | | | |
| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
| | Metric 11: Co-exposure Confounding | Medium | × 0.25 | 0.5 | Cannot rule out possibility of that findings are due to unmeasured co-exposures (e.g. other chemicals in household dust). |
| Domain 5: Analysis | | | | | |
| | Metric 12: Study Design and Methods | Unacceptable | × 0.4 | 0.16 | The study was exploratory to assess the association between exposure levels and hormone levels. However only a correlation analysis between HBCD and free androgen index was reported. |
| | Metric 13: Statistical power | Unacceptable | × 0.2 | 0.04 | The sample size is relatively small and the authors indicate that the study is exploratory in nature. |
| | Metric 14: Reproducibility of analyses | Medium | × 0.2 | 0.4 | The analysis is sufficiently described. |
| | Metric 15: Statistical models | Medium | × 0.2 | 0.4 | The authors provide an explanation for when data is combined with previous study data and limitations of the analysis in detail. |
| Domain 6: Other Considerations for Biomarker Selection and Measurement | | | | | |
| | Metric 16: Use of Biomarker of Exposure | Not Rated | NA | NA | No biomarker of exposure measured. |
| | Metric 17: Effect biomarker | Unacceptable | × 0.25 | 0.06 | Biomarker not specific to a health outcome. |
| | Metric 18: Method Sensitivity | Not Rated | NA | NA | Limit of detection not discussed in study, but no evidence of insufficient data. |
| | Metric 19: Biomarker stability | High | NA | NA | samples with known storage history and documented stability data |
| | Metric 20: Sample contamination | Medium | × 0.25 | 0.5 | No information to indicate sample contamination. |
| | Metric 21: Method requirements | High | × 0.25 | 0.25 | Method provides the identification and quantification of the biomarker. |
| | Metric 22: Matrix adjustment | Not Rated | NA | NA | No matrix adjustment. |
| Overall Quality Determination [‡] | | Unacceptable** | | 2.1 | |
| Extracted | | No | | | |

** Consistent with our *Application of Systematic Review in TSCARisk Evaluations* document, if a metric for a data source receives a score of Unacceptable (score = 4), EPA will determine the study to be unacceptable. In this case, one or more of the metrics were rated as unacceptable. As such, the study is considered unacceptable and the score is presented solely to increase transparency.

* MWF = Metric Weighting Factor

† High = 1; Medium = 2; Low = 3; Unacceptable = 4; N/A has no value.

‡ The overall rating is calculated as necessary. EPA may not always provide a comment for a metric that has been categorized as High.

$$\text{Overall rating} = \begin{cases} 4 & \text{if any metric is Unacceptable} \\ \left\lfloor \frac{\sum_i (\text{Metric Score}_i \times \text{MWF}_i)}{\sum_j \text{MWF}_j} \right\rfloor_{0.1} & \text{(round to the nearest tenth) otherwise} \end{cases}$$

where High = ≥ 1 to < 1.7 ; Medium = ≥ 1.7 to < 2.3 ; Low = ≥ 2.3 to ≤ 3.0 . If the reviewer determines that the overall rating needs adjustment, the original rating is crossed out and an arrow points to the new rating.

†† This metric met the criteria for high confidence as expected for this type of study 19

Table 6: **Kicinski et al. 2012: Evaluation of Neurological/Behavior Outcomes**

| Study Citation: | Kicinski, M., Viaene, M. K., Den Hond, E., Schoeters, G., Covaci, A., Dirtu, A.C., Nelen, V., Bruckers, L., Croes, K., Sioen, I., Baeyens, W., Van Larebeke, N., Nawrot, T. S. (2012). Neurobehavioral function and low-level exposure to brominated flame retardants in adolescents: A cross-sectional study <i>Environmental Health: A Global Access Science Source</i> , 11 86 | | | | | |
|-------------------------------------|---|---------------------|-------|-------|--|--|
| Data Type: | HBCD finger taps (change in number of taps with non-preferred hand)-Neurological/Behavior | | | | | |
| HERO ID: | 1927571 | | | | | |
| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} | |
| Domain 1: Study Participation | | | | | | |
| | Metric 1: Participant selection | High | × 0.4 | 0.4 | Participants were recruited during the same time frame (2008-2011) from the same two industrial areas and from the general population of Flemish adolescents using the same criteria. All adolescents from Genk and Menen were eligible. Random sampling of the general population was attained through a multistage sampling design (which is described). Details were provided for all aspects of the selection. The response rates were slightly higher in Genk, but non-responders were noted to not be different from the responders except that there was a higher proportion of girls responding. | |
| | Metric 2: Attrition | Medium | × 0.4 | 0.8 | 107 of the 606 subjects included were excluded because of missing covariates (n=84), missing blood measurements (n=3), or did not complete neurobehavioral tests (n=4). However, results have much fewer numbers for some results without full explanation. | |
| | Metric 3: Comparison Group | Medium | × 0.2 | 0.4 | Although a table of characteristics was provided, it was not broken down by area or general population. Differences that were expected to potentially bias the results were included in the analysis. However, there is not enough information provided about the two study areas to determine if there may have been other differences that varied by exposure. | |
| Domain 2: Exposure Characterization | | | | | | |
| | Metric 4: Measurement of Exposure | Low | × 0.4 | 1.2 | HBCD was measured in the serum according to methods by Covaci and Voorspoels (HERO ID 3113586). However, the method they cite does not indicate that this is a method for measuring HBCD nor do they provide recovery rates. Despite that there is no evidence that there would be poor validity or misclassification, it may just be more likely that samples would fall below the LOQ. | |
| | Metric 5: Exposure levels | Low | × 0.2 | 0.6 | For HBCD the effects of the concentrations above the LOQ compared to the concentrations below the LOQ were estimated (binary exposure). | |

Continued on next page ...

... continued from previous page

| Study Citation: | Kicinski, M., Viaene, M. K., Den Hond, E., Schoeters, G., Covaci, A., Dirtu, A.C., Nelen, V., Bruckers, L., Croes, K., Sioen, I., Baeyens, W., Van Larebeke, N., Nawrot, T. S. (2012). Neurobehavioral function and low-level exposure to brominated flame retardants in adolescents: A cross-sectional study Environmental Health: A Global Access Science Source, 11 86 | | | | | |
|---|---|---------------------|---------|-------|--|--|
| Data Type: | HBCD finger taps (change in number of taps with non-preferred hand)-Neurological/Behavior | | | | | |
| HERO ID: | 1927571 | | | | | |
| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} | |
| | Metric 6: Temporality | Low | × 0.4 | 1.2 | The temporality of exposure and outcome is uncertain . The cross-sectional nature of the study design makes it difficult to determine if exposure occurred prior to the outcome. | |
| Domain 3: Outcome Assessment | | | | | | |
| | Metric 7: Outcome measurement or characterization | High | × 0.667 | 0.67 | Neurobehavioral Evaluation System is a computerized battery of tests developed to study the neurological effects of an exposure to environmental agents. This study used four tests from the NES-3 version of the test battery. Study authors note these tests are reliable. | |
| | Metric 8: Reporting Bias | High | × 0.333 | 0.33 | Sufficient information is provided. All outcomes were reported with effect, 95% confidence intervals, and sample size. | |
| Domain 4: Potential Counfounding/Variable Control | | | | | | |
| | Metric 9: Covariate Adjustment | High | × 0.5 | 0.5 | Gender, age, type of education, parental education, owning the house, smoking , passive smoking, and blood lipids were included in the assessment. BMI, physical activity, computer use, alcohol use, fish consumption, blood lead, serum PCBs were also included in a stepwise regression procedure with p=0.15 for entering and p=0.10 for remaining in the model. | |
| | Metric 10: Covariate Characterization | Medium | × 0.25 | 0.5 | Information was obtained via questionnaires some information to be filled out by the adolescent and some for the parents. | |
| | Metric 11: Co-exposure Confounding | Medium | × 0.25 | 0.5 | Two of the groups were selected because they lived near industrial areas. No information was provided on these industrial areas and what else might be there. However, they did account for lead and PCBs (and possibly mercury via fish consumption) because these may impact the results. Although it is unclear if there might be other potential co-exposures, there is no indication that there would be anything additional that would greatly impact the results that was not considered. | |
| Domain 5: Analysis | | | | | | |
| Continued on next page ... | | | | | | |

... continued from previous page

| Study Citation: | Kicinski, M., Viaene, M. K., Den Hond, E., Schoeters, G., Covaci, A., Dirtu, A.C., Nelen, V., Bruckers, L., Croes, K., Sioen, I., Baeyens, W., Van Larebeke, N., Nawrot, T. S. (2012). Neurobehavioral function and low-level exposure to brominated flame retardants in adolescents: A cross-sectional study Environmental Health: A Global Access Science Source, 11 86 | | | | | |
|--|---|---------------------|-------|-------|---|--|
| Data Type: | HBCD finger taps (change in number of taps with non-preferred hand)-Neurological/Behavior | | | | | |
| HERO ID: | 1927571 | | | | | |
| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} | |
| Metric 12: | Study Design and Methods | Medium | × 0.4 | 0.8 | The cross sectional study design is appropriate for evaluating HBCD concentrations in adolescents with neurobehavioral effects. The study was part of a biomonitoring program for environmental health surveillance in Flanders, Belgium. | |
| Metric 13: | Statistical power | Medium | × 0.2 | 0.4 | Sufficient statistical power with 515 included subjects and outcome results available for 340 to 511 for any specific outcome. | |
| Metric 14: | Reproducibility of analyses | Low | × 0.2 | 0.6 | Description is not 100% clear on methods to be reproducible. | |
| Metric 15: | Statistical models | Medium | × 0.2 | 0.4 | The use of a linear regression or a negative binomial model were acceptable for the data with assumptions met or data transformed. | |
| Domain 6: Other | Considerations for Biomarker Selection and Measurement | | | | | |
| Metric 16: | Use of Biomarker of Exposure | Medium | × 0.2 | 0.4 | No information is provided to indicate serum HBCD is the appropriate, but the parent compound was measured. | |
| Metric 17: | Effect biomarker | Not Rated | NA | NA | No biomarker of effect was measured. | |
| Metric 18: | Method Sensitivity | Low | × 0.2 | 0.6 | Frequency of detection was low. Although they did not provide specific numbers below detection for HBCD, the P75 was still below the LOQ indicating that a large percent was below detection. | |
| Metric 19: | Biomarker stability | Medium | × 0.2 | 0.4 | No information was provided on storage history or stability of the HBCD in the sample. | |
| Metric 20: | Sample contamination | Medium | × 0.2 | 0.4 | There is incomplete documentation of the steps taken to provide the necessary assurance that the study data are reliable. | |
| Metric 21: | Method requirements | Medium | × 0.2 | 0.4 | Solid phase extraction followed by gas chromatography mass spectrometry in electron capture negative ion mode was used. Specifics of the extraction were not provided, but are assumed the same as used in cited reference (HERO ID 311586). Sensitivity of method for HBCD is not clear as recovery was not reported. The LOQ was 30 ng/L which seems high compared to the other PBDEs and the majority of the samples fell below the LOQ. | |
| Metric 22: | Matrix adjustment | Not Rated | NA | NA | Don't think matrix adjustment would be appropriate for this biomarker of exposure. | |
| Overall Quality Determination [‡] | | Medium | | 1.9 | | |

Continued on next page ...

...continued from previous page

Study Citation: Kicinski, M., Viaene, M. K., Den Hond, E., Schoeters, G., Covaci, A., Dirtu, A.C., Nelen, V., Bruckers, L., Croes, K., Sioen, I., Baeyens, W., Van Larebeke, N., Nawrot, T. S. (2012). Neurobehavioral function and low-level exposure to brominated flame retardants in adolescents: A cross-sectional study Environmental Health: A Global Access Science Source, 11 86
 Data Type: HBCD finger taps (change in number of taps with non-preferred hand)-Neurological/Behavior
 HERO ID: 1927571

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|-----------|--------|---------------------|------|-------|------------------------|
| Extracted | | Yes | | | |

* MWF = Metric Weighting Factor

[†] High = 1; Medium = 2; Low = 3; Unacceptable = 4; N/A has no value.

[‡] The overall rating is calculated as necessary. EPA may not always provide a comment for a metric that has been categorized as High.

$$\text{Overall rating} = \begin{cases} 4 & \text{if any metric is Unacceptable} \\ \left[\sum_i (\text{Metric Score}_i \times \text{MWF}_i) / \sum_j \text{MWF}_j \right]_{0.1} & \text{(round to the nearest tenth) otherwise} \end{cases}$$

where High ≥ 1 to < 1.7 ; Medium ≥ 1.7 to < 2.3 ; Low ≥ 2.3 to ≤ 3.0 . If the reviewer determines that the overall rating needs adjustment, the original rating is crossed out and an arrow points to the new rating.

^{††} This metric met the criteria for high confidence as expected for this type of study

Table 7: **Kicinski et al. 2012: Evaluation of Thyroid Outcomes**

| Study Citation: | Kicinski, M., Viaene, M. K., Den Hond, E., Schoeters, G., Covaci, A., Dirtu, A.C., Nelen, V., Bruckers, L., Croes, K., Sioen, I., Baeyens, W., Van Larebeke, N., Nawrot, T. S. (2012). Neurobehavioral function and low-level exposure to brominated flame retardants in adolescents: A cross-sectional study Environmental Health: A Global Access Science Source, 11 86 | | | | | |
|-------------------------------------|---|---------------------|-------|-------|--|--|
| Data Type: | HBCD T3 change-Thyroid | | | | | |
| HERO ID: | 1927571 | | | | | |
| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} | |
| Domain 1: Study Participation | | | | | | |
| | Metric 1: Participant selection | High | × 0.4 | 0.4 | Participants were recruited during the same time frame (2008-2011) from the same two industrial areas and from the general population of Flemish adolescents using the same criteria. All adolescents from Genk and Menen were eligible. Random sampling of the general population was attained through a multistage sampling design (which is described). Details were provided for all aspects of the selection. The response rates were slightly higher in Genk, but non-responders were noted to not be different from the responders except that there was a higher proportion of girls responding. | |
| | Metric 2: Attrition | Medium | × 0.4 | 0.8 | 107 of the 606 subjects included were excluded because of missing covariates (n=84), missing blood measurements (n=3), or did not complete neurobehavioral tests (n=4). However, results have much fewer numbers for some results without full explanation. | |
| | Metric 3: Comparison Group | Medium | × 0.2 | 0.4 | Although a table of characteristics was provided, it was not broken down by area or general population. Differences that were expected to potentially bias the results were included in the analysis. However, there is not enough information provided about the two study areas to determine if there may have been other differences that varied by exposure. | |
| Domain 2: Exposure Characterization | | | | | | |
| | Metric 4: Measurement of Exposure | Low | × 0.4 | 1.2 | HBCD was measured in the serum according to methods by Covaci and Voorspoels (HERO ID 3113586). However, the method they cite does not indicate that this is a method for measuring HBCD nor do they provide recovery rates. Despite that there is no evidence that there would be poor validity or misclassification, it may just be more likely that samples would fall below the LOQ. | |
| | Metric 5: Exposure levels | Low | × 0.2 | 0.6 | For HBCD the effects of the concentrations above the LOQ compared to the concentrations below the LOQ were estimated (binary exposure). | |

Continued on next page ...

... continued from previous page

| Study Citation: | Kicinski, M., Viaene, M. K., Den Hond, E., Schoeters, G., Covaci, A., Dirtu, A.C., Nelen, V., Bruckers, L., Croes, K., Sioen, I., Baeyens, W., Van Larebeke, N., Nawrot, T. S. (2012). Neurobehavioral function and low-level exposure to brominated flame retardants in adolescents: A cross-sectional study Environmental Health: A Global Access Science Source, 11 86 | | | | | |
|---|---|---------------------|---------|-------|--|--|
| Data Type: | HBCD T3 change-Thyroid | | | | | |
| HERO ID: | 1927571 | | | | | |
| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} | |
| | Metric 6: Temporality | Low | × 0.4 | 1.2 | The temporality of exposure and outcome is uncertain . The cross-sectional nature of the study design makes it difficult to determine if exposure occurred prior to the outcome. | |
| Domain 3: Outcome Assessment | | | | | | |
| | Metric 7: Outcome measurement or characterization | Medium | × 0.667 | 1.33 | Thyroid hormones were measured by competitive immune assays. No other information was provided. These are assumed to be standard assays. | |
| | Metric 8: Reporting Bias | Medium | × 0.333 | 0.67 | Information is provided, but not enough for complete extraction (sample size was not specified). | |
| Domain 4: Potential Counfounding/Variable Control | | | | | | |
| | Metric 9: Covariate Adjustment | High | × 0.5 | 0.5 | Gender, age, type of education, parental education, owning the house, smoking , passive smoking, and blood lipids were included in the assessment. BMI, physical activity, computer use, alcohol use, fish consumption, blood lead, serum PCBs were also included in a stepwise regression procedure with p=0.15 for entering and p=0.10 for remaining in the model. | |
| | Metric 10: Covariate Characterization | Medium | × 0.25 | 0.5 | Information was obtained via questionnaires some information to be filled out by the adolescent and some for the parents. | |
| | Metric 11: Co-exposure Confounding | Medium | × 0.25 | 0.5 | Two of the groups were selected because they lived near industrial areas. No information was provided on these industrial areas and what else might be there. However, they did account for lead and PCBs (and possibly mercury via fish consumption) because these may impact the results. Although it is unclear if there might be other potential co-exposures, there is no indication that there would be anything additional that would greatly impact the results that was not considered. | |
| Domain 5: Analysis | | | | | | |
| | Metric 12: Study Design and Methods | Medium | × 0.4 | 0.8 | The cross sectional study design is appropriate for evaluating HBCD concentrations in adolescents with thyroid hormone concentrations. The study was part of a biomonitoring program for environmental health surveillance in Flanders, Belgium. | |
| | Metric 13: Statistical power | Medium | × 0.2 | 0.4 | Sufficient statistical power with 515 included subjects. | |
| Continued on next page ... | | | | | | |

... continued from previous page

| Study Citation: | Kicinski, M., Viaene, M. K., Den Hond, E., Schoeters, G., Covaci, A., Dirtu, A.C., Nelen, V., Bruckers, L., Croes, K., Sioen, I., Baeyens, W., Van Larebeke, N., Nawrot, T. S. (2012). Neurobehavioral function and low-level exposure to brominated flame retardants in adolescents: A cross-sectional study Environmental Health: A Global Access Science Source, 11 86 | | | | | |
|--|---|---------------------|---------|-------|---|--|
| Data Type: | HBCD T3 change-Thyroid | | | | | |
| HERO ID: | 1927571 | | | | | |
| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} | |
| | Metric 14: Reproducibility of analyses | Low | × 0.2 | 0.6 | Description is not 100% clear on methods to be reproducible. | |
| | Metric 15: Statistical models | Medium | × 0.2 | 0.4 | The use of a linear regression or a negative binomial model were acceptable for the data with assumptions met or data transformed. | |
| Domain 6: Other | Considerations for Biomarker Selection and Measurement | | | | | |
| | Metric 16: Use of Biomarker of Exposure | Medium | × 0.167 | 0.33 | No information is provided to indicate serum HBCD is the appropriate, but the parent compound was measured. | |
| | Metric 17: Effect biomarker | Low | × 0.167 | 0.5 | Biomarkers of effect shown to have a relationship to health outcomes, but the method is not well validated and mechanism of action is not understood. | |
| | Metric 18: Method Sensitivity | Low | × 0.167 | 0.5 | Frequency of detection of serum HBCD was low. Although they did not provide specific numbers below detection for HBCD, the P75 was still below the LOQ indicating that a large percent was below detection. Sensitivity was likely okay for the thyroid hormones. | |
| | Metric 19: Biomarker stability | Medium | × 0.167 | 0.33 | No information was provided on storage history or stability of the HBCD or thyroid hormones in the sample. | |
| | Metric 20: Sample contamination | Medium | × 0.167 | 0.33 | There is incomplete documentation of the steps taken to provide the necessary assurance that the study data are reliable. | |
| | Metric 21: Method requirements | Medium | × 0.167 | 0.33 | Solid phase extraction followed by gas chromatography mass spectrometry in electron capture negative ion mode was used. Specifics of the extraction were not provided, but are assumed the same as used in cited reference (HERO ID 311586). Sensitivity of method for HBCD is not clear as recovery was not reported. The LOQ was 30 ng/L which seems high compared to the other PBDEs and the majority of the samples fell below the LOQ. Few details were provided on the thyroid hormone tests. | |
| | Metric 22: Matrix adjustment | Not Rated | NA | NA | Don't think matrix adjustment would be appropriate for this biomarker of exposure or thyroid hormones. | |
| Overall Quality Determination [‡] | | Medium | | 2.1 | | |
| Extracted | | Yes | | | | |
| Continued on next page ... | | | | | | |

...continued from previous page

Study Citation: Kicinski, M., Viaene, M. K., Den Hond, E., Schoeters, G., Covaci, A., Dirtu, A.C., Nelen, V., Bruckers, L., Croes, K., Sioen, I., Baeyens, W., Van Larebeke, N., Nawrot, T. S. (2012). Neurobehavioral function and low-level exposure to brominated flame retardants in adolescents: A cross-sectional study Environmental Health: A Global Access Science Source, 11 86

Data Type: HBCD T3 change-Thyroid

HERO ID: 1927571

| Domain | Metric | Rating [†] | MWF [*] | Score | Comments ^{††} |
|--------|--------|---------------------|------------------|-------|------------------------|
|--------|--------|---------------------|------------------|-------|------------------------|

* MWF = Metric Weighting Factor

[†] High = 1; Medium = 2; Low = 3; Unacceptable = 4; N/A has no value.

[‡] The overall rating is calculated as necessary. EPA may not always provide a comment for a metric that has been categorized as High.

$$\text{Overall rating} = \begin{cases} 4 & \text{if any metric is Unacceptable} \\ \left\lfloor \frac{\sum_i (\text{Metric Score}_i \times \text{MWF}_i)}{\sum_j \text{MWF}_j} \right\rfloor_{0.1} & \text{(round to the nearest tenth) otherwise} \end{cases}$$

where High = ≥ 1 to < 1.7 ; Medium = ≥ 1.7 to < 2.3 ; Low = ≥ 2.3 to ≤ 3.0 . If the reviewer determines that the overall rating needs adjustment, the original rating is crossed out and an arrow points to the new rating.

^{††} This metric met the criteria for high confidence as expected for this type of study

Table 8: **Kim and Oh 2014: Evaluation of Thyroid Outcomes**

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|---|-------------------------|---------------------|-------|-------|---|
| Study Citation: Kim, UJ; Oh, JE (2014). Tetrabromobisphenol A and hexabromocyclododecane flame retardants in infant-mother paired serum samples, and their relationships with thyroid hormones and environmental factors <i>Environmental Pollution</i> , 184 193-200 | | | | | |
| Data Type: HBCDs Mother & Infants THs (T3)-Thyroid | | | | | |
| HERO ID: 2324769 | | | | | |
| Domain 1: Study Participation | | | | | |
| Metric 1: | Participant selection | Low | × 0.4 | 1.2 | Information on participant selection can be found in a related reference—HERO ID 4182288 (Kim et al. 2012). 38 mother-infant pairs agreed to participate and had blood collected at a hospital in Seoul between Nov 2009 and May 2010. Participation eligibility criteria and participation rate were not reported. It is unclear whether this sample was drawn from another previous study (HERO ID 4182289; Kim et al. 2011). |
| Metric 2: | Attrition | High | × 0.4 | 0.4 | There was no withdrawal of participants from this sample. Use of imputation methods for missing exposure data; exposure measurements (BFR) below the MDL were imputed at 0.5 x MDL to prevent distortion of the data-set, then the data were normalized, excluding outliers, to the total BFR. |
| Metric 3: | Comparison Group | Medium | × 0.2 | 0.4 | Summary demographic descriptors of the entire population were reported in a prior study (HERO ID 4182288; Kim et al. 2012). Characteristics were not reported by case and control group, but there is no other indication that groups are not similar. It was reported in this reference that controls did not show any symptoms of thyroid disease or other metabolic disorders (including obesity). Therefore, there is indirect evidence (i.e., stated by the authors without providing a description of methods) that cases and controls are similar. |
| Domain 2: Exposure Characterization | | | | | |
| Metric 4: | Measurement of Exposure | High | × 0.4 | 0.4 | HBCD (three diastereomers: alpha-, beta-, gamma-) concentrations were measured in the serum of mothers and infants 1 to 3 months after birth. Quantification methods are provided in Thomsen et al. 2010 [HERO ID 1927695]. HBCDs analyzed by LC/MS/MS. It should be noted that two infants in the case group were unable to have blood drawn in the 1-3 month window. These two infants had samples collected 18-24 months after birth. |
| Continued on next page ... | | | | | |

...continued from previous page

| Study Citation: | Kim, UJ; Oh, JE (2014). Tetrabromobisphenol A and hexabromocyclododecane flame retardants in infant-mother paired serum samples, and their relationships with thyroid hormones and environmental factors Environmental Pollution, 184 193-200 | | | | | |
|---|---|---------------------|---------|-------|---|--|
| Data Type: | HBCDs Mother & Infants THs (T3)-Thyroid | | | | | |
| HERO ID: | 2324769 | | | | | |
| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} | |
| | Metric 5: Exposure levels | Medium | × 0.2 | 0.4 | Range is sufficiently large to determine an exposure-response estimate. Ranges were from below MDL (0.05 ng/g lipid) to 91 ng/g lipid. Smallest range was <MDL to 0.991 ng/g lipid. Comparison of means provided a summary measure of exposure levels for each outcome group. For Pearson correlations, the HBCD concentrations were analyzed continuously. | |
| | Metric 6: Temporality | Low | × 0.4 | 1.2 | Serum samples were taken from mother and infant within the first three months after birth. This does not adequately measure prenatal exposure to HBCDs and serves more as a cross-sectional measure of HBCD concentrations in cases and controls. Serum concentrations from the mother or infant after birth may be related to prenatal exposure, but do not give an accurate indication of prenatal exposure and it's relationship to congenital hypothyroidism. Thus, the temporality of exposure and outcome is uncertain. | |
| Domain 3: Outcome Assessment | | | | | | |
| | Metric 7: Outcome measurement or characterization | High | × 0.667 | 0.67 | Thyroid hormones were quantified by radioimmunoassay kits (Diagnostic Products Corp., Los Angeles, CA) with a detection limit for T4 and TSH of 1 ug/dL and 0.02 ug/dL, respectively. | |
| | Metric 8: Reporting Bias | Medium | × 0.333 | 0.67 | All of the study's measured outcomes outlined in the abstract, introduction, and methods were discussed in the results. Significant results are presented clearly in tables. However, many non-significant results were discussed in-text only and this does not allow for detailed extraction of non-significant values. | |
| Domain 4: Potential Counfounding/Variable Control | | | | | | |
| | Metric 9: Covariate Adjustment | Low | × 0.667 | 2 | There is no indication in this reference or the parent reference (HERO ID 4182288; Kim et al. 2012) that potential confounders were considered in the analysis. | |
| | Metric 10: Covariate Characterization | Not Rated | NA | NA | Covariates were not assessed. | |
| | Metric 11: Co-exposure Counfounding | Medium | × 0.333 | 0.67 | Other brominated flame retardants were measured and reported in this study. There is no indication of differential exposure between cases and controls. | |
| Domain 5: Analysis | | | | | | |

Continued on next page ...

... continued from previous page

| Study Citation: | Kim, UJ; Oh, JE (2014). Tetrabromobisphenol A and hexabromocyclododecane flame retardants in infant-mother paired serum samples, and their relationships with thyroid hormones and environmental factors Environmental Pollution, 184 193-200 | | | | | |
|-----------------|---|---------------------|---------|-------|--|--|
| Data Type: | HBCDs Mother & Infants THs (T3)-Thyroid | | | | | |
| HERO ID: | 2324769 | | | | | |
| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} | |
| | Metric 12: Study Design and Methods | Medium | × 0.5 | 1 | The study design chosen was appropriate for investigating thyroid hormone levels in relation to exposure to HBCDs. The study uses an appropriate statistical method to address the research question. | |
| | Metric 13: Statistical power | Medium | × 0.25 | 0.5 | The sample size of this study is small. There were 38 mother-infant pairs with only 12 mothers and 12 infants with congenital hypothyroidism (diagnosed in the infant) used in the analysis of correlation between HBCD concentrations and thyroid hormones. It is uncertain if the sample size is adequate to detect an effect in the exposed population. | |
| | Metric 14: Reproducibility of analyses | Medium | × 0.25 | 0.5 | The analyses (two-sided student's t-test, normalization of the data set, and outlier exclusions) are presented clearly in the methods and is sufficient to understand precisely what has been done and to be conceptually reproducible with access to the analytic data. | |
| | Metric 15: Statistical models | Not Rated | NA | NA | No statistical model used. | |
| Domain 6: Other | Considerations for Biomarker Selection and Measurement | | | | | |
| | Metric 16: Use of Biomarker of Exposure | High | × 0.143 | 0.14 | Three diastereomers of HBCD were measured in serum, accurately reflecting exposure to HBCDs. These biomarkers are in a specified matrix and are assumed to have an accurate and precise quantitative relationship with exposure. | |
| | Metric 17: Effect biomarker | High | × 0.143 | 0.14 | TSH, T4, and other thyroid hormone levels are appropriate measures of thyroid conditions. | |
| | Metric 18: Method Sensitivity | Medium | × 0.143 | 0.29 | The lowest rate of detection for HBCDs was 66% with a MDL of 50 pg/dL. This is low enough to detect chemicals in a sufficient percentage of the samples to address the research question. Analytical methods measuring biomarker are adequately reported. | |
| | Metric 19: Biomarker stability | High | NA | NA | No apparent issues; storage history is documented. | |
| | Metric 20: Sample contamination | High | × 0.143 | 0.14 | Use of blanks and QA/QC documented in detail. Detailed procedures can be found in the supplemental material of a parent reference (HERO ID 4182288; Kim et al. 2012). | |
| | Metric 21: Method requirements | High | × 0.143 | 0.14 | HBCDs were analyzed by LC/MS/MS (Agilent1200/6460QQMSD, Agilent Technologies, Santa Clara, CA). Detailed procedures can be found in the supplemental material of a parent reference (HERO ID 4182288; Kim et al. 2012). | |

Continued on next page ...

...continued from previous page

Study Citation: Kim, UJ; Oh, JE (2014). Tetrabromobisphenol A and hexabromocyclododecane flame retardants in infant-mother paired serum samples, and their relationships with thyroid hormones and environmental factors Environmental Pollution, 184 193-200
 Data Type: HBCDs Mother & Infants THs (T3)-Thyroid
 HERO ID: 2324769

| Domain | Metric | Rating [†] | MWF* | Score | Comments ^{††} |
|--|------------------------------|---------------------|---------|-------|--|
| | Metric 22: Matrix adjustment | Medium | × 0.143 | 0.29 | HBCDs in serum are presented only as matrix adjusted (ng/g lipid). |
| Overall Quality Determination [‡] | | Medium | | 1.9 | |
| Extracted | | Yes | | | |

* MWF = Metric Weighting Factor

[†] High = 1; Medium = 2; Low = 3; Unacceptable = 4; N/A has no value.

[‡] The overall rating is calculated as necessary. EPA may not always provide a comment for a metric that has been categorized as High.

$$\text{Overall rating} = \begin{cases} 4 & \text{if any metric is Unacceptable} \\ \left\lfloor \frac{\sum_i (\text{Metric Score}_i \times \text{MWF}_i)}{\sum_j \text{MWF}_j} \right\rfloor_{0.1} & \text{(round to the nearest tenth) otherwise} \end{cases},$$

where High = ≥ 1 to < 1.7 ; Medium = ≥ 1.7 to < 2.3 ; Low = ≥ 2.3 to ≤ 3.0 . If the reviewer determines that the overall rating needs adjustment, the original rating is crossed out and an arrow points to the new rating.

^{††} This metric met the criteria for high confidence as expected for this type of study